live sessions
PDT:
Pacific Daylight Time
PDT:
Pacific Daylight Time
Science SpotlightsTM Sessions
Live Now:
2:30 PM2:30 PM
300 - Understanding the Evolutionary Framework and Transmission Dynamics of Mpox in South Korea
Chihwan Choi
Korea Disease Control and Prevention Agency, Cheongju-si, South Korea
2:30 PM2:30 PM
301 - Fine-Tuning Viral Adaptation Through Genome Retraction: Insights From Mpox Outbreaks in South Korea
Minji Lee
Korea Disease Control and Prevention Agency, Cheongju-si, South Korea
2:30 PM2:30 PM
302 - Discovery of Aberrant Genomic Rearrangement in an Mpox Virus Genome Observed in a Japanese Patient
Takayuki Ishige
Chiba University, Chiba, Japan
2:30 PM2:30 PM
303 - Factors Associated With Detectable Viral Load Among PLHIV in Serodiscordant Partnerships in Tanzania
Abbas Ismail
US Centers for Disease Control and Prevention Dar es Salaam, Dar es Salaam, Tanzania
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-02) HIV-1 Envelope and Viral Tropism
2:30 PM2:30 PM
304 - Enhanced Recognition of V3 bNAb Epitopes Induced by Fostemsavir on Cell-Associated Primary HIV-1 Env
Svenja Weiss
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
305 - CXCR4-Using HIV-1 Variants Evolve in the Presence of and Co-Exist With CCR5-Using Variants
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
306 - Droplet Single Genome Amplification Allows for Characterization of Autologous HIV Envelope Sequences
Joseph McWhirter
Boston University, Boston, MA, USA
2:30 PM2:30 PM
307 - High Resistance of HIV-1CH040 Envelope Glycoproteins to bNAbs Without Loss of Efficient Viral Entry
Durgadevi Parthasarathy
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
308 - Sex Differences in Replication Kinetics of Primary HIV-1 Isolates in Monocyte-Derived Macrophages
Jake Robinson
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
331 - Impact of Pre-Existing Immune Activation on SARS-CoV-2 Incidence and Disease During the First Wave
Diana Yang
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
332 - Unique SARS-CoV-2 Variants and Inflammatory Milieu in Urine of Severe COVID-19 Participants
Aarthi Subramani
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
333 - Bile Acids in the Modulation of Antiviral Immune Response
Eileen F. Serrano
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
334 - The Bile Acids Complexity Underlies an Antiviral Interferon Innate Signaling During COVID-19 Disease
Diego A. Diaz-Dinamarca
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
335 - The Influence of Chronic HIV Inflammation on Post-COVID Immune Activation
Skye Opsteen
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
336 - Lipid Nanoparticles Targeting Neutrophil and NETs to Mitigate Lung Injury in SARS-CoV-2 Mice
Juwon Park
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
337 - Vitamins K2 and D3 Improve Long COVID Index, Fungal Translocation, and Inflammatory Biomarkers
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
338 - High-Fat and -Sugar Diet but Not SIV Coinfection Enhances SARS-CoV-2 Shedding in Infected Macaques
Kelsie Brooks
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
339 - Sustained Inflammation and Delayed Resolution of COVID-19 Disease in SIV-Infected Macaques
Dhiraj K. Singh
Texas Biomedical Research Institute, San Antonio, TX, USA
2:30 PM2:30 PM
340 - Monocyte Dysregulation in PASC With Ongoing Pulmonary Symptoms
Thomas K. Awamura
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
341 - Retroviral Infection Reprograms Mouse Embryonic Stem Cells
Andrew D. Mazzanti
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
342 - Untangling the Impact of CD101 on HIV-1 Transmission
Phuong Vo
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
343 - CD40L/IL-4 Stimulated B Cells as Efficient Mediators of HIV-1 Binding and Trans Infection
Abigail Gerberick
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
344 - Feminizing Hormone Therapy and the Rectal Mucosal Immune Environment
Stacey Smith
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
345 - HIV-1 Vpr Promotes Viral Replication, Granzyme B Expression, and Death of Gut CD4 T Cells Ex Vivo
Kaylee Mickens
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
346 - Early HIV-1 Genetic Diversity Includes CTL and Drug Resistance Mutations
John Coffin
Tufts University, Boston, MA, USA
2:30 PM2:30 PM
347 - Tuberculosis Promotes the Persistence of Genetically-Intact HIV in People With HIV and Tuberculosis
Samantha K. Cronin
The University of Sydney, Sydney, Australia
2:30 PM2:30 PM
348 - Species-Specific Splicing of DNA Editing Enzymes: Implications in HIV and SIV Mutagenesis
Diako Ebrahimi
Texas Biomedical Research Institute, San Antonio, TX, USA
2:30 PM2:30 PM
349 - Transcriptionally Active Defective HIV-1 Proviruses Persist in All CD4 T-Cell Subsets During ART
Hiromi Imamichi
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
2:30 PM2:30 PM
350 - Utilizing Defective HIV-1 Provirus as a Novel “Barcode” for Studying T-Cell Dynamics
Vinie Kouamou
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
351 - Similar Intact and Defective HIV Provirus Frequency in Suboptimal Immune Responders and Controls
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
352 - Impact of ART Initiation on HIV-1 Soluble gp120 Levels and CD4 Counts in PWH
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
2:30 PM2:30 PM
353 - Genetic Associations With CD4 Recovery in People With HIV After Initiation of Antiretroviral Therapy
Roxane Rohani
Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
2:30 PM2:30 PM
354 - R5-Tropic HIV Restricts X4-Tropic Virus via Type I IFN Signaling, Limiting Pathogenesis
Priya Pal
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
355 - Residual HIV Viremia Associates With Reservoir Size, but Not With Immune Activation or Inflammation
Twan Otten
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
356 - Relationship Between Gut Microbiome and Candida in PWH: Role of Bacterial Extracellular Vesicles
Aya Ishizaka
University of Tokyo Institute of Medical Science, Tokyo, Japan
2:30 PM2:30 PM
357 - The Mucosal Microbiome at Sites of HIV Acquisition Among Key Populations
Cassie G. Ackerley
Emory Vaccine Center, Atlanta, GA, USA
2:30 PM2:30 PM
358 - Virulent HIV-1B: Clinical Challenges and Proteomic Insights
Kavita Mehta
Ghent University, Ghent, Belgium
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-01) CD8 T Cells in Infection and After Vaccination
2:30 PM2:30 PM
400 - Duration of Viremia Modulates Antigen Sensitivity of HIV-Specific T-Cell Receptors
Funsho Ogunshola
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
401 - Low Post-ART SIV Viral Load Set Point Associated With Enhanced Lymph Node CD8+ T-Cell Proliferation
Gina Borgo
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
402 - The Soft Escape: HIV Alters Host Cell Cytoskeleton as a Mechanism of Resistance to CTL Killing
Louise Leyre
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
403 - CD8+ T-Cell Function During ART Is Associated With Provirus Suppression and Reduced Viral Rebound
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
404 - TCR Convergence in HIV Controllers: Insights Into Natural Viral Suppression
Alexandra Vujkovic
Institute of Tropical Medicine, Antwerp, Belgium
2:30 PM2:30 PM
405 - Robust CD8+ T-Cell Proliferation and Stem-Like Memory Phenotype Linked to HIV Post-Treatment Control
Charles Crain
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
406 - HIV-Infection Does Not Generally Confer Higher Resistance to CTL-Mediated Lysis
Niklas Bachmann
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
407 - HIV-Specific T & Humoral Response: Data From the First Pediatric Combined Therapeutic Vaccine Trial
Arianna Rotili
University of Rome Tor Vergata, Rome, Italy
2:30 PM2:30 PM
408 - HIV-1-Specific T Cells From Post-Treatment Controllers and Noncontrollers
Lisa L. Dietz
Aarhus University, Aarhus, Denmark
2:30 PM2:30 PM
409 - Impact of Gender-Affirming Hormone Therapy on T-Cell Phenotypes in Transgender Women With HIV
Elizabeth Hastie
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
410 - Differential Restoration of HIV-Specific CD8+ T Cells by Amino Acid and Lipid Metabolism Modulation
Enrique Martin Gayo
Universidad Autónoma de Madrid, Madrid, Spain
2:30 PM2:30 PM
411 - Unmodified mRNA Compared to Modified mRNA Induces Optimal CD8+ T-Cell Responses in Rhesus Macaques
Sampa Santra
Beth Israel Deaconess Medical Center, Boston, MA, USA
2:30 PM2:30 PM
412 - The Impact of Protein Specificity on Function and Crosstalk Between the HIV-Specific T Cells
Jernej Pusnik
Bonn University Hospital, Bonn, Germany
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-02) B Cells and Neutralizing Antibodies
2:30 PM2:30 PM
413 - Provirus From Early-Treated HIV Reveals Earlier Variants Targeted by Initial Neutralizing Antibodies
Hunter M. Courtney
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
414 - Structural Insight into the High- and Low-Affinity Alleles of Human and Macaque FcγRIIA (CD32A)
William D. Tolbert
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2:30 PM2:30 PM
415 - Antigen Affinity Ceiling for Selection of Functional Mutations and HIV-1 Neutralization
Ankita Singh
Duke Human Vaccine Institute, Durham, NC, USA
2:30 PM2:30 PM
416 - Maturation of B-Cell Lineages During cART in Chronic SHIV-Infected Juvenile Rhesus Macaques
Wilton Williams
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
417 - Public Trimer-Specific IgHV4-34 Clonotype in bNAb Inducers Includes a Novel V3-Glycan bNAb Subclass
Alexandra Trkola
University of Zurich, Zurich, Switzerland
2:30 PM2:30 PM
419 - In Nonsuppressible Viremia, HIV Env Can Maintain Resistance to Autologous Neutralizing Antibodies
Sang Hyeon Kim
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
420 - Molecular Mechanisms Underlying Anti-HIV-1 Fc-Effector Functions of Human IgA Allelic Variants
Marek K. Korzeniowski
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2:30 PM2:30 PM
421 - Sensitivity of HIV-1 CRF01_AE Envelopes to Broadly Neutralizing Antibodies VRC07-523 and PGDM1400
Gabriel Smith
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
422 - Transcriptional Analysis of Intestinal Immune Cells in People With HIV Receiving bNAbs
Connie A. Zhao
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
423 - Identification of an Autoantibody Against FCHSD2 in Adipose Tissue of PLWH With Diabetes
Laventa Obare
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
424 - Detection of Anti-Interferon Alpha/Omega Neutralizing Autoantibodies in PLWH
Alessandra D'Auria
Sapienza University of Rome, Rome, Italy
2:30 PM2:30 PM
484 - Delayed HIV-1 Rebound Correlates With Enhanced CD8+ T-Cell Activation in Human Trials
Rasmi Thomas
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
485 - Total HIV-1 Nucleic Acid Increases Precede Plasma RNA Rebound During Pediatric ATI
Gabriela Z. L. Cromhout
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
486 - Consecutive Analytical Treatment Interruption Improves CD8 T-Cell Activity During Viral Control
Sarah Palmer
The Westmead Institute for Medical Research, Westmead, Australia
2:30 PM2:30 PM
487 - Mitochondrial Gene Variants Influence VARS2, HIV Reservoir, and CD4+ T Cells in HIV Controllers
Victoria Rios Vazquez
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
488 - Clinical and Virologic Outcomes of an ART Interruption in Treated Controllers and Non-Controllers
Isaac E. Avila-Vargas
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
489 - HIV-1 Post-Treatment Control Occurs Despite HLA-Escape Mutations in the Intact Reservoir
Efthimios A. Deligiannidis
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
490 - Time to Viremia and Frequency of Post-Treatment Control Among 382 “Placebo-Treated” ATI Participants
Jesper D. Gunst
Aarhus University Hospital, Aarhus, Denmark
2:30 PM2:30 PM
491 - Characterization of HIV Antibodies and p24 Antigen During Analytical Treatment Interruption
Clara Di Germanio
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
492 - Post-Treatment HIV Controllers Exhibit Reduced Plasma Markers of Inflammation and Metabolic Stress
Leila B. Giron
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
493 - Population-Specific T-Cell Responses and Virologic Control After Analytical Treatment Interruption
Jorge Gallardo Cartagena
Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Lima, Peru
2:30 PM2:30 PM
494 - Loss of Virologic Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
2:30 PM2:30 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
499 - Genetic Regulation of Immune Responses to CMV in Spontaneous HIV Controllers
Suzanne D. E. Ruijten
Radboud University Medical Center, Nijmegen, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-02) Strategies for an HIV Cure
2:30 PM2:30 PM
500 - The Asymmetric Opening of HIV-1 Env by a Potent CD4 Mimetic Enables Anti-CoRBS Abs to Mediate ADCC
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
501 - TCR-Mimic ScDb Reduced HIV Provirus and Delayed the Viral Rebound in HLA-Specific BLT Hu-Mice
Zhe Yuan
The Wistar Institute, Philadelphia, PA, USA
2:30 PM2:30 PM
502 - Targeting TCF-1 to Potentiate the Functional Capacity of HIV/SIV-Specific CD8+ T Cells
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
503 - CD4 T Cell-Targeting Lipid Nanoparticles in the Search for a Genetic HIV Cure
Maaike De Cock
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
504 - CD4 Mimetics Sensitize HIV-Infected Cells to ADCC Mediated by Plasma From Early-Stage HIV Infection
Andrés Finzi
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
505 - Sustained Post-Rebound HIV Remission With Enhanced T-Cell Immunity After LS-bNAbs: A Case Report
John Frater
University of Oxford, Oxford, UK
2:30 PM2:30 PM
506 - Sustained T Cell-Mediated Immunity After LS-bNAbs in the RIO Trial: A Vaccinal Effect
John Frater
University of Oxford, Oxford, UK
2:30 PM2:30 PM
507 - Temsavir Treatment Improves Recognition of HIV-1 Infected Cells by Broadly Neutralizing Antibodies
Hangfei Qi
ViiV Healthcare, Durham, NC, USA
2:30 PM2:30 PM
508 - Maximizing Benefits to Participants in Analytic Treatment Interruption With Antibody Infusions
Yifan Li
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
509 - Myeloid Targeted and Enhanced Endosomal Escapable LNPs Improve Latent HIV-1 Elimination Efficacy
Soumya S. Dey
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
510 - A Novel and Promising Strategy of HIV Eradication via LTR-LTR Recombination
Feng Li
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
511 - Development and Delivery of Next-Generation Epigenome Editors for Long-Term HIV Silencing
Francisco J. Zapatero Belinchon
Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
2:30 PM2:30 PM
512 - RV550: Safety and Virologic Outcomes in Blood and Lymph Nodes of N-803 With ART in Acute Infection
Carlo Sacdalan
SEARCH, Bangkok, Thailand
2:30 PM2:30 PM
513 - HIV-1 Reservoir Decay During Broadly Neutralizing Antibody Therapy in the RIO Trial
Marcilio Jorge Fumagalli
The Rockefeller University, New York, NY, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-04) Transcription in the HIV Reservoir
2:30 PM2:30 PM
524 - Transcriptional Profiles of HIV RNA+ Cells in PWH on ART Differ From Those During Active Viremia
Julie Frouard
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
525 - Selective Decay of Different HIV Transcripts After ART Initiation in Chronic Infection
Cordelia M. Isbell
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
526 - Nonsuppressible HIV Viremia May Harbor Replication-Incompetent Viruses With 5' Leader Deletions
Zixin Hu
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
527 - HIV-1 Latency Reversal Augments Persistent HIV-1 Transcription During ART
Rowan Hassman
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
528 - MLN4924 Reduces HIV Transcription, Cell Survival, and HIV Infectivity After Latency Reversal In Vitro
Cristina C. Vaca
Northwestern University, Chicago, IL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-05) Novel Interventions Toward an HIV Cure
2:30 PM2:30 PM
529 - Venetoclax Decreases Intact Proviral DNA Frequency in SIV-Infected, ART-Suppressed Rhesus Macaques
Sydney N. Bergstresser
Yerkes National Primate Research Center, Atlanta, GA, USA
2:30 PM2:30 PM
530 - AZD5582 Inhibits Vaccine-Elicited CD8+ T-Cell Responses in SIV-Infected Rhesus Macaques on ART
Benjamin D. Varco-Merth
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
531 - Sustained HIV Remission Despite Transient Rebound Viremia After a CCR5∆32/∆32 Stem Cell Transplant
Paul Rubinstein
University of Illinois at Chicago, Chicago, IL, USA
2:30 PM2:30 PM
532 - HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant From CCR5Δ32/Δ32 Sibling Donor
Marius Trøseid
Oslo University Hospital, Oslo, Norway
2:30 PM2:30 PM
533 - Tazemetostat Enhances CTL Killing of HIV-Infected Cells and Reduces Reservoirs In Vivo
Itzayana G. Miller
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
534 - CXCR4-Targeted CRISPR/Cas9 Lipid Nanoparticles for Excision of Latent Proviral DNA
Sudipta Panja
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
535 - Efficient Generation of Anti-HIV TRAC-CAR T Cells to Enable High-Throughput Binder Screening
Gabriella Kimmerly
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
536 - Infusion of Autologous CCR5-Deleted CD4 Cells Does Not Change the HIV Reservoir: The TRAILBLAZER RCT
Carl J. Fichtenbaum
University of Cincinnati, Cincinnati, OH, USA
2:30 PM2:30 PM
537 - HIV-1 Reservoir Reduction in PWH Receiving ART and Dasatinib
Mario Manzanares
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
538 - Phase I Clinical Trial AMC097 Evaluating Engraftment and HIV Resistance of Gene-Modified Blood Cells
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
589 - Humanized Glia Mice Show HIV-Induced Behavioral, Neuro, and Metabolic Changes as in Clinical Disease
Amanda Fernandes
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
590 - Evaluating White Matter Integrity in Relation to HIV Severity and Cognitive Impairment
Beau Ances
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
591 - Interaction Between Age, Brain Volume, and HIV Status in Predicting Cognition
Beau Ances
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
592 - Plasma Inflammation Is Associated With Brain Cellularity in Diffusion-Based Spectral Imaging in HIV
Advika Srinivas
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
593 - The Effects of Depression and Antidepressants on Cognition and Brain Volume in PWH and PWoH
Sophie A. Sims
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
594 - Analyzing Neuroanatomical Heterogeneity in HIV-Associated Cognitive Impairment
Audrey Chun
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
595 - Preliminary Analysis of Longitudinal Synaptic Density Change in Virally Suppressed People With HIV
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
596 - Cannabis Use Is Associated With Reduced Brain Integrity in Persons With HIV
Sarah Cooley
Washington University in St Louis, St Louis, MO, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-02) Biomarkers for NeuroHIV Informing Pathogenesis
2:30 PM2:30 PM
597 - Inflammatory Biomarker Profiling to Predict Neuroinflammation and Depression in Adolescents With HIV
Shalena Naidoo
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
598 - No Decline in CSF or Plasma Neurofilament Light Chain Levels Post-Early ART Initiation
Nametso Kelentse
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
599 - Polypharmacy Is Associated With Neuronal Injury in PWH
Priya Kosana
East Carolina University, Greenville, NC, USA
2:30 PM2:30 PM
600 - Plasma CNS Tissue Markers in Heavily Treatment-Experienced PWH in the PRESTIGIO Registry
Andrea Calcagno
University of Turin, Turin, Italy
2:30 PM2:30 PM
601 - Comprehensive Study of CSF Fluid β2-Microglobulin, a Marker of CNS Immune Activation in HIV
Birgitta Anesten
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
2:30 PM2:30 PM
602 - Higher suPAR Relates to Domain-Specific Cognitive Function in Virally Suppressed Women With HIV
Hemil Gonzalez
Rush University Medical Center, Chicago, IL, USA
2:30 PM2:30 PM
603 - Cognitive Intra-Individual Variability Predicts IADL Function in the Women’s Interagency HIV Study
David E. Vance
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
604 - Influence of an Exercise Intervention or Dynamic Stretching on Cognition and Gut Microbiome in PWH
Sarah Cooley
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
605 - Longitudinal Changes in Neuronal Markers and Associations With ART Initiation and Cognitive Function
Merle Henderson
Imperial College Healthcare NHS Trust, London, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-03) Omics Approaches to Pathogenic Interrogation of NeuroHIV
2:30 PM2:30 PM
606 - Single-Nucleus Multiomics Reveals Dysfunction in Multiple Glial Cell Types in Brain Tissue of PWH
Kriti Agrawal
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
607 - CSF Memory B Cells Exhibit Distinct Molecular Footprints in Treated PWH
Paraskevas Filippidis
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
608 - T-Cell Receptor Repertoire and Cognitive Performance in People With HIV
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
609 - A Transcriptional Signature of Induced Neurons Differentiates PWH on cART From People Without HIV
Teresa H. Evering
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
610 - Cerebrospinal Fluid Proteomic Patterns Vary With Neurobehavioral Characteristics
Patricia K. Riggs
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
611 - DNA Methylation Clocks Are Altered in Persons With Undetectable HIV and Correlate With Brain Aging
Kalen J. Petersen
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
612 - Epigenetic Age Advancement Predicts Cognitive Performance in Older People With HIV
Carrie Johnston
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
613 - Epigenetic Modifications Predictive of Cognitive Frailty in Cocaine-Using People Living With HIV
Marianna Baum
Florida International University, Miami, FL, USA
2:30 PM2:30 PM
614 - Differential Effects of CB2 Agonism on HIV Replication and Inflammatory Activation in Myeloid Cells
Cagla Akay-Espinoza
University of Pennsylvania, Philadelphia, PA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-01) The Next Generation: Pharmacology of New Drugs, Formulations, and Modeling Strategies
2:30 PM2:30 PM
639 - First-in-Human Study of a Long-Acting Injectable 3 Antiretroviral Drug Combination Nanoparticle
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
640 - Preclinical Pharmacokinetic Assessment of a Long-Acting Solid Injectable for Hepatitis C Virus
Usman Arshad
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
641 - Fixed Dosing Versus Body-Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults
Yunda Huang
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
642 - Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir
Marjorie Imperial
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
643 - Modeling Accurately Predicts Efficacious Islatravir QW Dose With No Lymphocyte and CD4 Changes
Diane Longo
Merck & Co, Inc, Rahway, NJ, USA
2:30 PM2:30 PM
644 - Can “Equivalence” of a Generic Cabotegravir LA Be Inferred From a Shortened Pharmacokinetic Study?
Henry Pertinez
University of Liverpool, Liverpool, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-01) Antiviral Therapy: Simplify, Modify, and Why!
2:30 PM2:30 PM
658 - Integrase Inhibitor- Versus Protease Inhibitor-Based Therapy for People With Advanced HIV Disease
Georg M. N. Behrens
Hannover Medical School, Hannover, Germany
2:30 PM2:30 PM
659 - Safety, Tolerability, and Efficacy of a BIC/FTC/TAF Dose Reduction Strategy
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
660 - Switch of Virally Suppressed Adults ≥ 60 Years From First-Line ART to B/F/TAF: Week 96 Results
Loice Ombajo
University of Nairobi, Nairobi, Kenya
2:30 PM2:30 PM
661 - Switch to DTG/3TC vs B/F/TAF (PASO-DOBLE Study): Efficacy and Weight Changes by Predefined Subgroups
Juan Tiraboschi
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
2:30 PM2:30 PM
662 - Inflammatory Signatures Among People With HIV Initiating DTG/3TC vs BIC/F/TAF in the CoRIS Cohort
Claudio Díaz-García
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
663 - Effectiveness and Inflammatory Markers After 144 Weeks of Switch to DTG/3TC in a Randomized Trial
Evy Blomme
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
664 - Impact of ART Simplification With Dolutegravir and Lamivudine on the HIV Reservoir
Céline Fombellida-Lopez
University of Liège, Liege, Belgium
2:30 PM2:30 PM
665 - Effect of 12-Month Switch to Dual cART on T-Cell Homeostasis, Gut and Mitochondrial Damage
Valeria Bono
University of Milan, Milan, Italy
2:30 PM2:30 PM
666 - ALLIANCE OLE: Switch to B/F/TAF in People With Both HIV-1 and HBV
Anchalee Avihingsanon
HIV-NAT, Thai Red Cross AIDS and Infectious Disease Research Centre, Bangkok, Thailand
2:30 PM2:30 PM
667 - Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status
Giuseppe Lapadula
University of Milano–Bicocca, Milan, Italy
2:30 PM2:30 PM
668 - Impact of Switching From DTG/3TC to BIC/FTC/TAF on Weight, Cholesterol, and Inflammation in HIV
Laura Martín Pedraza
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
669 - 24-Month Outcomes on Second-Line Antiretroviral Therapy in South Africa: A Target Trial Emulation
Jennifer A. Brown
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
670 - Dolutegravir With Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes
Morgan Byrne
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
671 - Is It Effective to Switch Regimen in PWH With Low-Level Viremia in the Current Era?
Tommaso Clemente
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
672 - Impact of Antiretroviral Therapy (ART) Intensification on HIV-1 Virologic Markers (ACTG 5324)
Jonathan Reed
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
673 - Factors Affecting Long-Term Trends of Immunologic Markers After ART: Results From the START Trial
Giota Touloumi
National and Kapodistrian University of Athens, Athens, Greece
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-01) HIV Resistance to bNAbs, Cabotegravir, GS 1720, and Other Agents
2:30 PM2:30 PM
721 - The Genetic Barrier to Resistance to LEN Is Not Affected by Non-B Subtypes or Treatment Exposure
Niccolò Bartolini
University of Siena, Siena, Italy
2:30 PM2:30 PM
722 - Structural and Mechanistic Insights Into Cabotegravir Resistance in HIV-1 Integrase
Indrani Choudhuri
Salk Institute for Biological Sciences, La Jolla, CA, USA
2:30 PM2:30 PM
723 - The Barrier to Escape From Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates
Alex C. Stabell
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
724 - In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral InSTI in Clinical Development
Derek Hansen
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
725 - Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution
Gregory E. Edelstein
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
726 - HIV-1 Env Exhibits Distinct Conformations and Neutralization Profiles in CSF and Blood
Hillel Haim
University of Iowa, Iowa City, IA, USA
2:30 PM2:30 PM
727 - Modifying PF74 Improves Anti-HIV-1 Activity Against the Resistance-Associated Capsid Mutation N74D
William M. McFadden
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
728 - Viral Escape From Broadly Neutralizing Antibodies in Non-Subtype B Viruses
Teresa Murphy
George Washington University, Washington, DC, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-01) Hepatitis C Treatment and Outcomes
2:30 PM2:30 PM
748 - Safety and Efficacy of 8-Week Glecaprevir/Pibrentasvir for Acute HCV in People Living With HIV
Kimberly Workowski
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
749 - DAA Initiation Among People With HIV and HCV in North America: Factors Driving the Treatment Gap
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
750 - High HCV Reinfection Rates May Mask “True” Sustained Virologic Response in People Who Inject Drugs
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
751 - Increasing HCV Prevalence Among People Who Inject Drugs in India Despite Improved Treatment Uptake
Allison M. McFall
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
752 - Impact of an HCV Test and Treat Campaign on Hepatitis C Incidence in the ANRS PREVENIR PrEP Study
Geoffroy Liegeon
Université Paris Cité, Paris, France
2:30 PM2:30 PM
753 - Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure
Jesica Martín-Carmona
Hospital Universitario Virgen de Valme, Sevilla, Spain
2:30 PM2:30 PM
754 - Comorbidities Among Medicaid Enrollees With Chronic Hepatitis C, 2016-2020
Julie Dombrowski
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
755 - Cost-Effectiveness of Interventions to Reduce HCV Among People Who Inject Drugs in Haiphong, Vietnam
Adam Trickey
University of Bristol, Bristol, UK
2:30 PM2:30 PM
756 - CC-Genotype (IFNL4) in HCV/HIV Coinfection: Cellular Exhaustion but Balanced Inflammatory Profile
Sonia Arca De Lafuente
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
757 - Semaglutide Improves Steatohepatitis in People With HIV: The SLIM LIVER Study
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
2:30 PM2:30 PM
758 - Evaluation of Different Noninvasive Models in Assessing Lean MAFLD Among PLWH
Wei Xu
Shanghai Public Health Clinical Center, Shanghai, China
2:30 PM2:30 PM
759 - Effects of Semaglutide on Gut Microbiota in People With HIV: The SLIM LIVER Study
Stephanie M. Dillon
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
760 - Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV
Nadira Vadaq
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
761 - Incidence and Impact of Hepatic Steatosis in People With HIV: Insights From the NA-ACCORD Cohort
Jennifer Price
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
762 - Determinants of Steatotic Liver Disease Among People With HIV in Europe and Australia
Carlotta Riebensahm
University Hospital Bern, Bern, Switzerland
2:30 PM2:30 PM
763 - Diabetes Mellitus and Liver Disease Progression in PWH With Metabolic Dysfunction-Associated SLD
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
764 - Switching to DTG/3TC vs BIC/FTC/TAF and Steatotic Liver Disease: A Substudy of PASODOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
2:30 PM2:30 PM
765 - Liver Steatosis Progression With Integrase Inhibitors in HIV Adults in Low-/Middle-Income Countries
Marie Kerbie Plaisy
University of Bordeaux, Bordeaux, France
2:30 PM2:30 PM
766 - Lipidomics of Metabolic Dysfunction-Associated Steatotic Liver Disease Post-HCV Eradication in PWH
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-01) Liver Cancer, Lung Cancer, and NADC Pathogenesis
2:30 PM2:30 PM
786 - Lung Cancer Screening Eligibility and Uptake Among People With HIV: A Decade of Missed Opportunities
Subhashini A. Sellers
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
787 - Immune Tumor Microenvironment of HIV-Associated Lung Cancer Reveals Immunoregulatory Features
Brinda Emu
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
788 - Viral and Host Proteins Carried by Exosomes From PLWH Could Play a Role as Triggers of NADCs
Norma Rallón
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-02) Kaposi Sarcoma: Diagnosis, Treatment, Pathogenesis, and KSHV
2:30 PM2:30 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
790 - Kaposi Sarcoma in Relation to HIV Diagnosis: Which Comes First in East Africa in the Treat All Era?
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
2:30 PM2:30 PM
792 - Impact of Low-Dose Intralesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Chia-Ching Wang
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
793 - High Prevalence of Clonal Hematopoiesis Among Older People With HIV and Kaposi Sarcoma
Ramya Ramaswami
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
795 - Neuropilin-1 Is Required for KSHV Lytic Replication in Primary Effusion Lymphoma
Anna Serquina
National Cancer Institute, Bethesda, MD, USA
2:30 PM2:30 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
797 - Vascular Endothelial Growth Factor Receptor 3 (VEGFR3/FLT4) Regulates the KSHV Replication Cycle
Ameera Mungale
National Cancer Institute, Bethesda, MD, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-01) Heart Failure: Hiding in Plain Sight
2:30 PM2:30 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
2:30 PM2:30 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
816 - Long-Term Outcomes in People With HIV Who Survive a Major Adverse Cardiovascular Event
Rebecka Papaioannu Borjesson
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
817 - Epicardial Fat as a Predictor of Diastolic Dysfunction in Older People With HIV
Tanakorn Apornpong
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
818 - Heart Failure Risk and Events in People With HIV in the REPRIEVE Trial
Maya Watanabe
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
819 - Effect of the Transition to Dolutegravir on Blood Pressure in People Living With HIV in West Africa
Romain Millot
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
820 - No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for PrEP: Results From HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
821 - Low Hypertension Knowledge Among Clinicians Prescribing Antihypertensive Medications in Malawi
Risa Hoffman
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
822 - Social Determinants of Health and the Hypertension Care Cascade in a National HIV Cohort
Puja Van Epps
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
823 - Risk of Incident Hypertension With Common Antiretroviral Agent Combinations in the OPERA Cohort
Gerald Pierone Jr
Whole Family Health Center, Vero Beach, FL, USA
2:30 PM2:30 PM
854 - HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV
Grace Rozek
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
855 - APOL1 Genotype and Graft Function in South African HIV+-to-HIV+ Kidney Transplant Recipients
Robert Freercks
Nelson Mandela University, Gqeberha, South Africa
2:30 PM2:30 PM
856 - Human Antibody Repertoire and Allograft Rejection Among Kidney Transplant Recipients With HIV
Xianming Zhu
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
857 - Acute Drop in eGFR When Initiating SGLT2 Inhibitors vs Other Antihyperglycemic Medications Among PWH
Lara Haidar
University of Manitoba, Winnipeg, Canada
2:30 PM2:30 PM
858 - Associations Between Antiretroviral Therapy Use, Vitamin C Renal Leak, and Vitamin C Deficiency
Stephanie Teng
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
859 - Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF in Randomized Trials
Frank Post
King's College Hospital NHS Foundation Trust, London, UK
2:30 PM2:30 PM
860 - Racial Inequity in Initiation of Semaglutide Therapy Among People With HIV in Care Across the US
Andrew W. Hahn
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
861 - Cardiometabolic Effects of Semaglutide in People With HIV: The SLIM LIVER Study
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
2:30 PM2:30 PM
862 - Durability of Semaglutide Effects After Drug Discontinuation in HIV-Associated Lipohypertrophy
Allison Ross Eckard
Medical University of South Carolina, Charleston, SC, USA
2:30 PM2:30 PM
863 - Impact of Antidiabetic Medications on Weight Change Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
2:30 PM2:30 PM
864 - Liraglutide for Obesity in HIV (LIROH): A Single-Arm, Open-Label Clinical Trial in South Africa
Jennifer Manne-Goehler
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
865 - The Projected Impact of Post-ART BMI Maintenance on Diabetes Risk: A Modeling Study
Keri N. Althoff
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
866 - ART Exposure and Accelerated Aging in PLHIV: Insights From Proteomic and Methylation Clocks
Nadira Vadaq
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
867 - Epigenetic Age Acceleration and CD4/CD8 Ratio in People With Well-Controlled HIV Infection
Alejandro de Gea Grela
Hospital La Paz Institute for Health Research, Madrid, Spain
2:30 PM2:30 PM
868 - Inflammatory Markers and Frailty, Cognitive Impairment, Clinical Outcomes, and Mortality in PWH
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
869 - Novel Biomarkers Link Inflammation, T-Cell Exhaustion, Bone Health, and Frailty in People With HIV
Michael L. Freeman
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
870 - The Association of Cytomegalovirus Serostatus on Immune Recovery Among People With HIV
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
871 - Validation of SARC-F Tool for Sarcopenia Screening in People Aging With HIV
Joselito Malca Hernandez
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
872 - Mitochondrial DNA Variation and Physical Function Among Men With and Without HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
873 - Senescence-Associated Secretory Phenotype Biomarker Profiles of Age-Related Outcomes in PWH
Mary C. Masters
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
874 - Multicomponent Exercise Associated With a Healthier Gut Microbiota Profile in Older Adults With HIV
Laura Martín Pedraza
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
875 - Muscular Markers for Early Identification of Sarcopenia and Frailty States in Older People With HIV
Eugènia Negredo
Fundació Lluita contra les Infeccions, Barcelona, Spain
2:30 PM2:30 PM
876 - Metformin for Reversal of Accelerated Biological Aging in Persons With HIV: A Pilot Clinical Trial
Cristina Marcelo
Hospital Universitario La Paz, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-01) PASC: Natural History and Classification Systems
2:30 PM2:30 PM
917 - Higher Mortality Following SARS-CoV-2 Infection in Rural Dwellers Persists 2 Years After Infection
Jerrod Anzalone
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
918 - HIV Infection and Long COVID: A RECOVER Program, EHR-Based Cohort Study
Kellie L. Hawkins
Public Health Institute at Denver Health, Denver, CO, USA
2:30 PM2:30 PM
919 - Putting the PASC Score to the Test: Clinical vs Statistical Accuracy in Long COVID
Alba M. Azola
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
920 - Parametric Survival Analysis of Long COVID: A Cohort Study on the Time to Symptom Resolution
Warren Malambo
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
921 - Assessing the Burden of Long COVID in Persons With HIV Using the RECOVER Scoring System
Kamaria Dansby
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
922 - Long COVID Is a Multisystem Disorder: Assessment of the National Academies Definition
Jason D. Goldman
Swedish Medical Center, Seattle, WA, USA
2:30 PM2:30 PM
923 - Completeness of COVID-19 Outcomes Among People With HIV Receiving Care in New York City in 2020
David B. Hanna
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
924 - COVID-19 Symptoms, Vaccination, and Long COVID Between Cancer Survivors and the US General Population
Jincong Q. Freeman
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
925 - A Population-Based Study of Functional Disability, COVID-19 Symptoms, and Long COVID Among US Adults
Jincong Q. Freeman
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
926 - Cognitive Trajectories 1 Year Before and After COVID-19 in an Early-Treated HIV Cohort
Ferron Ocampo
University of Toronto, Toronto, Canada
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-01) ART-Related and Social Determinants of TB Transmission and Treatment Outcomes
2:30 PM2:30 PM
948 - Modelling the Contribution of Incarceration to TB Transmission in Ukraine
Jack Stone
University of Bristol, Bristol, UK
2:30 PM2:30 PM
949 - Mental and Physical Health of People With TB in Southern Africa at the Start of Treatment and Beyond
Guy K. Muula
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
2:30 PM2:30 PM
950 - HIV and Tuberculosis Stigma Affecting Individuals With Pulmonary Tuberculosis in East Africa
Kirsten K. Prabhudas-Strycker
Indiana University, Indianapolis, IN, USA
2:30 PM2:30 PM
951 - Neuropsychiatric Outcomes in Adults With HIV and TB on Twice-Daily BIC/FTC/TAF With Rifampicin
Gillian L. Dorse
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
952 - High Incident TB Among Individuals Switched to Dolutegravir or Protease Inhibitor Based 2nd Line ART
Claudia Danielle Minkoulou Engamba
University Teaching Hospital, Lusaka, Zambia
2:30 PM2:30 PM
953 - Unmasking and Tracking Tuberculosis Risk During HIV Acquisition and Antiretroviral Therapy
Fatoumatta Darboe
University of California San Francisco, San Francisco, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-01) Long-Acting Antiretrovirals for Pregnant and Breastfeeding Women
2:30 PM2:30 PM
1014 - LA-ART for Breastfeeding Women With HIV in Zimbabwe: Clinical Impact and Cost-Effectiveness
Sujata Tewari
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1015 - Long-Acting Cabotegravir/Rilpivirine in Pregnancy
William R. Short
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1016 - Modeling Tail-Phase PK From Early Pregnancy to Postpartum and Fetal Exposure to Long-Acting CAB-RPV
Shakir Atoyebi
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
1017 - A Long-Acting Dolutegravir Formulation Improves Drug Safety Profile During Pregnancy
Emma G. Foster
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
1018 - Population PK and CYP3A Inhibition Capacity of Ritonavir in Pregnancy: A Model-Based Meta-Analysis
Safa Algharbi
University of California San Diego, La Jolla, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-02) Complications in Maternal HIV
2:30 PM2:30 PM
984 - Patterns of Adiposity and Gestational Weight Gain in Pregnant South African Women Living With HIV
Mustafa Shuaib
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
985 - Genome-Wide Association With Postpartum Weight Change in Mothers on DTG or EFV in DolPHIN-2
Rebecca Jensen
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
986 - Depression, Sleep, and Anxiety Among Pregnant and Postpartum Women Using Dolutegravir and Efavirenz
Danni Wu
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
987 - Sleep Patterns in South African Pregnant Women Living With HIV on Dolutegravir: A Prospective Study
Hayli Geffen
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
988 - Prior Pregnancy Affects Aging-Related Non-AIDS Comorbidity Burden in US Women With and Without HIV
Lauren F. Collins
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
989 - Characteristics and Outcomes of Pregnant Women With HIV Undergoing Tuberculosis Screening in Uganda
Christina Yoon
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
990 - Incidence of Tuberculosis in South African Women Living With HIV During Pregnancy and Postpartum
Jasantha Odayar
University of Cape Town, Cape Town, South Africa
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-01) Health and Outcomes of Children Exposed to HIV/ART in Utero
2:30 PM2:30 PM
1019 - Neurodevelopmental Disorders in French HIV-/ARV-Exposed Uninfected Children: A National Cohort Study
Mathis Collier
Cochin Hospital, Paris, France
2:30 PM2:30 PM
1020 - Prenatal PrEP Exposure and Language Development Among Children at 5 Years
Lauren A. Gomez
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1025 - Transcriptome Perturbations in Peripheral Blood Cells of HIV-Exposed Uninfected Infants
Li Yin
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
2:30 PM2:30 PM
1026 - Comparing Telomere Length Between Children Who Were and Were Not Exposed to HIV in Kenya
Jillian Neary
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1027 - HIV Exposure Affects Gut Virome Richness but Not Diversity Among Kenyan Infants
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1028 - HIV Exposure Does Not Affect Cytomegalovirus Acquisition Risk in a Setting of Optimized Maternal ART
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1029 - Rapid Waning in Hepatitis B Virus Vaccine Immunity Among Children HIV-Exposed Uninfected in Botswana
Lynette Bhebhe
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
1090 - Understanding Mpox and HIV Coinfection: Insights From a Major Cohort Study in Brazil
Matheus Oliveira Bastos
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1092 - Mpox Reinfections in California, May 2022 to August 2024
Jessica Watson
California Department of Public Health, Richmond, CA, USA
2:30 PM2:30 PM
1093 - Sexual Behaviors Among GBMSM Infected With Mpox in California (May 2022 -July 2024)
Kayla Saadeh
California Department of Public Health, Richmond, CA, USA
2:30 PM2:30 PM
1094 - Long-Term Sequelae of Mpox: A Cohort Study in 2 Tertiary Centers
Rene Bulnes
UT Southwestern, Dallas, TX, USA
2:30 PM2:30 PM
1095 - Mpox Viral Load and Illness Severity in MSM Living With and Without HIV by Vaccine Status
Guido Schäfer
ICH Study Center, Hamburg, Germany
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-03) The Intersection of HIV With COVID-19
2:30 PM2:30 PM
1096 - Impact of COVID-19 Healthcare Disruptions on ART Initiation and Viral Suppression: US, 2018-2021
Sarita Shah
Rollins School of Public Health, Atlanta, GA, USA
2:30 PM2:30 PM
1097 - Disparities in COVID-19 Therapeutics Access Among People With and Without HIV: An N3C Analysis
Emmanuel Nazaire Essam Nkodo
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
1098 - Impact of COVID-19 Pandemic on the Newly Diagnosed PWH: Data From 2 Clinical Centres in Italy
Andrea Carbone
Universita Cattolica del Sacro Cuore, Milan, Italy
2:30 PM2:30 PM
1099 - Impact of COVID-19 Pandemic in Deaths of PLWH From ART Program of a Peruvian Hospital
Jorge Tello Arana
Universidad Científica del Sur, Lima, Peru
2:30 PM2:30 PM
1100 - Differential Impact of Social Determinants of Health by Sex in HIV for COVID-19 Hospitalizations
Rena C. Patel
University of Alabama, Tuscaloosa, AL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-04) Criminal Justice, Mental Health, and Syndemics Intersect With HIV
2:30 PM2:30 PM
1101 - A Syndemic View of Criminal Justice: Jail’s Impact on HIV, Syphilis, and Overdose in Washington 2023
Steven J. Erly
Washington State Department of Health, Olympia, WA, USA
2:30 PM2:30 PM
1102 - HIV Acquisition After Prison Release in Washington State and Implications for Prevention Efforts
Danika A. Troupe
Washington State Department of Health, Olympia, WA, USA
2:30 PM2:30 PM
1103 - Exploring Depression and Interventions Among PLHIV: Insights From the African Cohort Study
Gabriel Saemisch
United States Agency for International Development, Washington, DC, USA
2:30 PM2:30 PM
1105 - HIV Diagnosis Following Discharge From Psychiatric Hospitalization: A Claims-Based, Real-World Study
Samuel Bunting
University of Chicago Medical Center, Chicago, IL, USA
2:30 PM2:30 PM
1106 - Housing Status and HIV Outcomes Among Reproductive-Age Women Living With HIV in the Southern US
Shreya Ganguly
Emory University, Atlanta, GA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-05) Epidemiology of HIV in Transgender and Nonbinary Persons
2:30 PM2:30 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
2:30 PM2:30 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-01) Self, Couple, and Mobile Testing
2:30 PM2:30 PM
1177 - Expanding HIV Self-Test Reach: Comparative Outcomes Across Facility, Community, and Online Channels
Thi Thi Win
Community Partners International, Yangon, Myanmar
2:30 PM2:30 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis, and Treatment, 3/2023 - 5/2024
Allison Lale
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1180 - Engaging Male Partners of HIV-Negative Pregnant Women in HIV Testing Using Oral HIV Self-Test
Maganizo B. Chagomerana
University of North Carolina Project–Malawi, Lilongwe, Malawi
2:30 PM2:30 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
2:30 PM2:30 PM
1182 - Evaluating the Effectiveness and Population Impact of Status-Neutral HIV Screening in AZ
Lazaro Ruiz
University of Arizona, Tucson, AZ, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-01) Choice and Options as Prevention Tools
2:30 PM2:30 PM
1200 - Persistence of Oral PrEP Use in the United States, 2017-2023
Ya-Lin A. Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1201 - HIV Nonoccupational Post-Exposure Prophylaxis Use Among Transgender Women: 7 Cities, 2019-2020
Thomas G. Buchanan
Oak Ridge Institute for Science and Education, Atlanta, GA, USA
2:30 PM2:30 PM
1202 - Evaluating Pharmacy-Based PrEP Delivery for Sex Workers in Zimbabwe: Pilot Quasi-Experimental Study
Oppah Kuguyo
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
2:30 PM2:30 PM
1203 - Patterns of Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents
Laio Magno Santos de Sousa
Federal University of Bahia, Salvador, Brazil
2:30 PM2:30 PM
1204 - Support for Over-the-Counter PrEP Among Transgender Women and Transfeminine Nonbinary People
Lauren R. Violette
Harvard Medical School, Boston, MA, USA
2:30 PM2:30 PM
1205 - Male Circumcision, HIV, and Hepatitis B: Results From the Tanzania HIV Impact Survey
Alexander Kailembo
2:30 PM2:30 PM
1206 - Online and Less Frequent Monitoring of Oral HIV PrEP Use Are Noninferior to Standard of Care
Marije L. Groot Bruinderink
Public Health Service Amsterdam, Amsterdam, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-02) Epidemic Prevention Strategies
2:30 PM2:30 PM
1207 - Spillover Infections Drive Transmission in HIV Prevention Trials: BCPP/Ya Tsie Study
Sikhulile Moyo
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
1208 - Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England
Peter Vickerman
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1209 - Estimating Population Immunity and Impact of COVID-19 Vaccination in Washington and Oregon
Mia Moore
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1210 - Epidemiology and Predictors of COVID-19 Vaccine Uptake Among People With HIV in the US, 2020-23
Adrienne E. Shapiro
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1239 - Syphilis Screening in Hospitalized People With HIV: A Key Strategy to Tackle HIV and STI Epidemics
Mayara Secco Torres da Silva
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1240 - Differences in Presentation and Outcome of Subsequent Episodes of Syphilis in People Living With HIV
Jose L. Casado
Hospital Ramón y Cajal, Madrid, Spain
2:30 PM2:30 PM
1241 - Unravelling the Pathogenesis and Outcome of Serofast Status in People Living With HIV
Jose L. Casado
Hospital Ramón y Cajal, Madrid, Spain
2:30 PM2:30 PM
1242 - No CSF Study in Neuro Asymptomatic Syphilis in People With HIV: Clinical and Serologic Outcomes
María L. Otth
University of Chile, Santiago, Chile
2:30 PM2:30 PM
1243 - Describing the Cascade of Care for Neurosyphilis in People Living With HIV: Finding the Gaps
Shaul A. Navarro-Lara
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
1244 - Syphilis Among Women of Reproductive Age With or Without HIV in the Southern US
Maria L. Alcaide
University of Miami Miller, Miami, FL, USA
2:30 PM2:30 PM
1245 - Epidemic of Treponema pallidum Strains in Japan and Biomarkers for Molecular Epidemiology
Eisuke Adachi
University of Tokyo Institute of Medical Science, Tokyo, Japan
2:30 PM2:30 PM
1246 - Temporal Changes in Syphilis Prevalence and Population Characteristics Among MSM in India
Mihili Gunaratne
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1247 - Has Rapid Scale-Up of Dual HIV/Syphilis Testing in Antenatal Care Improved Syphilis Testing Coverage?
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
2:30 PM2:30 PM
1248 - Monitoring the Success of Public Health Efforts to Reduce Congenital Syphilis, King County, WA
Tim W. Menza
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1249 - Risk Factors for Incomplete Treatment for Syphilis in Pregnant Oral PrEP Users in South Africa
Kalisha Bheemraj
University of Cape Town, Cape Town, South Africa
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-02) Advances in Sexual and Reproductive Health in HIV
2:30 PM2:30 PM
1250 - HIV Status and Other Factors Associated With Infection Complicating Abortion in Botswana
Bogadi Loabile
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1251 - Irregular Menstruation Among Women Is Associated With COVID-19 Infection, but Not Vaccination
Emily M. Cherenack
University of Miami, Miami, FL, USA
2:30 PM2:30 PM
1252 - Incidence of Intended & Unintended Pregnancies Among Women With HIV on ART: 5-Year Cohort in Abidjan
Prescilia Visi Vumba
University of Bordeaux, Bordeaux, France
2:30 PM2:30 PM
1253 - Unmet Need for Family Planning Underestimated Among Women Living With HIV in Kenya
Alison Drake
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1254 - Effect of Antiretroviral Regimen on Contraceptive Failure Among Women Using Injectable Contraception
Karen Diepstra
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1255 - PrEP Eligible but Missed: Preliminary Evidence Unlocking the Potential of Family Planning Services
Brenice Duroseau
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
1256 - Multipurpose Vaginal Rings: Preferences From a National Discrete Choice Survey With US Women
Ann Gottert
Population Council, New York, NY, USA
2:30 PM2:30 PM
1257 - Oral PrEP and Sexual Health Screening Services Uptake Among Diverse Gender Identities in India
Rifa T. Khan
YR Gaitonde Center for AIDS Research and Education, Chennai, India
2:30 PM2:30 PM
1258 - STAR: A Prospective Cohort of Women of Reproductive Age With and Without HIV in the Southern US
Elizabeth F. Topper
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
1259 - Substance Use and Treatment Among Reproductive-Age Women With/Without HIV in the Southern US
Ayako W. Fujita
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1260 - Physical, Psychosocial, and Sexual Health in Adults Aged 50+ With and Without HIV in Denmark
Ditte Scofield
Hvidovre Hospital, Hvidovre, Denmark
2:30 PM2:30 PM
1289 - Testing Healthcare System Resilience Using Microsimulation Modeling Under Various Shocking Scenarios
Viviane D. Lima
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1290 - Estimated Benefits of Providing On-Demand PrEP Options for Women in Cape Town: A Modeling Study
Dobromir Dimitrov
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1291 - Model-Projected Costs Associated With Increasing Numbers of Medicare Beneficiaries With HIV Aged 65+
Emily Hyle
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1292 - Modeling the Impact of Increased PrEP Use on Sexually Acquired HIV Incidence in the United States
Tamar Tchelidze
Roche Diagnostics, Somerville, NJ, USA
2:30 PM2:30 PM
1293 - Dynamic Choice HIV Prevention With Cabotegravir (CAB-LA): A Model-Based Cost-Effectiveness Analysis
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1294 - Cost-Effectiveness of PrEP and Medications for Opioid Use Disorder in People Who Inject Drugs
John Chiosi
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1295 - Ending the HIV Epidemic Among Men Who Have Sex With Men in the United States: A Modeling Analysis
Kenneth A. Freedberg
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1296 - Optimizing Investment in HIV Testing Services, ART, and PrEP to Reduce HIV Incidence in South Africa
Caitlin Dugdale
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1297 - Impact of Rapid Long-Acting PrEP Scale-Up Among MSM: Closing the Unmet Needs and Towards Ending HIV
Haoyi Wang
Maastricht University, Maastricht, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-02) Cardiovascular Risk, Weight
2:30 PM2:30 PM
1298 - Trajectories of Weight Changes After GLP-1 Receptor Agonists Initiation Among Patients With HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1299 - Cardiometabolic Risks and the Transition to InSTIs in Aging PLWH in South Africa
Julia K. Rohr
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
1300 - Addressing Alcohol Use and Depression as a Strategy to Reduce HIV in KwaZulu-Natal, South Africa
Mellesia Jeetoo
New York University Langone Medical Center, New York, NY, USA
2:30 PM2:30 PM
1301 - Impact of SEARCH Person-Centered Care/Prevention on Clinical Outcomes by Alcohol Use in East Africa
James Ayieko
Kenya Medical Research Institute, Kilifi, Kenya
2:30 PM2:30 PM
1302 - Depression and Suicide Risk Among Sexual and Gender Minorities: Insights From the ImPrEP CAB Brasil
David Richer Araujo Coelho
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1303 - Effects of a Cash Transfer Intervention on Internalized HIV Stigma Among ART Initiates in Tanzania
Emmanuel Katabaro
Health for a Prosperous Nation, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
1304 - Low-Barrier HIV Care Outcomes in the Context of Homelessness, Substance Use, and Mental Illness
Julie Dombrowski
University of Washington, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-03) Persistence and Evolution of SARS-CoV-2
2:30 PM2:30 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
2:30 PM2:30 PM
310 - Emergence of Divergent Spike Haplotypes in Individuals With Persistent SARS-CoV-2 Infections
Luke Blagdon Snell
King's College London, London, UK
2:30 PM2:30 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
2:30 PM2:30 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
313 - SARS-CoV-2 Intrahost Evolution During Acute Infection in People With COVID-19
Agostino Riva
Luigi Sacco University Hospital, Milan, Italy
2:30 PM2:30 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-04) Nuclear Events in HIV-1 Replication and the Control of Gene Expression and Viral Production
2:30 PM2:30 PM
315 - CPSF6 Regulates Cellular Permissivity to HIV-1 Infection Through Alternative Polyadenylation
Daphne Cornish
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
316 - A Targeted CRISPR Screen Identifies ETS1 as a Regulator of HIV Latency
David M. Margolis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
317 - HIV-1 Membraneless Organelles Orchestrate Viral Genome Maturation and Immune Evasion
Francesca Di Nunzio
Institut Pasteur, Paris, France
2:30 PM2:30 PM
318 - Design of SHIVs Encoding HIV-1 Recombinase Brec1 Recognition Site for Nonhuman Primate Cure Studies
Ryan Krause
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
319 - Convergence of NF-κB Pathways Increases HIV-1C Transcriptional Fitness
Hrimkar B. Buch
Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
2:30 PM2:30 PM
320 - Fatty Acid Synthesis Controls Both Cellular Susceptibility to HIV and New Particle Production
Joshua A. Acklin
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
321 - Direct Sequencing of Full-Length HIV-1 RNA Reveals the Functional Significance of Site-Specific m6As
Sanggu Kim
Ohio State University, Columbus, OH, USA
2:30 PM2:30 PM
322 - Functional Study of N6-Methyladenosine (m6A) Machinery in HIV Infection of Primary CD4+ T Cells
Lacy M. Simons
Northwestern University, Chicago, IL, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-03) Effect of HIV on the Immune System
2:30 PM2:30 PM
359 - Single-Cell Multi-Omics Uncovers the Immune Heterogeneity in HIV-Infected INRs
Xiaosheng Liu
Tsinghua University, Beijing, China
2:30 PM2:30 PM
360 - Variability in Immunometabolic Signatures Among People w/ HIV Defines Immune Outcomes and Progression
Simon Gressens
French National Institute of Health and Medical Research (Inserm), Paris, France
2:30 PM2:30 PM
361 - Effect of Delayed ART Initiation on Anti-CD4 Autoantibodies in ART-Naive People With HIV
Shweta Mistry
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
362 - CD4-Binding Site Abs Modify the Negative Association Between Cluster A Abs and CD4 Count in PWH
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
2:30 PM2:30 PM
363 - Prevalence and Activity of Anti-Interferon Autoantibodies in People Living With HIV
Olivia Payne
University College London, London, UK
2:30 PM2:30 PM
364 - Secreted ORF8 Reprograms Macrophages to Enhance Lung Epithelial Cell Infection by SARS-CoV-2
Yusuke Matsui
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
365 - Occult CMV Replication Is a Persistent Driver of Effector T-Cell Expansion in PWH on Effective ART
Nived Collercandy
Toulouse University Hospital, Toulouse, France
2:30 PM2:30 PM
366 - IL-10/PD-1 Blockade Leads to Enhanced BA Synthesis and Type I IFN Production
Khader Ghneim
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
367 - Activated Platelets Render Functionally Deficient Natural Killer Cells in People Living With HIV
Brita Ostermeier
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
368 - Elevated Lymph Node Metabolic Activity During Long-Term Antiretroviral Therapy
Chuen-Yen Lau
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
369 - Immunometabolism of Innate Lymphocytes in People Living With HIV-1 Versus HIV-2
Maryam Khan
Queen Mary University of London, London, UK
2:30 PM2:30 PM
370 - Non-HIV Chronic/Latent Viruses and Immune Aging: Sex Effects Comparable to Those of HIV and CMV
Renying (Loulou) Cai
University of British Columbia, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-04) Nonimmune Effects of HIV Infection
2:30 PM2:30 PM
371 - Sex Differences in Cytokine Responses and Genetic Regulation Thereof in People Living With HIV
Suzanne D. E. Ruijten
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
372 - Dynamic Changes in the Peripheral Blood Monocytes Following Long-Acting Injectable CAB/RPV in PLWH
Maria Antonella Zingaropoli
Sapienza University of Rome, Rome, Italy
2:30 PM2:30 PM
373 - Changes in Serum Level of Cell-Free Mitochondrial DNA Fragments in Acute and Chronic HIV Infection
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
374 - The Molecular Cargo of Exosomes Is Able to Discriminate Between PLWH With or Without NADCs
Norma Rallón
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
375 - HIV-Encoded Proteins Induce Pulmonary Arterial Hypertension via Increases in Podocan-Like Protein 1
Laszlo Kovacs
Augusta University, Augusta, GA, USA
2:30 PM2:30 PM
376 - Compromised Intestinal Barrier Resilience to Cytokine Disruption Causing Leakage in People With HIV
Mohamed Abdel-Mohsen
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
377 - Acute HIV-1 Infection Triggers Myelopoiesis Suppression and Pancytopenia Through IFN-γ Signaling
Shuai Gao
Washington University, St Louis, MO, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-03) Using Vaccines for Therapy
2:30 PM2:30 PM
425 - Age Inversely Correlates With T-Cell Response to MVA.HIVconsvX Vaccination in PWH on ART
Nilu Goonetilleke
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
426 - Unadjuvanted CD40.HIVRI.ENV Vaccine Late Boost Induces Durable Immune Responses: ANRS/VRI06 Trial
Yves Levy
Vaccine Research Institute, Créteil, France
2:30 PM2:30 PM
427 - Augmenting HIV-Specific CAR-T Cell Functionality by Treatment With Novel Cytokine-Based Scaffold
Sara Lamcaj
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
428 - ChAdOx1.HIVconsvX and MVA.HIVconsvX Vaccination Is Safe and Immunogenic in PWH on ART: The CM Study
Cynthia L. Gay
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
429 - A Novel Immunotherapeutic Platform for Amplifying HIV, CMV, or SARS-CoV-2-Specific T-Cell Responses
Marta Santos Bravo
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
430 - Therapeutic HIV Vaccine ± TLR4 Adjuvant Impact on Monocyte Subsets in Early-Treated Youths With HIV
Alessia Neri
University of Rome Tor Vergata, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-04) Preventive Vaccine Strategies
2:30 PM2:30 PM
431 - Enhanced HIV Antibody Precursor Development With Early-Life Germline Targeting Immunization
Yasmine Issah
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
432 - A VLP-Forming mRNA Vaccine Protects Macaques From Heterologous SHIV Infection
Mamta Singh
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
433 - Cytoplasmic Tail Engineering of Stabilized mRNA Env Immunogens Enhances Neutralizing Response
Edward Kreider
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
434 - Improved Immunogenicity of a VLP-Forming mRNA Vaccine for HIV-1
Mamta Singh
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
435 - An AI-Redesigned Contemporary HIV-1 Env Consensus Antigen Is More Immunogenic Than a Native Sequence
Eric Lewitus
United States Military HIV Research Program
2:30 PM2:30 PM
436 - Incidence and Predictors of STIs and Effect on Immune Activation in the HVTN 705/HPX2008 Trial
Mitch M. Matoga
University of North Carolina Project–Malawi, Lilongwe, Malawi
2:30 PM2:30 PM
437 - 3-Step Heterologous Immunization Schema Results in Development of Cross-Neutralizing VRC01-Class Abs
Parul Agrawal
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
438 - Evolution and Durability of Mpox-Specific Antibodies Among Vaccinated or Infected Individuals
Wang-Da Liu
National Taiwan University Hospital, Taipei, Taiwan
2:30 PM2:30 PM
439 - Antibody Responses Decline Post-MVA Vaccination but Persist Following Mpox Infection
Joanne Byrne
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
440 - Immune Response to Mpox in PWH and PrEP Users After Infection, but Not in Response to Vaccination
Olivia de la Calle-Jiménez
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
441 - MVA Vaccine Produces Potent Serologic and Immunologic Response to Mpox in People With HIV
Maryam Khan
Queen Mary University of London, London, UK
2:30 PM2:30 PM
442 - Mpox-Specific T-Cell Responses in Recovered and Vaccinated Individuals
Aideen S. Teeling
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
443 - Immune Response After 2 Years From MVA-BN Vaccination by HIV Infection and CD4 Cell Count
Valentina Mazzotta
National Institute for Infectious Diseases L Spallanzani, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-06) Natural-Born Killers: NK Cells
2:30 PM2:30 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
2:30 PM2:30 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-07) New Concepts in Immunotherapy
2:30 PM2:30 PM
449 - Combination of eCD4-IgG1 Delivered by AAV9 and AZD5582 in SIV-Infected, ART-Suppressed Infant RM
Jairo A. Fonseca
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
450 - Using Nanobodies as an Intracellular Biological to Block HIV-1 Through Innate Antiviral Mechanisms
Florence M. Stel
Amsterdam University Medical Centers, Amsterdam, Netherlands
2:30 PM2:30 PM
451 - Viral Genetic Traits of Durable Control in Dual Immunotherapy-Treated SHIV-Infected Rhesus Macaques
Manukumar Honnayakanahalli Marichannegowda
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
453 - HIV-Induced Sialoglycans on Infected Cells Promote Immune Evasion From Myeloid Cell-Mediated Killing
Shalini Singh
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
454 - Sialidase Conjugation Enhances the Anti-HIV Activity of the 10-1074 Antibody in Humanized Mice
S. M. Shamsul Islam
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
455 - Cannabidiol Has Sex-Dependent Anti-Inflammatory Effects in Long-Term Suppressed HIV-1 Adults
Clémence Couton
Centre de Biophysique Moléculaire, Orléans, France
2:30 PM2:30 PM
456 - IFI16 Controls PVR and Gal-9 Expression and Its Targeting Improves Immunotherapy Against HIV-1
Enrique Martin Gayo
Universidad Autónoma de Madrid, Madrid, Spain
2:30 PM2:30 PM
457 - Investigating the Effects of ADCC and CAR NK/T Cells on HIV-1 Cell-to-Cell Transmission
Tanvi Mathur
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
458 - Natural Killer Cells Preferentially Kill HIV-Infected CD4 T Cells Using Death Receptors
Lesley R. de Armas
University of Miami, Miami, FL, USA
2:30 PM2:30 PM
459 - Tri-Specific Killer Engagers in Macaques Potently Induce NK Cell Responses in Blood and Tissues
Julien A. Clain
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
460 - Extracellular Acyl-CoA-Binding Protein Prevents Autophagy and T-Cell Function in People With HIV
Stephane Isnard
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
461 - Gut Microbiome Dynamics and Immune Responses in People With HIV Receiving N-803
Ashma Chakrawarti
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
462 - Heterogeneity of PD-1 Expression in PLHIV and Its Relationship With Host and Viral-Related Factors
Adriana Navas
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
463 - IL-10 Treatment Enhances CD8 T-Cell Activation and Cytotoxicity in SIV Infection: The Yin and Yang
Nongthombam Boby
Texas Biomedical Research Institute, San Antonio, TX, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-03) HIV Reservoirs in Cells and Tissues
2:30 PM2:30 PM
514 - CD4+ T Cells Harboring Inducible HIV Genomes Display a Senescent-Like Phenotype
Remi Fromentin
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
515 - Macrophage-Tropic TF SHIV D-Infected NHP Model of Reservoir Persistence and Decay on ART
Ryan Krause
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
516 - Anatomical Sites in FIND 2.0 Decedents Harbor Compartmentalized, Transcriptionally Intact HIV-1 Env
Melanie Moodie
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
517 - Biomarkers of HIV Latency in Tissues From People With HIV
Nadejda Beliakova-Bethell
Veterans Affairs San Diego Healthcare System, San Diego, CA, USA
2:30 PM2:30 PM
518 - HIV Can Persist in Multiple Subsets of SARS-CoV-2-Specific CD4+ T Cells in Tissues During ART
Xiaoyu Luo
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
519 - Women With HIV Have a Lower Frequency of Monocyte Reservoir Reactivation Than Men With HIV
Rebecca Veenhuis
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
520 - Well-Seeded Reservoirs in Gut Are Associated With Tertiary Lymphoid Structures With Activated ISR
Ramon Lorenzo-Redondo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
521 - HIV-1 Clade C Reservoir Traits in Blood and Lymph Node Tissue in Acute and Chronic Treated Infection
Kavidha Reddy
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
522 - HIV Burden Is Associated With Specific Bacteriome Profiles Relative to Specific Gut Segments
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
523 - Viral and Microbial Environment in the Male Genital Tract of People Living With HIV
Elizabeth Hastie
University of California San Diego, La Jolla, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-06) Immune Pressure on HIV Reservoirs
2:30 PM2:30 PM
539 - Resistance of Inducible, Infectious HIV-1 to Autologous Neutralizing IgG After Long-Term ART
Natalie F. McMyn
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
540 - High Networked CD8+ T-Cell Epitopes Exhibit Markedly Reduced Mutability in the Latent HIV Reservoir
Fernando Senjobe
Harvard University, Cambridge, MA, USA
2:30 PM2:30 PM
541 - Autologous IgGs Mediate Log Reductions in HIV Infection in a PTC, Contributing to ART-Free Remission
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
542 - Afucosylation of Broadly Neutralising Antibodies to Eliminate HIV+ CD4+ T Cells and Macrophages
Morgane Brunton-O'Sullivan
Burnet Institute, Melbourne, Australia
2:30 PM2:30 PM
543 - Immune Dynamics During Reproductive Aging and Substance Use in Women With HIV
Konstantin Leskov
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
544 - Latency Reversal Induced by CD4+ T-Cell Recognition of HIV-1 Alternate Reading Frame Proteins
Joel Sop
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
545 - Reduced Metabolic Flux Protects HIV-Expressing CD4+ T-Cells From CTL-Mediated Elimination
Alberto Herrera
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
546 - Engineering Natural Killer Cells With NKp30-Based Chimeric Antigen Receptors (CARs) to Target HIV
Ruoxi Pi
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
547 - Preclinical Evaluation of Effector Function-Enhanced Variants of N6 bNAb
David Wensel
ViiV Healthcare, Branford, CT, USA
2:30 PM2:30 PM
548 - Long-Term ART Enhances Cytotoxic Response and Reduces the Reactivation Capacity of HIV-1 Reservoir
Alicia Simón Rueda
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
549 - Plasma Cytokines and NF-κB Signaling Drive Transcriptomic Diversity in CD4+ T Cells From PWH on ART
Alton Barbehenn
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
550 - TLRS Ligands and IL-15 Induce Trained Immunity in CD4 Cells and Limit HIV Infection and Persistence
Muhammad Bilal Latif
Emory University, Atlanta, GA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-07) HIV Clones in the Reservoir
2:30 PM2:30 PM
551 - Phenotypic and Functional Heterogeneity Contribute to the Persistence of the Clonal CD4 Reservoir
Isabella A. T. M. Ferreira
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
552 - Latent HIV Clonal Dynamics: Integration Sites and Their Role in Maintenance of Latency In Vivo
Virender K. Pal
The Rockefeller University, New York, NY, USA
2:30 PM2:30 PM
553 - Targeting of HIV-Infected Clones by Cognate Peptide Stimulation and Antiproliferative Drugs
Filippo Dragoni
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
554 - Sequencing of HIV-1 Proviruses in Large Infected T-Cell Clones Reveals a Predominance of Solo-LTRs
Dimiter Demirov
Leidos Biomedical Research, Inc, Frederick, MD, USA
2:30 PM2:30 PM
555 - Chromosomal Integration Site Profile of HTLV-1-Infected Cells Is Distinct From HIV-1-Infected Cells
Alex Hochroth
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
556 - Reservoir-Harboring T-Cell Clones Have a Cytotoxic Immunophenotype That May Affect HIV Inducibility
Alberto Herrera
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
557 - The Paucity of Clonal SIV Proviral Sequences During Early ART Treatment
Margaret Hallmets
Tulane National Primate Research Center, Covington, LA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-04) Addressing NeuroHIV in Lower- and Middle-Income Settings
2:30 PM2:30 PM
615 - Neuronal Injury in a Subset of PWH During Acute HIV Infection and Up to 5 Years After Immediate ART
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
616 - Plasma Microbiome Composition Among Neurobehavioral Phenotypes (NBPs) in People With HIV (PWH)
Mohammadsobhan Sheikh Andalibi
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
617 - High Anticholinergic Burden and Poor Sleep Quality in People With HIV
Maria Mazzitelli
Azienda Ospedaliera di Padova, Padua, Italy
2:30 PM2:30 PM
618 - Prevalence of Mental Disorders Among PWH in Rwanda: A Low-Cost Nurse-Led Screening Approach
Michel Gasana
Rwanda Biomedical Centre, Kigali, Rwanda
2:30 PM2:30 PM
619 - Cognitive and Sensorimotor Difficulties in Well-Controlled People With HIV Living in Uganda
Leah H. Rubin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
620 - No Impact on the CNS After Switching to Dolutegravir/Lamivudine From a 3-Drug Regimen
Linn Renborg
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
2:30 PM2:30 PM
621 - Dual Group-Based Trajectories of Brain-Derived Neurotrophic Factor and Cognition in People With HIV
Henry U. Michael
Research Institute of McGill University Health Centre, Montreal, Canada
2:30 PM2:30 PM
622 - Greater Cognitive Decline in Cognitively Unimpaired Older Thai PWH at Baseline
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-05) It's All About the Vessels: NeuroHIV and Vascular Dysfunction
2:30 PM2:30 PM
623 - Hypertension: A Major Factor in Low Verbal Fluency Among People Aged 50+ Living With HIV in Senegal
Caroline Couturier
Université de Bordeaux, Bordeaux, France
2:30 PM2:30 PM
624 - No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People With HIV
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
625 - Number and Effectiveness of Antihypertensives Are Associated With Cognitive Performance in PWH
Azin Tavasoli
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
626 - Reduced Cerebral Arterial Transit Time in Obese Females With HIV and Metabolic Syndrome
Eric Decloedt
Stellenbosch University, Cape Town, South Africa
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-02) Drug-Drug Interactions and Pharmacology Challenges With Important Coconditions
2:30 PM2:30 PM
645 - Drug Interactions Between Dolutegravir (DTG) and Escalating Doses of Rifampicin (RIF): DORIS Study
Yashna Singh
Desmond Tutu HIV Foundation, Cape Town, South Africa
2:30 PM2:30 PM
646 - TAF Achieves Adequate Intracellular Tenofovir-DP Concentrations With Rifampicin-Based TB Therapy
Rephaim Mpofu
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
647 - Pharmacokinetics of Twice-Daily TAF in Adults With HIV-Associated TB on BIC/FTC/TAF and Rifampicin
Emmanuella C. Osuala
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
648 - Estradiol Concentrations in Trans Women on BIC/FTC/TAF Compared to Those Without HIV
Alice Tseng
University Health Network, Toronto, Canada
2:30 PM2:30 PM
649 - Reduced Metformin Concentrations in Obese Women With HIV Treated With Dolutegravir
Roland van Rensburg
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
650 - Pharmacokinetics of Switching to B/F/TAF in PWH Post-Renal Transplant: BIK Switch Study
Corwin Coppinger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-02) Long-Acting Therapy: What Observational Data Tell Us About the "Real World"
2:30 PM2:30 PM
674 - Long-Term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort
Michael Sension
CAN Community Health, Fort Lauderdale, FL, USA
2:30 PM2:30 PM
675 - Outcomes on Cabotegravir + Rilpivirine in Suppressed People With HIV (PWH) in TRIO Health US Cohort
Paul Sax
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
676 - Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort
Jessica A. Altamirano
CAN Community Health, Fort Lauderdale, FL, USA
2:30 PM2:30 PM
677 - Long-Acting Cabotegravir and Rilpivirine in Older People With HIV in the GEPPO Cohort
Andrea Calcagno
University of Turin, Turin, Italy
2:30 PM2:30 PM
678 - Long-Acting Cabotegravir/Rilpivirine in Real Life: Sex-Based Characteristics, PROs, and Effectiveness
Ana González-Cordón
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
679 - Interim Week 48 Results in Young South Africans on Long-Acting Injectable ART: The AFINAty Study
Lauren Jennings
Desmond Tutu HIV Foundation, Cape Town, South Africa
2:30 PM2:30 PM
680 - Impact of Oral Lead-In on PK and Virologic Outcomes in People With HIV Transitioning to CAB+RPV LA
Marta Fernández-González
Hospital General Universitario de Elche, Elche, Spain
2:30 PM2:30 PM
681 - Low-Level Viremia and Risk Factors for Failure on Long-Acting Cabotegravir/Rilpivirine (LA CAB/RPV)
Natalie Nielsen
Ohio State University, Columbus, OH, USA
2:30 PM2:30 PM
682 - Outcomes of LAI ART for People With Detectable HIV Viremia in the NYC Public Healthcare System
Anthony Gerber
Bellevue Hospital, New York, NY, USA
2:30 PM2:30 PM
683 - Why Do People With HIV Stop Long-Acting Injectable Cabotegravir/Rilpivirine and What Happens?
Katerina Christopoulos
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
684 - What Do Early Adopters of Long-Acting Injectable Cabotegravir/Rilpivirine Think About It?
Katerina Christopoulos
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
685 - Outcomes in Those Who Discontinued Injectable Cabotegravir/Rilpivirine and Resumed Oral ART
Tali Faggiano
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
686 - Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians
William R. Short
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
687 - Distance to Care Measures Predict Injection Visit No-Shows Among Cabotegravir/Rilpivirine Recipients
Nimish Patel
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
688 - First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort
Karam Mounzer
Philadelphia FIGHT, Philadelphia, PA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-04) New Agents and Novel Administration
2:30 PM2:30 PM
701 - A 24-Week Phase II Maintenance Study of TMB-365/TMB-380 Q8W in People With Suppressed HIV-1 Infection
Jacob P. Lalezari
Quest Clinical Research, San Francisco, CA, USA
2:30 PM2:30 PM
702 - A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection
Yuanyuan Qin
Chongqing Public Health Medical Center, Chongqing, China
2:30 PM2:30 PM
703 - Efficacy of Switching to Ainuovirine-Based Antiretroviral Regimen in Virologically Suppressed PWH
Hong Qin
Jiangsu Aidea Pharmaceutical Co, Ltd, Yangzhou, China
2:30 PM2:30 PM
704 - Evaluating Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube
Joshua T. Mercure
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
705 - Creating an Ultralong-Acting Dolutegravir Prodrug Homodimer
Bhoomika Gowda
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
706 - Development of a 2-Drug Long-Acting Removable Formulation for HIV Suppression
Manse Kim
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
707 - Identification and Characterization of Novel Chemical Scaffolds With Anti-HIV Activities
Ryan Jeep
Colorado State University, Fort Collins, CO, USA
2:30 PM2:30 PM
708 - A Strategy for Durable AAV-Vectored bNAb Expression in Adult Rhesus Macaques
Michael Kuipa
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
709 - Trosunilimab Safety, Pharmacokinetics, and Pharmacodynamics in People With and Without HIV-1
Franco Antonio Felizarta
Private Practice, Bakersfield, CA, USA
2:30 PM2:30 PM
710 - Preclinical Evaluation of an Ultra-Long-Acting Tenofovir Prodrug Nanosuspension
Samiksha S. Raut
University of Nebraska Medical Center, Omaha, NE, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-02) Epidemiology of HIV Drug Resistance
2:30 PM2:30 PM
729 - High Prevalence of Baseline NRTI Resistance in PWH Switched From Second-Line PI/r to B/F/TAF
Jean Bernard Marc
GHESKIO Center, Port-au-Prince, Haiti
2:30 PM2:30 PM
730 - HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024
Ron M. Kagan
Quest Diagnostics, San Clemente, CA, USA
2:30 PM2:30 PM
731 - Rilpivirine Drug-Resistant Mutations in Experienced Patients in Mexico: Impact on Long-Acting ART
Luis E. Soto-Ramirez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
732 - Despite Increasing Use of INIs to Treat HIV Infection, Resistance to This Class Remains Stable
Vincent Calvez
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
733 - Molecular Epidemiology of HIV-1 Transmitted Drug Resistance Among Subtypes Circulating in Italy
Daniele Armenia
Saint Camillus International University of Health Sciences, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-03) HBV Diagnostics and Treatment
2:30 PM2:30 PM
767 - Changes in Antiviral Treatment Eligibility With the New WHO 2024 Guidelines in Senegal
Bruce Shinga S. Wembulua
Centre Hospitalier Universitaire de Fann, Dakar, Senegal
2:30 PM2:30 PM
768 - Continuum of Hepatitis B Surface Antigen Expression Among PWID and MSM Living With HIV in India
Talia A. Loeb
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
769 - HBsAg Seroclearance in HBV-Coinfected People With HIV in the Era of Tenofovir-Containing Therapy
Chien-Ching Hung
National Taiwan General Hospital Yunlin, Yunlin, Taiwan
2:30 PM2:30 PM
770 - Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir
María del Mar Arcos-Rueda
La Paz University Hospital, Madrid, Spain
2:30 PM2:30 PM
771 - HBV Reactivation Post-Switch to HBV-Inactive ART: A Scoping Review
Kyle Ring
Queen Mary University of London, London, UK
2:30 PM2:30 PM
772 - Outcomes in HIV-Hepatitis B Coinfection Without Tenofovir-Containing Antiretroviral Therapy
Amir Mohareb
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
773 - Hepatic Flare Is Associated With HBsAg Seroclearance in HBV/HIV-1 Co-Infection
Weiyin Lin
Guangzhou Eighth People's Hospital, Guangzhou, China
2:30 PM2:30 PM
774 - Increased Detection of HBV DNA and Mutational Analysis in HBsAg-Negative Specimens at NHLS/DGM
Nondumiso A. Nkosi
Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa
2:30 PM2:30 PM
775 - HBV Seroconversion in People With HIV: Relevance of Clinical History and Viral Markers Monitoring
Marianna Menozzi
AOU Policlinico di Modena, Modena, Italy
2:30 PM2:30 PM
776 - Performance Evaluation of the Xpert Hepatitis B Molecular Test Among Pregnant Women in Uganda
Viola Kasone
Ministry of Health Uganda, Kampala, Uganda
2:30 PM2:30 PM
777 - The Impact of HIV Infection on All-Cause Mortality Among Individuals Treated for HBV in Rwanda
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-03) HIV-Related Cancer: Epidemiology, Incidence, Demographics
2:30 PM2:30 PM
798 - Trends in Common Cancer Diagnoses Among People With HIV in North America, 2006-2020
Sally B. Coburn
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
799 - Cancer Risk of People With HIV Younger Than 50 Years: Italy, 1997-2023
Camilla Muccini
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
800 - Predictors of Mortality Among Patients With Virus-Associated Cancers in a High HIV-Prevalence Region
Dorothy Mangale
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
802 - Cancer Risk Among People Who Inject Drugs With HIV in the United States, 2010-2019
Carol-Ann Swain
New York State Department of Health, Albany, NY, USA
2:30 PM2:30 PM
803 - Cancer Incidence in Women With HIV in Europe and Australia: A Combined D:A:D and Respond Analysis
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
804 - Low-Level HIV Viremia Increases Immunosuppressive Markers Elevating Cancer and CVD Risk in InSTI Era
Violeta Lara-Aguilar
Instituto de Salud Carlos III, Madrid, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-03) Antiretroviral Therapy and CVD Risk
2:30 PM2:30 PM
824 - Change in Cardiometabolic Risk Markers Following Switch to Integrase Inhibitors Differs by Sex
Cecile D. Lahiri
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
825 - Dolutegravir-Based Antiretroviral Therapy and Cardiometabolic Health Risk in Persons With HIV
Katuku Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
826 - Changes in Cardiometabolic Parameters After ART Initiated Within 1 Year of HIV Acquisition
Nikos Pantazis
National and Kapodistrian University of Athens, Athens, Greece
2:30 PM2:30 PM
827 - Potential of the Short Chain Fatty Acid Caproic Acid in Protection Against CVD in HIV Infection
Mohamed El-Far
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
877 - Statins Reduce Frailty in People With HIV
Giovanni Guaraldi
University of Modena and Reggio Emilia, Modena, Italy
2:30 PM2:30 PM
878 - Frailty and All-Cause Mortality Among People With HIV Engaged in Clinical Care in the United States
Stephanie A. Ruderman
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
879 - Clinical and Economic Benefits of Preventing Physical Frailty and Falls Among PWH in the US
Karen C. Smith
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
880 - Housing Instability and Frailty Among People With HIV Engaged in Clinical Care in the United States
Carolyn A. Fahey
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
881 - Prognostic Factors of Physical Function Decline in the PREPARE Study
Grace Ditzenberger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
882 - Understanding the Life Expectancy Sex Gap: Disparate Patterns in Noncommunicable Disease Mortality
Katherine Kooij
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
883 - 10-Minute Targeted Geriatric Assessment Identifies Vulnerable and Frail Older Persons With HIV
Marilia Bordignon Antonio
University of São Paulo, São Paulo, Brazil
2:30 PM2:30 PM
884 - The 10-Year Prevalence of Hearing Loss and Dementia Among People With HIV in the United States
Emily Hyle
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
885 - Clinical Outcomes of Immune Nonresponse Among Virally Suppressed Adults Living With HIV in Thailand
Worapong Nasomsong
Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
2:30 PM2:30 PM
886 - Falls Associated With High Medication Regimen Complexity in People With HIV
Yunhan Chen
Boston Medical Center, Boston, MA, USA
2:30 PM2:30 PM
887 - Integrated Digital Strategy for Stigma Evaluation in Routine Care for PWH
Alfonso Cabello
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
888 - Latent Class Analysis Identifies Distinct Comorbidity Profiles in Older (>65 years) People With HIV
Fabrizio Drago
Rutgers University, Piscataway, NJ, USA
2:30 PM2:30 PM
889 - Multimorbidity and Quality of Life Among Older People Living With HIV in Urban Tanzania
Theresia A. Ottaru
Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
890 - Weight and Body Composition After Switch to DTG/3TC From DTG/3TC/ABC: A Randomized Open-Label Trial
Thomas Benfield
University of Copenhagen, Copenhagen, Denmark
2:30 PM2:30 PM
891 - Re-Examining InSTI Effects on Weight Gain Among Treatment-Naive People With HIV in North America
Kassem Bourgi
Nashville CARES, Nashville, TN, USA
2:30 PM2:30 PM
892 - Weight Change on F/TAF vs Placebo: Using Common F/TDF Groups to Bridge Data Across Clinical Trials
David Glidden
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
893 - Body Composition Changes in People With HIV Switching From or Maintaining TDF-Based Regimens
Giovanni Guaraldi
University of Modena and Reggio Emilia, Modena, Italy
2:30 PM2:30 PM
894 - Risk Factors Associated With Extreme Weight Gain in People With HIV
Stefan Esser
University Hospital Essen, Essen, Germany
2:30 PM2:30 PM
895 - Serum Metabolomic Signatures Associated With InSTI-Related Weight Gain in Women With HIV
Chin-An Yang
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
896 - Weight Change in Trial of Switching From Second-Line bPI to B/F/TAF in a Context of Food Insecurity
Vanessa Rouzier
GHESKIO, Port-au-Prince, Haiti
2:30 PM2:30 PM
897 - Body Composition Changes in People With HIV Switching to DTG/3TC or BIC/TAF/FTC
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-02) PASC: Immunobiologic, Metabolic, and Cardiovascular Complications
2:30 PM2:30 PM
927 - Hormonal Dysregulation in Long COVID: Exploring the Salivary Cortisol Profile
Marta Camici
IRCCS Lazzaro Spallanzani, Rome, Italy
2:30 PM2:30 PM
928 - In Vitro Modeling of the Effects of Impaired HDL on Atherogenesis in Long COVID Syndrome
Theodoros Kelesidis
University of Texas Southwestern Medical Center, Dallas, TX, USA
2:30 PM2:30 PM
929 - Age-Dichotomous Associations of Long COVID With Frequency of Public SARS-CoV-2 Memory TCRs
Selin Akbas
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
930 - Persistent Immune Dysregulation and Metabolic Alterations Following SARS-CoV-2 Infection
Michael Peluso
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
931 - Immune and Virologic Trajectories 1.5 Years Before and After COVID-19 in an Early-Treated HIV Cohort
Ferron Ocampo
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
933 - [18F]F-AraG PET Imaging Reveals Increased Gut T-Cell Activation in People With Long COVID
Emilio De Narvaez
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
934 - Evidence of B-Cell Dysfunction in Individuals With Long COVID-Associated Dysautonomia
Montserrat Torres
Instituto de Salud Carlos III, Madrid, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-02) Pathogenesis of TB Disease/TB Drug Exposure Relationships
2:30 PM2:30 PM
954 - Impact of Cytomegalovirus Infection on the Progression of TB Disease in People With HIV on ART
Sivaporn Gatechompol
Mahidol University, Bangkok, Thailand
2:30 PM2:30 PM
955 - Immune Profiles Can Differentiate Mycobacterial and KSHV Inflammatory Syndromes in Advanced HIV
Shweta Mistry
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
956 - NAT-2 Polymorphism and Risk of Antituberculosis-Induced Hepatotoxicity in Thai People With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
957 - Isoniazid Exposure Among Patients With Tuberculosis and Diabetes in Brazil
Felipe Ridolfi
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
958 - Genetics of Plasma Rifapentine Clearance During Pulmonary Tuberculosis Treatment in Study 31/A5349
Ava Y. Xu
University of California San Francisco, San Francisco, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-03) Novel TB Case-Finding Strategies and Diagnostic Testing
2:30 PM2:30 PM
959 - High Diagnostic Yield of a Novel HIV-TB Case-Finding Strategy at Social Drinking Venues in Zambia
Andrew Kerkhoff
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
960 - Effectiveness of Portable Digital X-Ray Machine in Tuberculosis Case-Finding in Nigeria
Patrick Dakum
Institute of Human Virology Nigeria, Abuja, Nigeria
2:30 PM2:30 PM
961 - Machine Learning-Based Prediction of Active Tuberculosis in People With HIV Using Clinical Data
Johannes Nemeth
University Hospital Zurich, Zurich, Switzerland
2:30 PM2:30 PM
962 - Genome-Wide Meta-Analysis Identifies Genetic Associations With Resistance to Mtb Infection
Matheus Fernandes Gyorfy
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
963 - Healthcare Worker- Versus Self-Collected Tongue Swabs for Mycobacterium tuberculosis Detection
Anura David
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
2:30 PM2:30 PM
965 - Diagnostic Accuracy of the FujiLAM Assay to Detect Tuberculosis in Advanced HIV
Tessa Adzemovic
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
966 - Diagnosis and Prognosis of Blood XpertUltra and Myco/F Blood Culture for TB in Advanced HIV Disease
Phuong Le Trinh
Oxford University Clinical Research Unit in Vietnam, Hanoi, Vietnam
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-04) TB Preventive Therapy: Testing, Treatment Strategies, and Outcomes
2:30 PM2:30 PM
967 - Gaps in Latent Tuberculosis Infection Testing Practices: A 15-Year Serial Cross-Sectional Study
Jorge R. Ledesma
Kaiser Permanente Division of Research, Oakland, CA, USA
2:30 PM2:30 PM
968 - Effect of Alcohol Use on Active TB Incidence Among PWH With Prior Receipt of TB Preventive Therapy
Judith A. Hahn
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
2:30 PM2:30 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:30 PM2:30 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
2:30 PM2:30 PM
991 - High Viral Suppression in Pregnant/Postpartum Women With HIV in a Couples-Based Behavioral Trial
Karen Hampanda
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
992 - Childhood Exposure to Violence and Pregnancy-to-Postpartum Viral Load of US Women With HIV
Deborah Kacanek
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
993 - Rapid Return of Viral Load (VL) Results to Pregnant/Postpartum Women via Mentor Mothers in Kenya
Pam Murnane
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
994 - Evaluating and Revising an Adapted Scale for Antiretroviral Therapy (ART) Adherence Self-Efficacy
Lauren Sheu
University of Chicago, Chicago, IL, USA
2:30 PM2:30 PM
995 - The Impact of Care Transitions on Pregnant Youth Living With HIV in Kisumu, Kenya
Rabbia Imran
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
996 - HIV Drug Resistance Patterns Among Pregnant Women After Dolutegravir Scale-Up in Sub-Saharan Africa
Linda Stoeger
Barcelona Institute for Global Health, Barcelona, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-04) Antiretrovirals and Birth Outcomes
2:30 PM2:30 PM
1000 - Impact of TLD on Birth Outcomes in South African Women: The ORCHID Cohort
Jamie E. Meyer
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1001 - Impact of Gestational Diabetes on Pregnancy Outcomes in South African Women Living With HIV
Elton Mukonda
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1002 - Immune Markers During Pregnancy and Birth Outcomes in South African WLH
Thokozile R. Malaba
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1003 - Antiretroviral Drugs Disrupt Macrophage Function and Vascular Development
Doty B. A. Ojwach
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1004 - Antiretroviral Drugs Affect the Placental Vasculature
Micah Summerlin
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
997 - Perinatal and Infant Outcomes After Bictegravir Exposure in Pregnancy: A Canadian Surveillance Study
Jeffrey Man Hay Wong
University of British Columbia, Vancouver, Canada
2:30 PM2:30 PM
998 - Prematurity and Low Birth Weight in Children Born to Mothers Living With HIV in Spain
Talía Sainz
La Paz University Hospital, Madrid, Spain
2:30 PM2:30 PM
999 - Birth Outcomes and HIV-1 Transmission in a Contemporary HIV Pregnancy Cohort, Washington State
Jane Hitti
University of Washington, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-02) Exploring the Pediatric Reservoir
2:30 PM2:30 PM
1030 - Long-Term HIV Reservoir Dynamics in Early Treated Thai Children
Marta Massanella
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
1031 - NK Cell KIR Education Is Associated With Low HIV DNA Load in Early ART-Treated Children
Nicholas G. Herbert
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1032 - Evolving Expression of Co-Inhibitory Receptors and Plasma Cytokines in Children Living With HIV
Hugo Soudeyns
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
2:30 PM2:30 PM
1033 - Proviral HIV-1 DNA Below Detection in Early-Treated Adolescents After Prior Treatment Interruption
Louise Kuhn
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1034 - Pediatric ART Interruptions Transiently Raise HIV DNA Without Large Changes to Long-Term Reservoirs
Daniel B. Reeves
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1035 - Children With Very Early ART and Favorable Profiles for ART-Free Viral Control Research: Thai Cohort
Rapisa Nantanee
Chulalongkorn University, Bangkok, Thailand
2:30 PM2:30 PM
1036 - Association Between HIV-Specific Antibodies and HIV Reservoir Markers in Early-Treated Children
Rapisa Nantanee
Chulalongkorn University, Bangkok, Thailand
2:30 PM2:30 PM
1037 - Baseline Viral Load Impacts Premature Aging in Infants With Perinatally Acquired HIV in EARTH Cohort
Maria Raffaella Petrara
University of Padova, Padova, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-03) Informing Cure Strategies in Children and Youth
2:30 PM2:30 PM
1038 - Negative HIV Serology in Children Treated Early Reflects a Unique Immunologic Profile
Florence Buseyne
Institut Pasteur, Paris, France
2:30 PM2:30 PM
1039 - Distinct Innate Immune-Driven TNFa Pathway Is Linked With Durable ART-Free Aviremia in Pediatric HIV
Nicholas Lim
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1040 - Germline-Targeting SOSIP Trimer Immunizations Reduced Post-Rebound SHIV Loads in Infant Macaques
Ria Goswami
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1041 - Immune Correlates of Viral Rebound During Broadly Neutralizing Antibody Treatment in Children
Melanie Lancien
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
1042 - HIV-Specific T-Cell Dynamics in Acute-Treated, Chronic-Treated, and Elite Controller People With HIV
Alicer K. Andrew
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
1043 - Transcriptomics of Proviral Latency Reversal in Reservoirs of Youth With Perinatal HIV-1
Kristen Kelly
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-04) Pharmacokinetics, Safety, and Efficacy of Antiretrovirals
2:30 PM2:30 PM
1044 - Maternal Antiretroviral Formulation Preferences for Neonates
Lario Viljoen
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1045 - Acceptability of a Dolutegravir Dispersible Tablet and a Novel Oral Film Formulation in Neonates
Lario Viljoen
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1046 - Safety and Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Children 20 to 40 kg
Moherndran Archary
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
1047 - PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023)
Jeremiah Momper
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
1048 - Alternative Dosing of ABC/3TC Dispersible Tablets to Align With Dolutegravir Dosing in Neonates
Tim Cressey
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1049 - Week 24 Outcomes of F/TAF Plus Cobicistat-Boosted Protease Inhibitors in Children ≥2 y and ≥14 kg
Hilda A. Mujuru
University of Zimbabwe, Harare, Zimbabwe
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-01) The HIV Care and Prevention Cascades: Novel Insights
2:30 PM2:30 PM
1076 - Low Rates of HIV Pre-Exposure Prophylaxis Prescriptions Among US Youth in a Claims Database
Nicholas Venturelli
Boston Children's Hospital, Boston, MA, USA
2:30 PM2:30 PM
1077 - Oral and Injectable PrEP Use Among US Adolescents and Young Adults, 2019-2023
Laura M. Mann
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1078 - Durable Viral Suppression Using Different Definitions in a Ryan White HIV Program Clinic, 2018-2021
Kathleen A. McManus
University of Virginia, Charlottesville, VA, USA
2:30 PM2:30 PM
1079 - Characteristics of Men Who Have Sex With Men Recruited via Virtual- v In-Person Venue-Based Sampling
Danielle Lonbong Njiometio
Oak Ridge Institute for Science and Education, Atlanta, GA, USA
2:30 PM2:30 PM
1080 - Identifying Effective Recruitment Strategies to Engage Black Sexual Minority Men Living With HIV
Derek Dangerfield II
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1081 - Refining Clinical Retention Metrics to Reflect the Realities of HIV Care in North America
Peter F. Rebeiro
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
1082 - Neighborhood Resources and ARV Adherence Among Partnered US GBMSM: Mediation by Social Determinants
Loren Dobkin
University of Michigan, Ann Arbor, MI, USA
2:30 PM2:30 PM
1083 - Geographically Diverse National Survey of People With HIV on Grindr Shows High Virologic Suppression
Hannah R. Schmidt
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1084 - Viral Nonsuppression Among PWH Diagnosed at an Older Age: Implications for Secondary HIV Prevention
Lauren O'Connor
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1085 - Changes in the HIV Care Cascade and Prevalence From 2013 to 2023 in Rural Kenya and Uganda in SEARCH
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1086 - High Burden of Untreated HIV in Malawian Fishermen: Prospective Data From a Cluster Randomized Trial
Augustine T. Choko
Malawi Liverpool Wellcome Trust, Blantyre, Malawi
2:30 PM2:30 PM
1087 - PMTCT and KP Appropriate Services Improve HIV Viral Suppression Among Female Sex Workers: IBBSS 2023
Ikuzo Basile
Rwanda Biomedical Centre, Kigali, Rwanda
2:30 PM2:30 PM
1088 - Unique Predictors of Retention and Viral Suppression Among People With HIV in Dominican Republic
Wilfredo R. Matias
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
1089 - Higher Baseline CD4 and Treatment Initiation Among Contacts of PLHIV: Thailand, 2020-2023
Junya Danyuttapolchai
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1111 - Temporal Variations of Racial Disparities in HIV Incidence in the United States From 2008 to 2021
Fanghui Shi
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
1115 - Changes of Racial Disparities in Viral Suppression in People With HIV, 2013-2020
Xueying Yang
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
1116 - Effect of the Ending the HIV Epidemic (EHE) Initiative on Racial/Ethnic Disparities in HIV Incidence
Lauren Zalla
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1117 - Studying Medication Adherence for Black People Living With HIV: An Intersectional Lens
Anais Mahone
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
1118 - HIV Testing Barriers in Structurally Vulnerable Communities in St Louis: Best-Worst Scaling Survey
Noelle Le Tourneau
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
1120 - Racial/Ethnic and Regional Disparities in HIV Testing Before, During, and After COVID-19 in the US
Rena C. Patel
University of Alabama, Tuscaloosa, AL, USA
2:30 PM2:30 PM
1121 - Estimated HIV Incidence in 15-24-Year-Olds Across 2 Population HIV Impact Assessments (PHIA)
Elaine Abrams
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1122 - HIV Incidence and Viral Suppression Among Ugandan Males With Female Bar and Sex Worker Partners
Xinyi (Cindy) Feng
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1123 - HIV Incidence Among Adults With Multiple Sex Partners in Kisumu County, Western Kenya
John Owuoth
Walter Reed Project–Kisumu, Kisumu, Kenya
2:30 PM2:30 PM
1124 - Contact Investigation of Incident HIV in a Population Cohort: Implications for Case Finding and PrEP
Robert Ssekubugu
Rakai Health Sciences Program, Kalisizo, Uganda
2:30 PM2:30 PM
1125 - Uncovering Risk for Recent HIV Infections in 9 Provinces: Thailand, 2023-2024
Theerawit Tasaneeyapan
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1126 - Recent HIV Infection Among Youth in Thailand: Who Is at Risk?
Suvimon Tanpradech
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1127 - New HIV-1 Diagnoses Among Different Generations of MSM in the Netherlands: Focus on Gen-Z
Annemarie M. J. Wensing
University Medical Center Utrecht, Utrecht, Netherlands
2:30 PM2:30 PM
1128 - Development of an HIV Risk Prediction Model Using Electronic Health Record Data in Spain
Arkaitz Imaz
Bellvitge University Hospital, Barcelona, Spain
2:30 PM2:30 PM
1129 - Trend in the Proportion of Recent HIV Infections by Risk, Age, and Region in Armenia (2018-2022)
Tamara Hovsepyan
National Center for Infection Diseases, Yerevan, Armenia
2:30 PM2:30 PM
1130 - Examining PopART Intervention Impact on HIV in the General Populations of Zambia and South Africa
Bonnie Shook-Sa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1131 - Addressing Advanced HIV Disease: Insights on CD4 Testing and AHD Prevalence at PEPFAR Sites
Gabriel Saemisch
United States Agency for International Development, Washington, DC, USA
2:30 PM2:30 PM
1132 - Trends in Advanced HIV Disease Prevalence in 5 African Countries: An Analysis of Household Surveys
Mateo Prochazka
World Health Organization, Geneva, Switzerland
2:30 PM2:30 PM
1133 - Advanced HIV Disease in Individuals Already in Care: Incidence and Comparison With Late Presentation
Andrea Antinori
National Institute for Infectious Diseases L Spallanzani, Rome, Italy
2:30 PM2:30 PM
1134 - The Effect of Treat-All on People With Advanced HIV Disease in Lesotho
Shanyah L. Mitchell
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1135 - Burden of AIDS-Defining Conditions Among Adults With Perinatal HIV in North America, 2000-2022
Nel Jason Haw
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1136 - C-Reactive Protein as a Predictor of Hospitalization and Mortality in Advanced HIV Disease in Uganda
Elizabeth L. Schwartz
University of Minnesota, Minneapolis, MN, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-09) Sexual Partner, Sexual Risk
2:30 PM2:30 PM
1137 - Vaginal and Anal Intercourse With Women Reported by Men Who Have Sex With Men, 2015-2019
Karen W. Hoover
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1139 - Geospatial Heterogeneity in Potential HIV Transmission Locations Among MSM in Bhopal, India
Griffin J. Bell
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1140 - Age-Stratified Sexual Partner Profiles to Characterize HIV Risk Across Lifespan: Botswana and Zambia
Kristen A. Stafford
University of Maryland, Baltimore, MD, USA
2:30 PM2:30 PM
1141 - Couples-Based Homophily in HIV Testing and Treatment Engagement: A Multicountry Analysis
Kathryn Risher
Pennsylvania State University, Hershey, PA, USA
2:30 PM2:30 PM
1142 - HIV Prevalence in Intersecting Subgroups of Southern African Women: Insights From PHIA
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1143 - Utilization of Assisted Partner Notification Services and Outcomes: A Population-Based Study
Nakawooya Hadijja
Rakai Health Sciences Program, Kalisizo, Uganda
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-02) Improving HIV Testing in Clinical Settings
2:30 PM2:30 PM
1183 - Effectiveness of Clinical Decision Support in Improving HIV Screening in Pediatric Primary Care
Sarah Wood
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
1184 - Impact of a New Opt-In Targeted Strategy for HIV Testing in Emergency Departments
Jose Guardiola
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
2:30 PM2:30 PM
1185 - Validation of a National HIV Testing Eligibility Screening Tool in Tanzania
Galal N. King'ori
2:30 PM2:30 PM
1186 - Transfusion Risk of HIV, HBV, and HCV in Low- and Middle-Income Countries Without Nucleic Acid Testing
Jodie L. White
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1187 - Clinical Features Are Poor Identifiers of Advanced HIV Disease in the Absence of CD4 Quantification
Phoebe Allebone-Salt
St George's University of London, London, UK
2:30 PM2:30 PM
1188 - HIV Recent Infection Surveillance Adds 17 Minutes to HIV Testing Services per Patient With HIV
Suzue Saito
ICAP at Columbia University, New York, NY, USA
2:30 PM2:30 PM
1189 - Missed Opportunities: HIV Screening Deficits in Japanese Syphilis Patients
Toshibumi Taniguchi
Chiba University, Chiba, Japan
2:30 PM2:30 PM
1190 - Machine Learning Risk Stratification Compared With a Counselor-Guided Screening Tool
Daniel G. Wandina
Gold Star Kenya, Karuri, Kenya
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-03) Biomarkers and Technology to Support PrEP Use
2:30 PM2:30 PM
1211 - Self-Reported PrEP Use Is Associated With Short- and Long-Term Pharmacologic Metrics in Kenyan Women
Jennifer Velloza
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1212 - Point-of-Care Urine Tenofovir Feedback Counseling Improves PrEP Adherence for US MSM in Pilot RCT
Matthew A. Spinelli
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1213 - Oral Fluid Concentrations of Tenofovir and Emtricitabine for Antiretroviral Adherence Monitoring
Xin Niu
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1214 - Are Sex-Specific Cutoffs Needed With a Next-Gen Urine Tenofovir Assay for Adherence Monitoring?
Xin Niu
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1215 - Technology-Based Oral Daily Pre-Exposure Prophylaxis Intervention for Online Population in India
Jalpa Thakker
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-04) Barriers to Uptake and Persistence With Biomedical Prevention
2:30 PM2:30 PM
1216 - Suboptimal Laboratory Testing of PrEP Users: United States, 2022-2023
Karen W. Hoover
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1217 - Factors Associated With PrEP Uptake, Persistence, and Adherence Among Incarcerated People in Zambia
Brianna R. Lindsay-Renninger
University of Maryland, Baltimore, MD, USA
2:30 PM2:30 PM
1218 - Trends in 2016 CDC-Recommended PEP Regimens and Bictegravir for HIV PEP: United States, 2015-2023
Ya-Lin A. Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1219 - Impact of Initiation Delay, Duration, and Prior PrEP Usage on FTC/TDF-Containing PEP Efficacy
Lanxin Zhang
Robert Koch Institute, Berlin, Germany
2:30 PM2:30 PM
1220 - Impact of the Anti-Homosexuality Act 2024 on HIV Prevention Efforts and PrEP Uptake Among Young MSM
Cecilia Birungi
Makerere University, Kampala, Uganda
2:30 PM2:30 PM
1221 - Cost-Effectiveness of Different Risk-Group Targeting Across 3 Types of PrEP in Zimbabwe
Yao-Rui Yeo
New York University Langone Medical Center, New York, NY, USA
2:30 PM2:30 PM
1222 - Leveraging Community to Provide PrEP to Key Population in China: Results From a PrEP Clinical Trial
Weiming Tang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1223 - Longer Distances Traveled by Rural vs Urban PrEP Users for PrEP Care: United States, 2023
Weiming Zhu
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1224 - Pre-Exposure Prophylaxis Uptake in High Female-to-Male HIV Prevalence Regions in the US
Ashvini Vaidya
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1225 - Self-Reported Frequent vs Infrequent HIV Risk and Actual Diagnoses in MSM: Implications for PrEP
Nicolas Salvadori
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1226 - The Influence of Racialized Economic Segregation on Unmet HIV Prevention Needs in the Real World
Li Tao
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1227 - The County-Level Analysis of PrEP-to-Need Ratio With HIV Diagnosis in the US, 2012-2021
Xueying Yang
University of South Carolina, Columbia, SC, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-05) PrEP Implementation: Hopes, Dreams, and Aspirations
2:30 PM2:30 PM
1228 - Diagnosis, Resistance, and ART Outcomes After HIV Acquisition on CAB-LA PrEP in Routine Care in US
Catherine A. Koss
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1229 - The Cost-Effectiveness and Optimal Price Level of Injectable PrEP With Lenacapavir in South Africa
Gesine Meyer-Rath
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1230 - PURPOSE 1: Preference for Twice-Yearly Injection vs Daily Oral Pills for HIV PrEP in Cisgender Women
Leila E. Mansoor
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
1231 - Characteristics of Persons Diagnosed With HIV in a Population-Based PrEP Program in British Columbia
Raquel M. Espinoza
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1261 - Probability of Anal Human Papillomavirus Infection Following Acute HIV Acquisition in Thailand
Supanat Thitipatarakorn
Institute of HIV Research and Innovation, Bangkok, Thailand
2:30 PM2:30 PM
1262 - Incidence and Clearance of Anal Human Papillomavirus Infection in an Acute HIV Cohort in Thailand
Supanat Thitipatarakorn
Institute of HIV Research and Innovation, Bangkok, Thailand
2:30 PM2:30 PM
1263 - HPV Clearance After Immunization: Investigating Risk Factors Associated With Clearance at Anal Site
Elena Bruzzesi
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
1264 - Sustained HIV Viral Suppression as a Predictor of High-Risk Human Papillomavirus Infection
Douglas Gaitho
Academic Model Providing Access to Healthcare, Eldoret, Kenya
2:30 PM2:30 PM
1265 - Diagnostic Screening and Treatment of Curable STIs in Pregnancy and Impact on Pregnancy Outcomes
Dorothy C. Nyemba
University of Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1266 - High Incidence of Curable Sexually Transmitted Infections in HPTN 084: A Tertiary Analysis
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
2:30 PM2:30 PM
1267 - Geospatial Trends of Sexually Transmitted Infections in South Carolina (SC), 2008-2020
Syeda Shehirbano Akhtar
University of South Carolina at Columbia, Columbia, SC, USA
2:30 PM2:30 PM
1268 - Depressive Symptoms on the Incidence of Sexually Transmitted Infections Among Reproductive-Age Women
Paul N. Zivich III
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1269 - High STI Prevalence and Low Past PrEP Use Among Women Who Engage in Sex Work in Southwestern Uganda
Catherine A. Koss
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1270 - Sexually Transmitted Infection Prevalence Among Adolescents and Adults in Western Kenya
Julius L. Tonzel
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
1271 - Asymptomatic Sexually Transmitted Infections in a Population of High-Risk Men Who Have Sex With Men
Pierluigi Francesco Salvo
Universita Cattolica del Sacro Cuore, Milan, Italy
2:30 PM2:30 PM
1272 - Epidemiology of Bacterial STIs in MSM With or At Risk of HIV in the Region of Madrid (2021-2023)
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
2:30 PM2:30 PM
1273 - Identification of Clinical Phenotypes in MSM With HIV From a Prospective Study on Acute HCV and STIs
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
2:30 PM2:30 PM
1274 - Prevalence and Incidence of HIV/STIs Among MSM and Men Who Have Sex With Women in the SAMURAI Study
Elizabeth (Liz) Montgomery
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-04) Machine Learning and mHealth
2:30 PM2:30 PM
1305 - Comparing 2 mHealth Technologies to Support PrEP Use Among MSM and Transgender People in the US
Albert Y. Liu
San Francisco Department of Public Health, San Francisco, CA, USA
2:30 PM2:30 PM
1306 - Characteristics of Dapivirine Ring Users in the SEARCH Dynamic Choice HIV Prevention Studies
Elijah Kakande
Infectious Diseases Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:30 PM2:30 PM
1309 - Developing Machine Learning Algorithms to Predict Treatment Interruptions in HIV Care in Uganda
Alex Mirugwe
Makerere University–University of California San Francisco Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1310 - Exposure and Engagement Drive Impact: Results From a Digital Health Trial With Rwandan Adolescents
Rebecca Hemono
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
1311 - Digital Strategy to Improve PrEP Adherence Among MSM: A Stepped-Wedge Randomized Trial in China
Chunyan Li
University of Tokyo, Tokyo, Japan
2:30 PM2:30 PM
1312 - Impact Analysis and Machine Learning Forecasts of HIV Viral Load Suppression in 21 African Countries
Amobi A. Onovo
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
1314 - Hair Salons as a Promising Space to Offer HIV Prevention Services for Young Women in Lesotho
Mamaswatsi Kopeka
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1315 - Capacity for PrEP Implementation at Pharmacies in Baltimore and San Diego: A Mixed-Methods Study
Lipin Lukose
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1316 - Evaluating Spatially Targeted HIV and Harm Reduction Strategies Among People Who Inject Drugs
Jasmine Wang
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1317 - Traditional Healers: A Nontraditional Gateway to Engagement in HIV Care in Rural Uganda
Radhika Sundararajan
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1318 - Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in PWH With Adherence Challenges
Megan E. Dieterich
Whitman-Walker Health, Washington, DC, USA
2:30 PM2:30 PM
1319 - Uptake of Online HIV PrEP and PEP in Kenya After Removal of Subsidies: A Pilot Extension Study
Daniel K. Were
Jhpiego - Nairobi, Nairobi, Kenya
2:30 PM2:30 PM
1320 - Community-Based Versus Facility-Based Services to Improve HIV Care in the Gold Mining Zones of Mali
Luis Sagaon Teyssier
Aix-Marseille Université, Marseille, France
2:30 PM2:30 PM
1321 - Community FSW Peer Model or HIV Prevention to Reach Epidemic Control and Sustainability: Tanzania
Neema Makyao
Amref Health Africa in Tanzania, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
1322 - Trial of Enhanced Peer Referral With HIV Self-Testing on PrEP Initiation Among Young Kenyan Women
Katrina Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1323 - nPEP When You Need It: A 24/7 Post-Exposure Prophylaxis Hotline in the District of Columbia
Rachel Harold
District of Columbia Department of Health, Washington, DC, USA
2:30 PM2:30 PM
1324 - HIV Health Care Transition: Five-Year Rates of Retention and Viral Suppression
Camille Knable
University of Maryland Medical Center, Baltimore, MD, USA
2:30 PM2:30 PM
1325 - Impact of Differentiated HIV Service Delivery Models on Quality of Life in Uganda
Benson Nasasira
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
1326 - Trends in HIV Viral Nonsuppression and Drug Resistance Among PWID on Dolutegravir ART in Kenya
Loice W. Mbogo
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1327 - Heterogeneity of Disengagement From Antiretroviral Care Matters for Treatment Success
Claire M. Keene
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1328 - Patterns of Engagement After Restarting Antiretroviral Treatment in South Africa
Claire M. Keene
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1329 - Reasons for Discontinuation of Cabotegravir Long-Acting (CAB-LA) Among Clients in Zambia
Damian J. Phiri
John Snow, Inc, Lusaka, Zambia
2:30 PM2:30 PM
1330 - Detection and Linkage of PLWH Who Are Out of Care in 94 Emergency Departments Across the US
Jamie L. Mignano
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1331 - HIV Treatment Interruptions: A Lorenz Curve Analysis of Countries Achieving the 95-95-95 Targets
Rituparna Pati
PEPFAR, Washington, DC, USA
2:30 PM2:30 PM
1332 - Point-of-Care Urine Self-Testing Feasibility to Measure TFV Adherence and Predict Viral Suppression
Renata Buccheri
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
1333 - Effect of COVID-19 Pandemic on ART Access and Timely Initiation in Adults With HIV in 31 Countries
Ben Farhat Jihane
Epicentre, Paris, France
2:30 PM2:30 PM
1334 - HIV Treatment Continuity in Haiti: Lorenz Curve Analysis of IIT, 2022-2024
Michael J. A. Reid
PEPFAR, Washington, DC, USA
2:30 PM2:30 PM
1335 - Clinical and HIV Surveillance Data to Determine Care Status for People With HIV in Washington, DC
Shannon Hammerlund
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1336 - Does Retention in Care Still Correlate With HIV Viral Suppression: Do We Need Different Strategies?
Joshua Craft
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1337 - Uptake of Injectable Cabotegravir/Rilpivirine for Treatment of HIV Infection in US, 2021-2023
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1338 - Comparative Yield of Data Sources for Health Department Data to Care Services
Julie Dombrowski
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1339 - Developing Analytic Strategies to Investigate Long-Acting Injectable Antiretroviral Effectiveness
Sarah E. Rutstein
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1340 - Prevalence of Unsuppressed Viral Load: Comparison of 2016-17 and 2022-23 Tanzania HIV Impact Surveys
Abbas Ismail
US Centers for Disease Control and Prevention Dar es Salaam, Dar es Salaam, Tanzania
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-05) Antiviral Inhibition of Viral Replication and Evasion by HIV-1
2:30 PM2:30 PM
323 - Host Gene SLC35A2 Restricts CXCR4-Tropic HIV-1 Replication at the Stage of Viral Fusion
Jamie Guenthoer
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
324 - Novel Strategy to Inhibit HIV by Targeting Integrase/INI1 Interaction Based on the TAR RNA Mimicry
Swati Haldar
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
325 - Novel Functions of TRIM21: Post-Translational Regulation of Cytoplasmic Antiretroviral APOBEC3s
Aubrey M. Sawyer
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
326 - The Effects of Accessory Genes on T/F HIV Infection of Primary CD4+ T Cells From Tissues
Harnoor Virk
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
327 - RhoA Restricts HIV-1 by Modulating IFN Signaling and Is Counteracted by Vpr
Caterina Prelli Bozzo
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
328 - The Role of Capsid-Host Interaction on Lentiviral Evolution
Clare Gill
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
329 - Capsid Mutant HIV-CRISPR Screens Reveal Mechanisms of TRIM5 Restriction
Isaiah Grant
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
330 - A Virus-Packageable CRISPR Screen to Uncover Genes Underlying SIVcpz Replication in Human Cells
Michael Young
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
378 - HIV Drives CARD8 Inflammasome Activation and Proinflammatory Cytokine Release by Myeloid Cells
Marilia R. Pinzone
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
379 - Genome-Wide Association of NLRP3 Inflammasome Plasma Cytokines in Virally Suppressed People With HIV
Sonia Savur
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
380 - Extracellular Vesicles From the Cells Harboring HIV Defective Provirus Initiate Inflammatory Cascade
Hongyan Sui
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
2:30 PM2:30 PM
381 - Extracellular Vesicles’ miRNAs Correlate With Inflammatory Markers in Tanzanians With HIV
Mussa H. Bago
Kumamoto University, Kumamoto, Japan
2:30 PM2:30 PM
382 - Proinflammatory Markers in Persons Living With HIV, HCV, and/or Drug Use
Jason T. Blackard
University of Cincinnati Medical Center, Cincinnati, OH, USA
2:30 PM2:30 PM
383 - The Systemic Inflammatory Profile Differs According to the Mechanism of HIV Control
Jose M. Benito
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
384 - Host Transcriptional Signatures Associated With Distinct Inflammatory Bioprofiles in People With HIV
Dana Alalwan
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
385 - Intestinal CD4:CD8 Ratio and Systemic Inflammatory Parameters in Suppressed HIV-1 Infection
Francesca Cossarini
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
386 - Living With HIV Mimics the Proinflammatory FUT2 Non-Secretor Phenotype in the Intestines
Leila B. Giron
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
387 - Ultra-Low Level Soluble p24 Is Associated With Inflammation in People With HIV on Suppressive ART
Matteo Augello
University of Milan, Milan, Italy
2:30 PM2:30 PM
388 - Inflammatory and Microbial Signatures Linked to Cardiovascular Outcomes in People With/Without HIV
Rachel MacCann
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
389 - Methamphetamine Use Disorder in ART PWH Is Associated With Elevated NLRP3 Inflammasome Activation
Felipe Ten-Caten
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
390 - Understanding NLRP3 Inflammasome Activation at the Intersection of HIV and Aging
Heidi Zapata
Yale University, New Haven, CT, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-06) Animal Models of Infection
2:30 PM2:30 PM
391 - Ex Vivo Isolation and Characterization of Live, Envelope Expressing, SHIV-Infected CD4 T Cells
Joseph P. Casazza
Vaccine Research Center, Bethesda, MD, USA
2:30 PM2:30 PM
392 - Lobule Zone-Dependent Accumulation of Vd1 and Vd2 gd-T Cells in the Livers of SIV+ Infant Macaques
Nina Derby
Seattle Children's Research Institute, Seattle, WA, USA
2:30 PM2:30 PM
393 - IL-15, Type I Interferon, Fatty and Amino Acid Pathways Link to SIV Reservoir and Rebound in Infants
Tehillah Chinunga
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
394 - Immunometabolic Reprogramming by Caloric Restriction Leads to Protection From SIV in Rhesus Macaques
Naveen Suresh Babu
Tulane University, Metairie, LA, USA
2:30 PM2:30 PM
395 - A New Mouse Model of HIV in Pregnancy: The EcoHIV Pregnancy Model
Michelle M. Ranjbar
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
396 - Clinical and Immune Characteristics of ART+SIV/P. fragile Infected Macaques With Persistent Viremia
Sydney Nemphos
Tulane National Primate Research Center, Covington, LA, USA
2:30 PM2:30 PM
397 - Analysis of SIV Envelope Diversity During Untreated Infection
Haoyue Li
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
398 - STLV-1 in Chlorocebus aethiops as a Model for New Approaches to Human Retrovirus Research
Víctor Â. Folgosi
Universidade de São Paulo, São Paulo, Brazil
2:30 PM2:30 PM
399 - Western Diet Boosts Immune Activation and Inflammation in SIV-Infected Macaques on Antiretrovirals
Briana Thompson
University of Pittsburgh, Pittsburgh, PA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-08) Coordinated Immune Responses and Viral Control
2:30 PM2:30 PM
464 - Distinct Signatures of Trained Immunity Reveal Heterogeneity Among Elite HIV Controllers
Joao Lucas Lima Calandrini de Azevedo
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
465 - Lymph Node Dendritic Cells Harbor an Altered Transcriptomic Profile Despite Years of Suppressive ART
Riddhima Banga
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
2:30 PM2:30 PM
466 - Mapping the Spatial Landscape of Lymph Nodes With Undetectable Versus Active HIV Replication
Candace Liu
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
467 - Longitudinal Phenotypic and Transcriptional Profiling of Immune Cells in Early-Treated Acute HIV
Jozefien De Clercq
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
468 - Markers of Immunologic Control for Future Identification of HIV Post-Treatment Controllers
Elena Bruzzesi
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
469 - Impaired Antigen Presentation and TGFβ Signaling Fosters Th17 Differentiation in PLWH Under ART
Valentino D'Onofrio
Ghent University, Ghent, Belgium
2:30 PM2:30 PM
470 - Females With HIV Favor Interferon Responses Over Inflammation Upon TLR7 Activation
Alisa Huber
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
471 - CITE-Seq and Single Cell αβ TCRseq Unravels HIV-1 Specific GZMB Subset in Post-Treatment Controllers
Giacomo Schmidt Frattari
Aarhus University, Aarhus, Denmark
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-09) Immunity to SARS-CoV-2 and Other Viruses
2:30 PM2:30 PM
472 - Diminished Immune Imprinting at the Upper Respiratory Tract Following SARS-CoV-2 Breakthrough Infection
Xuan He
West China Hospital of Sichuan University, Chengdu, China
2:30 PM2:30 PM
473 - Spike Ferritin Nanoparticle (SpFN) Recalls Memory B Cells in SARS-CoV-2-Experienced Donors
Lauren Smith
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
474 - Optimized ACE2-Fc With Picomolar Pan-Neutralization of SARS-CoV-2 Variants, Including JN.1 and KP.2
Ferran Abancó i Espuga
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
475 - Long COVID Is Associated With Lower Percentages of Mature, Cytotoxic NK-Cell Phenotypes
Tasha Tsao
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
476 - The XBB.1.5 mRNA Booster Vaccine Does Not Significantly Increase XBB.1.5 Mono-Reactive T Cells
Joel Sop
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
477 - Evaluation of Salivary Antibody in Protection From SARS-CoV-2 Infection
Sharon Walmsley
University Health Network, Toronto, Canada
2:30 PM2:30 PM
478 - Evaluation of the PHH-1V COVID-19 Vaccine-Induced T-Cell Responses in Adolescents: HIPRA-HH-3 Study
Ignasi Esteban
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
479 - T-Cell Immunity of PHH-1V COVID-19 Vaccine in PWH and Adults With Immunosuppressive Conditions
Raúl Pérez-Caballero
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
480 - Torque Teno Virus: A Predictive Biomarker for SARS-CoV-2 Vaccine Response in Immunosuppressed People
Gonzalo Cabrerizo
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
2:30 PM2:30 PM
481 - Limited Effectiveness of High-Dose Flu Vaccine in Augmenting Immunity in Older People With HIV
Jonah Kupritz
University of Miami Miller, Miami, FL, USA
2:30 PM2:30 PM
482 - Herpes Zoster Reactivation in a Cohort of People Living With HIV Vaccinated With Recombinant Vaccine
Stefania Arsuffi
University of Brescia, Brescia, Italy
2:30 PM2:30 PM
483 - Persistence of Seroprotection After Modified Hepatitis B Vaccine Schedule in People Living With HIV
Caroline Troccoli
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-08) HIV Reservoir Landscape and Dynamics
2:30 PM2:30 PM
558 - Longitudinal Analysis of HIV Reservoir Dynamics Using Q4ddPCR in Individuals Who Are ART-Treated
Rachel K. Scheck
Charité – Universitätsmedizin Berlin, Berlin, Germany
2:30 PM2:30 PM
559 - Paucity of HIV Envelope Expressing Cells Upon Latency Reversal in ART-Suppressed PWH
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
560 - Early ART Initiation Is Associated With Faster Decay of the Transcriptionally Active HIV Reservoir
Cordelia M. Isbell
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
561 - In-Depth Evaluation of the Intact Proviral DNA Assay for the Quantification of HIV-1 Reservoir
Frank Maldarelli
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
562 - Deciphering the HIV-2 Proviral Reservoir in Antiretroviral-Naive Individuals
Charlotte Charpentier
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
563 - CCR5 Expression Is Critical for the Maintenance of HIV Control and Reservoir Size
Jéssica dos Santos
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
564 - Ex Vivo Antigen Stimulation Induces HIV-1 Viral Outgrowth From a Pericentromeric Provirus
Angelica Camilo-Contreras
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
565 - Multiomics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort
Victoria Rios Vazquez
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
566 - Sex-Specific Immune Responses Shape Proviral Landscapes in Individuals on Long-Term Suppressive ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
567 - Female Sex Is Associated With Continuous Decline in Intact HIV-1 Proviruses
Yijia Li
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
568 - A Virology Quality Assurance Program to Assess Inter-Lab Reproducibility of HIV-1 Reservoir Assays
Maria Blasi
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
569 - The Cross Subtype Intact Proviral DNA Assay Detects 97% of Proviruses From Diverse HIV Clades
Dara A. Lehman
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
570 - Impact of Early ART Initiation With BIC/FTC/TAF on HIV-1 Reservoir Decay During Primary Infection
Sònia Vicens-Artés
August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
2:30 PM2:30 PM
571 - Rapid Clearance of the Inducible HIV-1 Reservoir After Initiation of Antiretroviral Therapy
Maria C. Puertas
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
572 - HIV Proviral Populations Differ by Sex and Immune Activation Levels During Antiretroviral Therapy
Chuen-Yen Lau
National Institutes of Health, Bethesda, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-09) Molecular Mechanisms of HIV Persistence and Latency
2:30 PM2:30 PM
573 - BACH2 Controls Seeding and Establishment of Long-Lived HIV-1 Reservoir in Memory CD4+ T Cells
Hongbo Gao
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
574 - Blockade of HIV Latency Reversal in CD4+ T Cells From ART-Suppressed PLWH by the Antisense RNA AST
Rui Li
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
575 - HIV Reactivation Potential Evaluated by RNA-Seq and DNA Methylation Following LRA Stimulation
Giuseppe Rubens Pascucci
Bambino Gesu Children's Hospital, Rome, Italy
2:30 PM2:30 PM
576 - Activation of Latent HIV-1 by Retinol Binding Protein 4
Chiara Pastorio
Ulm University Medical Center, Ulm, Germany
2:30 PM2:30 PM
577 - Zaprinast Reprogrammes Resting CD4+ T-Cell Metabolism and Induces HIV Latency Reversal Ex Vivo
Valentin de Masson d'Autume
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
578 - Anti-HIV Gene Editing Is Inhibited in Active HIV Provirus Through Long-Terminal Repeat Demethylation
Mohamed Bouzidi
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
579 - Macrophage Training Reactivates Latent HIV-1 From HAART-Suppressed PBMCs of PLWH
Sinu P. John
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
580 - Interference of HIV Integration via Changes in CPSF6 and SC35 Expression Due to TKIs in Macrophages
Clara Sánchez Menéndez
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
581 - Thymosin α1 Enhances IL-15 Pathway Between MoDCs and CD8+ T Cells and Restrains HIV Latency In Vitro
Chaoyu Chen
Fudan University, Shanghai, China
2:30 PM2:30 PM
581.5 - Cyclic Adenosine 3',5'-Monophosphate Agonist Prevents Establishment and Reversal of HIV Latency
Prerna Dabral
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
583 - Lymph Node Immune Landscape Reveals the Role of Innate Immunity on HIV Reservoir in ART-PLWH
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
584 - Depletion of CX3CR1+ Effector CD8 TRM Cells Is Associated With HIV-1 Reservoir in the Colon on ART
Nived Collercandy
Toulouse University Hospital, Toulouse, France
2:30 PM2:30 PM
585 - HIV Reservoir in Jejunum Exhibits Distinct Phenotypic Features and Evokes Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
2:30 PM2:30 PM
586 - Single Cell Characterization of the Gastrointestinal HIV Reservoir
Nancie Archin
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
2:30 PM2:30 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
627 - HIV Transcripts in Blood May Identify Patients at Lower Risk of Brain Injury in Cure Research
Kazuo Suzuki
St Vincent's Centre for Applied Medical Research, Darlinghurst, Australia
2:30 PM2:30 PM
628 - Unmasking the Independent Role of CSF HIV RNA Dynamics by Single Copy Assay in Neurobiotypes
Lucette A. Cysique
University of New South Wales Sydney, Sydney, Australia
2:30 PM2:30 PM
629 - Adenosine, Guardian of the Brain: Possible Role in Protecting From HIV Neuropathogenesis
Yoelvis Garcia-Mesa
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
630 - Neuroinflammation Associated With Levels of HIV DNA in the Frontal Cortex of Virally Suppressed PWH
Thomas Angelovich
RMIT University, Melbourne, Australia
2:30 PM2:30 PM
631 - HIV-Infected Microglia Drive Transcriptional and Metabolic Changes in Complex Human Brain Organoids
Leanne C. Helgers
Academic Medical Center, Amsterdam, Netherlands
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-07) Aging and NeuroHIV: Understanding Pathogenesis and Trajectories
2:30 PM2:30 PM
633 - Plasma Neopterin as a Potential Biomarker for Neurocognitive Impairment in Aging People With HIV
Marta Ruiz-Riol
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
634 - A Blip or a Trend? Interpreting Fluctuations in Cognition Over Time in Older Adults With HIV
Marie-Josée Brouillette
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
635 - Obstructive Sleep Apnea Contributes to Cognitive Difficulties Among Older Adults With HIV
Marie-Josée Brouillette
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
636 - Association of Delayed HIV Diagnosis or ART Initiation With Risk of Age-Associated Dementia
Jennifer O. Lam
Kaiser Permanente Northern California, Oakland, CA, USA
2:30 PM2:30 PM
637 - Incidence and Risk Factors for Neurocognitive Disorders Among Persons With HIV in Washington, DC
Shannon K. Barth
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
638 - Systemic Immune-Inflammation Index Links to Slower Psychomotor Speed in Older People With HIV
Crystal Wang
University of California San Diego, La Jolla, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-03) Pharmacokinetics in the Real World: Long-Acting Drugs, Alternative Matrices, and Adherence
2:30 PM2:30 PM
651 - Tenofovir Diphosphate in Dried Blood Spots and HIV-1 RNA Suppression Among PWH on TAF (ACT Study)
Ryan P. Coyle
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
653 - TFV-DP Is Associated With Baseline Virologic Suppression in PWH on TAF: Results From ACTG A5359
Stefanie Schwab
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
654 - Association of Trough Concentrations of Cabotegravir and Rilpivirine and HIV-1 RNA
Sebastian Noe
MVZ München am Goetheplatz, Munich, Germany
2:30 PM2:30 PM
655 - Inter- and Intraindividual Variability of LA CAB/RPV Pharmacokinetics After 1 Year of Continuous Use
Shawnalyn W. Sunagawa
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
656 - Plasma Concentrations of Lenacapavir in People Living With Multidrug-Resistant HIV: Real-Life Study
Minh Le
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
657 - Intracellular Pharmacokinetics of Favipiravir-5’-Ribofuranosyl Triphosphate in People With COVID-19
Elizabeth Challenger
University of Liverpool, Liverpool, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-03) ART in Vulnerable and Treatment-Experienced Populations
2:30 PM2:30 PM
689 - Long-Term Virologic Suppression Rates in the Ward 86 HIV Clinic’s Long-Acting ART Program (SPLASH)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
690 - Long-Acting Injectable ART in Persons With HIV-1 Viremia in the South: A Tool to End the Epidemic
Jonathan Colasanti
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
691 - Long-Acting Injectable Versus Oral HIV Antiretroviral Therapy for People Experiencing Homelessness
Kathleen O'Connor
San Francisco Department of Public Health, San Francisco, CA, USA
2:30 PM2:30 PM
692 - A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
693 - Simplified Access and Retention Model for Vulnerable People With HIV: SIMPLIFIED Study Results
Pablo Ryan
Hospital Universitario Infanta Leonor, Madrid, Spain
2:30 PM2:30 PM
694 - Forgiveness of Dolutegravir-Based Regimens Using Medication Possession Ratio: Andhra Pradesh, India
Ramesh Allam
US Centers for Disease Control and Prevention, Delhi, India
2:30 PM2:30 PM
695 - Less Frequent Clinical and Viral Load Assessments During COVID-19 Did Not Increase Virologic Failure
Andrew Carr
St Vincent's Hospital, Sydney, Australia
2:30 PM2:30 PM
696 - Predictive Factors of Virologic Failure After Switching to B/F/TAF (ANRS-CO3-AquiVIH-NA)
Camille Tumiotto
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
697 - Achievement of Undetectable HIV RNA in the PROMISE-US Study in Subjects Viremic at Baseline
Smitha Gudipati
Henry Ford Hospital, Detroit, MI, USA
2:30 PM2:30 PM
698 - Outcomes for Persons With Triple-Class Resistant HIV and a History of Virologic Failure
Suzanne M. Ingle
University of Bristol, Bristol, UK
2:30 PM2:30 PM
699 - Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in the Trio Cohort
Moti Ramgopal
Midway Immunology and Research Center, Fort Pierce, FL, USA
2:30 PM2:30 PM
700 - Effectiveness of Antiretroviral Therapy in People With and Without TB in the IeDEA Cohort
Lea Faure
University of Bordeaux, Bordeaux, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-05) Antiviral Therapy for SARS-CoV-2
2:30 PM2:30 PM
711 - Potent, Pan-Coronavirus Antiviral Activity of the Novel 3CLpro Inhibitor ALG-097558
Andreas Jekle
Aligos Therapeutics, San Francisco, CA, USA
2:30 PM2:30 PM
712 - Novel Class of Small Molecules Inhibits SARS-CoV-2 PLpro Through Molecular Glue-Induced Dimerization
David Hardee
AbbVie, Inc, North Chicago, IL, USA
2:30 PM2:30 PM
713 - SARS-CoV-2 Ensitrelvir Resistance-Associated Mutations in Phase III Randomized Clinical Trial
Manish C. Choudhary
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
714 - Patterns of Remdesivir Initiation in Immunocompromised Patients Hospitalized With COVID-19
Mark Berry
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
715 - Machine Learning Identifies Predictors of Delayed Remdesivir Use in Hospitalized COVID-19 Patients
Anne-Maud Ferreira
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
716 - Tracking Key Remdesivir Resistance Mutations in SARS-CoV-2 Using GISAID Data (2020-2024)
Toshibumi Taniguchi
Chiba University, Chiba, Japan
2:30 PM2:30 PM
717 - Nirmatrelvir/Ritonavir for Chronic COVID-19: Outcome in 16 Severely Immunocompromised Patients
Hanne Lamberink
Erasmus University Medical Center, Rotterdam, Netherlands
2:30 PM2:30 PM
718 - Synergistic Effect of NMV/r and Acquired Immunity in Reducing Severe COVID-19
Warren Bao
Pfizer Biostatistics, New York, NY, USA
2:30 PM2:30 PM
719 - Metformin on Time to Sustained Recovery in Adults With COVID-19: ACTIV-6 Randomized Clinical Trial
Carolyn Bramante
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
720 - Optimal Timing and Immunogenicity of COVID-19 Booster Vaccination: The EU-COVAT-2 BOOSTAVAC Trial
Elena Alvarez
University College Dublin, Dublin, Ireland
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-03) Clinical Impact of Drug Resistance in Trials and Cohorts
2:30 PM2:30 PM
734 - No Virologic Failure in Patients Switched to Doravirine Treatment With Past Resistance Mutations
Basma Abdi
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
735 - HIV-1 Resistance Analysis of Treatment-Naive People With HIV and HBV Receiving B/F/TAF or DTG+F/TDF
Michelle D'Antoni
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
736 - Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks
Laurie Vanderveen
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
737 - Virologic Success on InSTI-Based ART Despite Archived InSTI DRMs
Yanis Merad
Hospices Civils de Lyon, Lyon, France
2:30 PM2:30 PM
738 - Bictegravir + Lenacapavir: Baseline and Week 48 Resistance in ARTISTRY-1 Phase II
Nicolas Margot
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
739 - Real-World Robustness of B/F/TAF at Virologic Failure in the ANRS-CO3-AquiVIH-NA Cohort
Camille Tumiotto
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
740 - Shifting Paradigms: Doravirine's Potential in Treating Non-Group M HIV-1, the DORAVI-O Study
Elodie Alessandri-Gradt
University of Rouen Normandy, Normandy, France
2:30 PM2:30 PM
741 - Impact of Resistance to Antiretroviral Therapy Among Veterans With Human Immunodeficiency Virus
Mary J. Christoph
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
742 - Population-Based Longitudinal Dynamics of HIV Drug Resistance During Dolutegravir Rollout in Uganda
Michael A. Martin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
743 - Plasma DTG Exposure Test as Objective Tool to Identify People With HIV at Highest Risk of Resistance
Kim Steegen
National Health Laboratory Service, Johannesburg, South Africa
2:30 PM2:30 PM
744 - Plasma Dolutegravir Exposure as a Triaging Tool for HIV Drug Resistance Testing by ONT Sequencing
Hendrik J. Coetser
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
745 - HIV Drug Resistance by Next-Generation Sequencing After Transition to TLD in Uganda and South Africa
Suzanne McCluskey
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
746 - HIV Drug Resistance Among Individuals on Dolutegravir With Low-Level Viremia in Malawi
Newton L. Kalata
US Centers for Disease Control and Prevention Lilongwe, Lilongwe, Malawi
2:30 PM2:30 PM
747 - Predictors of HIV Drug Resistance to Dolutegravir in 4 PEPFAR-Supported Countries
Juliana D. Da Silva
Centers for Disease Control and Prevention, Atlanta, GA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-04) Hepatitis Epidemiology and Immunology
2:30 PM2:30 PM
778 - HeCaPred: An AI-Based Algorithm for HCC Prediction in Patients With HCV Chronic Infection After SVR
Anaïs Corma-Gómez
Hospital Universitario Virgen de Valme, Sevilla, Spain
2:30 PM2:30 PM
779 - A New Point-of-Care Ultrasound Protocol for Chronic Hepatitis B and HBV/HIV Coinfection in Zambia
Costanza Bertoni
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
780 - High Prevalence of Triple Infection (HIV/HBV/HDV) Among Key Populations With HIV in India
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
782 - Simulation Modeling of Hepatitis B Virus Disease Progression, Hepatitis Flares, and Functional Cure
Amir Mohareb
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
783 - HIV/HCV Coinfection: Extracellular Vesicles Modulate NK Functionality in Relation to Liver Fibrosis
Ariel A. Osegueda
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
2:30 PM2:30 PM
784 - In Vitro and In Vivo Immunogenicity of a Dendritic Cell-Based Vaccine Targeting HBV Epitopes
Sylvain Cardinaud
Vaccine Research Institute, Créteil, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-04) Cervical and Anal Cancer: Prevention and Screening
2:30 PM2:30 PM
805 - HPV Detection by Vaginal Self-Sampling and Urine Collection in Women Living With HIV: AUTOCol Study
Jade Ghosn
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
806 - The Ivorian Cervical Cancer Screening Cascade: A 10-Year Program Evaluation According to HIV Status
Simon Boni
PAC-CI Program, Abidjan, Côte d'Ivoire
2:30 PM2:30 PM
807 - 2 vs 3 Doses of HPV9-Valent Vaccine in Women With HIV: Safety & Immunogenicity From Randomized Trial
Debora R. Konopnicki
Saint-Pierre University Hospital, Brussels, Belgium
2:30 PM2:30 PM
808 - Optimizing Anal Cancer Screening in PWH: The Role of ADAR1 mRNA in Predicting High-Grade Lesions
Melissa Bello-Perez
Hospital General Universitario de Elche, Elche, Spain
2:30 PM2:30 PM
809 - Anal Cancer Incidence Among Privately Insured People With and Without HIV in South Africa
Eliane Rohner
University of Bern, Bern, Switzerland
2:30 PM2:30 PM
810 - Evaluation of Anal Cancer Screening in 18–34-Year-Old Men Who Have Sex With Men Living With HIV
Serina S. Applebaum
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
828 - Genomic Analyses of Cardiovascular Risk in People With HIV From the MVP Cohort
Vincent C. Marconi
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
829 - The Additive Value of Coronary Calcium in Identifying Cardiovascular Risk in Ageing People With HIV
Maithili Varadarajan
Chelsea and Westminster Hospital, London, UK
2:30 PM2:30 PM
830 - BMI Is a Poor Surrogate for Excess Visceral Adiposity and Cardiovascular Risk in Persons With HIV
Karam Mounzer
Philadelphia FIGHT, Philadelphia, PA, USA
2:30 PM2:30 PM
831 - Investigating the Predictive Role of NLR and PLR in Cardiovascular and Neurologic Outcomes in PWH
Teresa H. Evering
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
832 - Cardiovascular Risk Assessment in Women Living With and Without HIV Using the PREVENT Model
Tetiana Povshedna
University of British Columbia, Vancouver, Canada
2:30 PM2:30 PM
833 - Prediction of Cardiovascular Risk Among PWH: Comparing the PREVENT and Pooled Cohort Equations
Matthew S. Durstenfeld
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
834 - Lipidomic, Metabolomic, and Immune Profiles Precede Cardiovascular Events in People With HIV
Joana Vitalle
Institute of Biomedicine of Sevilla, Sevilla, Spain
2:30 PM2:30 PM
835 - Patterns of Social and Biological Risk Factors in People With HIV and Risk of Cardiovascular Disease
Cynthia N. Ramirez
Kaiser Permanente Division of Research, Oakland, CA, USA
2:30 PM2:30 PM
836 - Agrarian Diet Intervention Improves Metabolic Health in Men With HIV Who Have Sex With Men
John O'Connor
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
837 - Decreased Anti-Inflammatory Tryptophan Metabolites Correlate With Higher CVD Risk in PWH
Manuela Ceccarelli
Università Kore di Enna, Enna, Italy
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-05) Atherosclerosis and Vascular Disease
2:30 PM2:30 PM
838 - Risk of Obesity, Cardiometabolic Disease, and MACE After Switch to Integrase Inhibitor in REPRIEVE
Emma M. Kileel
Boston University, Boston, MA, USA
2:30 PM2:30 PM
839 - Determinants of De-Novo High-Risk Carotid Ultrasound Features in Middle-Aged People Living With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
840 - Seven-Year Progression of Coronary Artery Calcium Score in Middle-Aged Thai People Living With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
841 - Markers of Arterial Stiffness in People Living With HIV and Echocardiographic Outcomes
Karl Reis
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
842 - Multiomics Profiles of SHBG Are Associated With Subclinical Atherosclerosis in Men With HIV
Yi Wang
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
843 - Multiomics Analysis of Gut Microbiome and Carotid Artery Atherosclerosis in Men With and Without HIV
Zheng Wang
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
844 - PLHIV Exhibit a COVID-19 Independent Increase of Cardiovascular Mortality in Brazil, 2019-2023
Rodrigo Moreira
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
845 - Effect of Treatment for Opioid Use Disorder on Endothelial Function in People With and Without HIV
Corrilynn O. Hileman
MetroHealth Medical Center, Cleveland, OH, USA
2:30 PM2:30 PM
846 - Cholesterol Synthesis Pathways in Monocyte-Derived Macrophages Link CMV and HIV to Atherosclerosis
Katelyn O'Hare
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
847 - Endothelial Colony-Forming Cells From People With HIV Display an Interferon Gene Signature
Akif A. Khawaja
Imperial College London, London, UK
2:30 PM2:30 PM
848 - CHIP Is Associated With Plasma Inflammatory Biomarkers and Vascular Events in People With HIV on ART
Caroline H. Sheikhzadeh
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
849 - ALDH Activity as a New Marker of Subclinical Atherosclerosis During ART-Treated HIV-1 Infection
Jonathan Dias
University of Montreal, Montreal, Canada
2:30 PM2:30 PM
850 - Statin Effect Heterogeneity on Plaque Volume and Composition in the REPRIEVE Mechanistic Substudy
Borek Foldyna
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
851 - People With HIV at High Cardiovascular Risk Were Undertreated With Statins
Stefan Esser
University Hospital Essen, Essen, Germany
2:30 PM2:30 PM
852 - Low-Density Lipoprotein Changes in People With HIV Initiating Statins for Primary Prevention
Thibaut Davy-Mendez
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
853 - Time-Updated Win Ratio Aligns With Primary REPRIEVE Findings and Suggests Early Pitavastatin Benefit
Emma Davies Smith
Harvard TH Chan School of Public Health, Boston, MA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-06) Diabetes and Metabolic Dysfunction
2:30 PM2:30 PM
898 - Incident Diabetes Among People With HIV After Switching to Integrase Strand Transfer Inhibitors
Y. Joseph Hwang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
899 - Decreased Adipose Tissue Gene Expression After a 48-Week Switch From an InSTI Regimen to TDF/3TC/DOR
Claudine Duvivier
Necker Hospital, Paris, France
2:30 PM2:30 PM
900 - In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens
Alessandra Guida
AORN dei Colli Ospedale Cotugno, Naples, Italy
2:30 PM2:30 PM
901 - HIV-Induced Immunomodulation and Cardiometabolic Disease Development in Mice on High-Fat Diets
Victoria R. Stephens
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
902 - HIV and Antiretrovirals Have Unique In Vivo Effects on Insulin Resistance in HIV
Theodoros Kelesidis
University of Texas Southwestern Medical Center, Dallas, TX, USA
2:30 PM2:30 PM
903 - Menopause Is Associated With Faster Increases in Insulin Resistance in Women With HIV
Rebecca Abelman
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
904 - Obstructive Sleep Apnea and Prevalent Diabetes Mellitus in the Multicenter AIDS Cohort Study
Wassim A. Bouhsane
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
905 - Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance
Diana L. Alba
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
906 - Early Pregnancy Insulin Dynamics in South African Women With HIV on Dolutegravir: The ORCHID Study
Jennifer Jao
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
907 - Noncommunicable Diseases: A Significant Cause of Death Among People Living With HIV in Nigeria
Chiamaka H. Onuoha
APIN Public Health Initiatives, Abuja, Nigeria
2:30 PM2:30 PM
908 - Risk Factors for Osteonecrosis Among People With HIV in Care Across the US in the Current ART Era
Heidi M. Crane
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
909 - Validation of SCORE and OST for Osteoporosis Risk Estimation in People Aging With HIV in Peru
Joselito Malca Hernandez
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
910 - Prevalence, Incidence, and Correlates of Autoimmune Diseases in People With HIV From 1997 to 2023
Emanuela Zappulo
University of Naples Federico II, Naples, Italy
2:30 PM2:30 PM
911 - Disparities in Hospitalization Among People in the HIV Outpatient Study, United States, 2008-2022
Kate Buchacz
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
912 - Uncovering Differential Disparities at the Intersection of Race, Sex, & HIV in Patients With Sepsis
Joshua A. Barocas
University of Colorado School of Medicine, Aurora, CO, USA
2:30 PM2:30 PM
913 - HIV Status and Psychiatric Diagnoses Among Transgender and Gender-Diverse Individuals
Fanghui Shi
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
914 - Kynurenine-Tryptophan (KT) Ratio and Inflammatory Biomarkers Associated With COPD in People With HIV
Kristina Crothers
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
915 - Characteristics of Secondary Hemophagocytic Lymphohistiocytosis in People Living With HIV/AIDS
Xavier A. Flores-Andrade
National Institute of Respiratory Diseases, Mexico City, Mexico
2:30 PM2:30 PM
916 - Safety of Full-Spectrum Cannabidiol for PWH: A Double-Blind, Randomized, Placebo-Controlled Study
Clémence Couton
Centre de Biophysique Moléculaire, Orléans, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-03) PASC: Biological Clues to Pathogenesis
2:30 PM2:30 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
937 - Lack of Association of SARS-CoV-2 N- and S-Antigenemia With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
938 - Exploring the Molecular Pathways of Long COVID With Post-Exertional Fatigue: A Multiomic Approach
Marta Massanella
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
939 - Distinct Proinflammatory/Proangiogenetic Signatures Distinguish Children With Long COVID
Danilo Buonsenso
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2:30 PM2:30 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
941 - Key Inflammatory Biomarkers Differentiate MIS-C From Convalescent COVID-19 and Kawasaki Disease
Tetyana Pidkova
IrsiCaixa Institute for AIDS Research, Badalona, Spain
2:30 PM2:30 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:30 PM2:30 PM
943 - Autoantibody Prevalence After SARS-CoV-2 Infection: Comparing Baltimore, USA, and Rakai, Uganda
Xianming Zhu
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
944 - Novel Plasma Biomarkers for the Detection of Long COVID Defined by Multiapproach Analysis
Mohamed R. Joma
French National Institute of Health and Medical Research (Inserm), Paris, France
2:30 PM2:30 PM
945 - ACE2 Autoantibodies in Post-Acute Sequelae of SARS-CoV-2 Infection
Melissa Agsalda-Garcia
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
946 - Shared Autoantibody Signature Is Not Identified in CSF During Long COVID
Debanjana Chakravarty
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
947 - Post-Acute SARS-CoV-2 Antigenemia Is Associated With Some but Not All Long COVID Symptoms
Michael Peluso
University of California San Francisco, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-05) Cryptococcal Meningitis: Where Do We Go From Here?
2:30 PM2:30 PM
973 - Uptake of New Guidelines for Cryptococcal Meningitis in Botswana, Malawi, Uganda, and Zimbabwe
David S. Lawrence
London School of Hygiene & Tropical Medicine, London, UK
2:30 PM2:30 PM
974 - Clinical Outcomes of People With HIV-Cryptococcal Meningitis on the New Treatment Regimen in Uganda
Esther M. Nasuuna
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
975 - Trends in Cryptococcal Meningitis Mortality Using Routine Longitudinal National Data From Botswana
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
976 - Pathway to Care Among Inpatients With Symptomatic Cryptococcal Meningitis in Johannesburg, SA
Lia F. Edkins
WITS Health Consortium, Johannesburg, South Africa
2:30 PM2:30 PM
977 - CMV and EBV Co-Infections and Mortality Risk in Patients With HIV-Associated Cryptococcal Meningitis
Jayne P. Ellis
London School of Hygiene & Tropical Medicine, London, UK
2:30 PM2:30 PM
978 - Catastrophic Healthcare Expenditure From Cryptococcal Meningitis in Eastern and Southern Africa
David S. Lawrence
London School of Hygiene & Tropical Medicine, London, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-06) OI Pathogenesis and Recent Trends in ART and OI Treatment Outcomes
2:30 PM2:30 PM
979 - Epigenetic Changes With T. gondii in Brains of People With HIV and Their Possible Link to Gliomas
Megha Srivatsa
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
980 - Factors Associated With Virologic Suppression in People Living With HIV and Tuberculosis in Brazil
Nathalie De Castro
Hôpital Saint-Louis, Paris, France
2:30 PM2:30 PM
981 - Recent Trends in Opportunistic Infections at ART Initiation in the NA-ACCORD of IeDEA, 2017-2021
Keri N. Althoff
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
982 - Ceftriaxone or Aqueous Penicillin for Neurosyphilis: A Mexican Multicentric Retrospective Study
Rodrigo Ville Benavides
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
983 - Burden of Opportunistic Infections and Causes of Death in Hospitalized Patients With AHD in Vietnam
Nam Xuan Ha
Oxford University Clinical Research Unit in Vietnam, Ho Chi Minh, Vietnam
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-05) HIV Acquisition and Prevention During Pregnancy and Breastfeeding
2:30 PM2:30 PM
1005 - Incident HIV Infection Among Pregnant Women in Botswana Has Decreased Since 2022
Aamirah Mussa
Botswana–Harvard AIDS Institute Partnership, Gaborone, Botswana
2:30 PM2:30 PM
1006 - Social Determinants Associated With Recent HIV Infection in Treatment-Naive Pregnant Women in Malawi
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1007 - STI Testing Is Associated With Lower PrEP Discontinuation Among Women Initiating PrEP in Pregnancy
Jerusha Mogaka
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1008 - Impact of Offering PrEP Choice on HIV Incidence in High-Risk Pregnant Women in Kenya
Tessa Concepcion
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1009 - PrEP Adherence and Acceptability of Urine Tenofovir Testing in Pregnant and Postpartum Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1010 - TFV-DP Concentrations in PBMCs and Safety of Daily Directly Observed F/TDF PrEP During Pregnancy
Linxuan Wu
University of Washington, Seattle, WA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-06) Emerging Perspectives on Perinatal HIV Transmission
2:30 PM2:30 PM
1011 - Vertical HIV Transmission: Substantial Reductions but Not Elimination With Universal ART
Nisha Jacob
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1012 - The Role of Maternal Broadly Neutralizing Antibody Activity in Perinatal Transmission of HIV-1
Krithika Karthigeyan
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1013 - ART Reverses Negative Natural Selection of HIV Disease-Linked HLA-I in KwaZulu-Natal, South Africa
Nicholas G. Herbert
University of Oxford, Oxford, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-05) Risks and Responses to ART
2:30 PM2:30 PM
1050 - Infants With HIV Starting ART Within 4 Months of Age Can Achieve Sustained Undetectable HIV-1 DNA
Alfredo Tagarro
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
2:30 PM2:30 PM
1051 - Hospitalization Incidence Among Young Children Living With HIV in the Western Cape, South Africa
Kim Anderson
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1052 - Inflammatory Cytokines in ART-Naive Kenyan Children Diagnosed With HIV at Hospital Admission
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1053 - HIV Viral Load Patterns Since Dolutegravir Initiation in Children and Adolescents Living With HIV
Sophie Desmonde
Université Toulouse III - Paul Sabatier, Toulouse, France
2:30 PM2:30 PM
1054 - Viral Suppression 12 Months After Switch to Dolutegravir by nRTI Backbone in Children/Adolescents
Renee de Waal
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1055 - Transitioning Adolescents With HIV to TDF/3TC+DTG Improves Virologic Outcome: CIPHER-ADOLA Study
Aude Christelle Ka'e
2:30 PM2:30 PM
1056 - Prevalence and Consequences of Low-Level Viremia Among Adolescents Living With HIV in South Africa
Zea Leon
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1057 - HIV-1 Drug Resistance at Low- and High-Level Viremia in Kenyan Youth on Dolutegravir-Based Therapy
Rami Kantor
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1058 - Enhanced Adherence Counselling Among Adolescents With Detectable Viremia in Cameroon
Alex Durand Nka
2:30 PM2:30 PM
1059 - Differentiated Service Delivery Programme Impact on Clinical Outcomes Among Adolescents With HIV
Lara Lewis
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
1060 - HIV Status Disclosure Among ART-Experienced Adolescents and Young Adults in 4 African Countries
Trevor Crowell
US Military HIV Research Program, Bethesda, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-06) Health and Outcomes of Young People With HIV
2:30 PM2:30 PM
1061 - Long-Term Outcomes of Young Adults With Perinatal HIV Infection in the US and Puerto Rico
Leah Kern
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
1063 - Psychotic Disorders in Young Adults With Perinatally Acquired HIV: A Multicentre UK Study
Indira Mallik
Imperial College Healthcare NHS Trust, London, UK
2:30 PM2:30 PM
1064 - Changes in Suicidality, Depression, and Anxiety After Integrative Mental Health Care in Thai Youth
Tavitiya Sudjaritruk
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1066 - Kidney Dysfunction in Young People Living With HIV on Dolutegravir-Based Regimens in Kampala, Uganda
Esther M. Nasuuna
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
1067 - Long-Term Immune Response to Vaccines in Vertically Infected People Living With HIV
Daniele Donà
University of Padova, Padova, Italy
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-07) Inflammation and Cardiovascular Complications
2:30 PM2:30 PM
1068 - Characterisation of Cardiac Disease in Adolescents With HIV in the Antiretroviral Therapy Era
Edith D. Majonga
Biomedical Research and Training Institute, Harare, Zimbabwe
2:30 PM2:30 PM
1069 - Left Ventricular Mass Adjustment for Body Size in Youth With Perinatal HIV or Perinatal HIV Exposure
George W. Sawyer
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
1070 - Distinct Metabolic and Inflammation Signatures in Urban vs Rural Ugandan Youth With HIV
Sahera Dirajlal-Fargo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1071 - US and Ugandan HIV Youth: Exploring Differences in Inflammatory, Chemokine, and Vascular Signatures
Sahera Dirajlal-Fargo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1072 - HIV Modifies Association of Biomarkers on Cardiac Fibrosis and Inflammation in South African Youth
Jennifer Jao
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1073 - Changes in Inflammatory Biomarkers Among Youth Living With Perinatal HIV Infection and Exposure
Russell B. Van Dyke
Tulane University, Metairie, LA, USA
2:30 PM2:30 PM
1074 - Inflammation Phenotypes in Children With Perinatally Acquired HIV in South Africa
Claire Davies
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1075 - Early-Treated Children With Perinatal HIV Show Elevated Monocyte Activation Into Late Childhood
Claire Davies
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1144 - Increasing Methamphetamine Use and Group Sex Observed in MSM With Acute HIV Infection in Bangkok
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
1145 - Unstable Housing, Methamphetamine Use, and HIV Incidence Among Racial and Ethnic Minority Men
Marjan Javanbakht
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1146 - Substance Use Is Associated With Higher HIV Viral Load and Reduced Viral Suppression in 6 US Cohorts
Ryan P. Kyle
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1147 - Missed Opportunities for Drug Use Screening and Discussions Among People With HIV
Sydney Bornstein
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1148 - Impact of Residing or Injecting in Testing Center Catchments on HIV Testing in Churachandpur, India
Talia A. Loeb
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1149 - HIV Outcomes Among People With HIV Who Inject Drugs in West Virginia
Rebecca Reece
West Virginia University, Morgantown, WV, USA
2:30 PM2:30 PM
1150 - Scope of the Overdose Crisis: Fatal Overdoses Among People With HIV Experiencing a Nonfatal Overdose
Megan E. Marziali
Columbia University, New York, NY, USA
2:30 PM2:30 PM
1151 - Progress Towards UNAIDS 95-95-95 Targets Among PWID Living With HIV Over 10 Years in Punjab, India
Griffin J. Bell
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1152 - The Impact of Semaglutide on Alcohol Use Among People With HIV in Routine Clinical Care in the US
Heidi M. Crane
University of Washington, Seattle, WA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-11) HIV Transmission Insights Through Phylogenetics
2:30 PM2:30 PM
1153 - Introduction and Acquisition of HIV-1 Related to Recent Migration to Quebec (2016-2023)
Jean-Pierre Routy
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
1154 - HIV Molecular Clusters Attributed to Sexual Transmission in the United States, 2015-2023
Kathryn G. Curran
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1155 - Changing Clustering Rates in the Rhode Island HIV-1 Epidemic
Rami Kantor
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1156 - Evolution of HIV-1 A6 Clusters in Poland Following Full-Scale Armed Conflict in Ukraine
Karol Serwin
Pomeranian Medical University, Szczecin, Poland
2:30 PM2:30 PM
1157 - People Living With HIV Diagnosed Late Provide Source of HIV Infection to Others With Recent Diagnosis
Evangelia G. Kostaki
National and Kapodistrian University of Athens, Athens, Greece
2:30 PM2:30 PM
1158 - Distribution of HIV-1 Variants in Population-Based National Surveys in Sub-Saharan Africa, 2015-2022
Peter D. Ghys
Independent Consultant, Tannay, Switzerland
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-12) Life Expectancy and Mortality Among People With HIV
2:30 PM2:30 PM
1159 - Life Expectancy Among Virally Suppressed Women and Men With HIV in the Bronx, New York, 1997-2021
Brandilyn A. Peters
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
1160 - Mortality Trends Among Persons With Perinatal HIV in United States and Territories, 1978-2022
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1161 - Mortality in the HIV Outpatient Study (HOPS), Trends and Risks: 2007-2022
Frank Palella
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1162 - Reducing HIV Diagnoses and Mortality Rate Further Increases Aging Resource Needs for PWH Into 2040
Siobhan M. O'Connor
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1163 - Factors Associated With Mortality Among People With Advanced HIV Disease in Rural Uganda, 2018-2021
Kabali Bwogi
C-CARE International Hospital, Kampala, Uganda
2:30 PM2:30 PM
1164 - Projecting Demographics and Causes of Death Among People With HIV in Western Europe to 2050
Julie Ambia
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1165 - Causes of Mortality Among Persons Living With HIV in Thailand, 2007-2022
Wiphawee Kiatchanon
Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand
2:30 PM2:30 PM
1166 - Text Clustering Model for Defining Cause of Death Among PLHIV in Thailand (2020-2022)
Apiratee Kanphukiew
Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand
2:30 PM2:30 PM
1167 - Changes Over Calendar Time in Discrimination of Prognostic Models for People With HIV Starting ART
Suzanne M. Ingle
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1168 - Clinical Outcomes in Lung Transplantation in People Living With HIV: A Competing Risk Analysis
German Contreras
University of Texas Medical Branch, Galveston, TX, USA
2:30 PM2:30 PM
1169 - Epigenetic Age Acceleration and Mortality Among Persons Who Inject Drugs With Poorly Controlled HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1170 - The HIV Epidemic Is Growing Faster in Countries Excluded From Gilead Voluntary Licenses
Samuel Cross
NHS Greater Glasgow and Clyde, Glasgow, UK
2:30 PM2:30 PM
1171 - Characteristics and Needs of Adult Lifetime Survivors With HIV in the United States, 2015-2022
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1172 - Clinical and Programmatic Factors Associated With Low-Level Viremia in West Africa
Ebiere C. Herbertson
Nigerian Institute of Medical Research, Lagos, Nigeria
2:30 PM2:30 PM
1175 - Prevalence and Risk Factors of HIV Viral Blips in the NA-ACCORD, 2010-2020
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
1176 - Time From HIV Infection to Diagnosis Using CD4 Depletion Model: Thailand, 2014-2021
Suchunya Aungkulanon
National Health Security Office, Chiang Mai, Thailand
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-03) Challenging and Innovative HIV Testing
2:30 PM2:30 PM
1191 - HIV Serologic Reactivity in Persons With HIV Who Started ART During Acute/Early Stages of Infection
Vivian I. Avelino-Silva
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
1192 - Laboratory-Based HIV-1/2 Ag/Ab Immunoassay Performance in the United States, 2019-2023
Patricia Bessler
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1193 - Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP
Jessica M. Fogel
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1194 - Can HIV Testing Data and Recent HIV Infection Surveillance Identify Similar Signals of Transmission?
Misheck Luhanga
US Centers for Disease Control and Prevention Lilongwe, Lilongwe, Malawi
2:30 PM2:30 PM
1195 - Preferences for HIV Testing Technologies in Seattle, Washington: A Mixed-Methods Study
Lauren R. Violette
Harvard Medical School, Boston, MA, USA
2:30 PM2:30 PM
1196 - Clinical Validation of iMune qPCR as a Novel Solution to CD4 Counting Off Dried Blood Spots
Tracy M. Sungu
University of Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1197 - Screening of MPXV, VZV, HSV-1, and HSV-2 Causing Mucocutaneous Vesicular Rashes by Multiplex HRM-PCR
Joany Guy
AFYIA Diagnostics, Grabels, France
2:30 PM2:30 PM
1198 - Impact of Point-of-Care HIV-1 RNA Testing on Time to HIV Confirmation and ART Start in Buenos Aires
Carina Cesar
Fundación Huésped, Buenos Aires, Argentina
2:30 PM2:30 PM
1199 - Characteristics of First-Time HIV Self-Testers Using the Online HIV Service ‘Stand By You’
Kantarida Sripanidkulchai
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-06) Innovations in PrEP Products
2:30 PM2:30 PM
1232 - MK-8527 PK/PD Threshold and Phase II Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Research Laboratories, Rahway, NJ, USA
2:30 PM2:30 PM
1233 - A Biodegradable Implant Releasing Low-Dose Islatravir Protects Macaques From Rectal SHIV Infection
Leah Johnson
RTI Health Solutions, Research Triangle Park, NC, USA
2:30 PM2:30 PM
1234 - Qualitative Assessment of Acceptability and Preferences for Injectable and Oral PrEP in PURPOSE 1
Elizabeth (Liz) Montgomery
2:30 PM2:30 PM
1235 - Cost-Effectiveness of Community Pharmacy-Based HIV PrEP for Men Who Have Sex With Men in Atlanta
Jacinda Tran
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1236 - Long-Acting Injectable CAB/MPA MPT Implant for Prevention of HIV and Unintended Pregnancy
Jasmine King
CIDRZ / University of North Carolina, Chapel Hill, NC, USA
2:30 PM2:30 PM
1237 - Acceptability and Usability of a TAF/EVG Insert Among Women in a Multinational Phase I Trial
Ellen Luecke
RTI International, Berkeley, CA, USA
2:30 PM2:30 PM
1238 - Dose-Ranging Pharmacokinetics and Efficacy of a 90-Day Multipurpose IVR Delivering Islatravir
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1275 - Postexposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Cristina Gómez-Ayerbe
Hospital Universitario Virgen de la Victoria, Málaga, Spain
2:30 PM2:30 PM
1276 - Doxycycline Post-Exposure Prophylaxis Continuum of Care Among MSM in Philadelphia, 2023
Tanner Nassau
Philadelphia Department of Public Health, Philadelphia, PA, USA
2:30 PM2:30 PM
1277 - Characteristics of Breakthrough Chlamydia Cases Among Cisgender Women Assigned to Doxycycline PEP
Jenell Stewart
Hennepin Healthcare Research Institute, Minneapolis, MN, USA
2:30 PM2:30 PM
1278 - Acceptability of Doxycycline as Post-Exposure Prophylaxis in Southeastern Louisiana
Shafay Shams
Louisiana State University, New Orleans, LA, USA
2:30 PM2:30 PM
1279 - Factors Influencing Doxy-PEP Awareness Among Sexual/Gender Minorities: A Web-Based Survey in Brazil
Mayara Secco Torres da Silva
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1280 - Young Black Sexually Minoritized Men Living With HIV, Substance Use, and Syphilis Want Doxy-PEP
Jade Pagkas-Bather
University of Chicago, Chicago, IL, USA
2:30 PM2:30 PM
1281 - Increased Knowledge and Use of Doxycycline Postexposure Prophylaxis in King County, Washington
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
2:30 PM2:30 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
2:30 PM2:30 PM
1283 - Topical Doxycycline Inserts Show High Efficacy Against Vaginal Chlamydia Acquisition in Macaques
David A. Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Postexposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
1285 - Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Clinic, 2023-2024
Philip A. Chan
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1286 - Effectiveness of Ceftriaxone Monotherapy for Gonorrhea Treatment
Chiara Fusetti
Luigi Sacco University Hospital, Milan, Italy
2:30 PM2:30 PM
1287 - Prevalence of Tetracycline-Resistant Gonorrhea in British Columbia’s HIV Treatment and PrEP Program
K. Junine Toy
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
2:30 PM2:30 PM
1341 - A Comparative Analysis of Access and Retention of Oral PrEP and CAB-LA at 1 Month in Zambia
Damian J. Phiri
John Snow, Inc, Lusaka, Zambia
2:30 PM2:30 PM
1342 - Patterns of PrEP Use Among Rural South Africa Youth Given Choice: Process Data From the LAPIS Trial
Maryam Shahmanesh
University College London, London, UK
2:30 PM2:30 PM
1343 - Peer Mobilisation Into Sexual Health Clinics Creates PrEP Demand Among High-Risk Rural Youth in SA
Maryam Shahmanesh
University College London, London, UK
2:30 PM2:30 PM
1344 - Injectable Cabotegravir PrEP Discontinuations at a Peer Specialist-Led Program in Washington, DC
Juan Carlos Loubriel
Whitman-Walker Health, Washington, DC, USA
2:30 PM2:30 PM
1345 - Outcomes From a Multilevel Trial With Clinics and Young Women for PrEP in South Africa
Alexandra Minnis
RTI International, Berkeley, CA, USA
2:30 PM2:30 PM
1346 - Impact of CAB-LA Versus Oral PrEP in Reducing HIV Incidence Among MSM in Thailand: A Modelling Study
David Van de Vijver
Erasmus University Medical Center, Rotterdam, Netherlands
2:30 PM2:30 PM
1347 - PrEP Use Trajectories and HIV Incidence Among PrEP Users in Brazil: Findings From the ImPrEP Study
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1348 - US Socioeconomic Disparities and Geographic Variations in HIV Preexposure Prophylaxis Providers
Li Tao
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1349 - Social Networks Influence PrEP Use and Preference for Long-Acting PrEP Among MSM In Baltimore
Steven J. Clipman
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1350 - Disparities in PrEP Use Among Latinx and Black Transgender Women in Los Angeles County, 2019 vs 2023
Yingbo Ma
Los Angeles County Department of Public Health, Los Angeles, CA, USA
2:30 PM2:30 PM
1351 - Early PEPFAR Implementation of Cabotegravir-LA and Implications for Long-Acting HIV Prevention
Carly E. LoVullo
PEPFAR, Washington, DC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-08) PrEP Choice and Preferences
2:30 PM2:30 PM
1352 - “I Like It but I Can’t Be the First”: Sex Workers’ Preferences for LAI PrEP Delivery in South Africa
Katherine Rucinski
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1353 - HIV PrEP Method Preferences Among Transgender and Gender-Diverse Adults in the United States
Dovie L. Watson
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1354 - Expanding the PrEP Market: Early Insights Offering Oral, Ring, and CAB PrEP in Sub-Saharan Africa
Urvi Parikh
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
1355 - Long-Acting PrEP Preference Among Brazilian Sexual and Gender Minorities: Key Influencing Factors
Thiago Torres
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1356 - PrEP Choices Among Sexual and Gender Minorities in Brazil: The ImPrEP CAB-LA Study
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1357 - Acceptability of Long-Acting Cabotegravir Among Pregnant and Lactating People in South Africa
Nafisa Wara
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1358 - Regional Disparities in DoxyPEP Uptake Despite High Awareness Among MSM With HIV in the US
Tyler Martinson
University of California San Francisco, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-09) Long-Acting Injectable ART Implementation
2:30 PM2:30 PM
1359 - Characteristics of People With HIV Prescribed Long-Acting Cabotegravir/Rilpivirine in a US Cohort
Sita Lujintanon
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1360 - Clinical Consequences of Delaying Implementation of LA-ART for PWH With Persistent Viremia in the US
Kenneth A. Freedberg
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1361 - Longitudinal Renal Safety of a Population-Level TDF-Based HIV PrEP Program in British Columbia
K. Junine Toy
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1362 - Disposition of Referrals for Long-Acting Antiretrovirals at the Ward 86 HIV Clinic in San Francisco
Chesa Cox
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1363 - Impact of 6-Monthly ART Dispensing on Retention in Malawi: A Target Trial Emulation Study
Khumbo Shumba
Health Economics and Epidemiology Research Office, Johannesburg, South Africa
Upcoming:
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-01) Mpox and HIV Virology
2:30 PM2:30 PM
300 - Understanding the Evolutionary Framework and Transmission Dynamics of Mpox in South Korea
Chihwan Choi
Korea Disease Control and Prevention Agency, Cheongju-si, South Korea
2:30 PM2:30 PM
301 - Fine-Tuning Viral Adaptation Through Genome Retraction: Insights From Mpox Outbreaks in South Korea
Minji Lee
Korea Disease Control and Prevention Agency, Cheongju-si, South Korea
2:30 PM2:30 PM
302 - Discovery of Aberrant Genomic Rearrangement in an Mpox Virus Genome Observed in a Japanese Patient
Takayuki Ishige
Chiba University, Chiba, Japan
2:30 PM2:30 PM
303 - Factors Associated With Detectable Viral Load Among PLHIV in Serodiscordant Partnerships in Tanzania
Abbas Ismail
US Centers for Disease Control and Prevention Dar es Salaam, Dar es Salaam, Tanzania
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-02) HIV-1 Envelope and Viral Tropism
2:30 PM2:30 PM
304 - Enhanced Recognition of V3 bNAb Epitopes Induced by Fostemsavir on Cell-Associated Primary HIV-1 Env
Svenja Weiss
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
305 - CXCR4-Using HIV-1 Variants Evolve in the Presence of and Co-Exist With CCR5-Using Variants
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
306 - Droplet Single Genome Amplification Allows for Characterization of Autologous HIV Envelope Sequences
Joseph McWhirter
Boston University, Boston, MA, USA
2:30 PM2:30 PM
307 - High Resistance of HIV-1CH040 Envelope Glycoproteins to bNAbs Without Loss of Efficient Viral Entry
Durgadevi Parthasarathy
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
308 - Sex Differences in Replication Kinetics of Primary HIV-1 Isolates in Monocyte-Derived Macrophages
Jake Robinson
University of Pennsylvania, Philadelphia, PA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-01) Non-HIV Viruses
2:30 PM2:30 PM
331 - Impact of Pre-Existing Immune Activation on SARS-CoV-2 Incidence and Disease During the First Wave
Diana Yang
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
332 - Unique SARS-CoV-2 Variants and Inflammatory Milieu in Urine of Severe COVID-19 Participants
Aarthi Subramani
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
333 - Bile Acids in the Modulation of Antiviral Immune Response
Eileen F. Serrano
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
334 - The Bile Acids Complexity Underlies an Antiviral Interferon Innate Signaling During COVID-19 Disease
Diego A. Diaz-Dinamarca
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
335 - The Influence of Chronic HIV Inflammation on Post-COVID Immune Activation
Skye Opsteen
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
336 - Lipid Nanoparticles Targeting Neutrophil and NETs to Mitigate Lung Injury in SARS-CoV-2 Mice
Juwon Park
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
337 - Vitamins K2 and D3 Improve Long COVID Index, Fungal Translocation, and Inflammatory Biomarkers
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
338 - High-Fat and -Sugar Diet but Not SIV Coinfection Enhances SARS-CoV-2 Shedding in Infected Macaques
Kelsie Brooks
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
339 - Sustained Inflammation and Delayed Resolution of COVID-19 Disease in SIV-Infected Macaques
Dhiraj K. Singh
Texas Biomedical Research Institute, San Antonio, TX, USA
2:30 PM2:30 PM
340 - Monocyte Dysregulation in PASC With Ongoing Pulmonary Symptoms
Thomas K. Awamura
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
341 - Retroviral Infection Reprograms Mouse Embryonic Stem Cells
Andrew D. Mazzanti
University of Toronto, Toronto, Canada
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-02) Host-HIV Interaction
2:30 PM2:30 PM
342 - Untangling the Impact of CD101 on HIV-1 Transmission
Phuong Vo
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
343 - CD40L/IL-4 Stimulated B Cells as Efficient Mediators of HIV-1 Binding and Trans Infection
Abigail Gerberick
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
344 - Feminizing Hormone Therapy and the Rectal Mucosal Immune Environment
Stacey Smith
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
345 - HIV-1 Vpr Promotes Viral Replication, Granzyme B Expression, and Death of Gut CD4 T Cells Ex Vivo
Kaylee Mickens
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
346 - Early HIV-1 Genetic Diversity Includes CTL and Drug Resistance Mutations
John Coffin
Tufts University, Boston, MA, USA
2:30 PM2:30 PM
347 - Tuberculosis Promotes the Persistence of Genetically-Intact HIV in People With HIV and Tuberculosis
Samantha K. Cronin
The University of Sydney, Sydney, Australia
2:30 PM2:30 PM
348 - Species-Specific Splicing of DNA Editing Enzymes: Implications in HIV and SIV Mutagenesis
Diako Ebrahimi
Texas Biomedical Research Institute, San Antonio, TX, USA
2:30 PM2:30 PM
349 - Transcriptionally Active Defective HIV-1 Proviruses Persist in All CD4 T-Cell Subsets During ART
Hiromi Imamichi
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
2:30 PM2:30 PM
350 - Utilizing Defective HIV-1 Provirus as a Novel “Barcode” for Studying T-Cell Dynamics
Vinie Kouamou
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
351 - Similar Intact and Defective HIV Provirus Frequency in Suboptimal Immune Responders and Controls
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
352 - Impact of ART Initiation on HIV-1 Soluble gp120 Levels and CD4 Counts in PWH
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
2:30 PM2:30 PM
353 - Genetic Associations With CD4 Recovery in People With HIV After Initiation of Antiretroviral Therapy
Roxane Rohani
Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
2:30 PM2:30 PM
354 - R5-Tropic HIV Restricts X4-Tropic Virus via Type I IFN Signaling, Limiting Pathogenesis
Priya Pal
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
355 - Residual HIV Viremia Associates With Reservoir Size, but Not With Immune Activation or Inflammation
Twan Otten
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
356 - Relationship Between Gut Microbiome and Candida in PWH: Role of Bacterial Extracellular Vesicles
Aya Ishizaka
University of Tokyo Institute of Medical Science, Tokyo, Japan
2:30 PM2:30 PM
357 - The Mucosal Microbiome at Sites of HIV Acquisition Among Key Populations
Cassie G. Ackerley
Emory Vaccine Center, Atlanta, GA, USA
2:30 PM2:30 PM
358 - Virulent HIV-1B: Clinical Challenges and Proteomic Insights
Kavita Mehta
Ghent University, Ghent, Belgium
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-01) CD8 T Cells in Infection and After Vaccination
2:30 PM2:30 PM
400 - Duration of Viremia Modulates Antigen Sensitivity of HIV-Specific T-Cell Receptors
Funsho Ogunshola
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
401 - Low Post-ART SIV Viral Load Set Point Associated With Enhanced Lymph Node CD8+ T-Cell Proliferation
Gina Borgo
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
402 - The Soft Escape: HIV Alters Host Cell Cytoskeleton as a Mechanism of Resistance to CTL Killing
Louise Leyre
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
403 - CD8+ T-Cell Function During ART Is Associated With Provirus Suppression and Reduced Viral Rebound
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
404 - TCR Convergence in HIV Controllers: Insights Into Natural Viral Suppression
Alexandra Vujkovic
Institute of Tropical Medicine, Antwerp, Belgium
2:30 PM2:30 PM
405 - Robust CD8+ T-Cell Proliferation and Stem-Like Memory Phenotype Linked to HIV Post-Treatment Control
Charles Crain
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
406 - HIV-Infection Does Not Generally Confer Higher Resistance to CTL-Mediated Lysis
Niklas Bachmann
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
407 - HIV-Specific T & Humoral Response: Data From the First Pediatric Combined Therapeutic Vaccine Trial
Arianna Rotili
University of Rome Tor Vergata, Rome, Italy
2:30 PM2:30 PM
408 - HIV-1-Specific T Cells From Post-Treatment Controllers and Noncontrollers
Lisa L. Dietz
Aarhus University, Aarhus, Denmark
2:30 PM2:30 PM
409 - Impact of Gender-Affirming Hormone Therapy on T-Cell Phenotypes in Transgender Women With HIV
Elizabeth Hastie
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
410 - Differential Restoration of HIV-Specific CD8+ T Cells by Amino Acid and Lipid Metabolism Modulation
Enrique Martin Gayo
Universidad Autónoma de Madrid, Madrid, Spain
2:30 PM2:30 PM
411 - Unmodified mRNA Compared to Modified mRNA Induces Optimal CD8+ T-Cell Responses in Rhesus Macaques
Sampa Santra
Beth Israel Deaconess Medical Center, Boston, MA, USA
2:30 PM2:30 PM
412 - The Impact of Protein Specificity on Function and Crosstalk Between the HIV-Specific T Cells
Jernej Pusnik
Bonn University Hospital, Bonn, Germany
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-02) B Cells and Neutralizing Antibodies
2:30 PM2:30 PM
413 - Provirus From Early-Treated HIV Reveals Earlier Variants Targeted by Initial Neutralizing Antibodies
Hunter M. Courtney
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
414 - Structural Insight into the High- and Low-Affinity Alleles of Human and Macaque FcγRIIA (CD32A)
William D. Tolbert
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2:30 PM2:30 PM
415 - Antigen Affinity Ceiling for Selection of Functional Mutations and HIV-1 Neutralization
Ankita Singh
Duke Human Vaccine Institute, Durham, NC, USA
2:30 PM2:30 PM
416 - Maturation of B-Cell Lineages During cART in Chronic SHIV-Infected Juvenile Rhesus Macaques
Wilton Williams
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
417 - Public Trimer-Specific IgHV4-34 Clonotype in bNAb Inducers Includes a Novel V3-Glycan bNAb Subclass
Alexandra Trkola
University of Zurich, Zurich, Switzerland
2:30 PM2:30 PM
419 - In Nonsuppressible Viremia, HIV Env Can Maintain Resistance to Autologous Neutralizing Antibodies
Sang Hyeon Kim
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
420 - Molecular Mechanisms Underlying Anti-HIV-1 Fc-Effector Functions of Human IgA Allelic Variants
Marek K. Korzeniowski
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2:30 PM2:30 PM
421 - Sensitivity of HIV-1 CRF01_AE Envelopes to Broadly Neutralizing Antibodies VRC07-523 and PGDM1400
Gabriel Smith
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
422 - Transcriptional Analysis of Intestinal Immune Cells in People With HIV Receiving bNAbs
Connie A. Zhao
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
423 - Identification of an Autoantibody Against FCHSD2 in Adipose Tissue of PLWH With Diabetes
Laventa Obare
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
424 - Detection of Anti-Interferon Alpha/Omega Neutralizing Autoantibodies in PLWH
Alessandra D'Auria
Sapienza University of Rome, Rome, Italy
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-01) Viral Rebound and Control
2:30 PM2:30 PM
484 - Delayed HIV-1 Rebound Correlates With Enhanced CD8+ T-Cell Activation in Human Trials
Rasmi Thomas
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
485 - Total HIV-1 Nucleic Acid Increases Precede Plasma RNA Rebound During Pediatric ATI
Gabriela Z. L. Cromhout
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
486 - Consecutive Analytical Treatment Interruption Improves CD8 T-Cell Activity During Viral Control
Sarah Palmer
The Westmead Institute for Medical Research, Westmead, Australia
2:30 PM2:30 PM
487 - Mitochondrial Gene Variants Influence VARS2, HIV Reservoir, and CD4+ T Cells in HIV Controllers
Victoria Rios Vazquez
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
488 - Clinical and Virologic Outcomes of an ART Interruption in Treated Controllers and Non-Controllers
Isaac E. Avila-Vargas
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
489 - HIV-1 Post-Treatment Control Occurs Despite HLA-Escape Mutations in the Intact Reservoir
Efthimios A. Deligiannidis
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
490 - Time to Viremia and Frequency of Post-Treatment Control Among 382 “Placebo-Treated” ATI Participants
Jesper D. Gunst
Aarhus University Hospital, Aarhus, Denmark
2:30 PM2:30 PM
491 - Characterization of HIV Antibodies and p24 Antigen During Analytical Treatment Interruption
Clara Di Germanio
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
492 - Post-Treatment HIV Controllers Exhibit Reduced Plasma Markers of Inflammation and Metabolic Stress
Leila B. Giron
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
493 - Population-Specific T-Cell Responses and Virologic Control After Analytical Treatment Interruption
Jorge Gallardo Cartagena
Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Lima, Peru
2:30 PM2:30 PM
494 - Loss of Virologic Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
2:30 PM2:30 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
499 - Genetic Regulation of Immune Responses to CMV in Spontaneous HIV Controllers
Suzanne D. E. Ruijten
Radboud University Medical Center, Nijmegen, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-02) Strategies for an HIV Cure
2:30 PM2:30 PM
500 - The Asymmetric Opening of HIV-1 Env by a Potent CD4 Mimetic Enables Anti-CoRBS Abs to Mediate ADCC
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
501 - TCR-Mimic ScDb Reduced HIV Provirus and Delayed the Viral Rebound in HLA-Specific BLT Hu-Mice
Zhe Yuan
The Wistar Institute, Philadelphia, PA, USA
2:30 PM2:30 PM
502 - Targeting TCF-1 to Potentiate the Functional Capacity of HIV/SIV-Specific CD8+ T Cells
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
503 - CD4 T Cell-Targeting Lipid Nanoparticles in the Search for a Genetic HIV Cure
Maaike De Cock
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
504 - CD4 Mimetics Sensitize HIV-Infected Cells to ADCC Mediated by Plasma From Early-Stage HIV Infection
Andrés Finzi
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
505 - Sustained Post-Rebound HIV Remission With Enhanced T-Cell Immunity After LS-bNAbs: A Case Report
John Frater
University of Oxford, Oxford, UK
2:30 PM2:30 PM
506 - Sustained T Cell-Mediated Immunity After LS-bNAbs in the RIO Trial: A Vaccinal Effect
John Frater
University of Oxford, Oxford, UK
2:30 PM2:30 PM
507 - Temsavir Treatment Improves Recognition of HIV-1 Infected Cells by Broadly Neutralizing Antibodies
Hangfei Qi
ViiV Healthcare, Durham, NC, USA
2:30 PM2:30 PM
508 - Maximizing Benefits to Participants in Analytic Treatment Interruption With Antibody Infusions
Yifan Li
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
509 - Myeloid Targeted and Enhanced Endosomal Escapable LNPs Improve Latent HIV-1 Elimination Efficacy
Soumya S. Dey
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
510 - A Novel and Promising Strategy of HIV Eradication via LTR-LTR Recombination
Feng Li
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
511 - Development and Delivery of Next-Generation Epigenome Editors for Long-Term HIV Silencing
Francisco J. Zapatero Belinchon
Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
2:30 PM2:30 PM
512 - RV550: Safety and Virologic Outcomes in Blood and Lymph Nodes of N-803 With ART in Acute Infection
Carlo Sacdalan
SEARCH, Bangkok, Thailand
2:30 PM2:30 PM
513 - HIV-1 Reservoir Decay During Broadly Neutralizing Antibody Therapy in the RIO Trial
Marcilio Jorge Fumagalli
The Rockefeller University, New York, NY, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-04) Transcription in the HIV Reservoir
2:30 PM2:30 PM
524 - Transcriptional Profiles of HIV RNA+ Cells in PWH on ART Differ From Those During Active Viremia
Julie Frouard
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
525 - Selective Decay of Different HIV Transcripts After ART Initiation in Chronic Infection
Cordelia M. Isbell
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
526 - Nonsuppressible HIV Viremia May Harbor Replication-Incompetent Viruses With 5' Leader Deletions
Zixin Hu
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
527 - HIV-1 Latency Reversal Augments Persistent HIV-1 Transcription During ART
Rowan Hassman
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
528 - MLN4924 Reduces HIV Transcription, Cell Survival, and HIV Infectivity After Latency Reversal In Vitro
Cristina C. Vaca
Northwestern University, Chicago, IL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-05) Novel Interventions Toward an HIV Cure
2:30 PM2:30 PM
529 - Venetoclax Decreases Intact Proviral DNA Frequency in SIV-Infected, ART-Suppressed Rhesus Macaques
Sydney N. Bergstresser
Yerkes National Primate Research Center, Atlanta, GA, USA
2:30 PM2:30 PM
530 - AZD5582 Inhibits Vaccine-Elicited CD8+ T-Cell Responses in SIV-Infected Rhesus Macaques on ART
Benjamin D. Varco-Merth
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
531 - Sustained HIV Remission Despite Transient Rebound Viremia After a CCR5∆32/∆32 Stem Cell Transplant
Paul Rubinstein
University of Illinois at Chicago, Chicago, IL, USA
2:30 PM2:30 PM
532 - HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant From CCR5Δ32/Δ32 Sibling Donor
Marius Trøseid
Oslo University Hospital, Oslo, Norway
2:30 PM2:30 PM
533 - Tazemetostat Enhances CTL Killing of HIV-Infected Cells and Reduces Reservoirs In Vivo
Itzayana G. Miller
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
534 - CXCR4-Targeted CRISPR/Cas9 Lipid Nanoparticles for Excision of Latent Proviral DNA
Sudipta Panja
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
535 - Efficient Generation of Anti-HIV TRAC-CAR T Cells to Enable High-Throughput Binder Screening
Gabriella Kimmerly
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
536 - Infusion of Autologous CCR5-Deleted CD4 Cells Does Not Change the HIV Reservoir: The TRAILBLAZER RCT
Carl J. Fichtenbaum
University of Cincinnati, Cincinnati, OH, USA
2:30 PM2:30 PM
537 - HIV-1 Reservoir Reduction in PWH Receiving ART and Dasatinib
Mario Manzanares
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
538 - Phase I Clinical Trial AMC097 Evaluating Engraftment and HIV Resistance of Gene-Modified Blood Cells
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-01) Neuroimaging in HIV
2:30 PM2:30 PM
589 - Humanized Glia Mice Show HIV-Induced Behavioral, Neuro, and Metabolic Changes as in Clinical Disease
Amanda Fernandes
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
590 - Evaluating White Matter Integrity in Relation to HIV Severity and Cognitive Impairment
Beau Ances
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
591 - Interaction Between Age, Brain Volume, and HIV Status in Predicting Cognition
Beau Ances
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
592 - Plasma Inflammation Is Associated With Brain Cellularity in Diffusion-Based Spectral Imaging in HIV
Advika Srinivas
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
593 - The Effects of Depression and Antidepressants on Cognition and Brain Volume in PWH and PWoH
Sophie A. Sims
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
594 - Analyzing Neuroanatomical Heterogeneity in HIV-Associated Cognitive Impairment
Audrey Chun
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
595 - Preliminary Analysis of Longitudinal Synaptic Density Change in Virally Suppressed People With HIV
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
596 - Cannabis Use Is Associated With Reduced Brain Integrity in Persons With HIV
Sarah Cooley
Washington University in St Louis, St Louis, MO, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-02) Biomarkers for NeuroHIV Informing Pathogenesis
2:30 PM2:30 PM
597 - Inflammatory Biomarker Profiling to Predict Neuroinflammation and Depression in Adolescents With HIV
Shalena Naidoo
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
598 - No Decline in CSF or Plasma Neurofilament Light Chain Levels Post-Early ART Initiation
Nametso Kelentse
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
599 - Polypharmacy Is Associated With Neuronal Injury in PWH
Priya Kosana
East Carolina University, Greenville, NC, USA
2:30 PM2:30 PM
600 - Plasma CNS Tissue Markers in Heavily Treatment-Experienced PWH in the PRESTIGIO Registry
Andrea Calcagno
University of Turin, Turin, Italy
2:30 PM2:30 PM
601 - Comprehensive Study of CSF Fluid β2-Microglobulin, a Marker of CNS Immune Activation in HIV
Birgitta Anesten
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
2:30 PM2:30 PM
602 - Higher suPAR Relates to Domain-Specific Cognitive Function in Virally Suppressed Women With HIV
Hemil Gonzalez
Rush University Medical Center, Chicago, IL, USA
2:30 PM2:30 PM
603 - Cognitive Intra-Individual Variability Predicts IADL Function in the Women’s Interagency HIV Study
David E. Vance
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
604 - Influence of an Exercise Intervention or Dynamic Stretching on Cognition and Gut Microbiome in PWH
Sarah Cooley
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
605 - Longitudinal Changes in Neuronal Markers and Associations With ART Initiation and Cognitive Function
Merle Henderson
Imperial College Healthcare NHS Trust, London, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-03) Omics Approaches to Pathogenic Interrogation of NeuroHIV
2:30 PM2:30 PM
606 - Single-Nucleus Multiomics Reveals Dysfunction in Multiple Glial Cell Types in Brain Tissue of PWH
Kriti Agrawal
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
607 - CSF Memory B Cells Exhibit Distinct Molecular Footprints in Treated PWH
Paraskevas Filippidis
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
608 - T-Cell Receptor Repertoire and Cognitive Performance in People With HIV
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
609 - A Transcriptional Signature of Induced Neurons Differentiates PWH on cART From People Without HIV
Teresa H. Evering
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
610 - Cerebrospinal Fluid Proteomic Patterns Vary With Neurobehavioral Characteristics
Patricia K. Riggs
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
611 - DNA Methylation Clocks Are Altered in Persons With Undetectable HIV and Correlate With Brain Aging
Kalen J. Petersen
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
612 - Epigenetic Age Advancement Predicts Cognitive Performance in Older People With HIV
Carrie Johnston
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
613 - Epigenetic Modifications Predictive of Cognitive Frailty in Cocaine-Using People Living With HIV
Marianna Baum
Florida International University, Miami, FL, USA
2:30 PM2:30 PM
614 - Differential Effects of CB2 Agonism on HIV Replication and Inflammatory Activation in Myeloid Cells
Cagla Akay-Espinoza
University of Pennsylvania, Philadelphia, PA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-01) The Next Generation: Pharmacology of New Drugs, Formulations, and Modeling Strategies
2:30 PM2:30 PM
639 - First-in-Human Study of a Long-Acting Injectable 3 Antiretroviral Drug Combination Nanoparticle
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
640 - Preclinical Pharmacokinetic Assessment of a Long-Acting Solid Injectable for Hepatitis C Virus
Usman Arshad
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
641 - Fixed Dosing Versus Body-Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults
Yunda Huang
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
642 - Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir
Marjorie Imperial
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
643 - Modeling Accurately Predicts Efficacious Islatravir QW Dose With No Lymphocyte and CD4 Changes
Diane Longo
Merck & Co, Inc, Rahway, NJ, USA
2:30 PM2:30 PM
644 - Can “Equivalence” of a Generic Cabotegravir LA Be Inferred From a Shortened Pharmacokinetic Study?
Henry Pertinez
University of Liverpool, Liverpool, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-01) Antiviral Therapy: Simplify, Modify, and Why!
2:30 PM2:30 PM
658 - Integrase Inhibitor- Versus Protease Inhibitor-Based Therapy for People With Advanced HIV Disease
Georg M. N. Behrens
Hannover Medical School, Hannover, Germany
2:30 PM2:30 PM
659 - Safety, Tolerability, and Efficacy of a BIC/FTC/TAF Dose Reduction Strategy
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
660 - Switch of Virally Suppressed Adults ≥ 60 Years From First-Line ART to B/F/TAF: Week 96 Results
Loice Ombajo
University of Nairobi, Nairobi, Kenya
2:30 PM2:30 PM
661 - Switch to DTG/3TC vs B/F/TAF (PASO-DOBLE Study): Efficacy and Weight Changes by Predefined Subgroups
Juan Tiraboschi
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
2:30 PM2:30 PM
662 - Inflammatory Signatures Among People With HIV Initiating DTG/3TC vs BIC/F/TAF in the CoRIS Cohort
Claudio Díaz-García
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
663 - Effectiveness and Inflammatory Markers After 144 Weeks of Switch to DTG/3TC in a Randomized Trial
Evy Blomme
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
664 - Impact of ART Simplification With Dolutegravir and Lamivudine on the HIV Reservoir
Céline Fombellida-Lopez
University of Liège, Liege, Belgium
2:30 PM2:30 PM
665 - Effect of 12-Month Switch to Dual cART on T-Cell Homeostasis, Gut and Mitochondrial Damage
Valeria Bono
University of Milan, Milan, Italy
2:30 PM2:30 PM
666 - ALLIANCE OLE: Switch to B/F/TAF in People With Both HIV-1 and HBV
Anchalee Avihingsanon
HIV-NAT, Thai Red Cross AIDS and Infectious Disease Research Centre, Bangkok, Thailand
2:30 PM2:30 PM
667 - Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status
Giuseppe Lapadula
University of Milano–Bicocca, Milan, Italy
2:30 PM2:30 PM
668 - Impact of Switching From DTG/3TC to BIC/FTC/TAF on Weight, Cholesterol, and Inflammation in HIV
Laura Martín Pedraza
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
669 - 24-Month Outcomes on Second-Line Antiretroviral Therapy in South Africa: A Target Trial Emulation
Jennifer A. Brown
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
670 - Dolutegravir With Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes
Morgan Byrne
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
671 - Is It Effective to Switch Regimen in PWH With Low-Level Viremia in the Current Era?
Tommaso Clemente
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
672 - Impact of Antiretroviral Therapy (ART) Intensification on HIV-1 Virologic Markers (ACTG 5324)
Jonathan Reed
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
673 - Factors Affecting Long-Term Trends of Immunologic Markers After ART: Results From the START Trial
Giota Touloumi
National and Kapodistrian University of Athens, Athens, Greece
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-01) HIV Resistance to bNAbs, Cabotegravir, GS 1720, and Other Agents
2:30 PM2:30 PM
721 - The Genetic Barrier to Resistance to LEN Is Not Affected by Non-B Subtypes or Treatment Exposure
Niccolò Bartolini
University of Siena, Siena, Italy
2:30 PM2:30 PM
722 - Structural and Mechanistic Insights Into Cabotegravir Resistance in HIV-1 Integrase
Indrani Choudhuri
Salk Institute for Biological Sciences, La Jolla, CA, USA
2:30 PM2:30 PM
723 - The Barrier to Escape From Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates
Alex C. Stabell
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
724 - In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral InSTI in Clinical Development
Derek Hansen
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
725 - Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution
Gregory E. Edelstein
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
726 - HIV-1 Env Exhibits Distinct Conformations and Neutralization Profiles in CSF and Blood
Hillel Haim
University of Iowa, Iowa City, IA, USA
2:30 PM2:30 PM
727 - Modifying PF74 Improves Anti-HIV-1 Activity Against the Resistance-Associated Capsid Mutation N74D
William M. McFadden
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
728 - Viral Escape From Broadly Neutralizing Antibodies in Non-Subtype B Viruses
Teresa Murphy
George Washington University, Washington, DC, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-01) Hepatitis C Treatment and Outcomes
2:30 PM2:30 PM
748 - Safety and Efficacy of 8-Week Glecaprevir/Pibrentasvir for Acute HCV in People Living With HIV
Kimberly Workowski
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
749 - DAA Initiation Among People With HIV and HCV in North America: Factors Driving the Treatment Gap
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
750 - High HCV Reinfection Rates May Mask “True” Sustained Virologic Response in People Who Inject Drugs
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
751 - Increasing HCV Prevalence Among People Who Inject Drugs in India Despite Improved Treatment Uptake
Allison M. McFall
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
752 - Impact of an HCV Test and Treat Campaign on Hepatitis C Incidence in the ANRS PREVENIR PrEP Study
Geoffroy Liegeon
Université Paris Cité, Paris, France
2:30 PM2:30 PM
753 - Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure
Jesica Martín-Carmona
Hospital Universitario Virgen de Valme, Sevilla, Spain
2:30 PM2:30 PM
754 - Comorbidities Among Medicaid Enrollees With Chronic Hepatitis C, 2016-2020
Julie Dombrowski
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
755 - Cost-Effectiveness of Interventions to Reduce HCV Among People Who Inject Drugs in Haiphong, Vietnam
Adam Trickey
University of Bristol, Bristol, UK
2:30 PM2:30 PM
756 - CC-Genotype (IFNL4) in HCV/HIV Coinfection: Cellular Exhaustion but Balanced Inflammatory Profile
Sonia Arca De Lafuente
Instituto de Salud Carlos III, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-02) Steatotic Liver Disease
2:30 PM2:30 PM
757 - Semaglutide Improves Steatohepatitis in People With HIV: The SLIM LIVER Study
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
2:30 PM2:30 PM
758 - Evaluation of Different Noninvasive Models in Assessing Lean MAFLD Among PLWH
Wei Xu
Shanghai Public Health Clinical Center, Shanghai, China
2:30 PM2:30 PM
759 - Effects of Semaglutide on Gut Microbiota in People With HIV: The SLIM LIVER Study
Stephanie M. Dillon
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
760 - Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV
Nadira Vadaq
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
761 - Incidence and Impact of Hepatic Steatosis in People With HIV: Insights From the NA-ACCORD Cohort
Jennifer Price
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
762 - Determinants of Steatotic Liver Disease Among People With HIV in Europe and Australia
Carlotta Riebensahm
University Hospital Bern, Bern, Switzerland
2:30 PM2:30 PM
763 - Diabetes Mellitus and Liver Disease Progression in PWH With Metabolic Dysfunction-Associated SLD
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
764 - Switching to DTG/3TC vs BIC/FTC/TAF and Steatotic Liver Disease: A Substudy of PASODOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
2:30 PM2:30 PM
765 - Liver Steatosis Progression With Integrase Inhibitors in HIV Adults in Low-/Middle-Income Countries
Marie Kerbie Plaisy
University of Bordeaux, Bordeaux, France
2:30 PM2:30 PM
766 - Lipidomics of Metabolic Dysfunction-Associated Steatotic Liver Disease Post-HCV Eradication in PWH
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-01) Liver Cancer, Lung Cancer, and NADC Pathogenesis
2:30 PM2:30 PM
786 - Lung Cancer Screening Eligibility and Uptake Among People With HIV: A Decade of Missed Opportunities
Subhashini A. Sellers
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
787 - Immune Tumor Microenvironment of HIV-Associated Lung Cancer Reveals Immunoregulatory Features
Brinda Emu
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
788 - Viral and Host Proteins Carried by Exosomes From PLWH Could Play a Role as Triggers of NADCs
Norma Rallón
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-02) Kaposi Sarcoma: Diagnosis, Treatment, Pathogenesis, and KSHV
2:30 PM2:30 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
790 - Kaposi Sarcoma in Relation to HIV Diagnosis: Which Comes First in East Africa in the Treat All Era?
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
2:30 PM2:30 PM
792 - Impact of Low-Dose Intralesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Chia-Ching Wang
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
793 - High Prevalence of Clonal Hematopoiesis Among Older People With HIV and Kaposi Sarcoma
Ramya Ramaswami
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
795 - Neuropilin-1 Is Required for KSHV Lytic Replication in Primary Effusion Lymphoma
Anna Serquina
National Cancer Institute, Bethesda, MD, USA
2:30 PM2:30 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
797 - Vascular Endothelial Growth Factor Receptor 3 (VEGFR3/FLT4) Regulates the KSHV Replication Cycle
Ameera Mungale
National Cancer Institute, Bethesda, MD, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-01) Heart Failure: Hiding in Plain Sight
2:30 PM2:30 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
2:30 PM2:30 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
816 - Long-Term Outcomes in People With HIV Who Survive a Major Adverse Cardiovascular Event
Rebecka Papaioannu Borjesson
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
817 - Epicardial Fat as a Predictor of Diastolic Dysfunction in Older People With HIV
Tanakorn Apornpong
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-02) Hypertension
2:30 PM2:30 PM
818 - Heart Failure Risk and Events in People With HIV in the REPRIEVE Trial
Maya Watanabe
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
819 - Effect of the Transition to Dolutegravir on Blood Pressure in People Living With HIV in West Africa
Romain Millot
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
820 - No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for PrEP: Results From HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
821 - Low Hypertension Knowledge Among Clinicians Prescribing Antihypertensive Medications in Malawi
Risa Hoffman
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
822 - Social Determinants of Health and the Hypertension Care Cascade in a National HIV Cohort
Puja Van Epps
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
823 - Risk of Incident Hypertension With Common Antiretroviral Agent Combinations in the OPERA Cohort
Gerald Pierone Jr
Whole Family Health Center, Vero Beach, FL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-01) Renal Disease
2:30 PM2:30 PM
854 - HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV
Grace Rozek
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
855 - APOL1 Genotype and Graft Function in South African HIV+-to-HIV+ Kidney Transplant Recipients
Robert Freercks
Nelson Mandela University, Gqeberha, South Africa
2:30 PM2:30 PM
856 - Human Antibody Repertoire and Allograft Rejection Among Kidney Transplant Recipients With HIV
Xianming Zhu
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
857 - Acute Drop in eGFR When Initiating SGLT2 Inhibitors vs Other Antihyperglycemic Medications Among PWH
Lara Haidar
University of Manitoba, Winnipeg, Canada
2:30 PM2:30 PM
858 - Associations Between Antiretroviral Therapy Use, Vitamin C Renal Leak, and Vitamin C Deficiency
Stephanie Teng
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
859 - Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF in Randomized Trials
Frank Post
King's College Hospital NHS Foundation Trust, London, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-02) GLP-1 Receptor Agonists
2:30 PM2:30 PM
860 - Racial Inequity in Initiation of Semaglutide Therapy Among People With HIV in Care Across the US
Andrew W. Hahn
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
861 - Cardiometabolic Effects of Semaglutide in People With HIV: The SLIM LIVER Study
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
2:30 PM2:30 PM
862 - Durability of Semaglutide Effects After Drug Discontinuation in HIV-Associated Lipohypertrophy
Allison Ross Eckard
Medical University of South Carolina, Charleston, SC, USA
2:30 PM2:30 PM
863 - Impact of Antidiabetic Medications on Weight Change Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
2:30 PM2:30 PM
864 - Liraglutide for Obesity in HIV (LIROH): A Single-Arm, Open-Label Clinical Trial in South Africa
Jennifer Manne-Goehler
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
865 - The Projected Impact of Post-ART BMI Maintenance on Diabetes Risk: A Modeling Study
Keri N. Althoff
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-03) Biomarkers of Aging
2:30 PM2:30 PM
866 - ART Exposure and Accelerated Aging in PLHIV: Insights From Proteomic and Methylation Clocks
Nadira Vadaq
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
867 - Epigenetic Age Acceleration and CD4/CD8 Ratio in People With Well-Controlled HIV Infection
Alejandro de Gea Grela
Hospital La Paz Institute for Health Research, Madrid, Spain
2:30 PM2:30 PM
868 - Inflammatory Markers and Frailty, Cognitive Impairment, Clinical Outcomes, and Mortality in PWH
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
869 - Novel Biomarkers Link Inflammation, T-Cell Exhaustion, Bone Health, and Frailty in People With HIV
Michael L. Freeman
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
870 - The Association of Cytomegalovirus Serostatus on Immune Recovery Among People With HIV
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
871 - Validation of SARC-F Tool for Sarcopenia Screening in People Aging With HIV
Joselito Malca Hernandez
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
872 - Mitochondrial DNA Variation and Physical Function Among Men With and Without HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
873 - Senescence-Associated Secretory Phenotype Biomarker Profiles of Age-Related Outcomes in PWH
Mary C. Masters
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
874 - Multicomponent Exercise Associated With a Healthier Gut Microbiota Profile in Older Adults With HIV
Laura Martín Pedraza
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
875 - Muscular Markers for Early Identification of Sarcopenia and Frailty States in Older People With HIV
Eugènia Negredo
Fundació Lluita contra les Infeccions, Barcelona, Spain
2:30 PM2:30 PM
876 - Metformin for Reversal of Accelerated Biological Aging in Persons With HIV: A Pilot Clinical Trial
Cristina Marcelo
Hospital Universitario La Paz, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-01) PASC: Natural History and Classification Systems
2:30 PM2:30 PM
917 - Higher Mortality Following SARS-CoV-2 Infection in Rural Dwellers Persists 2 Years After Infection
Jerrod Anzalone
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
918 - HIV Infection and Long COVID: A RECOVER Program, EHR-Based Cohort Study
Kellie L. Hawkins
Public Health Institute at Denver Health, Denver, CO, USA
2:30 PM2:30 PM
919 - Putting the PASC Score to the Test: Clinical vs Statistical Accuracy in Long COVID
Alba M. Azola
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
920 - Parametric Survival Analysis of Long COVID: A Cohort Study on the Time to Symptom Resolution
Warren Malambo
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
921 - Assessing the Burden of Long COVID in Persons With HIV Using the RECOVER Scoring System
Kamaria Dansby
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
922 - Long COVID Is a Multisystem Disorder: Assessment of the National Academies Definition
Jason D. Goldman
Swedish Medical Center, Seattle, WA, USA
2:30 PM2:30 PM
923 - Completeness of COVID-19 Outcomes Among People With HIV Receiving Care in New York City in 2020
David B. Hanna
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
924 - COVID-19 Symptoms, Vaccination, and Long COVID Between Cancer Survivors and the US General Population
Jincong Q. Freeman
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
925 - A Population-Based Study of Functional Disability, COVID-19 Symptoms, and Long COVID Among US Adults
Jincong Q. Freeman
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
926 - Cognitive Trajectories 1 Year Before and After COVID-19 in an Early-Treated HIV Cohort
Ferron Ocampo
University of Toronto, Toronto, Canada
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-01) ART-Related and Social Determinants of TB Transmission and Treatment Outcomes
2:30 PM2:30 PM
948 - Modelling the Contribution of Incarceration to TB Transmission in Ukraine
Jack Stone
University of Bristol, Bristol, UK
2:30 PM2:30 PM
949 - Mental and Physical Health of People With TB in Southern Africa at the Start of Treatment and Beyond
Guy K. Muula
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
2:30 PM2:30 PM
950 - HIV and Tuberculosis Stigma Affecting Individuals With Pulmonary Tuberculosis in East Africa
Kirsten K. Prabhudas-Strycker
Indiana University, Indianapolis, IN, USA
2:30 PM2:30 PM
951 - Neuropsychiatric Outcomes in Adults With HIV and TB on Twice-Daily BIC/FTC/TAF With Rifampicin
Gillian L. Dorse
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
952 - High Incident TB Among Individuals Switched to Dolutegravir or Protease Inhibitor Based 2nd Line ART
Claudia Danielle Minkoulou Engamba
University Teaching Hospital, Lusaka, Zambia
2:30 PM2:30 PM
953 - Unmasking and Tracking Tuberculosis Risk During HIV Acquisition and Antiretroviral Therapy
Fatoumatta Darboe
University of California San Francisco, San Francisco, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-01) Long-Acting Antiretrovirals for Pregnant and Breastfeeding Women
2:30 PM2:30 PM
1014 - LA-ART for Breastfeeding Women With HIV in Zimbabwe: Clinical Impact and Cost-Effectiveness
Sujata Tewari
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1015 - Long-Acting Cabotegravir/Rilpivirine in Pregnancy
William R. Short
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1016 - Modeling Tail-Phase PK From Early Pregnancy to Postpartum and Fetal Exposure to Long-Acting CAB-RPV
Shakir Atoyebi
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
1017 - A Long-Acting Dolutegravir Formulation Improves Drug Safety Profile During Pregnancy
Emma G. Foster
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
1018 - Population PK and CYP3A Inhibition Capacity of Ritonavir in Pregnancy: A Model-Based Meta-Analysis
Safa Algharbi
University of California San Diego, La Jolla, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-02) Complications in Maternal HIV
2:30 PM2:30 PM
984 - Patterns of Adiposity and Gestational Weight Gain in Pregnant South African Women Living With HIV
Mustafa Shuaib
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
985 - Genome-Wide Association With Postpartum Weight Change in Mothers on DTG or EFV in DolPHIN-2
Rebecca Jensen
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
986 - Depression, Sleep, and Anxiety Among Pregnant and Postpartum Women Using Dolutegravir and Efavirenz
Danni Wu
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
987 - Sleep Patterns in South African Pregnant Women Living With HIV on Dolutegravir: A Prospective Study
Hayli Geffen
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
988 - Prior Pregnancy Affects Aging-Related Non-AIDS Comorbidity Burden in US Women With and Without HIV
Lauren F. Collins
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
989 - Characteristics and Outcomes of Pregnant Women With HIV Undergoing Tuberculosis Screening in Uganda
Christina Yoon
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
990 - Incidence of Tuberculosis in South African Women Living With HIV During Pregnancy and Postpartum
Jasantha Odayar
University of Cape Town, Cape Town, South Africa
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-01) Health and Outcomes of Children Exposed to HIV/ART in Utero
2:30 PM2:30 PM
1019 - Neurodevelopmental Disorders in French HIV-/ARV-Exposed Uninfected Children: A National Cohort Study
Mathis Collier
Cochin Hospital, Paris, France
2:30 PM2:30 PM
1020 - Prenatal PrEP Exposure and Language Development Among Children at 5 Years
Lauren A. Gomez
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1025 - Transcriptome Perturbations in Peripheral Blood Cells of HIV-Exposed Uninfected Infants
Li Yin
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
2:30 PM2:30 PM
1026 - Comparing Telomere Length Between Children Who Were and Were Not Exposed to HIV in Kenya
Jillian Neary
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1027 - HIV Exposure Affects Gut Virome Richness but Not Diversity Among Kenyan Infants
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1028 - HIV Exposure Does Not Affect Cytomegalovirus Acquisition Risk in a Setting of Optimized Maternal ART
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1029 - Rapid Waning in Hepatitis B Virus Vaccine Immunity Among Children HIV-Exposed Uninfected in Botswana
Lynette Bhebhe
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-02) Mpox Epidemiology
2:30 PM2:30 PM
1090 - Understanding Mpox and HIV Coinfection: Insights From a Major Cohort Study in Brazil
Matheus Oliveira Bastos
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1092 - Mpox Reinfections in California, May 2022 to August 2024
Jessica Watson
California Department of Public Health, Richmond, CA, USA
2:30 PM2:30 PM
1093 - Sexual Behaviors Among GBMSM Infected With Mpox in California (May 2022 -July 2024)
Kayla Saadeh
California Department of Public Health, Richmond, CA, USA
2:30 PM2:30 PM
1094 - Long-Term Sequelae of Mpox: A Cohort Study in 2 Tertiary Centers
Rene Bulnes
UT Southwestern, Dallas, TX, USA
2:30 PM2:30 PM
1095 - Mpox Viral Load and Illness Severity in MSM Living With and Without HIV by Vaccine Status
Guido Schäfer
ICH Study Center, Hamburg, Germany
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-03) The Intersection of HIV With COVID-19
2:30 PM2:30 PM
1096 - Impact of COVID-19 Healthcare Disruptions on ART Initiation and Viral Suppression: US, 2018-2021
Sarita Shah
Rollins School of Public Health, Atlanta, GA, USA
2:30 PM2:30 PM
1097 - Disparities in COVID-19 Therapeutics Access Among People With and Without HIV: An N3C Analysis
Emmanuel Nazaire Essam Nkodo
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
1098 - Impact of COVID-19 Pandemic on the Newly Diagnosed PWH: Data From 2 Clinical Centres in Italy
Andrea Carbone
Universita Cattolica del Sacro Cuore, Milan, Italy
2:30 PM2:30 PM
1099 - Impact of COVID-19 Pandemic in Deaths of PLWH From ART Program of a Peruvian Hospital
Jorge Tello Arana
Universidad Científica del Sur, Lima, Peru
2:30 PM2:30 PM
1100 - Differential Impact of Social Determinants of Health by Sex in HIV for COVID-19 Hospitalizations
Rena C. Patel
University of Alabama, Tuscaloosa, AL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-04) Criminal Justice, Mental Health, and Syndemics Intersect With HIV
2:30 PM2:30 PM
1101 - A Syndemic View of Criminal Justice: Jail’s Impact on HIV, Syphilis, and Overdose in Washington 2023
Steven J. Erly
Washington State Department of Health, Olympia, WA, USA
2:30 PM2:30 PM
1102 - HIV Acquisition After Prison Release in Washington State and Implications for Prevention Efforts
Danika A. Troupe
Washington State Department of Health, Olympia, WA, USA
2:30 PM2:30 PM
1103 - Exploring Depression and Interventions Among PLHIV: Insights From the African Cohort Study
Gabriel Saemisch
United States Agency for International Development, Washington, DC, USA
2:30 PM2:30 PM
1105 - HIV Diagnosis Following Discharge From Psychiatric Hospitalization: A Claims-Based, Real-World Study
Samuel Bunting
University of Chicago Medical Center, Chicago, IL, USA
2:30 PM2:30 PM
1106 - Housing Status and HIV Outcomes Among Reproductive-Age Women Living With HIV in the Southern US
Shreya Ganguly
Emory University, Atlanta, GA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-05) Epidemiology of HIV in Transgender and Nonbinary Persons
2:30 PM2:30 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
2:30 PM2:30 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-01) Self, Couple, and Mobile Testing
2:30 PM2:30 PM
1177 - Expanding HIV Self-Test Reach: Comparative Outcomes Across Facility, Community, and Online Channels
Thi Thi Win
Community Partners International, Yangon, Myanmar
2:30 PM2:30 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis, and Treatment, 3/2023 - 5/2024
Allison Lale
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1180 - Engaging Male Partners of HIV-Negative Pregnant Women in HIV Testing Using Oral HIV Self-Test
Maganizo B. Chagomerana
University of North Carolina Project–Malawi, Lilongwe, Malawi
2:30 PM2:30 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
2:30 PM2:30 PM
1182 - Evaluating the Effectiveness and Population Impact of Status-Neutral HIV Screening in AZ
Lazaro Ruiz
University of Arizona, Tucson, AZ, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-01) Choice and Options as Prevention Tools
2:30 PM2:30 PM
1200 - Persistence of Oral PrEP Use in the United States, 2017-2023
Ya-Lin A. Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1201 - HIV Nonoccupational Post-Exposure Prophylaxis Use Among Transgender Women: 7 Cities, 2019-2020
Thomas G. Buchanan
Oak Ridge Institute for Science and Education, Atlanta, GA, USA
2:30 PM2:30 PM
1202 - Evaluating Pharmacy-Based PrEP Delivery for Sex Workers in Zimbabwe: Pilot Quasi-Experimental Study
Oppah Kuguyo
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
2:30 PM2:30 PM
1203 - Patterns of Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents
Laio Magno Santos de Sousa
Federal University of Bahia, Salvador, Brazil
2:30 PM2:30 PM
1204 - Support for Over-the-Counter PrEP Among Transgender Women and Transfeminine Nonbinary People
Lauren R. Violette
Harvard Medical School, Boston, MA, USA
2:30 PM2:30 PM
1205 - Male Circumcision, HIV, and Hepatitis B: Results From the Tanzania HIV Impact Survey
Alexander Kailembo
2:30 PM2:30 PM
1206 - Online and Less Frequent Monitoring of Oral HIV PrEP Use Are Noninferior to Standard of Care
Marije L. Groot Bruinderink
Public Health Service Amsterdam, Amsterdam, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-02) Epidemic Prevention Strategies
2:30 PM2:30 PM
1207 - Spillover Infections Drive Transmission in HIV Prevention Trials: BCPP/Ya Tsie Study
Sikhulile Moyo
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
1208 - Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England
Peter Vickerman
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1209 - Estimating Population Immunity and Impact of COVID-19 Vaccination in Washington and Oregon
Mia Moore
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1210 - Epidemiology and Predictors of COVID-19 Vaccine Uptake Among People With HIV in the US, 2020-23
Adrienne E. Shapiro
University of Washington, Seattle, WA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-01) Still Here: Syphilis
2:30 PM2:30 PM
1239 - Syphilis Screening in Hospitalized People With HIV: A Key Strategy to Tackle HIV and STI Epidemics
Mayara Secco Torres da Silva
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1240 - Differences in Presentation and Outcome of Subsequent Episodes of Syphilis in People Living With HIV
Jose L. Casado
Hospital Ramón y Cajal, Madrid, Spain
2:30 PM2:30 PM
1241 - Unravelling the Pathogenesis and Outcome of Serofast Status in People Living With HIV
Jose L. Casado
Hospital Ramón y Cajal, Madrid, Spain
2:30 PM2:30 PM
1242 - No CSF Study in Neuro Asymptomatic Syphilis in People With HIV: Clinical and Serologic Outcomes
María L. Otth
University of Chile, Santiago, Chile
2:30 PM2:30 PM
1243 - Describing the Cascade of Care for Neurosyphilis in People Living With HIV: Finding the Gaps
Shaul A. Navarro-Lara
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
1244 - Syphilis Among Women of Reproductive Age With or Without HIV in the Southern US
Maria L. Alcaide
University of Miami Miller, Miami, FL, USA
2:30 PM2:30 PM
1245 - Epidemic of Treponema pallidum Strains in Japan and Biomarkers for Molecular Epidemiology
Eisuke Adachi
University of Tokyo Institute of Medical Science, Tokyo, Japan
2:30 PM2:30 PM
1246 - Temporal Changes in Syphilis Prevalence and Population Characteristics Among MSM in India
Mihili Gunaratne
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1247 - Has Rapid Scale-Up of Dual HIV/Syphilis Testing in Antenatal Care Improved Syphilis Testing Coverage?
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
2:30 PM2:30 PM
1248 - Monitoring the Success of Public Health Efforts to Reduce Congenital Syphilis, King County, WA
Tim W. Menza
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1249 - Risk Factors for Incomplete Treatment for Syphilis in Pregnant Oral PrEP Users in South Africa
Kalisha Bheemraj
University of Cape Town, Cape Town, South Africa
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-02) Advances in Sexual and Reproductive Health in HIV
2:30 PM2:30 PM
1250 - HIV Status and Other Factors Associated With Infection Complicating Abortion in Botswana
Bogadi Loabile
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1251 - Irregular Menstruation Among Women Is Associated With COVID-19 Infection, but Not Vaccination
Emily M. Cherenack
University of Miami, Miami, FL, USA
2:30 PM2:30 PM
1252 - Incidence of Intended & Unintended Pregnancies Among Women With HIV on ART: 5-Year Cohort in Abidjan
Prescilia Visi Vumba
University of Bordeaux, Bordeaux, France
2:30 PM2:30 PM
1253 - Unmet Need for Family Planning Underestimated Among Women Living With HIV in Kenya
Alison Drake
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1254 - Effect of Antiretroviral Regimen on Contraceptive Failure Among Women Using Injectable Contraception
Karen Diepstra
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1255 - PrEP Eligible but Missed: Preliminary Evidence Unlocking the Potential of Family Planning Services
Brenice Duroseau
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
1256 - Multipurpose Vaginal Rings: Preferences From a National Discrete Choice Survey With US Women
Ann Gottert
Population Council, New York, NY, USA
2:30 PM2:30 PM
1257 - Oral PrEP and Sexual Health Screening Services Uptake Among Diverse Gender Identities in India
Rifa T. Khan
YR Gaitonde Center for AIDS Research and Education, Chennai, India
2:30 PM2:30 PM
1258 - STAR: A Prospective Cohort of Women of Reproductive Age With and Without HIV in the Southern US
Elizabeth F. Topper
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
1259 - Substance Use and Treatment Among Reproductive-Age Women With/Without HIV in the Southern US
Ayako W. Fujita
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1260 - Physical, Psychosocial, and Sexual Health in Adults Aged 50+ With and Without HIV in Denmark
Ditte Scofield
Hvidovre Hospital, Hvidovre, Denmark
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-01) Modeling
2:30 PM2:30 PM
1289 - Testing Healthcare System Resilience Using Microsimulation Modeling Under Various Shocking Scenarios
Viviane D. Lima
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1290 - Estimated Benefits of Providing On-Demand PrEP Options for Women in Cape Town: A Modeling Study
Dobromir Dimitrov
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1291 - Model-Projected Costs Associated With Increasing Numbers of Medicare Beneficiaries With HIV Aged 65+
Emily Hyle
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1292 - Modeling the Impact of Increased PrEP Use on Sexually Acquired HIV Incidence in the United States
Tamar Tchelidze
Roche Diagnostics, Somerville, NJ, USA
2:30 PM2:30 PM
1293 - Dynamic Choice HIV Prevention With Cabotegravir (CAB-LA): A Model-Based Cost-Effectiveness Analysis
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1294 - Cost-Effectiveness of PrEP and Medications for Opioid Use Disorder in People Who Inject Drugs
John Chiosi
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1295 - Ending the HIV Epidemic Among Men Who Have Sex With Men in the United States: A Modeling Analysis
Kenneth A. Freedberg
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1296 - Optimizing Investment in HIV Testing Services, ART, and PrEP to Reduce HIV Incidence in South Africa
Caitlin Dugdale
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1297 - Impact of Rapid Long-Acting PrEP Scale-Up Among MSM: Closing the Unmet Needs and Towards Ending HIV
Haoyi Wang
Maastricht University, Maastricht, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-02) Cardiovascular Risk, Weight
2:30 PM2:30 PM
1298 - Trajectories of Weight Changes After GLP-1 Receptor Agonists Initiation Among Patients With HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1299 - Cardiometabolic Risks and the Transition to InSTIs in Aging PLWH in South Africa
Julia K. Rohr
Harvard TH Chan School of Public Health, Boston, MA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-03) Mental Health
2:30 PM2:30 PM
1300 - Addressing Alcohol Use and Depression as a Strategy to Reduce HIV in KwaZulu-Natal, South Africa
Mellesia Jeetoo
New York University Langone Medical Center, New York, NY, USA
2:30 PM2:30 PM
1301 - Impact of SEARCH Person-Centered Care/Prevention on Clinical Outcomes by Alcohol Use in East Africa
James Ayieko
Kenya Medical Research Institute, Kilifi, Kenya
2:30 PM2:30 PM
1302 - Depression and Suicide Risk Among Sexual and Gender Minorities: Insights From the ImPrEP CAB Brasil
David Richer Araujo Coelho
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1303 - Effects of a Cash Transfer Intervention on Internalized HIV Stigma Among ART Initiates in Tanzania
Emmanuel Katabaro
Health for a Prosperous Nation, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
1304 - Low-Barrier HIV Care Outcomes in the Context of Homelessness, Substance Use, and Mental Illness
Julie Dombrowski
University of Washington, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-03) Persistence and Evolution of SARS-CoV-2
2:30 PM2:30 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
2:30 PM2:30 PM
310 - Emergence of Divergent Spike Haplotypes in Individuals With Persistent SARS-CoV-2 Infections
Luke Blagdon Snell
King's College London, London, UK
2:30 PM2:30 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
2:30 PM2:30 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
313 - SARS-CoV-2 Intrahost Evolution During Acute Infection in People With COVID-19
Agostino Riva
Luigi Sacco University Hospital, Milan, Italy
2:30 PM2:30 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-04) Nuclear Events in HIV-1 Replication and the Control of Gene Expression and Viral Production
2:30 PM2:30 PM
315 - CPSF6 Regulates Cellular Permissivity to HIV-1 Infection Through Alternative Polyadenylation
Daphne Cornish
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
316 - A Targeted CRISPR Screen Identifies ETS1 as a Regulator of HIV Latency
David M. Margolis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
317 - HIV-1 Membraneless Organelles Orchestrate Viral Genome Maturation and Immune Evasion
Francesca Di Nunzio
Institut Pasteur, Paris, France
2:30 PM2:30 PM
318 - Design of SHIVs Encoding HIV-1 Recombinase Brec1 Recognition Site for Nonhuman Primate Cure Studies
Ryan Krause
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
319 - Convergence of NF-κB Pathways Increases HIV-1C Transcriptional Fitness
Hrimkar B. Buch
Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
2:30 PM2:30 PM
320 - Fatty Acid Synthesis Controls Both Cellular Susceptibility to HIV and New Particle Production
Joshua A. Acklin
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
321 - Direct Sequencing of Full-Length HIV-1 RNA Reveals the Functional Significance of Site-Specific m6As
Sanggu Kim
Ohio State University, Columbus, OH, USA
2:30 PM2:30 PM
322 - Functional Study of N6-Methyladenosine (m6A) Machinery in HIV Infection of Primary CD4+ T Cells
Lacy M. Simons
Northwestern University, Chicago, IL, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-03) Effect of HIV on the Immune System
2:30 PM2:30 PM
359 - Single-Cell Multi-Omics Uncovers the Immune Heterogeneity in HIV-Infected INRs
Xiaosheng Liu
Tsinghua University, Beijing, China
2:30 PM2:30 PM
360 - Variability in Immunometabolic Signatures Among People w/ HIV Defines Immune Outcomes and Progression
Simon Gressens
French National Institute of Health and Medical Research (Inserm), Paris, France
2:30 PM2:30 PM
361 - Effect of Delayed ART Initiation on Anti-CD4 Autoantibodies in ART-Naive People With HIV
Shweta Mistry
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
362 - CD4-Binding Site Abs Modify the Negative Association Between Cluster A Abs and CD4 Count in PWH
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
2:30 PM2:30 PM
363 - Prevalence and Activity of Anti-Interferon Autoantibodies in People Living With HIV
Olivia Payne
University College London, London, UK
2:30 PM2:30 PM
364 - Secreted ORF8 Reprograms Macrophages to Enhance Lung Epithelial Cell Infection by SARS-CoV-2
Yusuke Matsui
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
365 - Occult CMV Replication Is a Persistent Driver of Effector T-Cell Expansion in PWH on Effective ART
Nived Collercandy
Toulouse University Hospital, Toulouse, France
2:30 PM2:30 PM
366 - IL-10/PD-1 Blockade Leads to Enhanced BA Synthesis and Type I IFN Production
Khader Ghneim
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
367 - Activated Platelets Render Functionally Deficient Natural Killer Cells in People Living With HIV
Brita Ostermeier
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
368 - Elevated Lymph Node Metabolic Activity During Long-Term Antiretroviral Therapy
Chuen-Yen Lau
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
369 - Immunometabolism of Innate Lymphocytes in People Living With HIV-1 Versus HIV-2
Maryam Khan
Queen Mary University of London, London, UK
2:30 PM2:30 PM
370 - Non-HIV Chronic/Latent Viruses and Immune Aging: Sex Effects Comparable to Those of HIV and CMV
Renying (Loulou) Cai
University of British Columbia, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-04) Nonimmune Effects of HIV Infection
2:30 PM2:30 PM
371 - Sex Differences in Cytokine Responses and Genetic Regulation Thereof in People Living With HIV
Suzanne D. E. Ruijten
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
372 - Dynamic Changes in the Peripheral Blood Monocytes Following Long-Acting Injectable CAB/RPV in PLWH
Maria Antonella Zingaropoli
Sapienza University of Rome, Rome, Italy
2:30 PM2:30 PM
373 - Changes in Serum Level of Cell-Free Mitochondrial DNA Fragments in Acute and Chronic HIV Infection
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
374 - The Molecular Cargo of Exosomes Is Able to Discriminate Between PLWH With or Without NADCs
Norma Rallón
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
375 - HIV-Encoded Proteins Induce Pulmonary Arterial Hypertension via Increases in Podocan-Like Protein 1
Laszlo Kovacs
Augusta University, Augusta, GA, USA
2:30 PM2:30 PM
376 - Compromised Intestinal Barrier Resilience to Cytokine Disruption Causing Leakage in People With HIV
Mohamed Abdel-Mohsen
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
377 - Acute HIV-1 Infection Triggers Myelopoiesis Suppression and Pancytopenia Through IFN-γ Signaling
Shuai Gao
Washington University, St Louis, MO, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-03) Using Vaccines for Therapy
2:30 PM2:30 PM
425 - Age Inversely Correlates With T-Cell Response to MVA.HIVconsvX Vaccination in PWH on ART
Nilu Goonetilleke
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
426 - Unadjuvanted CD40.HIVRI.ENV Vaccine Late Boost Induces Durable Immune Responses: ANRS/VRI06 Trial
Yves Levy
Vaccine Research Institute, Créteil, France
2:30 PM2:30 PM
427 - Augmenting HIV-Specific CAR-T Cell Functionality by Treatment With Novel Cytokine-Based Scaffold
Sara Lamcaj
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
428 - ChAdOx1.HIVconsvX and MVA.HIVconsvX Vaccination Is Safe and Immunogenic in PWH on ART: The CM Study
Cynthia L. Gay
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
429 - A Novel Immunotherapeutic Platform for Amplifying HIV, CMV, or SARS-CoV-2-Specific T-Cell Responses
Marta Santos Bravo
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
430 - Therapeutic HIV Vaccine ± TLR4 Adjuvant Impact on Monocyte Subsets in Early-Treated Youths With HIV
Alessia Neri
University of Rome Tor Vergata, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-04) Preventive Vaccine Strategies
2:30 PM2:30 PM
431 - Enhanced HIV Antibody Precursor Development With Early-Life Germline Targeting Immunization
Yasmine Issah
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
432 - A VLP-Forming mRNA Vaccine Protects Macaques From Heterologous SHIV Infection
Mamta Singh
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
433 - Cytoplasmic Tail Engineering of Stabilized mRNA Env Immunogens Enhances Neutralizing Response
Edward Kreider
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
434 - Improved Immunogenicity of a VLP-Forming mRNA Vaccine for HIV-1
Mamta Singh
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
435 - An AI-Redesigned Contemporary HIV-1 Env Consensus Antigen Is More Immunogenic Than a Native Sequence
Eric Lewitus
United States Military HIV Research Program
2:30 PM2:30 PM
436 - Incidence and Predictors of STIs and Effect on Immune Activation in the HVTN 705/HPX2008 Trial
Mitch M. Matoga
University of North Carolina Project–Malawi, Lilongwe, Malawi
2:30 PM2:30 PM
437 - 3-Step Heterologous Immunization Schema Results in Development of Cross-Neutralizing VRC01-Class Abs
Parul Agrawal
Fred Hutchinson Cancer Center, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-05) Immunity to Mpox
2:30 PM2:30 PM
438 - Evolution and Durability of Mpox-Specific Antibodies Among Vaccinated or Infected Individuals
Wang-Da Liu
National Taiwan University Hospital, Taipei, Taiwan
2:30 PM2:30 PM
439 - Antibody Responses Decline Post-MVA Vaccination but Persist Following Mpox Infection
Joanne Byrne
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
440 - Immune Response to Mpox in PWH and PrEP Users After Infection, but Not in Response to Vaccination
Olivia de la Calle-Jiménez
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
441 - MVA Vaccine Produces Potent Serologic and Immunologic Response to Mpox in People With HIV
Maryam Khan
Queen Mary University of London, London, UK
2:30 PM2:30 PM
442 - Mpox-Specific T-Cell Responses in Recovered and Vaccinated Individuals
Aideen S. Teeling
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
443 - Immune Response After 2 Years From MVA-BN Vaccination by HIV Infection and CD4 Cell Count
Valentina Mazzotta
National Institute for Infectious Diseases L Spallanzani, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-06) Natural-Born Killers: NK Cells
2:30 PM2:30 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
2:30 PM2:30 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-07) New Concepts in Immunotherapy
2:30 PM2:30 PM
449 - Combination of eCD4-IgG1 Delivered by AAV9 and AZD5582 in SIV-Infected, ART-Suppressed Infant RM
Jairo A. Fonseca
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
450 - Using Nanobodies as an Intracellular Biological to Block HIV-1 Through Innate Antiviral Mechanisms
Florence M. Stel
Amsterdam University Medical Centers, Amsterdam, Netherlands
2:30 PM2:30 PM
451 - Viral Genetic Traits of Durable Control in Dual Immunotherapy-Treated SHIV-Infected Rhesus Macaques
Manukumar Honnayakanahalli Marichannegowda
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
453 - HIV-Induced Sialoglycans on Infected Cells Promote Immune Evasion From Myeloid Cell-Mediated Killing
Shalini Singh
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
454 - Sialidase Conjugation Enhances the Anti-HIV Activity of the 10-1074 Antibody in Humanized Mice
S. M. Shamsul Islam
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
455 - Cannabidiol Has Sex-Dependent Anti-Inflammatory Effects in Long-Term Suppressed HIV-1 Adults
Clémence Couton
Centre de Biophysique Moléculaire, Orléans, France
2:30 PM2:30 PM
456 - IFI16 Controls PVR and Gal-9 Expression and Its Targeting Improves Immunotherapy Against HIV-1
Enrique Martin Gayo
Universidad Autónoma de Madrid, Madrid, Spain
2:30 PM2:30 PM
457 - Investigating the Effects of ADCC and CAR NK/T Cells on HIV-1 Cell-to-Cell Transmission
Tanvi Mathur
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
458 - Natural Killer Cells Preferentially Kill HIV-Infected CD4 T Cells Using Death Receptors
Lesley R. de Armas
University of Miami, Miami, FL, USA
2:30 PM2:30 PM
459 - Tri-Specific Killer Engagers in Macaques Potently Induce NK Cell Responses in Blood and Tissues
Julien A. Clain
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
460 - Extracellular Acyl-CoA-Binding Protein Prevents Autophagy and T-Cell Function in People With HIV
Stephane Isnard
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
461 - Gut Microbiome Dynamics and Immune Responses in People With HIV Receiving N-803
Ashma Chakrawarti
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
462 - Heterogeneity of PD-1 Expression in PLHIV and Its Relationship With Host and Viral-Related Factors
Adriana Navas
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
463 - IL-10 Treatment Enhances CD8 T-Cell Activation and Cytotoxicity in SIV Infection: The Yin and Yang
Nongthombam Boby
Texas Biomedical Research Institute, San Antonio, TX, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-03) HIV Reservoirs in Cells and Tissues
2:30 PM2:30 PM
514 - CD4+ T Cells Harboring Inducible HIV Genomes Display a Senescent-Like Phenotype
Remi Fromentin
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
515 - Macrophage-Tropic TF SHIV D-Infected NHP Model of Reservoir Persistence and Decay on ART
Ryan Krause
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
516 - Anatomical Sites in FIND 2.0 Decedents Harbor Compartmentalized, Transcriptionally Intact HIV-1 Env
Melanie Moodie
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
517 - Biomarkers of HIV Latency in Tissues From People With HIV
Nadejda Beliakova-Bethell
Veterans Affairs San Diego Healthcare System, San Diego, CA, USA
2:30 PM2:30 PM
518 - HIV Can Persist in Multiple Subsets of SARS-CoV-2-Specific CD4+ T Cells in Tissues During ART
Xiaoyu Luo
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
519 - Women With HIV Have a Lower Frequency of Monocyte Reservoir Reactivation Than Men With HIV
Rebecca Veenhuis
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
520 - Well-Seeded Reservoirs in Gut Are Associated With Tertiary Lymphoid Structures With Activated ISR
Ramon Lorenzo-Redondo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
521 - HIV-1 Clade C Reservoir Traits in Blood and Lymph Node Tissue in Acute and Chronic Treated Infection
Kavidha Reddy
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
522 - HIV Burden Is Associated With Specific Bacteriome Profiles Relative to Specific Gut Segments
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
523 - Viral and Microbial Environment in the Male Genital Tract of People Living With HIV
Elizabeth Hastie
University of California San Diego, La Jolla, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-06) Immune Pressure on HIV Reservoirs
2:30 PM2:30 PM
539 - Resistance of Inducible, Infectious HIV-1 to Autologous Neutralizing IgG After Long-Term ART
Natalie F. McMyn
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
540 - High Networked CD8+ T-Cell Epitopes Exhibit Markedly Reduced Mutability in the Latent HIV Reservoir
Fernando Senjobe
Harvard University, Cambridge, MA, USA
2:30 PM2:30 PM
541 - Autologous IgGs Mediate Log Reductions in HIV Infection in a PTC, Contributing to ART-Free Remission
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
542 - Afucosylation of Broadly Neutralising Antibodies to Eliminate HIV+ CD4+ T Cells and Macrophages
Morgane Brunton-O'Sullivan
Burnet Institute, Melbourne, Australia
2:30 PM2:30 PM
543 - Immune Dynamics During Reproductive Aging and Substance Use in Women With HIV
Konstantin Leskov
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
544 - Latency Reversal Induced by CD4+ T-Cell Recognition of HIV-1 Alternate Reading Frame Proteins
Joel Sop
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
545 - Reduced Metabolic Flux Protects HIV-Expressing CD4+ T-Cells From CTL-Mediated Elimination
Alberto Herrera
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
546 - Engineering Natural Killer Cells With NKp30-Based Chimeric Antigen Receptors (CARs) to Target HIV
Ruoxi Pi
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
547 - Preclinical Evaluation of Effector Function-Enhanced Variants of N6 bNAb
David Wensel
ViiV Healthcare, Branford, CT, USA
2:30 PM2:30 PM
548 - Long-Term ART Enhances Cytotoxic Response and Reduces the Reactivation Capacity of HIV-1 Reservoir
Alicia Simón Rueda
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
549 - Plasma Cytokines and NF-κB Signaling Drive Transcriptomic Diversity in CD4+ T Cells From PWH on ART
Alton Barbehenn
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
550 - TLRS Ligands and IL-15 Induce Trained Immunity in CD4 Cells and Limit HIV Infection and Persistence
Muhammad Bilal Latif
Emory University, Atlanta, GA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-07) HIV Clones in the Reservoir
2:30 PM2:30 PM
551 - Phenotypic and Functional Heterogeneity Contribute to the Persistence of the Clonal CD4 Reservoir
Isabella A. T. M. Ferreira
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
552 - Latent HIV Clonal Dynamics: Integration Sites and Their Role in Maintenance of Latency In Vivo
Virender K. Pal
The Rockefeller University, New York, NY, USA
2:30 PM2:30 PM
553 - Targeting of HIV-Infected Clones by Cognate Peptide Stimulation and Antiproliferative Drugs
Filippo Dragoni
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
554 - Sequencing of HIV-1 Proviruses in Large Infected T-Cell Clones Reveals a Predominance of Solo-LTRs
Dimiter Demirov
Leidos Biomedical Research, Inc, Frederick, MD, USA
2:30 PM2:30 PM
555 - Chromosomal Integration Site Profile of HTLV-1-Infected Cells Is Distinct From HIV-1-Infected Cells
Alex Hochroth
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
556 - Reservoir-Harboring T-Cell Clones Have a Cytotoxic Immunophenotype That May Affect HIV Inducibility
Alberto Herrera
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
557 - The Paucity of Clonal SIV Proviral Sequences During Early ART Treatment
Margaret Hallmets
Tulane National Primate Research Center, Covington, LA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-04) Addressing NeuroHIV in Lower- and Middle-Income Settings
2:30 PM2:30 PM
615 - Neuronal Injury in a Subset of PWH During Acute HIV Infection and Up to 5 Years After Immediate ART
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
616 - Plasma Microbiome Composition Among Neurobehavioral Phenotypes (NBPs) in People With HIV (PWH)
Mohammadsobhan Sheikh Andalibi
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
617 - High Anticholinergic Burden and Poor Sleep Quality in People With HIV
Maria Mazzitelli
Azienda Ospedaliera di Padova, Padua, Italy
2:30 PM2:30 PM
618 - Prevalence of Mental Disorders Among PWH in Rwanda: A Low-Cost Nurse-Led Screening Approach
Michel Gasana
Rwanda Biomedical Centre, Kigali, Rwanda
2:30 PM2:30 PM
619 - Cognitive and Sensorimotor Difficulties in Well-Controlled People With HIV Living in Uganda
Leah H. Rubin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
620 - No Impact on the CNS After Switching to Dolutegravir/Lamivudine From a 3-Drug Regimen
Linn Renborg
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
2:30 PM2:30 PM
621 - Dual Group-Based Trajectories of Brain-Derived Neurotrophic Factor and Cognition in People With HIV
Henry U. Michael
Research Institute of McGill University Health Centre, Montreal, Canada
2:30 PM2:30 PM
622 - Greater Cognitive Decline in Cognitively Unimpaired Older Thai PWH at Baseline
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-05) It's All About the Vessels: NeuroHIV and Vascular Dysfunction
2:30 PM2:30 PM
623 - Hypertension: A Major Factor in Low Verbal Fluency Among People Aged 50+ Living With HIV in Senegal
Caroline Couturier
Université de Bordeaux, Bordeaux, France
2:30 PM2:30 PM
624 - No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People With HIV
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
625 - Number and Effectiveness of Antihypertensives Are Associated With Cognitive Performance in PWH
Azin Tavasoli
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
626 - Reduced Cerebral Arterial Transit Time in Obese Females With HIV and Metabolic Syndrome
Eric Decloedt
Stellenbosch University, Cape Town, South Africa
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-02) Drug-Drug Interactions and Pharmacology Challenges With Important Coconditions
2:30 PM2:30 PM
645 - Drug Interactions Between Dolutegravir (DTG) and Escalating Doses of Rifampicin (RIF): DORIS Study
Yashna Singh
Desmond Tutu HIV Foundation, Cape Town, South Africa
2:30 PM2:30 PM
646 - TAF Achieves Adequate Intracellular Tenofovir-DP Concentrations With Rifampicin-Based TB Therapy
Rephaim Mpofu
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
647 - Pharmacokinetics of Twice-Daily TAF in Adults With HIV-Associated TB on BIC/FTC/TAF and Rifampicin
Emmanuella C. Osuala
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
648 - Estradiol Concentrations in Trans Women on BIC/FTC/TAF Compared to Those Without HIV
Alice Tseng
University Health Network, Toronto, Canada
2:30 PM2:30 PM
649 - Reduced Metformin Concentrations in Obese Women With HIV Treated With Dolutegravir
Roland van Rensburg
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
650 - Pharmacokinetics of Switching to B/F/TAF in PWH Post-Renal Transplant: BIK Switch Study
Corwin Coppinger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-02) Long-Acting Therapy: What Observational Data Tell Us About the "Real World"
2:30 PM2:30 PM
674 - Long-Term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort
Michael Sension
CAN Community Health, Fort Lauderdale, FL, USA
2:30 PM2:30 PM
675 - Outcomes on Cabotegravir + Rilpivirine in Suppressed People With HIV (PWH) in TRIO Health US Cohort
Paul Sax
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
676 - Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort
Jessica A. Altamirano
CAN Community Health, Fort Lauderdale, FL, USA
2:30 PM2:30 PM
677 - Long-Acting Cabotegravir and Rilpivirine in Older People With HIV in the GEPPO Cohort
Andrea Calcagno
University of Turin, Turin, Italy
2:30 PM2:30 PM
678 - Long-Acting Cabotegravir/Rilpivirine in Real Life: Sex-Based Characteristics, PROs, and Effectiveness
Ana González-Cordón
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
679 - Interim Week 48 Results in Young South Africans on Long-Acting Injectable ART: The AFINAty Study
Lauren Jennings
Desmond Tutu HIV Foundation, Cape Town, South Africa
2:30 PM2:30 PM
680 - Impact of Oral Lead-In on PK and Virologic Outcomes in People With HIV Transitioning to CAB+RPV LA
Marta Fernández-González
Hospital General Universitario de Elche, Elche, Spain
2:30 PM2:30 PM
681 - Low-Level Viremia and Risk Factors for Failure on Long-Acting Cabotegravir/Rilpivirine (LA CAB/RPV)
Natalie Nielsen
Ohio State University, Columbus, OH, USA
2:30 PM2:30 PM
682 - Outcomes of LAI ART for People With Detectable HIV Viremia in the NYC Public Healthcare System
Anthony Gerber
Bellevue Hospital, New York, NY, USA
2:30 PM2:30 PM
683 - Why Do People With HIV Stop Long-Acting Injectable Cabotegravir/Rilpivirine and What Happens?
Katerina Christopoulos
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
684 - What Do Early Adopters of Long-Acting Injectable Cabotegravir/Rilpivirine Think About It?
Katerina Christopoulos
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
685 - Outcomes in Those Who Discontinued Injectable Cabotegravir/Rilpivirine and Resumed Oral ART
Tali Faggiano
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
686 - Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians
William R. Short
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
687 - Distance to Care Measures Predict Injection Visit No-Shows Among Cabotegravir/Rilpivirine Recipients
Nimish Patel
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
688 - First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort
Karam Mounzer
Philadelphia FIGHT, Philadelphia, PA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-04) New Agents and Novel Administration
2:30 PM2:30 PM
701 - A 24-Week Phase II Maintenance Study of TMB-365/TMB-380 Q8W in People With Suppressed HIV-1 Infection
Jacob P. Lalezari
Quest Clinical Research, San Francisco, CA, USA
2:30 PM2:30 PM
702 - A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection
Yuanyuan Qin
Chongqing Public Health Medical Center, Chongqing, China
2:30 PM2:30 PM
703 - Efficacy of Switching to Ainuovirine-Based Antiretroviral Regimen in Virologically Suppressed PWH
Hong Qin
Jiangsu Aidea Pharmaceutical Co, Ltd, Yangzhou, China
2:30 PM2:30 PM
704 - Evaluating Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube
Joshua T. Mercure
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
705 - Creating an Ultralong-Acting Dolutegravir Prodrug Homodimer
Bhoomika Gowda
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
706 - Development of a 2-Drug Long-Acting Removable Formulation for HIV Suppression
Manse Kim
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
707 - Identification and Characterization of Novel Chemical Scaffolds With Anti-HIV Activities
Ryan Jeep
Colorado State University, Fort Collins, CO, USA
2:30 PM2:30 PM
708 - A Strategy for Durable AAV-Vectored bNAb Expression in Adult Rhesus Macaques
Michael Kuipa
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
709 - Trosunilimab Safety, Pharmacokinetics, and Pharmacodynamics in People With and Without HIV-1
Franco Antonio Felizarta
Private Practice, Bakersfield, CA, USA
2:30 PM2:30 PM
710 - Preclinical Evaluation of an Ultra-Long-Acting Tenofovir Prodrug Nanosuspension
Samiksha S. Raut
University of Nebraska Medical Center, Omaha, NE, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-02) Epidemiology of HIV Drug Resistance
2:30 PM2:30 PM
729 - High Prevalence of Baseline NRTI Resistance in PWH Switched From Second-Line PI/r to B/F/TAF
Jean Bernard Marc
GHESKIO Center, Port-au-Prince, Haiti
2:30 PM2:30 PM
730 - HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024
Ron M. Kagan
Quest Diagnostics, San Clemente, CA, USA
2:30 PM2:30 PM
731 - Rilpivirine Drug-Resistant Mutations in Experienced Patients in Mexico: Impact on Long-Acting ART
Luis E. Soto-Ramirez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
732 - Despite Increasing Use of INIs to Treat HIV Infection, Resistance to This Class Remains Stable
Vincent Calvez
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
733 - Molecular Epidemiology of HIV-1 Transmitted Drug Resistance Among Subtypes Circulating in Italy
Daniele Armenia
Saint Camillus International University of Health Sciences, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-03) HBV Diagnostics and Treatment
2:30 PM2:30 PM
767 - Changes in Antiviral Treatment Eligibility With the New WHO 2024 Guidelines in Senegal
Bruce Shinga S. Wembulua
Centre Hospitalier Universitaire de Fann, Dakar, Senegal
2:30 PM2:30 PM
768 - Continuum of Hepatitis B Surface Antigen Expression Among PWID and MSM Living With HIV in India
Talia A. Loeb
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
769 - HBsAg Seroclearance in HBV-Coinfected People With HIV in the Era of Tenofovir-Containing Therapy
Chien-Ching Hung
National Taiwan General Hospital Yunlin, Yunlin, Taiwan
2:30 PM2:30 PM
770 - Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir
María del Mar Arcos-Rueda
La Paz University Hospital, Madrid, Spain
2:30 PM2:30 PM
771 - HBV Reactivation Post-Switch to HBV-Inactive ART: A Scoping Review
Kyle Ring
Queen Mary University of London, London, UK
2:30 PM2:30 PM
772 - Outcomes in HIV-Hepatitis B Coinfection Without Tenofovir-Containing Antiretroviral Therapy
Amir Mohareb
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
773 - Hepatic Flare Is Associated With HBsAg Seroclearance in HBV/HIV-1 Co-Infection
Weiyin Lin
Guangzhou Eighth People's Hospital, Guangzhou, China
2:30 PM2:30 PM
774 - Increased Detection of HBV DNA and Mutational Analysis in HBsAg-Negative Specimens at NHLS/DGM
Nondumiso A. Nkosi
Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa
2:30 PM2:30 PM
775 - HBV Seroconversion in People With HIV: Relevance of Clinical History and Viral Markers Monitoring
Marianna Menozzi
AOU Policlinico di Modena, Modena, Italy
2:30 PM2:30 PM
776 - Performance Evaluation of the Xpert Hepatitis B Molecular Test Among Pregnant Women in Uganda
Viola Kasone
Ministry of Health Uganda, Kampala, Uganda
2:30 PM2:30 PM
777 - The Impact of HIV Infection on All-Cause Mortality Among Individuals Treated for HBV in Rwanda
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-03) HIV-Related Cancer: Epidemiology, Incidence, Demographics
2:30 PM2:30 PM
798 - Trends in Common Cancer Diagnoses Among People With HIV in North America, 2006-2020
Sally B. Coburn
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
799 - Cancer Risk of People With HIV Younger Than 50 Years: Italy, 1997-2023
Camilla Muccini
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
800 - Predictors of Mortality Among Patients With Virus-Associated Cancers in a High HIV-Prevalence Region
Dorothy Mangale
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
802 - Cancer Risk Among People Who Inject Drugs With HIV in the United States, 2010-2019
Carol-Ann Swain
New York State Department of Health, Albany, NY, USA
2:30 PM2:30 PM
803 - Cancer Incidence in Women With HIV in Europe and Australia: A Combined D:A:D and Respond Analysis
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
804 - Low-Level HIV Viremia Increases Immunosuppressive Markers Elevating Cancer and CVD Risk in InSTI Era
Violeta Lara-Aguilar
Instituto de Salud Carlos III, Madrid, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-03) Antiretroviral Therapy and CVD Risk
2:30 PM2:30 PM
824 - Change in Cardiometabolic Risk Markers Following Switch to Integrase Inhibitors Differs by Sex
Cecile D. Lahiri
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
825 - Dolutegravir-Based Antiretroviral Therapy and Cardiometabolic Health Risk in Persons With HIV
Katuku Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
826 - Changes in Cardiometabolic Parameters After ART Initiated Within 1 Year of HIV Acquisition
Nikos Pantazis
National and Kapodistrian University of Athens, Athens, Greece
2:30 PM2:30 PM
827 - Potential of the Short Chain Fatty Acid Caproic Acid in Protection Against CVD in HIV Infection
Mohamed El-Far
Centre de Recherche du CHUM, Montreal, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-04) Frailty and Aging
2:30 PM2:30 PM
877 - Statins Reduce Frailty in People With HIV
Giovanni Guaraldi
University of Modena and Reggio Emilia, Modena, Italy
2:30 PM2:30 PM
878 - Frailty and All-Cause Mortality Among People With HIV Engaged in Clinical Care in the United States
Stephanie A. Ruderman
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
879 - Clinical and Economic Benefits of Preventing Physical Frailty and Falls Among PWH in the US
Karen C. Smith
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
880 - Housing Instability and Frailty Among People With HIV Engaged in Clinical Care in the United States
Carolyn A. Fahey
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
881 - Prognostic Factors of Physical Function Decline in the PREPARE Study
Grace Ditzenberger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
882 - Understanding the Life Expectancy Sex Gap: Disparate Patterns in Noncommunicable Disease Mortality
Katherine Kooij
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
883 - 10-Minute Targeted Geriatric Assessment Identifies Vulnerable and Frail Older Persons With HIV
Marilia Bordignon Antonio
University of São Paulo, São Paulo, Brazil
2:30 PM2:30 PM
884 - The 10-Year Prevalence of Hearing Loss and Dementia Among People With HIV in the United States
Emily Hyle
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
885 - Clinical Outcomes of Immune Nonresponse Among Virally Suppressed Adults Living With HIV in Thailand
Worapong Nasomsong
Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
2:30 PM2:30 PM
886 - Falls Associated With High Medication Regimen Complexity in People With HIV
Yunhan Chen
Boston Medical Center, Boston, MA, USA
2:30 PM2:30 PM
887 - Integrated Digital Strategy for Stigma Evaluation in Routine Care for PWH
Alfonso Cabello
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
888 - Latent Class Analysis Identifies Distinct Comorbidity Profiles in Older (>65 years) People With HIV
Fabrizio Drago
Rutgers University, Piscataway, NJ, USA
2:30 PM2:30 PM
889 - Multimorbidity and Quality of Life Among Older People Living With HIV in Urban Tanzania
Theresia A. Ottaru
Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-05) Weight Gain
2:30 PM2:30 PM
890 - Weight and Body Composition After Switch to DTG/3TC From DTG/3TC/ABC: A Randomized Open-Label Trial
Thomas Benfield
University of Copenhagen, Copenhagen, Denmark
2:30 PM2:30 PM
891 - Re-Examining InSTI Effects on Weight Gain Among Treatment-Naive People With HIV in North America
Kassem Bourgi
Nashville CARES, Nashville, TN, USA
2:30 PM2:30 PM
892 - Weight Change on F/TAF vs Placebo: Using Common F/TDF Groups to Bridge Data Across Clinical Trials
David Glidden
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
893 - Body Composition Changes in People With HIV Switching From or Maintaining TDF-Based Regimens
Giovanni Guaraldi
University of Modena and Reggio Emilia, Modena, Italy
2:30 PM2:30 PM
894 - Risk Factors Associated With Extreme Weight Gain in People With HIV
Stefan Esser
University Hospital Essen, Essen, Germany
2:30 PM2:30 PM
895 - Serum Metabolomic Signatures Associated With InSTI-Related Weight Gain in Women With HIV
Chin-An Yang
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
896 - Weight Change in Trial of Switching From Second-Line bPI to B/F/TAF in a Context of Food Insecurity
Vanessa Rouzier
GHESKIO, Port-au-Prince, Haiti
2:30 PM2:30 PM
897 - Body Composition Changes in People With HIV Switching to DTG/3TC or BIC/TAF/FTC
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-02) PASC: Immunobiologic, Metabolic, and Cardiovascular Complications
2:30 PM2:30 PM
927 - Hormonal Dysregulation in Long COVID: Exploring the Salivary Cortisol Profile
Marta Camici
IRCCS Lazzaro Spallanzani, Rome, Italy
2:30 PM2:30 PM
928 - In Vitro Modeling of the Effects of Impaired HDL on Atherogenesis in Long COVID Syndrome
Theodoros Kelesidis
University of Texas Southwestern Medical Center, Dallas, TX, USA
2:30 PM2:30 PM
929 - Age-Dichotomous Associations of Long COVID With Frequency of Public SARS-CoV-2 Memory TCRs
Selin Akbas
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
930 - Persistent Immune Dysregulation and Metabolic Alterations Following SARS-CoV-2 Infection
Michael Peluso
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
931 - Immune and Virologic Trajectories 1.5 Years Before and After COVID-19 in an Early-Treated HIV Cohort
Ferron Ocampo
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
933 - [18F]F-AraG PET Imaging Reveals Increased Gut T-Cell Activation in People With Long COVID
Emilio De Narvaez
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
934 - Evidence of B-Cell Dysfunction in Individuals With Long COVID-Associated Dysautonomia
Montserrat Torres
Instituto de Salud Carlos III, Madrid, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-02) Pathogenesis of TB Disease/TB Drug Exposure Relationships
2:30 PM2:30 PM
954 - Impact of Cytomegalovirus Infection on the Progression of TB Disease in People With HIV on ART
Sivaporn Gatechompol
Mahidol University, Bangkok, Thailand
2:30 PM2:30 PM
955 - Immune Profiles Can Differentiate Mycobacterial and KSHV Inflammatory Syndromes in Advanced HIV
Shweta Mistry
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
956 - NAT-2 Polymorphism and Risk of Antituberculosis-Induced Hepatotoxicity in Thai People With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
957 - Isoniazid Exposure Among Patients With Tuberculosis and Diabetes in Brazil
Felipe Ridolfi
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
958 - Genetics of Plasma Rifapentine Clearance During Pulmonary Tuberculosis Treatment in Study 31/A5349
Ava Y. Xu
University of California San Francisco, San Francisco, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-03) Novel TB Case-Finding Strategies and Diagnostic Testing
2:30 PM2:30 PM
959 - High Diagnostic Yield of a Novel HIV-TB Case-Finding Strategy at Social Drinking Venues in Zambia
Andrew Kerkhoff
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
960 - Effectiveness of Portable Digital X-Ray Machine in Tuberculosis Case-Finding in Nigeria
Patrick Dakum
Institute of Human Virology Nigeria, Abuja, Nigeria
2:30 PM2:30 PM
961 - Machine Learning-Based Prediction of Active Tuberculosis in People With HIV Using Clinical Data
Johannes Nemeth
University Hospital Zurich, Zurich, Switzerland
2:30 PM2:30 PM
962 - Genome-Wide Meta-Analysis Identifies Genetic Associations With Resistance to Mtb Infection
Matheus Fernandes Gyorfy
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
963 - Healthcare Worker- Versus Self-Collected Tongue Swabs for Mycobacterium tuberculosis Detection
Anura David
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
2:30 PM2:30 PM
965 - Diagnostic Accuracy of the FujiLAM Assay to Detect Tuberculosis in Advanced HIV
Tessa Adzemovic
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
966 - Diagnosis and Prognosis of Blood XpertUltra and Myco/F Blood Culture for TB in Advanced HIV Disease
Phuong Le Trinh
Oxford University Clinical Research Unit in Vietnam, Hanoi, Vietnam
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-04) TB Preventive Therapy: Testing, Treatment Strategies, and Outcomes
2:30 PM2:30 PM
967 - Gaps in Latent Tuberculosis Infection Testing Practices: A 15-Year Serial Cross-Sectional Study
Jorge R. Ledesma
Kaiser Permanente Division of Research, Oakland, CA, USA
2:30 PM2:30 PM
968 - Effect of Alcohol Use on Active TB Incidence Among PWH With Prior Receipt of TB Preventive Therapy
Judith A. Hahn
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
2:30 PM2:30 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:30 PM2:30 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-03) Managing Maternal HIV
2:30 PM2:30 PM
991 - High Viral Suppression in Pregnant/Postpartum Women With HIV in a Couples-Based Behavioral Trial
Karen Hampanda
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
992 - Childhood Exposure to Violence and Pregnancy-to-Postpartum Viral Load of US Women With HIV
Deborah Kacanek
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
993 - Rapid Return of Viral Load (VL) Results to Pregnant/Postpartum Women via Mentor Mothers in Kenya
Pam Murnane
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
994 - Evaluating and Revising an Adapted Scale for Antiretroviral Therapy (ART) Adherence Self-Efficacy
Lauren Sheu
University of Chicago, Chicago, IL, USA
2:30 PM2:30 PM
995 - The Impact of Care Transitions on Pregnant Youth Living With HIV in Kisumu, Kenya
Rabbia Imran
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
996 - HIV Drug Resistance Patterns Among Pregnant Women After Dolutegravir Scale-Up in Sub-Saharan Africa
Linda Stoeger
Barcelona Institute for Global Health, Barcelona, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-04) Antiretrovirals and Birth Outcomes
2:30 PM2:30 PM
1000 - Impact of TLD on Birth Outcomes in South African Women: The ORCHID Cohort
Jamie E. Meyer
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1001 - Impact of Gestational Diabetes on Pregnancy Outcomes in South African Women Living With HIV
Elton Mukonda
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1002 - Immune Markers During Pregnancy and Birth Outcomes in South African WLH
Thokozile R. Malaba
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1003 - Antiretroviral Drugs Disrupt Macrophage Function and Vascular Development
Doty B. A. Ojwach
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1004 - Antiretroviral Drugs Affect the Placental Vasculature
Micah Summerlin
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
997 - Perinatal and Infant Outcomes After Bictegravir Exposure in Pregnancy: A Canadian Surveillance Study
Jeffrey Man Hay Wong
University of British Columbia, Vancouver, Canada
2:30 PM2:30 PM
998 - Prematurity and Low Birth Weight in Children Born to Mothers Living With HIV in Spain
Talía Sainz
La Paz University Hospital, Madrid, Spain
2:30 PM2:30 PM
999 - Birth Outcomes and HIV-1 Transmission in a Contemporary HIV Pregnancy Cohort, Washington State
Jane Hitti
University of Washington, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-02) Exploring the Pediatric Reservoir
2:30 PM2:30 PM
1030 - Long-Term HIV Reservoir Dynamics in Early Treated Thai Children
Marta Massanella
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
1031 - NK Cell KIR Education Is Associated With Low HIV DNA Load in Early ART-Treated Children
Nicholas G. Herbert
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1032 - Evolving Expression of Co-Inhibitory Receptors and Plasma Cytokines in Children Living With HIV
Hugo Soudeyns
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
2:30 PM2:30 PM
1033 - Proviral HIV-1 DNA Below Detection in Early-Treated Adolescents After Prior Treatment Interruption
Louise Kuhn
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1034 - Pediatric ART Interruptions Transiently Raise HIV DNA Without Large Changes to Long-Term Reservoirs
Daniel B. Reeves
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1035 - Children With Very Early ART and Favorable Profiles for ART-Free Viral Control Research: Thai Cohort
Rapisa Nantanee
Chulalongkorn University, Bangkok, Thailand
2:30 PM2:30 PM
1036 - Association Between HIV-Specific Antibodies and HIV Reservoir Markers in Early-Treated Children
Rapisa Nantanee
Chulalongkorn University, Bangkok, Thailand
2:30 PM2:30 PM
1037 - Baseline Viral Load Impacts Premature Aging in Infants With Perinatally Acquired HIV in EARTH Cohort
Maria Raffaella Petrara
University of Padova, Padova, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-03) Informing Cure Strategies in Children and Youth
2:30 PM2:30 PM
1038 - Negative HIV Serology in Children Treated Early Reflects a Unique Immunologic Profile
Florence Buseyne
Institut Pasteur, Paris, France
2:30 PM2:30 PM
1039 - Distinct Innate Immune-Driven TNFa Pathway Is Linked With Durable ART-Free Aviremia in Pediatric HIV
Nicholas Lim
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1040 - Germline-Targeting SOSIP Trimer Immunizations Reduced Post-Rebound SHIV Loads in Infant Macaques
Ria Goswami
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1041 - Immune Correlates of Viral Rebound During Broadly Neutralizing Antibody Treatment in Children
Melanie Lancien
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
1042 - HIV-Specific T-Cell Dynamics in Acute-Treated, Chronic-Treated, and Elite Controller People With HIV
Alicer K. Andrew
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
1043 - Transcriptomics of Proviral Latency Reversal in Reservoirs of Youth With Perinatal HIV-1
Kristen Kelly
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-04) Pharmacokinetics, Safety, and Efficacy of Antiretrovirals
2:30 PM2:30 PM
1044 - Maternal Antiretroviral Formulation Preferences for Neonates
Lario Viljoen
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1045 - Acceptability of a Dolutegravir Dispersible Tablet and a Novel Oral Film Formulation in Neonates
Lario Viljoen
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1046 - Safety and Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Children 20 to 40 kg
Moherndran Archary
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
1047 - PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023)
Jeremiah Momper
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
1048 - Alternative Dosing of ABC/3TC Dispersible Tablets to Align With Dolutegravir Dosing in Neonates
Tim Cressey
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1049 - Week 24 Outcomes of F/TAF Plus Cobicistat-Boosted Protease Inhibitors in Children ≥2 y and ≥14 kg
Hilda A. Mujuru
University of Zimbabwe, Harare, Zimbabwe
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-01) The HIV Care and Prevention Cascades: Novel Insights
2:30 PM2:30 PM
1076 - Low Rates of HIV Pre-Exposure Prophylaxis Prescriptions Among US Youth in a Claims Database
Nicholas Venturelli
Boston Children's Hospital, Boston, MA, USA
2:30 PM2:30 PM
1077 - Oral and Injectable PrEP Use Among US Adolescents and Young Adults, 2019-2023
Laura M. Mann
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1078 - Durable Viral Suppression Using Different Definitions in a Ryan White HIV Program Clinic, 2018-2021
Kathleen A. McManus
University of Virginia, Charlottesville, VA, USA
2:30 PM2:30 PM
1079 - Characteristics of Men Who Have Sex With Men Recruited via Virtual- v In-Person Venue-Based Sampling
Danielle Lonbong Njiometio
Oak Ridge Institute for Science and Education, Atlanta, GA, USA
2:30 PM2:30 PM
1080 - Identifying Effective Recruitment Strategies to Engage Black Sexual Minority Men Living With HIV
Derek Dangerfield II
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1081 - Refining Clinical Retention Metrics to Reflect the Realities of HIV Care in North America
Peter F. Rebeiro
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
1082 - Neighborhood Resources and ARV Adherence Among Partnered US GBMSM: Mediation by Social Determinants
Loren Dobkin
University of Michigan, Ann Arbor, MI, USA
2:30 PM2:30 PM
1083 - Geographically Diverse National Survey of People With HIV on Grindr Shows High Virologic Suppression
Hannah R. Schmidt
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1084 - Viral Nonsuppression Among PWH Diagnosed at an Older Age: Implications for Secondary HIV Prevention
Lauren O'Connor
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1085 - Changes in the HIV Care Cascade and Prevalence From 2013 to 2023 in Rural Kenya and Uganda in SEARCH
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1086 - High Burden of Untreated HIV in Malawian Fishermen: Prospective Data From a Cluster Randomized Trial
Augustine T. Choko
Malawi Liverpool Wellcome Trust, Blantyre, Malawi
2:30 PM2:30 PM
1087 - PMTCT and KP Appropriate Services Improve HIV Viral Suppression Among Female Sex Workers: IBBSS 2023
Ikuzo Basile
Rwanda Biomedical Centre, Kigali, Rwanda
2:30 PM2:30 PM
1088 - Unique Predictors of Retention and Viral Suppression Among People With HIV in Dominican Republic
Wilfredo R. Matias
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
1089 - Higher Baseline CD4 and Treatment Initiation Among Contacts of PLHIV: Thailand, 2020-2023
Junya Danyuttapolchai
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-06) Race/Ethnicity and HIV
2:30 PM2:30 PM
1111 - Temporal Variations of Racial Disparities in HIV Incidence in the United States From 2008 to 2021
Fanghui Shi
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
1115 - Changes of Racial Disparities in Viral Suppression in People With HIV, 2013-2020
Xueying Yang
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
1116 - Effect of the Ending the HIV Epidemic (EHE) Initiative on Racial/Ethnic Disparities in HIV Incidence
Lauren Zalla
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1117 - Studying Medication Adherence for Black People Living With HIV: An Intersectional Lens
Anais Mahone
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
1118 - HIV Testing Barriers in Structurally Vulnerable Communities in St Louis: Best-Worst Scaling Survey
Noelle Le Tourneau
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
1120 - Racial/Ethnic and Regional Disparities in HIV Testing Before, During, and After COVID-19 in the US
Rena C. Patel
University of Alabama, Tuscaloosa, AL, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-07) Incident HIV Infection
2:30 PM2:30 PM
1121 - Estimated HIV Incidence in 15-24-Year-Olds Across 2 Population HIV Impact Assessments (PHIA)
Elaine Abrams
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1122 - HIV Incidence and Viral Suppression Among Ugandan Males With Female Bar and Sex Worker Partners
Xinyi (Cindy) Feng
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1123 - HIV Incidence Among Adults With Multiple Sex Partners in Kisumu County, Western Kenya
John Owuoth
Walter Reed Project–Kisumu, Kisumu, Kenya
2:30 PM2:30 PM
1124 - Contact Investigation of Incident HIV in a Population Cohort: Implications for Case Finding and PrEP
Robert Ssekubugu
Rakai Health Sciences Program, Kalisizo, Uganda
2:30 PM2:30 PM
1125 - Uncovering Risk for Recent HIV Infections in 9 Provinces: Thailand, 2023-2024
Theerawit Tasaneeyapan
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1126 - Recent HIV Infection Among Youth in Thailand: Who Is at Risk?
Suvimon Tanpradech
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1127 - New HIV-1 Diagnoses Among Different Generations of MSM in the Netherlands: Focus on Gen-Z
Annemarie M. J. Wensing
University Medical Center Utrecht, Utrecht, Netherlands
2:30 PM2:30 PM
1128 - Development of an HIV Risk Prediction Model Using Electronic Health Record Data in Spain
Arkaitz Imaz
Bellvitge University Hospital, Barcelona, Spain
2:30 PM2:30 PM
1129 - Trend in the Proportion of Recent HIV Infections by Risk, Age, and Region in Armenia (2018-2022)
Tamara Hovsepyan
National Center for Infection Diseases, Yerevan, Armenia
2:30 PM2:30 PM
1130 - Examining PopART Intervention Impact on HIV in the General Populations of Zambia and South Africa
Bonnie Shook-Sa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-08) Advanced HIV
2:30 PM2:30 PM
1131 - Addressing Advanced HIV Disease: Insights on CD4 Testing and AHD Prevalence at PEPFAR Sites
Gabriel Saemisch
United States Agency for International Development, Washington, DC, USA
2:30 PM2:30 PM
1132 - Trends in Advanced HIV Disease Prevalence in 5 African Countries: An Analysis of Household Surveys
Mateo Prochazka
World Health Organization, Geneva, Switzerland
2:30 PM2:30 PM
1133 - Advanced HIV Disease in Individuals Already in Care: Incidence and Comparison With Late Presentation
Andrea Antinori
National Institute for Infectious Diseases L Spallanzani, Rome, Italy
2:30 PM2:30 PM
1134 - The Effect of Treat-All on People With Advanced HIV Disease in Lesotho
Shanyah L. Mitchell
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1135 - Burden of AIDS-Defining Conditions Among Adults With Perinatal HIV in North America, 2000-2022
Nel Jason Haw
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1136 - C-Reactive Protein as a Predictor of Hospitalization and Mortality in Advanced HIV Disease in Uganda
Elizabeth L. Schwartz
University of Minnesota, Minneapolis, MN, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-09) Sexual Partner, Sexual Risk
2:30 PM2:30 PM
1137 - Vaginal and Anal Intercourse With Women Reported by Men Who Have Sex With Men, 2015-2019
Karen W. Hoover
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1139 - Geospatial Heterogeneity in Potential HIV Transmission Locations Among MSM in Bhopal, India
Griffin J. Bell
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1140 - Age-Stratified Sexual Partner Profiles to Characterize HIV Risk Across Lifespan: Botswana and Zambia
Kristen A. Stafford
University of Maryland, Baltimore, MD, USA
2:30 PM2:30 PM
1141 - Couples-Based Homophily in HIV Testing and Treatment Engagement: A Multicountry Analysis
Kathryn Risher
Pennsylvania State University, Hershey, PA, USA
2:30 PM2:30 PM
1142 - HIV Prevalence in Intersecting Subgroups of Southern African Women: Insights From PHIA
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1143 - Utilization of Assisted Partner Notification Services and Outcomes: A Population-Based Study
Nakawooya Hadijja
Rakai Health Sciences Program, Kalisizo, Uganda
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-02) Improving HIV Testing in Clinical Settings
2:30 PM2:30 PM
1183 - Effectiveness of Clinical Decision Support in Improving HIV Screening in Pediatric Primary Care
Sarah Wood
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
1184 - Impact of a New Opt-In Targeted Strategy for HIV Testing in Emergency Departments
Jose Guardiola
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
2:30 PM2:30 PM
1185 - Validation of a National HIV Testing Eligibility Screening Tool in Tanzania
Galal N. King'ori
2:30 PM2:30 PM
1186 - Transfusion Risk of HIV, HBV, and HCV in Low- and Middle-Income Countries Without Nucleic Acid Testing
Jodie L. White
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1187 - Clinical Features Are Poor Identifiers of Advanced HIV Disease in the Absence of CD4 Quantification
Phoebe Allebone-Salt
St George's University of London, London, UK
2:30 PM2:30 PM
1188 - HIV Recent Infection Surveillance Adds 17 Minutes to HIV Testing Services per Patient With HIV
Suzue Saito
ICAP at Columbia University, New York, NY, USA
2:30 PM2:30 PM
1189 - Missed Opportunities: HIV Screening Deficits in Japanese Syphilis Patients
Toshibumi Taniguchi
Chiba University, Chiba, Japan
2:30 PM2:30 PM
1190 - Machine Learning Risk Stratification Compared With a Counselor-Guided Screening Tool
Daniel G. Wandina
Gold Star Kenya, Karuri, Kenya
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-03) Biomarkers and Technology to Support PrEP Use
2:30 PM2:30 PM
1211 - Self-Reported PrEP Use Is Associated With Short- and Long-Term Pharmacologic Metrics in Kenyan Women
Jennifer Velloza
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1212 - Point-of-Care Urine Tenofovir Feedback Counseling Improves PrEP Adherence for US MSM in Pilot RCT
Matthew A. Spinelli
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1213 - Oral Fluid Concentrations of Tenofovir and Emtricitabine for Antiretroviral Adherence Monitoring
Xin Niu
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1214 - Are Sex-Specific Cutoffs Needed With a Next-Gen Urine Tenofovir Assay for Adherence Monitoring?
Xin Niu
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1215 - Technology-Based Oral Daily Pre-Exposure Prophylaxis Intervention for Online Population in India
Jalpa Thakker
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-04) Barriers to Uptake and Persistence With Biomedical Prevention
2:30 PM2:30 PM
1216 - Suboptimal Laboratory Testing of PrEP Users: United States, 2022-2023
Karen W. Hoover
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1217 - Factors Associated With PrEP Uptake, Persistence, and Adherence Among Incarcerated People in Zambia
Brianna R. Lindsay-Renninger
University of Maryland, Baltimore, MD, USA
2:30 PM2:30 PM
1218 - Trends in 2016 CDC-Recommended PEP Regimens and Bictegravir for HIV PEP: United States, 2015-2023
Ya-Lin A. Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1219 - Impact of Initiation Delay, Duration, and Prior PrEP Usage on FTC/TDF-Containing PEP Efficacy
Lanxin Zhang
Robert Koch Institute, Berlin, Germany
2:30 PM2:30 PM
1220 - Impact of the Anti-Homosexuality Act 2024 on HIV Prevention Efforts and PrEP Uptake Among Young MSM
Cecilia Birungi
Makerere University, Kampala, Uganda
2:30 PM2:30 PM
1221 - Cost-Effectiveness of Different Risk-Group Targeting Across 3 Types of PrEP in Zimbabwe
Yao-Rui Yeo
New York University Langone Medical Center, New York, NY, USA
2:30 PM2:30 PM
1222 - Leveraging Community to Provide PrEP to Key Population in China: Results From a PrEP Clinical Trial
Weiming Tang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1223 - Longer Distances Traveled by Rural vs Urban PrEP Users for PrEP Care: United States, 2023
Weiming Zhu
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1224 - Pre-Exposure Prophylaxis Uptake in High Female-to-Male HIV Prevalence Regions in the US
Ashvini Vaidya
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1225 - Self-Reported Frequent vs Infrequent HIV Risk and Actual Diagnoses in MSM: Implications for PrEP
Nicolas Salvadori
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1226 - The Influence of Racialized Economic Segregation on Unmet HIV Prevention Needs in the Real World
Li Tao
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1227 - The County-Level Analysis of PrEP-to-Need Ratio With HIV Diagnosis in the US, 2012-2021
Xueying Yang
University of South Carolina, Columbia, SC, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-05) PrEP Implementation: Hopes, Dreams, and Aspirations
2:30 PM2:30 PM
1228 - Diagnosis, Resistance, and ART Outcomes After HIV Acquisition on CAB-LA PrEP in Routine Care in US
Catherine A. Koss
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1229 - The Cost-Effectiveness and Optimal Price Level of Injectable PrEP With Lenacapavir in South Africa
Gesine Meyer-Rath
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1230 - PURPOSE 1: Preference for Twice-Yearly Injection vs Daily Oral Pills for HIV PrEP in Cisgender Women
Leila E. Mansoor
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
1231 - Characteristics of Persons Diagnosed With HIV in a Population-Based PrEP Program in British Columbia
Raquel M. Espinoza
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-03) Understanding HPV
2:30 PM2:30 PM
1261 - Probability of Anal Human Papillomavirus Infection Following Acute HIV Acquisition in Thailand
Supanat Thitipatarakorn
Institute of HIV Research and Innovation, Bangkok, Thailand
2:30 PM2:30 PM
1262 - Incidence and Clearance of Anal Human Papillomavirus Infection in an Acute HIV Cohort in Thailand
Supanat Thitipatarakorn
Institute of HIV Research and Innovation, Bangkok, Thailand
2:30 PM2:30 PM
1263 - HPV Clearance After Immunization: Investigating Risk Factors Associated With Clearance at Anal Site
Elena Bruzzesi
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
1264 - Sustained HIV Viral Suppression as a Predictor of High-Risk Human Papillomavirus Infection
Douglas Gaitho
Academic Model Providing Access to Healthcare, Eldoret, Kenya
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-04) Global STI Epidemiology
2:30 PM2:30 PM
1265 - Diagnostic Screening and Treatment of Curable STIs in Pregnancy and Impact on Pregnancy Outcomes
Dorothy C. Nyemba
University of Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1266 - High Incidence of Curable Sexually Transmitted Infections in HPTN 084: A Tertiary Analysis
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
2:30 PM2:30 PM
1267 - Geospatial Trends of Sexually Transmitted Infections in South Carolina (SC), 2008-2020
Syeda Shehirbano Akhtar
University of South Carolina at Columbia, Columbia, SC, USA
2:30 PM2:30 PM
1268 - Depressive Symptoms on the Incidence of Sexually Transmitted Infections Among Reproductive-Age Women
Paul N. Zivich III
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1269 - High STI Prevalence and Low Past PrEP Use Among Women Who Engage in Sex Work in Southwestern Uganda
Catherine A. Koss
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1270 - Sexually Transmitted Infection Prevalence Among Adolescents and Adults in Western Kenya
Julius L. Tonzel
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
1271 - Asymptomatic Sexually Transmitted Infections in a Population of High-Risk Men Who Have Sex With Men
Pierluigi Francesco Salvo
Universita Cattolica del Sacro Cuore, Milan, Italy
2:30 PM2:30 PM
1272 - Epidemiology of Bacterial STIs in MSM With or At Risk of HIV in the Region of Madrid (2021-2023)
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
2:30 PM2:30 PM
1273 - Identification of Clinical Phenotypes in MSM With HIV From a Prospective Study on Acute HCV and STIs
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
2:30 PM2:30 PM
1274 - Prevalence and Incidence of HIV/STIs Among MSM and Men Who Have Sex With Women in the SAMURAI Study
Elizabeth (Liz) Montgomery
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-04) Machine Learning and mHealth
2:30 PM2:30 PM
1305 - Comparing 2 mHealth Technologies to Support PrEP Use Among MSM and Transgender People in the US
Albert Y. Liu
San Francisco Department of Public Health, San Francisco, CA, USA
2:30 PM2:30 PM
1306 - Characteristics of Dapivirine Ring Users in the SEARCH Dynamic Choice HIV Prevention Studies
Elijah Kakande
Infectious Diseases Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:30 PM2:30 PM
1309 - Developing Machine Learning Algorithms to Predict Treatment Interruptions in HIV Care in Uganda
Alex Mirugwe
Makerere University–University of California San Francisco Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1310 - Exposure and Engagement Drive Impact: Results From a Digital Health Trial With Rwandan Adolescents
Rebecca Hemono
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
1311 - Digital Strategy to Improve PrEP Adherence Among MSM: A Stepped-Wedge Randomized Trial in China
Chunyan Li
University of Tokyo, Tokyo, Japan
2:30 PM2:30 PM
1312 - Impact Analysis and Machine Learning Forecasts of HIV Viral Load Suppression in 21 African Countries
Amobi A. Onovo
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-05) Novel Interventions
2:30 PM2:30 PM
1314 - Hair Salons as a Promising Space to Offer HIV Prevention Services for Young Women in Lesotho
Mamaswatsi Kopeka
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1315 - Capacity for PrEP Implementation at Pharmacies in Baltimore and San Diego: A Mixed-Methods Study
Lipin Lukose
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1316 - Evaluating Spatially Targeted HIV and Harm Reduction Strategies Among People Who Inject Drugs
Jasmine Wang
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1317 - Traditional Healers: A Nontraditional Gateway to Engagement in HIV Care in Rural Uganda
Radhika Sundararajan
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1318 - Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in PWH With Adherence Challenges
Megan E. Dieterich
Whitman-Walker Health, Washington, DC, USA
2:30 PM2:30 PM
1319 - Uptake of Online HIV PrEP and PEP in Kenya After Removal of Subsidies: A Pilot Extension Study
Daniel K. Were
Jhpiego - Nairobi, Nairobi, Kenya
2:30 PM2:30 PM
1320 - Community-Based Versus Facility-Based Services to Improve HIV Care in the Gold Mining Zones of Mali
Luis Sagaon Teyssier
Aix-Marseille Université, Marseille, France
2:30 PM2:30 PM
1321 - Community FSW Peer Model or HIV Prevention to Reach Epidemic Control and Sustainability: Tanzania
Neema Makyao
Amref Health Africa in Tanzania, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
1322 - Trial of Enhanced Peer Referral With HIV Self-Testing on PrEP Initiation Among Young Kenyan Women
Katrina Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1323 - nPEP When You Need It: A 24/7 Post-Exposure Prophylaxis Hotline in the District of Columbia
Rachel Harold
District of Columbia Department of Health, Washington, DC, USA
2:30 PM2:30 PM
1324 - HIV Health Care Transition: Five-Year Rates of Retention and Viral Suppression
Camille Knable
University of Maryland Medical Center, Baltimore, MD, USA
2:30 PM2:30 PM
1325 - Impact of Differentiated HIV Service Delivery Models on Quality of Life in Uganda
Benson Nasasira
Infectious Diseases Institute, Kampala, Uganda
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-06) Treatment Continuity
2:30 PM2:30 PM
1326 - Trends in HIV Viral Nonsuppression and Drug Resistance Among PWID on Dolutegravir ART in Kenya
Loice W. Mbogo
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1327 - Heterogeneity of Disengagement From Antiretroviral Care Matters for Treatment Success
Claire M. Keene
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1328 - Patterns of Engagement After Restarting Antiretroviral Treatment in South Africa
Claire M. Keene
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1329 - Reasons for Discontinuation of Cabotegravir Long-Acting (CAB-LA) Among Clients in Zambia
Damian J. Phiri
John Snow, Inc, Lusaka, Zambia
2:30 PM2:30 PM
1330 - Detection and Linkage of PLWH Who Are Out of Care in 94 Emergency Departments Across the US
Jamie L. Mignano
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1331 - HIV Treatment Interruptions: A Lorenz Curve Analysis of Countries Achieving the 95-95-95 Targets
Rituparna Pati
PEPFAR, Washington, DC, USA
2:30 PM2:30 PM
1332 - Point-of-Care Urine Self-Testing Feasibility to Measure TFV Adherence and Predict Viral Suppression
Renata Buccheri
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
1333 - Effect of COVID-19 Pandemic on ART Access and Timely Initiation in Adults With HIV in 31 Countries
Ben Farhat Jihane
Epicentre, Paris, France
2:30 PM2:30 PM
1334 - HIV Treatment Continuity in Haiti: Lorenz Curve Analysis of IIT, 2022-2024
Michael J. A. Reid
PEPFAR, Washington, DC, USA
2:30 PM2:30 PM
1335 - Clinical and HIV Surveillance Data to Determine Care Status for People With HIV in Washington, DC
Shannon Hammerlund
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1336 - Does Retention in Care Still Correlate With HIV Viral Suppression: Do We Need Different Strategies?
Joshua Craft
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1337 - Uptake of Injectable Cabotegravir/Rilpivirine for Treatment of HIV Infection in US, 2021-2023
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1338 - Comparative Yield of Data Sources for Health Department Data to Care Services
Julie Dombrowski
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1339 - Developing Analytic Strategies to Investigate Long-Acting Injectable Antiretroviral Effectiveness
Sarah E. Rutstein
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1340 - Prevalence of Unsuppressed Viral Load: Comparison of 2016-17 and 2022-23 Tanzania HIV Impact Surveys
Abbas Ismail
US Centers for Disease Control and Prevention Dar es Salaam, Dar es Salaam, Tanzania
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-05) Antiviral Inhibition of Viral Replication and Evasion by HIV-1
2:30 PM2:30 PM
323 - Host Gene SLC35A2 Restricts CXCR4-Tropic HIV-1 Replication at the Stage of Viral Fusion
Jamie Guenthoer
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
324 - Novel Strategy to Inhibit HIV by Targeting Integrase/INI1 Interaction Based on the TAR RNA Mimicry
Swati Haldar
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
325 - Novel Functions of TRIM21: Post-Translational Regulation of Cytoplasmic Antiretroviral APOBEC3s
Aubrey M. Sawyer
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
326 - The Effects of Accessory Genes on T/F HIV Infection of Primary CD4+ T Cells From Tissues
Harnoor Virk
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
327 - RhoA Restricts HIV-1 by Modulating IFN Signaling and Is Counteracted by Vpr
Caterina Prelli Bozzo
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
328 - The Role of Capsid-Host Interaction on Lentiviral Evolution
Clare Gill
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
329 - Capsid Mutant HIV-CRISPR Screens Reveal Mechanisms of TRIM5 Restriction
Isaiah Grant
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
330 - A Virus-Packageable CRISPR Screen to Uncover Genes Underlying SIVcpz Replication in Human Cells
Michael Young
University of California Berkeley, Berkeley, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-05) HIV and Inflammation
2:30 PM2:30 PM
378 - HIV Drives CARD8 Inflammasome Activation and Proinflammatory Cytokine Release by Myeloid Cells
Marilia R. Pinzone
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
379 - Genome-Wide Association of NLRP3 Inflammasome Plasma Cytokines in Virally Suppressed People With HIV
Sonia Savur
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
380 - Extracellular Vesicles From the Cells Harboring HIV Defective Provirus Initiate Inflammatory Cascade
Hongyan Sui
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
2:30 PM2:30 PM
381 - Extracellular Vesicles’ miRNAs Correlate With Inflammatory Markers in Tanzanians With HIV
Mussa H. Bago
Kumamoto University, Kumamoto, Japan
2:30 PM2:30 PM
382 - Proinflammatory Markers in Persons Living With HIV, HCV, and/or Drug Use
Jason T. Blackard
University of Cincinnati Medical Center, Cincinnati, OH, USA
2:30 PM2:30 PM
383 - The Systemic Inflammatory Profile Differs According to the Mechanism of HIV Control
Jose M. Benito
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
384 - Host Transcriptional Signatures Associated With Distinct Inflammatory Bioprofiles in People With HIV
Dana Alalwan
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
385 - Intestinal CD4:CD8 Ratio and Systemic Inflammatory Parameters in Suppressed HIV-1 Infection
Francesca Cossarini
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
386 - Living With HIV Mimics the Proinflammatory FUT2 Non-Secretor Phenotype in the Intestines
Leila B. Giron
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
387 - Ultra-Low Level Soluble p24 Is Associated With Inflammation in People With HIV on Suppressive ART
Matteo Augello
University of Milan, Milan, Italy
2:30 PM2:30 PM
388 - Inflammatory and Microbial Signatures Linked to Cardiovascular Outcomes in People With/Without HIV
Rachel MacCann
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
389 - Methamphetamine Use Disorder in ART PWH Is Associated With Elevated NLRP3 Inflammasome Activation
Felipe Ten-Caten
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
390 - Understanding NLRP3 Inflammasome Activation at the Intersection of HIV and Aging
Heidi Zapata
Yale University, New Haven, CT, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-06) Animal Models of Infection
2:30 PM2:30 PM
391 - Ex Vivo Isolation and Characterization of Live, Envelope Expressing, SHIV-Infected CD4 T Cells
Joseph P. Casazza
Vaccine Research Center, Bethesda, MD, USA
2:30 PM2:30 PM
392 - Lobule Zone-Dependent Accumulation of Vd1 and Vd2 gd-T Cells in the Livers of SIV+ Infant Macaques
Nina Derby
Seattle Children's Research Institute, Seattle, WA, USA
2:30 PM2:30 PM
393 - IL-15, Type I Interferon, Fatty and Amino Acid Pathways Link to SIV Reservoir and Rebound in Infants
Tehillah Chinunga
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
394 - Immunometabolic Reprogramming by Caloric Restriction Leads to Protection From SIV in Rhesus Macaques
Naveen Suresh Babu
Tulane University, Metairie, LA, USA
2:30 PM2:30 PM
395 - A New Mouse Model of HIV in Pregnancy: The EcoHIV Pregnancy Model
Michelle M. Ranjbar
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
396 - Clinical and Immune Characteristics of ART+SIV/P. fragile Infected Macaques With Persistent Viremia
Sydney Nemphos
Tulane National Primate Research Center, Covington, LA, USA
2:30 PM2:30 PM
397 - Analysis of SIV Envelope Diversity During Untreated Infection
Haoyue Li
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
398 - STLV-1 in Chlorocebus aethiops as a Model for New Approaches to Human Retrovirus Research
Víctor Â. Folgosi
Universidade de São Paulo, São Paulo, Brazil
2:30 PM2:30 PM
399 - Western Diet Boosts Immune Activation and Inflammation in SIV-Infected Macaques on Antiretrovirals
Briana Thompson
University of Pittsburgh, Pittsburgh, PA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-08) Coordinated Immune Responses and Viral Control
2:30 PM2:30 PM
464 - Distinct Signatures of Trained Immunity Reveal Heterogeneity Among Elite HIV Controllers
Joao Lucas Lima Calandrini de Azevedo
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
465 - Lymph Node Dendritic Cells Harbor an Altered Transcriptomic Profile Despite Years of Suppressive ART
Riddhima Banga
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
2:30 PM2:30 PM
466 - Mapping the Spatial Landscape of Lymph Nodes With Undetectable Versus Active HIV Replication
Candace Liu
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
467 - Longitudinal Phenotypic and Transcriptional Profiling of Immune Cells in Early-Treated Acute HIV
Jozefien De Clercq
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
468 - Markers of Immunologic Control for Future Identification of HIV Post-Treatment Controllers
Elena Bruzzesi
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
469 - Impaired Antigen Presentation and TGFβ Signaling Fosters Th17 Differentiation in PLWH Under ART
Valentino D'Onofrio
Ghent University, Ghent, Belgium
2:30 PM2:30 PM
470 - Females With HIV Favor Interferon Responses Over Inflammation Upon TLR7 Activation
Alisa Huber
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
471 - CITE-Seq and Single Cell αβ TCRseq Unravels HIV-1 Specific GZMB Subset in Post-Treatment Controllers
Giacomo Schmidt Frattari
Aarhus University, Aarhus, Denmark
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-09) Immunity to SARS-CoV-2 and Other Viruses
2:30 PM2:30 PM
472 - Diminished Immune Imprinting at the Upper Respiratory Tract Following SARS-CoV-2 Breakthrough Infection
Xuan He
West China Hospital of Sichuan University, Chengdu, China
2:30 PM2:30 PM
473 - Spike Ferritin Nanoparticle (SpFN) Recalls Memory B Cells in SARS-CoV-2-Experienced Donors
Lauren Smith
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
474 - Optimized ACE2-Fc With Picomolar Pan-Neutralization of SARS-CoV-2 Variants, Including JN.1 and KP.2
Ferran Abancó i Espuga
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
475 - Long COVID Is Associated With Lower Percentages of Mature, Cytotoxic NK-Cell Phenotypes
Tasha Tsao
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
476 - The XBB.1.5 mRNA Booster Vaccine Does Not Significantly Increase XBB.1.5 Mono-Reactive T Cells
Joel Sop
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
477 - Evaluation of Salivary Antibody in Protection From SARS-CoV-2 Infection
Sharon Walmsley
University Health Network, Toronto, Canada
2:30 PM2:30 PM
478 - Evaluation of the PHH-1V COVID-19 Vaccine-Induced T-Cell Responses in Adolescents: HIPRA-HH-3 Study
Ignasi Esteban
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
479 - T-Cell Immunity of PHH-1V COVID-19 Vaccine in PWH and Adults With Immunosuppressive Conditions
Raúl Pérez-Caballero
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
480 - Torque Teno Virus: A Predictive Biomarker for SARS-CoV-2 Vaccine Response in Immunosuppressed People
Gonzalo Cabrerizo
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
2:30 PM2:30 PM
481 - Limited Effectiveness of High-Dose Flu Vaccine in Augmenting Immunity in Older People With HIV
Jonah Kupritz
University of Miami Miller, Miami, FL, USA
2:30 PM2:30 PM
482 - Herpes Zoster Reactivation in a Cohort of People Living With HIV Vaccinated With Recombinant Vaccine
Stefania Arsuffi
University of Brescia, Brescia, Italy
2:30 PM2:30 PM
483 - Persistence of Seroprotection After Modified Hepatitis B Vaccine Schedule in People Living With HIV
Caroline Troccoli
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-08) HIV Reservoir Landscape and Dynamics
2:30 PM2:30 PM
558 - Longitudinal Analysis of HIV Reservoir Dynamics Using Q4ddPCR in Individuals Who Are ART-Treated
Rachel K. Scheck
Charité – Universitätsmedizin Berlin, Berlin, Germany
2:30 PM2:30 PM
559 - Paucity of HIV Envelope Expressing Cells Upon Latency Reversal in ART-Suppressed PWH
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
560 - Early ART Initiation Is Associated With Faster Decay of the Transcriptionally Active HIV Reservoir
Cordelia M. Isbell
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
561 - In-Depth Evaluation of the Intact Proviral DNA Assay for the Quantification of HIV-1 Reservoir
Frank Maldarelli
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
562 - Deciphering the HIV-2 Proviral Reservoir in Antiretroviral-Naive Individuals
Charlotte Charpentier
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
563 - CCR5 Expression Is Critical for the Maintenance of HIV Control and Reservoir Size
Jéssica dos Santos
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
564 - Ex Vivo Antigen Stimulation Induces HIV-1 Viral Outgrowth From a Pericentromeric Provirus
Angelica Camilo-Contreras
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
565 - Multiomics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort
Victoria Rios Vazquez
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
566 - Sex-Specific Immune Responses Shape Proviral Landscapes in Individuals on Long-Term Suppressive ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
567 - Female Sex Is Associated With Continuous Decline in Intact HIV-1 Proviruses
Yijia Li
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
568 - A Virology Quality Assurance Program to Assess Inter-Lab Reproducibility of HIV-1 Reservoir Assays
Maria Blasi
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
569 - The Cross Subtype Intact Proviral DNA Assay Detects 97% of Proviruses From Diverse HIV Clades
Dara A. Lehman
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
570 - Impact of Early ART Initiation With BIC/FTC/TAF on HIV-1 Reservoir Decay During Primary Infection
Sònia Vicens-Artés
August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
2:30 PM2:30 PM
571 - Rapid Clearance of the Inducible HIV-1 Reservoir After Initiation of Antiretroviral Therapy
Maria C. Puertas
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
572 - HIV Proviral Populations Differ by Sex and Immune Activation Levels During Antiretroviral Therapy
Chuen-Yen Lau
National Institutes of Health, Bethesda, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-09) Molecular Mechanisms of HIV Persistence and Latency
2:30 PM2:30 PM
573 - BACH2 Controls Seeding and Establishment of Long-Lived HIV-1 Reservoir in Memory CD4+ T Cells
Hongbo Gao
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
574 - Blockade of HIV Latency Reversal in CD4+ T Cells From ART-Suppressed PLWH by the Antisense RNA AST
Rui Li
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
575 - HIV Reactivation Potential Evaluated by RNA-Seq and DNA Methylation Following LRA Stimulation
Giuseppe Rubens Pascucci
Bambino Gesu Children's Hospital, Rome, Italy
2:30 PM2:30 PM
576 - Activation of Latent HIV-1 by Retinol Binding Protein 4
Chiara Pastorio
Ulm University Medical Center, Ulm, Germany
2:30 PM2:30 PM
577 - Zaprinast Reprogrammes Resting CD4+ T-Cell Metabolism and Induces HIV Latency Reversal Ex Vivo
Valentin de Masson d'Autume
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
578 - Anti-HIV Gene Editing Is Inhibited in Active HIV Provirus Through Long-Terminal Repeat Demethylation
Mohamed Bouzidi
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
579 - Macrophage Training Reactivates Latent HIV-1 From HAART-Suppressed PBMCs of PLWH
Sinu P. John
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
580 - Interference of HIV Integration via Changes in CPSF6 and SC35 Expression Due to TKIs in Macrophages
Clara Sánchez Menéndez
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
581 - Thymosin α1 Enhances IL-15 Pathway Between MoDCs and CD8+ T Cells and Restrains HIV Latency In Vitro
Chaoyu Chen
Fudan University, Shanghai, China
2:30 PM2:30 PM
581.5 - Cyclic Adenosine 3',5'-Monophosphate Agonist Prevents Establishment and Reversal of HIV Latency
Prerna Dabral
Vitalant Research Institute, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-10) HIV Reservoirs in Tissues
2:30 PM2:30 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
583 - Lymph Node Immune Landscape Reveals the Role of Innate Immunity on HIV Reservoir in ART-PLWH
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
584 - Depletion of CX3CR1+ Effector CD8 TRM Cells Is Associated With HIV-1 Reservoir in the Colon on ART
Nived Collercandy
Toulouse University Hospital, Toulouse, France
2:30 PM2:30 PM
585 - HIV Reservoir in Jejunum Exhibits Distinct Phenotypic Features and Evokes Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
2:30 PM2:30 PM
586 - Single Cell Characterization of the Gastrointestinal HIV Reservoir
Nancie Archin
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
2:30 PM2:30 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-06) CNS HIV Reservoirs
2:30 PM2:30 PM
627 - HIV Transcripts in Blood May Identify Patients at Lower Risk of Brain Injury in Cure Research
Kazuo Suzuki
St Vincent's Centre for Applied Medical Research, Darlinghurst, Australia
2:30 PM2:30 PM
628 - Unmasking the Independent Role of CSF HIV RNA Dynamics by Single Copy Assay in Neurobiotypes
Lucette A. Cysique
University of New South Wales Sydney, Sydney, Australia
2:30 PM2:30 PM
629 - Adenosine, Guardian of the Brain: Possible Role in Protecting From HIV Neuropathogenesis
Yoelvis Garcia-Mesa
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
630 - Neuroinflammation Associated With Levels of HIV DNA in the Frontal Cortex of Virally Suppressed PWH
Thomas Angelovich
RMIT University, Melbourne, Australia
2:30 PM2:30 PM
631 - HIV-Infected Microglia Drive Transcriptional and Metabolic Changes in Complex Human Brain Organoids
Leanne C. Helgers
Academic Medical Center, Amsterdam, Netherlands
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-07) Aging and NeuroHIV: Understanding Pathogenesis and Trajectories
2:30 PM2:30 PM
633 - Plasma Neopterin as a Potential Biomarker for Neurocognitive Impairment in Aging People With HIV
Marta Ruiz-Riol
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
634 - A Blip or a Trend? Interpreting Fluctuations in Cognition Over Time in Older Adults With HIV
Marie-Josée Brouillette
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
635 - Obstructive Sleep Apnea Contributes to Cognitive Difficulties Among Older Adults With HIV
Marie-Josée Brouillette
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
636 - Association of Delayed HIV Diagnosis or ART Initiation With Risk of Age-Associated Dementia
Jennifer O. Lam
Kaiser Permanente Northern California, Oakland, CA, USA
2:30 PM2:30 PM
637 - Incidence and Risk Factors for Neurocognitive Disorders Among Persons With HIV in Washington, DC
Shannon K. Barth
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
638 - Systemic Immune-Inflammation Index Links to Slower Psychomotor Speed in Older People With HIV
Crystal Wang
University of California San Diego, La Jolla, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-03) Pharmacokinetics in the Real World: Long-Acting Drugs, Alternative Matrices, and Adherence
2:30 PM2:30 PM
651 - Tenofovir Diphosphate in Dried Blood Spots and HIV-1 RNA Suppression Among PWH on TAF (ACT Study)
Ryan P. Coyle
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
653 - TFV-DP Is Associated With Baseline Virologic Suppression in PWH on TAF: Results From ACTG A5359
Stefanie Schwab
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
654 - Association of Trough Concentrations of Cabotegravir and Rilpivirine and HIV-1 RNA
Sebastian Noe
MVZ München am Goetheplatz, Munich, Germany
2:30 PM2:30 PM
655 - Inter- and Intraindividual Variability of LA CAB/RPV Pharmacokinetics After 1 Year of Continuous Use
Shawnalyn W. Sunagawa
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
656 - Plasma Concentrations of Lenacapavir in People Living With Multidrug-Resistant HIV: Real-Life Study
Minh Le
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
657 - Intracellular Pharmacokinetics of Favipiravir-5’-Ribofuranosyl Triphosphate in People With COVID-19
Elizabeth Challenger
University of Liverpool, Liverpool, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-03) ART in Vulnerable and Treatment-Experienced Populations
2:30 PM2:30 PM
689 - Long-Term Virologic Suppression Rates in the Ward 86 HIV Clinic’s Long-Acting ART Program (SPLASH)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
690 - Long-Acting Injectable ART in Persons With HIV-1 Viremia in the South: A Tool to End the Epidemic
Jonathan Colasanti
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
691 - Long-Acting Injectable Versus Oral HIV Antiretroviral Therapy for People Experiencing Homelessness
Kathleen O'Connor
San Francisco Department of Public Health, San Francisco, CA, USA
2:30 PM2:30 PM
692 - A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
693 - Simplified Access and Retention Model for Vulnerable People With HIV: SIMPLIFIED Study Results
Pablo Ryan
Hospital Universitario Infanta Leonor, Madrid, Spain
2:30 PM2:30 PM
694 - Forgiveness of Dolutegravir-Based Regimens Using Medication Possession Ratio: Andhra Pradesh, India
Ramesh Allam
US Centers for Disease Control and Prevention, Delhi, India
2:30 PM2:30 PM
695 - Less Frequent Clinical and Viral Load Assessments During COVID-19 Did Not Increase Virologic Failure
Andrew Carr
St Vincent's Hospital, Sydney, Australia
2:30 PM2:30 PM
696 - Predictive Factors of Virologic Failure After Switching to B/F/TAF (ANRS-CO3-AquiVIH-NA)
Camille Tumiotto
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
697 - Achievement of Undetectable HIV RNA in the PROMISE-US Study in Subjects Viremic at Baseline
Smitha Gudipati
Henry Ford Hospital, Detroit, MI, USA
2:30 PM2:30 PM
698 - Outcomes for Persons With Triple-Class Resistant HIV and a History of Virologic Failure
Suzanne M. Ingle
University of Bristol, Bristol, UK
2:30 PM2:30 PM
699 - Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in the Trio Cohort
Moti Ramgopal
Midway Immunology and Research Center, Fort Pierce, FL, USA
2:30 PM2:30 PM
700 - Effectiveness of Antiretroviral Therapy in People With and Without TB in the IeDEA Cohort
Lea Faure
University of Bordeaux, Bordeaux, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-05) Antiviral Therapy for SARS-CoV-2
2:30 PM2:30 PM
711 - Potent, Pan-Coronavirus Antiviral Activity of the Novel 3CLpro Inhibitor ALG-097558
Andreas Jekle
Aligos Therapeutics, San Francisco, CA, USA
2:30 PM2:30 PM
712 - Novel Class of Small Molecules Inhibits SARS-CoV-2 PLpro Through Molecular Glue-Induced Dimerization
David Hardee
AbbVie, Inc, North Chicago, IL, USA
2:30 PM2:30 PM
713 - SARS-CoV-2 Ensitrelvir Resistance-Associated Mutations in Phase III Randomized Clinical Trial
Manish C. Choudhary
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
714 - Patterns of Remdesivir Initiation in Immunocompromised Patients Hospitalized With COVID-19
Mark Berry
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
715 - Machine Learning Identifies Predictors of Delayed Remdesivir Use in Hospitalized COVID-19 Patients
Anne-Maud Ferreira
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
716 - Tracking Key Remdesivir Resistance Mutations in SARS-CoV-2 Using GISAID Data (2020-2024)
Toshibumi Taniguchi
Chiba University, Chiba, Japan
2:30 PM2:30 PM
717 - Nirmatrelvir/Ritonavir for Chronic COVID-19: Outcome in 16 Severely Immunocompromised Patients
Hanne Lamberink
Erasmus University Medical Center, Rotterdam, Netherlands
2:30 PM2:30 PM
718 - Synergistic Effect of NMV/r and Acquired Immunity in Reducing Severe COVID-19
Warren Bao
Pfizer Biostatistics, New York, NY, USA
2:30 PM2:30 PM
719 - Metformin on Time to Sustained Recovery in Adults With COVID-19: ACTIV-6 Randomized Clinical Trial
Carolyn Bramante
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
720 - Optimal Timing and Immunogenicity of COVID-19 Booster Vaccination: The EU-COVAT-2 BOOSTAVAC Trial
Elena Alvarez
University College Dublin, Dublin, Ireland
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-03) Clinical Impact of Drug Resistance in Trials and Cohorts
2:30 PM2:30 PM
734 - No Virologic Failure in Patients Switched to Doravirine Treatment With Past Resistance Mutations
Basma Abdi
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
735 - HIV-1 Resistance Analysis of Treatment-Naive People With HIV and HBV Receiving B/F/TAF or DTG+F/TDF
Michelle D'Antoni
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
736 - Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks
Laurie Vanderveen
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
737 - Virologic Success on InSTI-Based ART Despite Archived InSTI DRMs
Yanis Merad
Hospices Civils de Lyon, Lyon, France
2:30 PM2:30 PM
738 - Bictegravir + Lenacapavir: Baseline and Week 48 Resistance in ARTISTRY-1 Phase II
Nicolas Margot
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
739 - Real-World Robustness of B/F/TAF at Virologic Failure in the ANRS-CO3-AquiVIH-NA Cohort
Camille Tumiotto
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
740 - Shifting Paradigms: Doravirine's Potential in Treating Non-Group M HIV-1, the DORAVI-O Study
Elodie Alessandri-Gradt
University of Rouen Normandy, Normandy, France
2:30 PM2:30 PM
741 - Impact of Resistance to Antiretroviral Therapy Among Veterans With Human Immunodeficiency Virus
Mary J. Christoph
Gilead Sciences, Inc, Foster City, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-04) Dolutegravir Resistance
2:30 PM2:30 PM
742 - Population-Based Longitudinal Dynamics of HIV Drug Resistance During Dolutegravir Rollout in Uganda
Michael A. Martin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
743 - Plasma DTG Exposure Test as Objective Tool to Identify People With HIV at Highest Risk of Resistance
Kim Steegen
National Health Laboratory Service, Johannesburg, South Africa
2:30 PM2:30 PM
744 - Plasma Dolutegravir Exposure as a Triaging Tool for HIV Drug Resistance Testing by ONT Sequencing
Hendrik J. Coetser
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
745 - HIV Drug Resistance by Next-Generation Sequencing After Transition to TLD in Uganda and South Africa
Suzanne McCluskey
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
746 - HIV Drug Resistance Among Individuals on Dolutegravir With Low-Level Viremia in Malawi
Newton L. Kalata
US Centers for Disease Control and Prevention Lilongwe, Lilongwe, Malawi
2:30 PM2:30 PM
747 - Predictors of HIV Drug Resistance to Dolutegravir in 4 PEPFAR-Supported Countries
Juliana D. Da Silva
Centers for Disease Control and Prevention, Atlanta, GA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-04) Hepatitis Epidemiology and Immunology
2:30 PM2:30 PM
778 - HeCaPred: An AI-Based Algorithm for HCC Prediction in Patients With HCV Chronic Infection After SVR
Anaïs Corma-Gómez
Hospital Universitario Virgen de Valme, Sevilla, Spain
2:30 PM2:30 PM
779 - A New Point-of-Care Ultrasound Protocol for Chronic Hepatitis B and HBV/HIV Coinfection in Zambia
Costanza Bertoni
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
780 - High Prevalence of Triple Infection (HIV/HBV/HDV) Among Key Populations With HIV in India
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
782 - Simulation Modeling of Hepatitis B Virus Disease Progression, Hepatitis Flares, and Functional Cure
Amir Mohareb
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
783 - HIV/HCV Coinfection: Extracellular Vesicles Modulate NK Functionality in Relation to Liver Fibrosis
Ariel A. Osegueda
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
2:30 PM2:30 PM
784 - In Vitro and In Vivo Immunogenicity of a Dendritic Cell-Based Vaccine Targeting HBV Epitopes
Sylvain Cardinaud
Vaccine Research Institute, Créteil, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-04) Cervical and Anal Cancer: Prevention and Screening
2:30 PM2:30 PM
805 - HPV Detection by Vaginal Self-Sampling and Urine Collection in Women Living With HIV: AUTOCol Study
Jade Ghosn
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
806 - The Ivorian Cervical Cancer Screening Cascade: A 10-Year Program Evaluation According to HIV Status
Simon Boni
PAC-CI Program, Abidjan, Côte d'Ivoire
2:30 PM2:30 PM
807 - 2 vs 3 Doses of HPV9-Valent Vaccine in Women With HIV: Safety & Immunogenicity From Randomized Trial
Debora R. Konopnicki
Saint-Pierre University Hospital, Brussels, Belgium
2:30 PM2:30 PM
808 - Optimizing Anal Cancer Screening in PWH: The Role of ADAR1 mRNA in Predicting High-Grade Lesions
Melissa Bello-Perez
Hospital General Universitario de Elche, Elche, Spain
2:30 PM2:30 PM
809 - Anal Cancer Incidence Among Privately Insured People With and Without HIV in South Africa
Eliane Rohner
University of Bern, Bern, Switzerland
2:30 PM2:30 PM
810 - Evaluation of Anal Cancer Screening in 18–34-Year-Old Men Who Have Sex With Men Living With HIV
Serina S. Applebaum
Yale University, New Haven, CT, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-04) CVD Risk Prediction
2:30 PM2:30 PM
828 - Genomic Analyses of Cardiovascular Risk in People With HIV From the MVP Cohort
Vincent C. Marconi
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
829 - The Additive Value of Coronary Calcium in Identifying Cardiovascular Risk in Ageing People With HIV
Maithili Varadarajan
Chelsea and Westminster Hospital, London, UK
2:30 PM2:30 PM
830 - BMI Is a Poor Surrogate for Excess Visceral Adiposity and Cardiovascular Risk in Persons With HIV
Karam Mounzer
Philadelphia FIGHT, Philadelphia, PA, USA
2:30 PM2:30 PM
831 - Investigating the Predictive Role of NLR and PLR in Cardiovascular and Neurologic Outcomes in PWH
Teresa H. Evering
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
832 - Cardiovascular Risk Assessment in Women Living With and Without HIV Using the PREVENT Model
Tetiana Povshedna
University of British Columbia, Vancouver, Canada
2:30 PM2:30 PM
833 - Prediction of Cardiovascular Risk Among PWH: Comparing the PREVENT and Pooled Cohort Equations
Matthew S. Durstenfeld
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
834 - Lipidomic, Metabolomic, and Immune Profiles Precede Cardiovascular Events in People With HIV
Joana Vitalle
Institute of Biomedicine of Sevilla, Sevilla, Spain
2:30 PM2:30 PM
835 - Patterns of Social and Biological Risk Factors in People With HIV and Risk of Cardiovascular Disease
Cynthia N. Ramirez
Kaiser Permanente Division of Research, Oakland, CA, USA
2:30 PM2:30 PM
836 - Agrarian Diet Intervention Improves Metabolic Health in Men With HIV Who Have Sex With Men
John O'Connor
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
837 - Decreased Anti-Inflammatory Tryptophan Metabolites Correlate With Higher CVD Risk in PWH
Manuela Ceccarelli
Università Kore di Enna, Enna, Italy
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-05) Atherosclerosis and Vascular Disease
2:30 PM2:30 PM
838 - Risk of Obesity, Cardiometabolic Disease, and MACE After Switch to Integrase Inhibitor in REPRIEVE
Emma M. Kileel
Boston University, Boston, MA, USA
2:30 PM2:30 PM
839 - Determinants of De-Novo High-Risk Carotid Ultrasound Features in Middle-Aged People Living With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
840 - Seven-Year Progression of Coronary Artery Calcium Score in Middle-Aged Thai People Living With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
841 - Markers of Arterial Stiffness in People Living With HIV and Echocardiographic Outcomes
Karl Reis
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
842 - Multiomics Profiles of SHBG Are Associated With Subclinical Atherosclerosis in Men With HIV
Yi Wang
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
843 - Multiomics Analysis of Gut Microbiome and Carotid Artery Atherosclerosis in Men With and Without HIV
Zheng Wang
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
844 - PLHIV Exhibit a COVID-19 Independent Increase of Cardiovascular Mortality in Brazil, 2019-2023
Rodrigo Moreira
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
845 - Effect of Treatment for Opioid Use Disorder on Endothelial Function in People With and Without HIV
Corrilynn O. Hileman
MetroHealth Medical Center, Cleveland, OH, USA
2:30 PM2:30 PM
846 - Cholesterol Synthesis Pathways in Monocyte-Derived Macrophages Link CMV and HIV to Atherosclerosis
Katelyn O'Hare
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
847 - Endothelial Colony-Forming Cells From People With HIV Display an Interferon Gene Signature
Akif A. Khawaja
Imperial College London, London, UK
2:30 PM2:30 PM
848 - CHIP Is Associated With Plasma Inflammatory Biomarkers and Vascular Events in People With HIV on ART
Caroline H. Sheikhzadeh
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
849 - ALDH Activity as a New Marker of Subclinical Atherosclerosis During ART-Treated HIV-1 Infection
Jonathan Dias
University of Montreal, Montreal, Canada
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-06) Statins: Impact and Usage
2:30 PM2:30 PM
850 - Statin Effect Heterogeneity on Plaque Volume and Composition in the REPRIEVE Mechanistic Substudy
Borek Foldyna
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
851 - People With HIV at High Cardiovascular Risk Were Undertreated With Statins
Stefan Esser
University Hospital Essen, Essen, Germany
2:30 PM2:30 PM
852 - Low-Density Lipoprotein Changes in People With HIV Initiating Statins for Primary Prevention
Thibaut Davy-Mendez
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
853 - Time-Updated Win Ratio Aligns With Primary REPRIEVE Findings and Suggests Early Pitavastatin Benefit
Emma Davies Smith
Harvard TH Chan School of Public Health, Boston, MA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-06) Diabetes and Metabolic Dysfunction
2:30 PM2:30 PM
898 - Incident Diabetes Among People With HIV After Switching to Integrase Strand Transfer Inhibitors
Y. Joseph Hwang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
899 - Decreased Adipose Tissue Gene Expression After a 48-Week Switch From an InSTI Regimen to TDF/3TC/DOR
Claudine Duvivier
Necker Hospital, Paris, France
2:30 PM2:30 PM
900 - In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens
Alessandra Guida
AORN dei Colli Ospedale Cotugno, Naples, Italy
2:30 PM2:30 PM
901 - HIV-Induced Immunomodulation and Cardiometabolic Disease Development in Mice on High-Fat Diets
Victoria R. Stephens
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
902 - HIV and Antiretrovirals Have Unique In Vivo Effects on Insulin Resistance in HIV
Theodoros Kelesidis
University of Texas Southwestern Medical Center, Dallas, TX, USA
2:30 PM2:30 PM
903 - Menopause Is Associated With Faster Increases in Insulin Resistance in Women With HIV
Rebecca Abelman
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
904 - Obstructive Sleep Apnea and Prevalent Diabetes Mellitus in the Multicenter AIDS Cohort Study
Wassim A. Bouhsane
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
905 - Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance
Diana L. Alba
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
906 - Early Pregnancy Insulin Dynamics in South African Women With HIV on Dolutegravir: The ORCHID Study
Jennifer Jao
Northwestern University, Chicago, IL, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-07) Other Comorbidities
2:30 PM2:30 PM
907 - Noncommunicable Diseases: A Significant Cause of Death Among People Living With HIV in Nigeria
Chiamaka H. Onuoha
APIN Public Health Initiatives, Abuja, Nigeria
2:30 PM2:30 PM
908 - Risk Factors for Osteonecrosis Among People With HIV in Care Across the US in the Current ART Era
Heidi M. Crane
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
909 - Validation of SCORE and OST for Osteoporosis Risk Estimation in People Aging With HIV in Peru
Joselito Malca Hernandez
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
910 - Prevalence, Incidence, and Correlates of Autoimmune Diseases in People With HIV From 1997 to 2023
Emanuela Zappulo
University of Naples Federico II, Naples, Italy
2:30 PM2:30 PM
911 - Disparities in Hospitalization Among People in the HIV Outpatient Study, United States, 2008-2022
Kate Buchacz
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
912 - Uncovering Differential Disparities at the Intersection of Race, Sex, & HIV in Patients With Sepsis
Joshua A. Barocas
University of Colorado School of Medicine, Aurora, CO, USA
2:30 PM2:30 PM
913 - HIV Status and Psychiatric Diagnoses Among Transgender and Gender-Diverse Individuals
Fanghui Shi
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
914 - Kynurenine-Tryptophan (KT) Ratio and Inflammatory Biomarkers Associated With COPD in People With HIV
Kristina Crothers
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
915 - Characteristics of Secondary Hemophagocytic Lymphohistiocytosis in People Living With HIV/AIDS
Xavier A. Flores-Andrade
National Institute of Respiratory Diseases, Mexico City, Mexico
2:30 PM2:30 PM
916 - Safety of Full-Spectrum Cannabidiol for PWH: A Double-Blind, Randomized, Placebo-Controlled Study
Clémence Couton
Centre de Biophysique Moléculaire, Orléans, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-03) PASC: Biological Clues to Pathogenesis
2:30 PM2:30 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
937 - Lack of Association of SARS-CoV-2 N- and S-Antigenemia With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
938 - Exploring the Molecular Pathways of Long COVID With Post-Exertional Fatigue: A Multiomic Approach
Marta Massanella
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
939 - Distinct Proinflammatory/Proangiogenetic Signatures Distinguish Children With Long COVID
Danilo Buonsenso
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2:30 PM2:30 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
941 - Key Inflammatory Biomarkers Differentiate MIS-C From Convalescent COVID-19 and Kawasaki Disease
Tetyana Pidkova
IrsiCaixa Institute for AIDS Research, Badalona, Spain
2:30 PM2:30 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:30 PM2:30 PM
943 - Autoantibody Prevalence After SARS-CoV-2 Infection: Comparing Baltimore, USA, and Rakai, Uganda
Xianming Zhu
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
944 - Novel Plasma Biomarkers for the Detection of Long COVID Defined by Multiapproach Analysis
Mohamed R. Joma
French National Institute of Health and Medical Research (Inserm), Paris, France
2:30 PM2:30 PM
945 - ACE2 Autoantibodies in Post-Acute Sequelae of SARS-CoV-2 Infection
Melissa Agsalda-Garcia
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
946 - Shared Autoantibody Signature Is Not Identified in CSF During Long COVID
Debanjana Chakravarty
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
947 - Post-Acute SARS-CoV-2 Antigenemia Is Associated With Some but Not All Long COVID Symptoms
Michael Peluso
University of California San Francisco, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-05) Cryptococcal Meningitis: Where Do We Go From Here?
2:30 PM2:30 PM
973 - Uptake of New Guidelines for Cryptococcal Meningitis in Botswana, Malawi, Uganda, and Zimbabwe
David S. Lawrence
London School of Hygiene & Tropical Medicine, London, UK
2:30 PM2:30 PM
974 - Clinical Outcomes of People With HIV-Cryptococcal Meningitis on the New Treatment Regimen in Uganda
Esther M. Nasuuna
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
975 - Trends in Cryptococcal Meningitis Mortality Using Routine Longitudinal National Data From Botswana
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
976 - Pathway to Care Among Inpatients With Symptomatic Cryptococcal Meningitis in Johannesburg, SA
Lia F. Edkins
WITS Health Consortium, Johannesburg, South Africa
2:30 PM2:30 PM
977 - CMV and EBV Co-Infections and Mortality Risk in Patients With HIV-Associated Cryptococcal Meningitis
Jayne P. Ellis
London School of Hygiene & Tropical Medicine, London, UK
2:30 PM2:30 PM
978 - Catastrophic Healthcare Expenditure From Cryptococcal Meningitis in Eastern and Southern Africa
David S. Lawrence
London School of Hygiene & Tropical Medicine, London, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-06) OI Pathogenesis and Recent Trends in ART and OI Treatment Outcomes
2:30 PM2:30 PM
979 - Epigenetic Changes With T. gondii in Brains of People With HIV and Their Possible Link to Gliomas
Megha Srivatsa
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
980 - Factors Associated With Virologic Suppression in People Living With HIV and Tuberculosis in Brazil
Nathalie De Castro
Hôpital Saint-Louis, Paris, France
2:30 PM2:30 PM
981 - Recent Trends in Opportunistic Infections at ART Initiation in the NA-ACCORD of IeDEA, 2017-2021
Keri N. Althoff
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
982 - Ceftriaxone or Aqueous Penicillin for Neurosyphilis: A Mexican Multicentric Retrospective Study
Rodrigo Ville Benavides
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
983 - Burden of Opportunistic Infections and Causes of Death in Hospitalized Patients With AHD in Vietnam
Nam Xuan Ha
Oxford University Clinical Research Unit in Vietnam, Ho Chi Minh, Vietnam
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-05) HIV Acquisition and Prevention During Pregnancy and Breastfeeding
2:30 PM2:30 PM
1005 - Incident HIV Infection Among Pregnant Women in Botswana Has Decreased Since 2022
Aamirah Mussa
Botswana–Harvard AIDS Institute Partnership, Gaborone, Botswana
2:30 PM2:30 PM
1006 - Social Determinants Associated With Recent HIV Infection in Treatment-Naive Pregnant Women in Malawi
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1007 - STI Testing Is Associated With Lower PrEP Discontinuation Among Women Initiating PrEP in Pregnancy
Jerusha Mogaka
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1008 - Impact of Offering PrEP Choice on HIV Incidence in High-Risk Pregnant Women in Kenya
Tessa Concepcion
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1009 - PrEP Adherence and Acceptability of Urine Tenofovir Testing in Pregnant and Postpartum Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1010 - TFV-DP Concentrations in PBMCs and Safety of Daily Directly Observed F/TDF PrEP During Pregnancy
Linxuan Wu
University of Washington, Seattle, WA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-06) Emerging Perspectives on Perinatal HIV Transmission
2:30 PM2:30 PM
1011 - Vertical HIV Transmission: Substantial Reductions but Not Elimination With Universal ART
Nisha Jacob
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1012 - The Role of Maternal Broadly Neutralizing Antibody Activity in Perinatal Transmission of HIV-1
Krithika Karthigeyan
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1013 - ART Reverses Negative Natural Selection of HIV Disease-Linked HLA-I in KwaZulu-Natal, South Africa
Nicholas G. Herbert
University of Oxford, Oxford, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-05) Risks and Responses to ART
2:30 PM2:30 PM
1050 - Infants With HIV Starting ART Within 4 Months of Age Can Achieve Sustained Undetectable HIV-1 DNA
Alfredo Tagarro
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
2:30 PM2:30 PM
1051 - Hospitalization Incidence Among Young Children Living With HIV in the Western Cape, South Africa
Kim Anderson
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1052 - Inflammatory Cytokines in ART-Naive Kenyan Children Diagnosed With HIV at Hospital Admission
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1053 - HIV Viral Load Patterns Since Dolutegravir Initiation in Children and Adolescents Living With HIV
Sophie Desmonde
Université Toulouse III - Paul Sabatier, Toulouse, France
2:30 PM2:30 PM
1054 - Viral Suppression 12 Months After Switch to Dolutegravir by nRTI Backbone in Children/Adolescents
Renee de Waal
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1055 - Transitioning Adolescents With HIV to TDF/3TC+DTG Improves Virologic Outcome: CIPHER-ADOLA Study
Aude Christelle Ka'e
2:30 PM2:30 PM
1056 - Prevalence and Consequences of Low-Level Viremia Among Adolescents Living With HIV in South Africa
Zea Leon
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1057 - HIV-1 Drug Resistance at Low- and High-Level Viremia in Kenyan Youth on Dolutegravir-Based Therapy
Rami Kantor
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1058 - Enhanced Adherence Counselling Among Adolescents With Detectable Viremia in Cameroon
Alex Durand Nka
2:30 PM2:30 PM
1059 - Differentiated Service Delivery Programme Impact on Clinical Outcomes Among Adolescents With HIV
Lara Lewis
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
1060 - HIV Status Disclosure Among ART-Experienced Adolescents and Young Adults in 4 African Countries
Trevor Crowell
US Military HIV Research Program, Bethesda, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-06) Health and Outcomes of Young People With HIV
2:30 PM2:30 PM
1061 - Long-Term Outcomes of Young Adults With Perinatal HIV Infection in the US and Puerto Rico
Leah Kern
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
1063 - Psychotic Disorders in Young Adults With Perinatally Acquired HIV: A Multicentre UK Study
Indira Mallik
Imperial College Healthcare NHS Trust, London, UK
2:30 PM2:30 PM
1064 - Changes in Suicidality, Depression, and Anxiety After Integrative Mental Health Care in Thai Youth
Tavitiya Sudjaritruk
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1066 - Kidney Dysfunction in Young People Living With HIV on Dolutegravir-Based Regimens in Kampala, Uganda
Esther M. Nasuuna
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
1067 - Long-Term Immune Response to Vaccines in Vertically Infected People Living With HIV
Daniele Donà
University of Padova, Padova, Italy
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-07) Inflammation and Cardiovascular Complications
2:30 PM2:30 PM
1068 - Characterisation of Cardiac Disease in Adolescents With HIV in the Antiretroviral Therapy Era
Edith D. Majonga
Biomedical Research and Training Institute, Harare, Zimbabwe
2:30 PM2:30 PM
1069 - Left Ventricular Mass Adjustment for Body Size in Youth With Perinatal HIV or Perinatal HIV Exposure
George W. Sawyer
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
1070 - Distinct Metabolic and Inflammation Signatures in Urban vs Rural Ugandan Youth With HIV
Sahera Dirajlal-Fargo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1071 - US and Ugandan HIV Youth: Exploring Differences in Inflammatory, Chemokine, and Vascular Signatures
Sahera Dirajlal-Fargo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1072 - HIV Modifies Association of Biomarkers on Cardiac Fibrosis and Inflammation in South African Youth
Jennifer Jao
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1073 - Changes in Inflammatory Biomarkers Among Youth Living With Perinatal HIV Infection and Exposure
Russell B. Van Dyke
Tulane University, Metairie, LA, USA
2:30 PM2:30 PM
1074 - Inflammation Phenotypes in Children With Perinatally Acquired HIV in South Africa
Claire Davies
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1075 - Early-Treated Children With Perinatal HIV Show Elevated Monocyte Activation Into Late Childhood
Claire Davies
Stellenbosch University, Cape Town, South Africa
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-10) HIV and Substance Use
2:30 PM2:30 PM
1144 - Increasing Methamphetamine Use and Group Sex Observed in MSM With Acute HIV Infection in Bangkok
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
1145 - Unstable Housing, Methamphetamine Use, and HIV Incidence Among Racial and Ethnic Minority Men
Marjan Javanbakht
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1146 - Substance Use Is Associated With Higher HIV Viral Load and Reduced Viral Suppression in 6 US Cohorts
Ryan P. Kyle
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1147 - Missed Opportunities for Drug Use Screening and Discussions Among People With HIV
Sydney Bornstein
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1148 - Impact of Residing or Injecting in Testing Center Catchments on HIV Testing in Churachandpur, India
Talia A. Loeb
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1149 - HIV Outcomes Among People With HIV Who Inject Drugs in West Virginia
Rebecca Reece
West Virginia University, Morgantown, WV, USA
2:30 PM2:30 PM
1150 - Scope of the Overdose Crisis: Fatal Overdoses Among People With HIV Experiencing a Nonfatal Overdose
Megan E. Marziali
Columbia University, New York, NY, USA
2:30 PM2:30 PM
1151 - Progress Towards UNAIDS 95-95-95 Targets Among PWID Living With HIV Over 10 Years in Punjab, India
Griffin J. Bell
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1152 - The Impact of Semaglutide on Alcohol Use Among People With HIV in Routine Clinical Care in the US
Heidi M. Crane
University of Washington, Seattle, WA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-11) HIV Transmission Insights Through Phylogenetics
2:30 PM2:30 PM
1153 - Introduction and Acquisition of HIV-1 Related to Recent Migration to Quebec (2016-2023)
Jean-Pierre Routy
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
1154 - HIV Molecular Clusters Attributed to Sexual Transmission in the United States, 2015-2023
Kathryn G. Curran
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1155 - Changing Clustering Rates in the Rhode Island HIV-1 Epidemic
Rami Kantor
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1156 - Evolution of HIV-1 A6 Clusters in Poland Following Full-Scale Armed Conflict in Ukraine
Karol Serwin
Pomeranian Medical University, Szczecin, Poland
2:30 PM2:30 PM
1157 - People Living With HIV Diagnosed Late Provide Source of HIV Infection to Others With Recent Diagnosis
Evangelia G. Kostaki
National and Kapodistrian University of Athens, Athens, Greece
2:30 PM2:30 PM
1158 - Distribution of HIV-1 Variants in Population-Based National Surveys in Sub-Saharan Africa, 2015-2022
Peter D. Ghys
Independent Consultant, Tannay, Switzerland
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-12) Life Expectancy and Mortality Among People With HIV
2:30 PM2:30 PM
1159 - Life Expectancy Among Virally Suppressed Women and Men With HIV in the Bronx, New York, 1997-2021
Brandilyn A. Peters
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
1160 - Mortality Trends Among Persons With Perinatal HIV in United States and Territories, 1978-2022
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1161 - Mortality in the HIV Outpatient Study (HOPS), Trends and Risks: 2007-2022
Frank Palella
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1162 - Reducing HIV Diagnoses and Mortality Rate Further Increases Aging Resource Needs for PWH Into 2040
Siobhan M. O'Connor
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1163 - Factors Associated With Mortality Among People With Advanced HIV Disease in Rural Uganda, 2018-2021
Kabali Bwogi
C-CARE International Hospital, Kampala, Uganda
2:30 PM2:30 PM
1164 - Projecting Demographics and Causes of Death Among People With HIV in Western Europe to 2050
Julie Ambia
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1165 - Causes of Mortality Among Persons Living With HIV in Thailand, 2007-2022
Wiphawee Kiatchanon
Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand
2:30 PM2:30 PM
1166 - Text Clustering Model for Defining Cause of Death Among PLHIV in Thailand (2020-2022)
Apiratee Kanphukiew
Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand
2:30 PM2:30 PM
1167 - Changes Over Calendar Time in Discrimination of Prognostic Models for People With HIV Starting ART
Suzanne M. Ingle
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1168 - Clinical Outcomes in Lung Transplantation in People Living With HIV: A Competing Risk Analysis
German Contreras
University of Texas Medical Branch, Galveston, TX, USA
2:30 PM2:30 PM
1169 - Epigenetic Age Acceleration and Mortality Among Persons Who Inject Drugs With Poorly Controlled HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-13) HIV Epidemiology
2:30 PM2:30 PM
1170 - The HIV Epidemic Is Growing Faster in Countries Excluded From Gilead Voluntary Licenses
Samuel Cross
NHS Greater Glasgow and Clyde, Glasgow, UK
2:30 PM2:30 PM
1171 - Characteristics and Needs of Adult Lifetime Survivors With HIV in the United States, 2015-2022
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1172 - Clinical and Programmatic Factors Associated With Low-Level Viremia in West Africa
Ebiere C. Herbertson
Nigerian Institute of Medical Research, Lagos, Nigeria
2:30 PM2:30 PM
1175 - Prevalence and Risk Factors of HIV Viral Blips in the NA-ACCORD, 2010-2020
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
1176 - Time From HIV Infection to Diagnosis Using CD4 Depletion Model: Thailand, 2014-2021
Suchunya Aungkulanon
National Health Security Office, Chiang Mai, Thailand
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-03) Challenging and Innovative HIV Testing
2:30 PM2:30 PM
1191 - HIV Serologic Reactivity in Persons With HIV Who Started ART During Acute/Early Stages of Infection
Vivian I. Avelino-Silva
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
1192 - Laboratory-Based HIV-1/2 Ag/Ab Immunoassay Performance in the United States, 2019-2023
Patricia Bessler
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1193 - Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP
Jessica M. Fogel
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1194 - Can HIV Testing Data and Recent HIV Infection Surveillance Identify Similar Signals of Transmission?
Misheck Luhanga
US Centers for Disease Control and Prevention Lilongwe, Lilongwe, Malawi
2:30 PM2:30 PM
1195 - Preferences for HIV Testing Technologies in Seattle, Washington: A Mixed-Methods Study
Lauren R. Violette
Harvard Medical School, Boston, MA, USA
2:30 PM2:30 PM
1196 - Clinical Validation of iMune qPCR as a Novel Solution to CD4 Counting Off Dried Blood Spots
Tracy M. Sungu
University of Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1197 - Screening of MPXV, VZV, HSV-1, and HSV-2 Causing Mucocutaneous Vesicular Rashes by Multiplex HRM-PCR
Joany Guy
AFYIA Diagnostics, Grabels, France
2:30 PM2:30 PM
1198 - Impact of Point-of-Care HIV-1 RNA Testing on Time to HIV Confirmation and ART Start in Buenos Aires
Carina Cesar
Fundación Huésped, Buenos Aires, Argentina
2:30 PM2:30 PM
1199 - Characteristics of First-Time HIV Self-Testers Using the Online HIV Service ‘Stand By You’
Kantarida Sripanidkulchai
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-06) Innovations in PrEP Products
2:30 PM2:30 PM
1232 - MK-8527 PK/PD Threshold and Phase II Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Research Laboratories, Rahway, NJ, USA
2:30 PM2:30 PM
1233 - A Biodegradable Implant Releasing Low-Dose Islatravir Protects Macaques From Rectal SHIV Infection
Leah Johnson
RTI Health Solutions, Research Triangle Park, NC, USA
2:30 PM2:30 PM
1234 - Qualitative Assessment of Acceptability and Preferences for Injectable and Oral PrEP in PURPOSE 1
Elizabeth (Liz) Montgomery
2:30 PM2:30 PM
1235 - Cost-Effectiveness of Community Pharmacy-Based HIV PrEP for Men Who Have Sex With Men in Atlanta
Jacinda Tran
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1236 - Long-Acting Injectable CAB/MPA MPT Implant for Prevention of HIV and Unintended Pregnancy
Jasmine King
CIDRZ / University of North Carolina, Chapel Hill, NC, USA
2:30 PM2:30 PM
1237 - Acceptability and Usability of a TAF/EVG Insert Among Women in a Multinational Phase I Trial
Ellen Luecke
RTI International, Berkeley, CA, USA
2:30 PM2:30 PM
1238 - Dose-Ranging Pharmacokinetics and Efficacy of a 90-Day Multipurpose IVR Delivering Islatravir
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-05) DoxyPEP Reflections
2:30 PM2:30 PM
1275 - Postexposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Cristina Gómez-Ayerbe
Hospital Universitario Virgen de la Victoria, Málaga, Spain
2:30 PM2:30 PM
1276 - Doxycycline Post-Exposure Prophylaxis Continuum of Care Among MSM in Philadelphia, 2023
Tanner Nassau
Philadelphia Department of Public Health, Philadelphia, PA, USA
2:30 PM2:30 PM
1277 - Characteristics of Breakthrough Chlamydia Cases Among Cisgender Women Assigned to Doxycycline PEP
Jenell Stewart
Hennepin Healthcare Research Institute, Minneapolis, MN, USA
2:30 PM2:30 PM
1278 - Acceptability of Doxycycline as Post-Exposure Prophylaxis in Southeastern Louisiana
Shafay Shams
Louisiana State University, New Orleans, LA, USA
2:30 PM2:30 PM
1279 - Factors Influencing Doxy-PEP Awareness Among Sexual/Gender Minorities: A Web-Based Survey in Brazil
Mayara Secco Torres da Silva
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1280 - Young Black Sexually Minoritized Men Living With HIV, Substance Use, and Syphilis Want Doxy-PEP
Jade Pagkas-Bather
University of Chicago, Chicago, IL, USA
2:30 PM2:30 PM
1281 - Increased Knowledge and Use of Doxycycline Postexposure Prophylaxis in King County, Washington
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
2:30 PM2:30 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
2:30 PM2:30 PM
1283 - Topical Doxycycline Inserts Show High Efficacy Against Vaginal Chlamydia Acquisition in Macaques
David A. Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Postexposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
1285 - Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Clinic, 2023-2024
Philip A. Chan
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1286 - Effectiveness of Ceftriaxone Monotherapy for Gonorrhea Treatment
Chiara Fusetti
Luigi Sacco University Hospital, Milan, Italy
2:30 PM2:30 PM
1287 - Prevalence of Tetracycline-Resistant Gonorrhea in British Columbia’s HIV Treatment and PrEP Program
K. Junine Toy
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-07) PrEP and PEP Use
2:30 PM2:30 PM
1341 - A Comparative Analysis of Access and Retention of Oral PrEP and CAB-LA at 1 Month in Zambia
Damian J. Phiri
John Snow, Inc, Lusaka, Zambia
2:30 PM2:30 PM
1342 - Patterns of PrEP Use Among Rural South Africa Youth Given Choice: Process Data From the LAPIS Trial
Maryam Shahmanesh
University College London, London, UK
2:30 PM2:30 PM
1343 - Peer Mobilisation Into Sexual Health Clinics Creates PrEP Demand Among High-Risk Rural Youth in SA
Maryam Shahmanesh
University College London, London, UK
2:30 PM2:30 PM
1344 - Injectable Cabotegravir PrEP Discontinuations at a Peer Specialist-Led Program in Washington, DC
Juan Carlos Loubriel
Whitman-Walker Health, Washington, DC, USA
2:30 PM2:30 PM
1345 - Outcomes From a Multilevel Trial With Clinics and Young Women for PrEP in South Africa
Alexandra Minnis
RTI International, Berkeley, CA, USA
2:30 PM2:30 PM
1346 - Impact of CAB-LA Versus Oral PrEP in Reducing HIV Incidence Among MSM in Thailand: A Modelling Study
David Van de Vijver
Erasmus University Medical Center, Rotterdam, Netherlands
2:30 PM2:30 PM
1347 - PrEP Use Trajectories and HIV Incidence Among PrEP Users in Brazil: Findings From the ImPrEP Study
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1348 - US Socioeconomic Disparities and Geographic Variations in HIV Preexposure Prophylaxis Providers
Li Tao
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1349 - Social Networks Influence PrEP Use and Preference for Long-Acting PrEP Among MSM In Baltimore
Steven J. Clipman
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1350 - Disparities in PrEP Use Among Latinx and Black Transgender Women in Los Angeles County, 2019 vs 2023
Yingbo Ma
Los Angeles County Department of Public Health, Los Angeles, CA, USA
2:30 PM2:30 PM
1351 - Early PEPFAR Implementation of Cabotegravir-LA and Implications for Long-Acting HIV Prevention
Carly E. LoVullo
PEPFAR, Washington, DC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-08) PrEP Choice and Preferences
2:30 PM2:30 PM
1352 - “I Like It but I Can’t Be the First”: Sex Workers’ Preferences for LAI PrEP Delivery in South Africa
Katherine Rucinski
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1353 - HIV PrEP Method Preferences Among Transgender and Gender-Diverse Adults in the United States
Dovie L. Watson
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1354 - Expanding the PrEP Market: Early Insights Offering Oral, Ring, and CAB PrEP in Sub-Saharan Africa
Urvi Parikh
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
1355 - Long-Acting PrEP Preference Among Brazilian Sexual and Gender Minorities: Key Influencing Factors
Thiago Torres
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1356 - PrEP Choices Among Sexual and Gender Minorities in Brazil: The ImPrEP CAB-LA Study
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1357 - Acceptability of Long-Acting Cabotegravir Among Pregnant and Lactating People in South Africa
Nafisa Wara
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1358 - Regional Disparities in DoxyPEP Uptake Despite High Awareness Among MSM With HIV in the US
Tyler Martinson
University of California San Francisco, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-09) Long-Acting Injectable ART Implementation
2:30 PM2:30 PM
1359 - Characteristics of People With HIV Prescribed Long-Acting Cabotegravir/Rilpivirine in a US Cohort
Sita Lujintanon
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1360 - Clinical Consequences of Delaying Implementation of LA-ART for PWH With Persistent Viremia in the US
Kenneth A. Freedberg
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1361 - Longitudinal Renal Safety of a Population-Level TDF-Based HIV PrEP Program in British Columbia
K. Junine Toy
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1362 - Disposition of Referrals for Long-Acting Antiretrovirals at the Ward 86 HIV Clinic in San Francisco
Chesa Cox
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1363 - Impact of 6-Monthly ART Dispensing on Retention in Malawi: A Target Trial Emulation Study
Khumbo Shumba
Health Economics and Epidemiology Research Office, Johannesburg, South Africa
Previous:
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-01) Mpox and HIV Virology
2:30 PM2:30 PM
300 - Understanding the Evolutionary Framework and Transmission Dynamics of Mpox in South Korea
Chihwan Choi
Korea Disease Control and Prevention Agency, Cheongju-si, South Korea
2:30 PM2:30 PM
301 - Fine-Tuning Viral Adaptation Through Genome Retraction: Insights From Mpox Outbreaks in South Korea
Minji Lee
Korea Disease Control and Prevention Agency, Cheongju-si, South Korea
2:30 PM2:30 PM
302 - Discovery of Aberrant Genomic Rearrangement in an Mpox Virus Genome Observed in a Japanese Patient
Takayuki Ishige
Chiba University, Chiba, Japan
2:30 PM2:30 PM
303 - Factors Associated With Detectable Viral Load Among PLHIV in Serodiscordant Partnerships in Tanzania
Abbas Ismail
US Centers for Disease Control and Prevention Dar es Salaam, Dar es Salaam, Tanzania
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-02) HIV-1 Envelope and Viral Tropism
2:30 PM2:30 PM
304 - Enhanced Recognition of V3 bNAb Epitopes Induced by Fostemsavir on Cell-Associated Primary HIV-1 Env
Svenja Weiss
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
305 - CXCR4-Using HIV-1 Variants Evolve in the Presence of and Co-Exist With CCR5-Using Variants
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
306 - Droplet Single Genome Amplification Allows for Characterization of Autologous HIV Envelope Sequences
Joseph McWhirter
Boston University, Boston, MA, USA
2:30 PM2:30 PM
307 - High Resistance of HIV-1CH040 Envelope Glycoproteins to bNAbs Without Loss of Efficient Viral Entry
Durgadevi Parthasarathy
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
308 - Sex Differences in Replication Kinetics of Primary HIV-1 Isolates in Monocyte-Derived Macrophages
Jake Robinson
University of Pennsylvania, Philadelphia, PA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-01) Non-HIV Viruses
2:30 PM2:30 PM
331 - Impact of Pre-Existing Immune Activation on SARS-CoV-2 Incidence and Disease During the First Wave
Diana Yang
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
332 - Unique SARS-CoV-2 Variants and Inflammatory Milieu in Urine of Severe COVID-19 Participants
Aarthi Subramani
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
333 - Bile Acids in the Modulation of Antiviral Immune Response
Eileen F. Serrano
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
334 - The Bile Acids Complexity Underlies an Antiviral Interferon Innate Signaling During COVID-19 Disease
Diego A. Diaz-Dinamarca
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
335 - The Influence of Chronic HIV Inflammation on Post-COVID Immune Activation
Skye Opsteen
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
336 - Lipid Nanoparticles Targeting Neutrophil and NETs to Mitigate Lung Injury in SARS-CoV-2 Mice
Juwon Park
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
337 - Vitamins K2 and D3 Improve Long COVID Index, Fungal Translocation, and Inflammatory Biomarkers
Ornina Atieh
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
338 - High-Fat and -Sugar Diet but Not SIV Coinfection Enhances SARS-CoV-2 Shedding in Infected Macaques
Kelsie Brooks
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
339 - Sustained Inflammation and Delayed Resolution of COVID-19 Disease in SIV-Infected Macaques
Dhiraj K. Singh
Texas Biomedical Research Institute, San Antonio, TX, USA
2:30 PM2:30 PM
340 - Monocyte Dysregulation in PASC With Ongoing Pulmonary Symptoms
Thomas K. Awamura
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
341 - Retroviral Infection Reprograms Mouse Embryonic Stem Cells
Andrew D. Mazzanti
University of Toronto, Toronto, Canada
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-02) Host-HIV Interaction
2:30 PM2:30 PM
342 - Untangling the Impact of CD101 on HIV-1 Transmission
Phuong Vo
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
343 - CD40L/IL-4 Stimulated B Cells as Efficient Mediators of HIV-1 Binding and Trans Infection
Abigail Gerberick
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
344 - Feminizing Hormone Therapy and the Rectal Mucosal Immune Environment
Stacey Smith
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
345 - HIV-1 Vpr Promotes Viral Replication, Granzyme B Expression, and Death of Gut CD4 T Cells Ex Vivo
Kaylee Mickens
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
346 - Early HIV-1 Genetic Diversity Includes CTL and Drug Resistance Mutations
John Coffin
Tufts University, Boston, MA, USA
2:30 PM2:30 PM
347 - Tuberculosis Promotes the Persistence of Genetically-Intact HIV in People With HIV and Tuberculosis
Samantha K. Cronin
The University of Sydney, Sydney, Australia
2:30 PM2:30 PM
348 - Species-Specific Splicing of DNA Editing Enzymes: Implications in HIV and SIV Mutagenesis
Diako Ebrahimi
Texas Biomedical Research Institute, San Antonio, TX, USA
2:30 PM2:30 PM
349 - Transcriptionally Active Defective HIV-1 Proviruses Persist in All CD4 T-Cell Subsets During ART
Hiromi Imamichi
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
2:30 PM2:30 PM
350 - Utilizing Defective HIV-1 Provirus as a Novel “Barcode” for Studying T-Cell Dynamics
Vinie Kouamou
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
351 - Similar Intact and Defective HIV Provirus Frequency in Suboptimal Immune Responders and Controls
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
352 - Impact of ART Initiation on HIV-1 Soluble gp120 Levels and CD4 Counts in PWH
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
2:30 PM2:30 PM
353 - Genetic Associations With CD4 Recovery in People With HIV After Initiation of Antiretroviral Therapy
Roxane Rohani
Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA
2:30 PM2:30 PM
354 - R5-Tropic HIV Restricts X4-Tropic Virus via Type I IFN Signaling, Limiting Pathogenesis
Priya Pal
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
355 - Residual HIV Viremia Associates With Reservoir Size, but Not With Immune Activation or Inflammation
Twan Otten
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
356 - Relationship Between Gut Microbiome and Candida in PWH: Role of Bacterial Extracellular Vesicles
Aya Ishizaka
University of Tokyo Institute of Medical Science, Tokyo, Japan
2:30 PM2:30 PM
357 - The Mucosal Microbiome at Sites of HIV Acquisition Among Key Populations
Cassie G. Ackerley
Emory Vaccine Center, Atlanta, GA, USA
2:30 PM2:30 PM
358 - Virulent HIV-1B: Clinical Challenges and Proteomic Insights
Kavita Mehta
Ghent University, Ghent, Belgium
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-01) CD8 T Cells in Infection and After Vaccination
2:30 PM2:30 PM
400 - Duration of Viremia Modulates Antigen Sensitivity of HIV-Specific T-Cell Receptors
Funsho Ogunshola
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
401 - Low Post-ART SIV Viral Load Set Point Associated With Enhanced Lymph Node CD8+ T-Cell Proliferation
Gina Borgo
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
402 - The Soft Escape: HIV Alters Host Cell Cytoskeleton as a Mechanism of Resistance to CTL Killing
Louise Leyre
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
403 - CD8+ T-Cell Function During ART Is Associated With Provirus Suppression and Reduced Viral Rebound
David R. Collins
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
404 - TCR Convergence in HIV Controllers: Insights Into Natural Viral Suppression
Alexandra Vujkovic
Institute of Tropical Medicine, Antwerp, Belgium
2:30 PM2:30 PM
405 - Robust CD8+ T-Cell Proliferation and Stem-Like Memory Phenotype Linked to HIV Post-Treatment Control
Charles Crain
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
406 - HIV-Infection Does Not Generally Confer Higher Resistance to CTL-Mediated Lysis
Niklas Bachmann
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
407 - HIV-Specific T & Humoral Response: Data From the First Pediatric Combined Therapeutic Vaccine Trial
Arianna Rotili
University of Rome Tor Vergata, Rome, Italy
2:30 PM2:30 PM
408 - HIV-1-Specific T Cells From Post-Treatment Controllers and Noncontrollers
Lisa L. Dietz
Aarhus University, Aarhus, Denmark
2:30 PM2:30 PM
409 - Impact of Gender-Affirming Hormone Therapy on T-Cell Phenotypes in Transgender Women With HIV
Elizabeth Hastie
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
410 - Differential Restoration of HIV-Specific CD8+ T Cells by Amino Acid and Lipid Metabolism Modulation
Enrique Martin Gayo
Universidad Autónoma de Madrid, Madrid, Spain
2:30 PM2:30 PM
411 - Unmodified mRNA Compared to Modified mRNA Induces Optimal CD8+ T-Cell Responses in Rhesus Macaques
Sampa Santra
Beth Israel Deaconess Medical Center, Boston, MA, USA
2:30 PM2:30 PM
412 - The Impact of Protein Specificity on Function and Crosstalk Between the HIV-Specific T Cells
Jernej Pusnik
Bonn University Hospital, Bonn, Germany
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-02) B Cells and Neutralizing Antibodies
2:30 PM2:30 PM
413 - Provirus From Early-Treated HIV Reveals Earlier Variants Targeted by Initial Neutralizing Antibodies
Hunter M. Courtney
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
414 - Structural Insight into the High- and Low-Affinity Alleles of Human and Macaque FcγRIIA (CD32A)
William D. Tolbert
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2:30 PM2:30 PM
415 - Antigen Affinity Ceiling for Selection of Functional Mutations and HIV-1 Neutralization
Ankita Singh
Duke Human Vaccine Institute, Durham, NC, USA
2:30 PM2:30 PM
416 - Maturation of B-Cell Lineages During cART in Chronic SHIV-Infected Juvenile Rhesus Macaques
Wilton Williams
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
417 - Public Trimer-Specific IgHV4-34 Clonotype in bNAb Inducers Includes a Novel V3-Glycan bNAb Subclass
Alexandra Trkola
University of Zurich, Zurich, Switzerland
2:30 PM2:30 PM
419 - In Nonsuppressible Viremia, HIV Env Can Maintain Resistance to Autologous Neutralizing Antibodies
Sang Hyeon Kim
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
420 - Molecular Mechanisms Underlying Anti-HIV-1 Fc-Effector Functions of Human IgA Allelic Variants
Marek K. Korzeniowski
Uniformed Services University of the Health Sciences, Bethesda, MD, USA
2:30 PM2:30 PM
421 - Sensitivity of HIV-1 CRF01_AE Envelopes to Broadly Neutralizing Antibodies VRC07-523 and PGDM1400
Gabriel Smith
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
422 - Transcriptional Analysis of Intestinal Immune Cells in People With HIV Receiving bNAbs
Connie A. Zhao
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
423 - Identification of an Autoantibody Against FCHSD2 in Adipose Tissue of PLWH With Diabetes
Laventa Obare
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
424 - Detection of Anti-Interferon Alpha/Omega Neutralizing Autoantibodies in PLWH
Alessandra D'Auria
Sapienza University of Rome, Rome, Italy
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-01) Viral Rebound and Control
2:30 PM2:30 PM
484 - Delayed HIV-1 Rebound Correlates With Enhanced CD8+ T-Cell Activation in Human Trials
Rasmi Thomas
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
485 - Total HIV-1 Nucleic Acid Increases Precede Plasma RNA Rebound During Pediatric ATI
Gabriela Z. L. Cromhout
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
486 - Consecutive Analytical Treatment Interruption Improves CD8 T-Cell Activity During Viral Control
Sarah Palmer
The Westmead Institute for Medical Research, Westmead, Australia
2:30 PM2:30 PM
487 - Mitochondrial Gene Variants Influence VARS2, HIV Reservoir, and CD4+ T Cells in HIV Controllers
Victoria Rios Vazquez
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
488 - Clinical and Virologic Outcomes of an ART Interruption in Treated Controllers and Non-Controllers
Isaac E. Avila-Vargas
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
489 - HIV-1 Post-Treatment Control Occurs Despite HLA-Escape Mutations in the Intact Reservoir
Efthimios A. Deligiannidis
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
490 - Time to Viremia and Frequency of Post-Treatment Control Among 382 “Placebo-Treated” ATI Participants
Jesper D. Gunst
Aarhus University Hospital, Aarhus, Denmark
2:30 PM2:30 PM
491 - Characterization of HIV Antibodies and p24 Antigen During Analytical Treatment Interruption
Clara Di Germanio
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
492 - Post-Treatment HIV Controllers Exhibit Reduced Plasma Markers of Inflammation and Metabolic Stress
Leila B. Giron
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
493 - Population-Specific T-Cell Responses and Virologic Control After Analytical Treatment Interruption
Jorge Gallardo Cartagena
Centro de Investigaciones Tecnológicas Biomédicas y Medioambientales, Lima, Peru
2:30 PM2:30 PM
494 - Loss of Virologic Control 32 Years After HIV-1 Diagnosis in an Exceptional Elite Controller
Anna Pons-Grífols
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
495 - Effect of ART Start Time, ART Duration, and Elite Control on HIV Transcription
Adam Wedrychowski
San Francisco VA Medical Center, San Francisco, CA, USA
2:30 PM2:30 PM
496 - Viral Reservoir Characteristics in Lymphoid Tissues of HIV-1 Elite Controllers
Samantha K. Marzi
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
497 - CD8+ T Cells Shape the HIV Integration Site Landscape According to the Degree of T-Cell Pressure
Noemi L. Linden
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
498 - Anti-IL-10/Anti-PD-1 Dual Blockade Leads to IFN-Related HIV Elite Control Signatures
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
499 - Genetic Regulation of Immune Responses to CMV in Spontaneous HIV Controllers
Suzanne D. E. Ruijten
Radboud University Medical Center, Nijmegen, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-02) Strategies for an HIV Cure
2:30 PM2:30 PM
500 - The Asymmetric Opening of HIV-1 Env by a Potent CD4 Mimetic Enables Anti-CoRBS Abs to Mediate ADCC
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
501 - TCR-Mimic ScDb Reduced HIV Provirus and Delayed the Viral Rebound in HLA-Specific BLT Hu-Mice
Zhe Yuan
The Wistar Institute, Philadelphia, PA, USA
2:30 PM2:30 PM
502 - Targeting TCF-1 to Potentiate the Functional Capacity of HIV/SIV-Specific CD8+ T Cells
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
503 - CD4 T Cell-Targeting Lipid Nanoparticles in the Search for a Genetic HIV Cure
Maaike De Cock
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
504 - CD4 Mimetics Sensitize HIV-Infected Cells to ADCC Mediated by Plasma From Early-Stage HIV Infection
Andrés Finzi
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
505 - Sustained Post-Rebound HIV Remission With Enhanced T-Cell Immunity After LS-bNAbs: A Case Report
John Frater
University of Oxford, Oxford, UK
2:30 PM2:30 PM
506 - Sustained T Cell-Mediated Immunity After LS-bNAbs in the RIO Trial: A Vaccinal Effect
John Frater
University of Oxford, Oxford, UK
2:30 PM2:30 PM
507 - Temsavir Treatment Improves Recognition of HIV-1 Infected Cells by Broadly Neutralizing Antibodies
Hangfei Qi
ViiV Healthcare, Durham, NC, USA
2:30 PM2:30 PM
508 - Maximizing Benefits to Participants in Analytic Treatment Interruption With Antibody Infusions
Yifan Li
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
509 - Myeloid Targeted and Enhanced Endosomal Escapable LNPs Improve Latent HIV-1 Elimination Efficacy
Soumya S. Dey
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
510 - A Novel and Promising Strategy of HIV Eradication via LTR-LTR Recombination
Feng Li
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
511 - Development and Delivery of Next-Generation Epigenome Editors for Long-Term HIV Silencing
Francisco J. Zapatero Belinchon
Gladstone Institute of Virology and Immunology, San Francisco, CA, USA
2:30 PM2:30 PM
512 - RV550: Safety and Virologic Outcomes in Blood and Lymph Nodes of N-803 With ART in Acute Infection
Carlo Sacdalan
SEARCH, Bangkok, Thailand
2:30 PM2:30 PM
513 - HIV-1 Reservoir Decay During Broadly Neutralizing Antibody Therapy in the RIO Trial
Marcilio Jorge Fumagalli
The Rockefeller University, New York, NY, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-04) Transcription in the HIV Reservoir
2:30 PM2:30 PM
524 - Transcriptional Profiles of HIV RNA+ Cells in PWH on ART Differ From Those During Active Viremia
Julie Frouard
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
525 - Selective Decay of Different HIV Transcripts After ART Initiation in Chronic Infection
Cordelia M. Isbell
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
526 - Nonsuppressible HIV Viremia May Harbor Replication-Incompetent Viruses With 5' Leader Deletions
Zixin Hu
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
527 - HIV-1 Latency Reversal Augments Persistent HIV-1 Transcription During ART
Rowan Hassman
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
528 - MLN4924 Reduces HIV Transcription, Cell Survival, and HIV Infectivity After Latency Reversal In Vitro
Cristina C. Vaca
Northwestern University, Chicago, IL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-05) Novel Interventions Toward an HIV Cure
2:30 PM2:30 PM
529 - Venetoclax Decreases Intact Proviral DNA Frequency in SIV-Infected, ART-Suppressed Rhesus Macaques
Sydney N. Bergstresser
Yerkes National Primate Research Center, Atlanta, GA, USA
2:30 PM2:30 PM
530 - AZD5582 Inhibits Vaccine-Elicited CD8+ T-Cell Responses in SIV-Infected Rhesus Macaques on ART
Benjamin D. Varco-Merth
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
531 - Sustained HIV Remission Despite Transient Rebound Viremia After a CCR5∆32/∆32 Stem Cell Transplant
Paul Rubinstein
University of Illinois at Chicago, Chicago, IL, USA
2:30 PM2:30 PM
532 - HIV Remission After Allogeneic Hematopoietic Stem Cell Transplant From CCR5Δ32/Δ32 Sibling Donor
Marius Trøseid
Oslo University Hospital, Oslo, Norway
2:30 PM2:30 PM
533 - Tazemetostat Enhances CTL Killing of HIV-Infected Cells and Reduces Reservoirs In Vivo
Itzayana G. Miller
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
534 - CXCR4-Targeted CRISPR/Cas9 Lipid Nanoparticles for Excision of Latent Proviral DNA
Sudipta Panja
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
535 - Efficient Generation of Anti-HIV TRAC-CAR T Cells to Enable High-Throughput Binder Screening
Gabriella Kimmerly
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
536 - Infusion of Autologous CCR5-Deleted CD4 Cells Does Not Change the HIV Reservoir: The TRAILBLAZER RCT
Carl J. Fichtenbaum
University of Cincinnati, Cincinnati, OH, USA
2:30 PM2:30 PM
537 - HIV-1 Reservoir Reduction in PWH Receiving ART and Dasatinib
Mario Manzanares
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
538 - Phase I Clinical Trial AMC097 Evaluating Engraftment and HIV Resistance of Gene-Modified Blood Cells
Timothy J. Henrich
University of California San Francisco, San Francisco, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-01) Neuroimaging in HIV
2:30 PM2:30 PM
589 - Humanized Glia Mice Show HIV-Induced Behavioral, Neuro, and Metabolic Changes as in Clinical Disease
Amanda Fernandes
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
590 - Evaluating White Matter Integrity in Relation to HIV Severity and Cognitive Impairment
Beau Ances
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
591 - Interaction Between Age, Brain Volume, and HIV Status in Predicting Cognition
Beau Ances
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
592 - Plasma Inflammation Is Associated With Brain Cellularity in Diffusion-Based Spectral Imaging in HIV
Advika Srinivas
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
593 - The Effects of Depression and Antidepressants on Cognition and Brain Volume in PWH and PWoH
Sophie A. Sims
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
594 - Analyzing Neuroanatomical Heterogeneity in HIV-Associated Cognitive Impairment
Audrey Chun
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
595 - Preliminary Analysis of Longitudinal Synaptic Density Change in Virally Suppressed People With HIV
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
596 - Cannabis Use Is Associated With Reduced Brain Integrity in Persons With HIV
Sarah Cooley
Washington University in St Louis, St Louis, MO, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-02) Biomarkers for NeuroHIV Informing Pathogenesis
2:30 PM2:30 PM
597 - Inflammatory Biomarker Profiling to Predict Neuroinflammation and Depression in Adolescents With HIV
Shalena Naidoo
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
598 - No Decline in CSF or Plasma Neurofilament Light Chain Levels Post-Early ART Initiation
Nametso Kelentse
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
599 - Polypharmacy Is Associated With Neuronal Injury in PWH
Priya Kosana
East Carolina University, Greenville, NC, USA
2:30 PM2:30 PM
600 - Plasma CNS Tissue Markers in Heavily Treatment-Experienced PWH in the PRESTIGIO Registry
Andrea Calcagno
University of Turin, Turin, Italy
2:30 PM2:30 PM
601 - Comprehensive Study of CSF Fluid β2-Microglobulin, a Marker of CNS Immune Activation in HIV
Birgitta Anesten
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
2:30 PM2:30 PM
602 - Higher suPAR Relates to Domain-Specific Cognitive Function in Virally Suppressed Women With HIV
Hemil Gonzalez
Rush University Medical Center, Chicago, IL, USA
2:30 PM2:30 PM
603 - Cognitive Intra-Individual Variability Predicts IADL Function in the Women’s Interagency HIV Study
David E. Vance
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
604 - Influence of an Exercise Intervention or Dynamic Stretching on Cognition and Gut Microbiome in PWH
Sarah Cooley
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
605 - Longitudinal Changes in Neuronal Markers and Associations With ART Initiation and Cognitive Function
Merle Henderson
Imperial College Healthcare NHS Trust, London, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-03) Omics Approaches to Pathogenic Interrogation of NeuroHIV
2:30 PM2:30 PM
606 - Single-Nucleus Multiomics Reveals Dysfunction in Multiple Glial Cell Types in Brain Tissue of PWH
Kriti Agrawal
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
607 - CSF Memory B Cells Exhibit Distinct Molecular Footprints in Treated PWH
Paraskevas Filippidis
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
608 - T-Cell Receptor Repertoire and Cognitive Performance in People With HIV
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
609 - A Transcriptional Signature of Induced Neurons Differentiates PWH on cART From People Without HIV
Teresa H. Evering
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
610 - Cerebrospinal Fluid Proteomic Patterns Vary With Neurobehavioral Characteristics
Patricia K. Riggs
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
611 - DNA Methylation Clocks Are Altered in Persons With Undetectable HIV and Correlate With Brain Aging
Kalen J. Petersen
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
612 - Epigenetic Age Advancement Predicts Cognitive Performance in Older People With HIV
Carrie Johnston
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
613 - Epigenetic Modifications Predictive of Cognitive Frailty in Cocaine-Using People Living With HIV
Marianna Baum
Florida International University, Miami, FL, USA
2:30 PM2:30 PM
614 - Differential Effects of CB2 Agonism on HIV Replication and Inflammatory Activation in Myeloid Cells
Cagla Akay-Espinoza
University of Pennsylvania, Philadelphia, PA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-01) The Next Generation: Pharmacology of New Drugs, Formulations, and Modeling Strategies
2:30 PM2:30 PM
639 - First-in-Human Study of a Long-Acting Injectable 3 Antiretroviral Drug Combination Nanoparticle
Rachel A. Bender Ignacio
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
640 - Preclinical Pharmacokinetic Assessment of a Long-Acting Solid Injectable for Hepatitis C Virus
Usman Arshad
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
641 - Fixed Dosing Versus Body-Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults
Yunda Huang
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
642 - Pharmacokinetic Modeling of Missed Dose Scenario of Oral Weekly Islatravir Plus Lenacapavir
Marjorie Imperial
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
643 - Modeling Accurately Predicts Efficacious Islatravir QW Dose With No Lymphocyte and CD4 Changes
Diane Longo
Merck & Co, Inc, Rahway, NJ, USA
2:30 PM2:30 PM
644 - Can “Equivalence” of a Generic Cabotegravir LA Be Inferred From a Shortened Pharmacokinetic Study?
Henry Pertinez
University of Liverpool, Liverpool, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-01) Antiviral Therapy: Simplify, Modify, and Why!
2:30 PM2:30 PM
658 - Integrase Inhibitor- Versus Protease Inhibitor-Based Therapy for People With Advanced HIV Disease
Georg M. N. Behrens
Hannover Medical School, Hannover, Germany
2:30 PM2:30 PM
659 - Safety, Tolerability, and Efficacy of a BIC/FTC/TAF Dose Reduction Strategy
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
660 - Switch of Virally Suppressed Adults ≥ 60 Years From First-Line ART to B/F/TAF: Week 96 Results
Loice Ombajo
University of Nairobi, Nairobi, Kenya
2:30 PM2:30 PM
661 - Switch to DTG/3TC vs B/F/TAF (PASO-DOBLE Study): Efficacy and Weight Changes by Predefined Subgroups
Juan Tiraboschi
Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Spain
2:30 PM2:30 PM
662 - Inflammatory Signatures Among People With HIV Initiating DTG/3TC vs BIC/F/TAF in the CoRIS Cohort
Claudio Díaz-García
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
663 - Effectiveness and Inflammatory Markers After 144 Weeks of Switch to DTG/3TC in a Randomized Trial
Evy Blomme
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
664 - Impact of ART Simplification With Dolutegravir and Lamivudine on the HIV Reservoir
Céline Fombellida-Lopez
University of Liège, Liege, Belgium
2:30 PM2:30 PM
665 - Effect of 12-Month Switch to Dual cART on T-Cell Homeostasis, Gut and Mitochondrial Damage
Valeria Bono
University of Milan, Milan, Italy
2:30 PM2:30 PM
666 - ALLIANCE OLE: Switch to B/F/TAF in People With Both HIV-1 and HBV
Anchalee Avihingsanon
HIV-NAT, Thai Red Cross AIDS and Infectious Disease Research Centre, Bangkok, Thailand
2:30 PM2:30 PM
667 - Transaminase Decrease Upon Switch From TDF to TAF in PWH Is Modulated by HBV Status
Giuseppe Lapadula
University of Milano–Bicocca, Milan, Italy
2:30 PM2:30 PM
668 - Impact of Switching From DTG/3TC to BIC/FTC/TAF on Weight, Cholesterol, and Inflammation in HIV
Laura Martín Pedraza
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
669 - 24-Month Outcomes on Second-Line Antiretroviral Therapy in South Africa: A Target Trial Emulation
Jennifer A. Brown
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
670 - Dolutegravir With Either Doravirine or Rilpivirine: Two-Drug Antiretroviral Therapy Outcomes
Morgan Byrne
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
671 - Is It Effective to Switch Regimen in PWH With Low-Level Viremia in the Current Era?
Tommaso Clemente
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
672 - Impact of Antiretroviral Therapy (ART) Intensification on HIV-1 Virologic Markers (ACTG 5324)
Jonathan Reed
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
673 - Factors Affecting Long-Term Trends of Immunologic Markers After ART: Results From the START Trial
Giota Touloumi
National and Kapodistrian University of Athens, Athens, Greece
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-01) HIV Resistance to bNAbs, Cabotegravir, GS 1720, and Other Agents
2:30 PM2:30 PM
721 - The Genetic Barrier to Resistance to LEN Is Not Affected by Non-B Subtypes or Treatment Exposure
Niccolò Bartolini
University of Siena, Siena, Italy
2:30 PM2:30 PM
722 - Structural and Mechanistic Insights Into Cabotegravir Resistance in HIV-1 Integrase
Indrani Choudhuri
Salk Institute for Biological Sciences, La Jolla, CA, USA
2:30 PM2:30 PM
723 - The Barrier to Escape From Broadly Neutralizing Antibodies Varies Between Different HIV-1 Isolates
Alex C. Stabell
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
724 - In Vitro Resistance Profile for GS-1720, a Potent Once-Weekly Oral InSTI in Clinical Development
Derek Hansen
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
725 - Effect of SNG001, Inhaled IFN-β1a, on SARS-CoV-2 Diversity and Evolution
Gregory E. Edelstein
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
726 - HIV-1 Env Exhibits Distinct Conformations and Neutralization Profiles in CSF and Blood
Hillel Haim
University of Iowa, Iowa City, IA, USA
2:30 PM2:30 PM
727 - Modifying PF74 Improves Anti-HIV-1 Activity Against the Resistance-Associated Capsid Mutation N74D
William M. McFadden
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
728 - Viral Escape From Broadly Neutralizing Antibodies in Non-Subtype B Viruses
Teresa Murphy
George Washington University, Washington, DC, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-01) Hepatitis C Treatment and Outcomes
2:30 PM2:30 PM
748 - Safety and Efficacy of 8-Week Glecaprevir/Pibrentasvir for Acute HCV in People Living With HIV
Kimberly Workowski
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
749 - DAA Initiation Among People With HIV and HCV in North America: Factors Driving the Treatment Gap
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
750 - High HCV Reinfection Rates May Mask “True” Sustained Virologic Response in People Who Inject Drugs
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
751 - Increasing HCV Prevalence Among People Who Inject Drugs in India Despite Improved Treatment Uptake
Allison M. McFall
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
752 - Impact of an HCV Test and Treat Campaign on Hepatitis C Incidence in the ANRS PREVENIR PrEP Study
Geoffroy Liegeon
Université Paris Cité, Paris, France
2:30 PM2:30 PM
753 - Impact of HIV Infection on the Dynamics of Liver Stiffness After HCV Cure
Jesica Martín-Carmona
Hospital Universitario Virgen de Valme, Sevilla, Spain
2:30 PM2:30 PM
754 - Comorbidities Among Medicaid Enrollees With Chronic Hepatitis C, 2016-2020
Julie Dombrowski
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
755 - Cost-Effectiveness of Interventions to Reduce HCV Among People Who Inject Drugs in Haiphong, Vietnam
Adam Trickey
University of Bristol, Bristol, UK
2:30 PM2:30 PM
756 - CC-Genotype (IFNL4) in HCV/HIV Coinfection: Cellular Exhaustion but Balanced Inflammatory Profile
Sonia Arca De Lafuente
Instituto de Salud Carlos III, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-02) Steatotic Liver Disease
2:30 PM2:30 PM
757 - Semaglutide Improves Steatohepatitis in People With HIV: The SLIM LIVER Study
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
2:30 PM2:30 PM
758 - Evaluation of Different Noninvasive Models in Assessing Lean MAFLD Among PLWH
Wei Xu
Shanghai Public Health Clinical Center, Shanghai, China
2:30 PM2:30 PM
759 - Effects of Semaglutide on Gut Microbiota in People With HIV: The SLIM LIVER Study
Stephanie M. Dillon
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
760 - Distinct Metabolic Perturbations Link Liver Steatosis and Incident CVD in Lean but Not Obese PLHIV
Nadira Vadaq
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
761 - Incidence and Impact of Hepatic Steatosis in People With HIV: Insights From the NA-ACCORD Cohort
Jennifer Price
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
762 - Determinants of Steatotic Liver Disease Among People With HIV in Europe and Australia
Carlotta Riebensahm
University Hospital Bern, Bern, Switzerland
2:30 PM2:30 PM
763 - Diabetes Mellitus and Liver Disease Progression in PWH With Metabolic Dysfunction-Associated SLD
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
764 - Switching to DTG/3TC vs BIC/FTC/TAF and Steatotic Liver Disease: A Substudy of PASODOBLE Trial
Juan Macias
University of Sevilla, Sevilla, Spain
2:30 PM2:30 PM
765 - Liver Steatosis Progression With Integrase Inhibitors in HIV Adults in Low-/Middle-Income Countries
Marie Kerbie Plaisy
University of Bordeaux, Bordeaux, France
2:30 PM2:30 PM
766 - Lipidomics of Metabolic Dysfunction-Associated Steatotic Liver Disease Post-HCV Eradication in PWH
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-01) Liver Cancer, Lung Cancer, and NADC Pathogenesis
2:30 PM2:30 PM
786 - Lung Cancer Screening Eligibility and Uptake Among People With HIV: A Decade of Missed Opportunities
Subhashini A. Sellers
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
787 - Immune Tumor Microenvironment of HIV-Associated Lung Cancer Reveals Immunoregulatory Features
Brinda Emu
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
788 - Viral and Host Proteins Carried by Exosomes From PLWH Could Play a Role as Triggers of NADCs
Norma Rallón
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-02) Kaposi Sarcoma: Diagnosis, Treatment, Pathogenesis, and KSHV
2:30 PM2:30 PM
789 - Validation of Quantification of Lesional KSHV DNA Content for Diagnosis of Kaposi Sarcoma in Africa
Aggrey Semeere
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
790 - Kaposi Sarcoma in Relation to HIV Diagnosis: Which Comes First in East Africa in the Treat All Era?
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
791 - Immunologic Responses to Pomalidomide and Liposomal Doxorubicin for Kaposi Sarcoma Treatment
Matthew Witterholt
National Cancer Institute, Bethesda, MD, USA
2:30 PM2:30 PM
792 - Impact of Low-Dose Intralesional Nivolumab for Kaposi Sarcoma on T-Cell Proliferation and Function
Chia-Ching Wang
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
793 - High Prevalence of Clonal Hematopoiesis Among Older People With HIV and Kaposi Sarcoma
Ramya Ramaswami
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
794 - Causes of Death Among Adults With HIV-Associated Kaposi Sarcoma in East Africa in the Treat All Era
Helen Byakwaga
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
795 - Neuropilin-1 Is Required for KSHV Lytic Replication in Primary Effusion Lymphoma
Anna Serquina
National Cancer Institute, Bethesda, MD, USA
2:30 PM2:30 PM
796 - Genome Evolution of Kaposi Sarcoma-Associated Herpesvirus (KSHV) in PLWH
Dirk P. Dittmer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
797 - Vascular Endothelial Growth Factor Receptor 3 (VEGFR3/FLT4) Regulates the KSHV Replication Cycle
Ameera Mungale
National Cancer Institute, Bethesda, MD, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-01) Heart Failure: Hiding in Plain Sight
2:30 PM2:30 PM
811 - Sex Differences in Myocardial Steatosis in South African Youth With Perinatally Acquired HIV
Morne Kahts
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
812 - Heart Failure Among People With HIV: Prescription of Guideline-Directed Medical Therapy
Melissa K. Cutshaw
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
813 - Mitochondrial Haplogroups and Left Ventricular Dysfunction in People Living With and Without HIV
Craig Cronin
The Johns Hopkins Hospital, Baltimore, MD, USA
2:30 PM2:30 PM
814 - Physician-Confirmed Incident Heart Failure Phenotypes and Etiologies Within CNICS
Matthew J. Feinstein
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
815 - Readmission Risk for Adults With HIV Hospitalized for Heart Failure or Acute Myocardial Infarction
Ping Yang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
816 - Long-Term Outcomes in People With HIV Who Survive a Major Adverse Cardiovascular Event
Rebecka Papaioannu Borjesson
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
817 - Epicardial Fat as a Predictor of Diastolic Dysfunction in Older People With HIV
Tanakorn Apornpong
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-02) Hypertension
2:30 PM2:30 PM
818 - Heart Failure Risk and Events in People With HIV in the REPRIEVE Trial
Maya Watanabe
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
819 - Effect of the Transition to Dolutegravir on Blood Pressure in People Living With HIV in West Africa
Romain Millot
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
820 - No Increased Risk for Hypertension With CAB-LA Compared to TDF/FTC for PrEP: Results From HPTN 084
Sinead Delany-Moretlwe
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
821 - Low Hypertension Knowledge Among Clinicians Prescribing Antihypertensive Medications in Malawi
Risa Hoffman
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
822 - Social Determinants of Health and the Hypertension Care Cascade in a National HIV Cohort
Puja Van Epps
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
823 - Risk of Incident Hypertension With Common Antiretroviral Agent Combinations in the OPERA Cohort
Gerald Pierone Jr
Whole Family Health Center, Vero Beach, FL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-01) Renal Disease
2:30 PM2:30 PM
854 - HIV Superinfection in Kidney Transplant Recipients With HIV Who Received Organs From Donors With HIV
Grace Rozek
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
855 - APOL1 Genotype and Graft Function in South African HIV+-to-HIV+ Kidney Transplant Recipients
Robert Freercks
Nelson Mandela University, Gqeberha, South Africa
2:30 PM2:30 PM
856 - Human Antibody Repertoire and Allograft Rejection Among Kidney Transplant Recipients With HIV
Xianming Zhu
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
857 - Acute Drop in eGFR When Initiating SGLT2 Inhibitors vs Other Antihyperglycemic Medications Among PWH
Lara Haidar
University of Manitoba, Winnipeg, Canada
2:30 PM2:30 PM
858 - Associations Between Antiretroviral Therapy Use, Vitamin C Renal Leak, and Vitamin C Deficiency
Stephanie Teng
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
859 - Renal Outcomes in People With HIV-1 and Renal Impairment Treated With B/F/TAF in Randomized Trials
Frank Post
King's College Hospital NHS Foundation Trust, London, UK
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-02) GLP-1 Receptor Agonists
2:30 PM2:30 PM
860 - Racial Inequity in Initiation of Semaglutide Therapy Among People With HIV in Care Across the US
Andrew W. Hahn
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
861 - Cardiometabolic Effects of Semaglutide in People With HIV: The SLIM LIVER Study
Jordan E. Lake
University of Texas Health Science Center at Houston, Houston, TX, USA
2:30 PM2:30 PM
862 - Durability of Semaglutide Effects After Drug Discontinuation in HIV-Associated Lipohypertrophy
Allison Ross Eckard
Medical University of South Carolina, Charleston, SC, USA
2:30 PM2:30 PM
863 - Impact of Antidiabetic Medications on Weight Change Among People With HIV
Lara Haidar
University of Manitoba, Winnipeg, Canada
2:30 PM2:30 PM
864 - Liraglutide for Obesity in HIV (LIROH): A Single-Arm, Open-Label Clinical Trial in South Africa
Jennifer Manne-Goehler
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
865 - The Projected Impact of Post-ART BMI Maintenance on Diabetes Risk: A Modeling Study
Keri N. Althoff
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-03) Biomarkers of Aging
2:30 PM2:30 PM
866 - ART Exposure and Accelerated Aging in PLHIV: Insights From Proteomic and Methylation Clocks
Nadira Vadaq
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
867 - Epigenetic Age Acceleration and CD4/CD8 Ratio in People With Well-Controlled HIV Infection
Alejandro de Gea Grela
Hospital La Paz Institute for Health Research, Madrid, Spain
2:30 PM2:30 PM
868 - Inflammatory Markers and Frailty, Cognitive Impairment, Clinical Outcomes, and Mortality in PWH
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
869 - Novel Biomarkers Link Inflammation, T-Cell Exhaustion, Bone Health, and Frailty in People With HIV
Michael L. Freeman
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
870 - The Association of Cytomegalovirus Serostatus on Immune Recovery Among People With HIV
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
871 - Validation of SARC-F Tool for Sarcopenia Screening in People Aging With HIV
Joselito Malca Hernandez
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
872 - Mitochondrial DNA Variation and Physical Function Among Men With and Without HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
873 - Senescence-Associated Secretory Phenotype Biomarker Profiles of Age-Related Outcomes in PWH
Mary C. Masters
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
874 - Multicomponent Exercise Associated With a Healthier Gut Microbiota Profile in Older Adults With HIV
Laura Martín Pedraza
Hospital Universitario Ramon y Cajal, Madrid, Spain
2:30 PM2:30 PM
875 - Muscular Markers for Early Identification of Sarcopenia and Frailty States in Older People With HIV
Eugènia Negredo
Fundació Lluita contra les Infeccions, Barcelona, Spain
2:30 PM2:30 PM
876 - Metformin for Reversal of Accelerated Biological Aging in Persons With HIV: A Pilot Clinical Trial
Cristina Marcelo
Hospital Universitario La Paz, Madrid, Spain
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-01) PASC: Natural History and Classification Systems
2:30 PM2:30 PM
917 - Higher Mortality Following SARS-CoV-2 Infection in Rural Dwellers Persists 2 Years After Infection
Jerrod Anzalone
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
918 - HIV Infection and Long COVID: A RECOVER Program, EHR-Based Cohort Study
Kellie L. Hawkins
Public Health Institute at Denver Health, Denver, CO, USA
2:30 PM2:30 PM
919 - Putting the PASC Score to the Test: Clinical vs Statistical Accuracy in Long COVID
Alba M. Azola
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
920 - Parametric Survival Analysis of Long COVID: A Cohort Study on the Time to Symptom Resolution
Warren Malambo
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
921 - Assessing the Burden of Long COVID in Persons With HIV Using the RECOVER Scoring System
Kamaria Dansby
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
922 - Long COVID Is a Multisystem Disorder: Assessment of the National Academies Definition
Jason D. Goldman
Swedish Medical Center, Seattle, WA, USA
2:30 PM2:30 PM
923 - Completeness of COVID-19 Outcomes Among People With HIV Receiving Care in New York City in 2020
David B. Hanna
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
924 - COVID-19 Symptoms, Vaccination, and Long COVID Between Cancer Survivors and the US General Population
Jincong Q. Freeman
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
925 - A Population-Based Study of Functional Disability, COVID-19 Symptoms, and Long COVID Among US Adults
Jincong Q. Freeman
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
926 - Cognitive Trajectories 1 Year Before and After COVID-19 in an Early-Treated HIV Cohort
Ferron Ocampo
University of Toronto, Toronto, Canada
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-01) ART-Related and Social Determinants of TB Transmission and Treatment Outcomes
2:30 PM2:30 PM
948 - Modelling the Contribution of Incarceration to TB Transmission in Ukraine
Jack Stone
University of Bristol, Bristol, UK
2:30 PM2:30 PM
949 - Mental and Physical Health of People With TB in Southern Africa at the Start of Treatment and Beyond
Guy K. Muula
Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
2:30 PM2:30 PM
950 - HIV and Tuberculosis Stigma Affecting Individuals With Pulmonary Tuberculosis in East Africa
Kirsten K. Prabhudas-Strycker
Indiana University, Indianapolis, IN, USA
2:30 PM2:30 PM
951 - Neuropsychiatric Outcomes in Adults With HIV and TB on Twice-Daily BIC/FTC/TAF With Rifampicin
Gillian L. Dorse
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
952 - High Incident TB Among Individuals Switched to Dolutegravir or Protease Inhibitor Based 2nd Line ART
Claudia Danielle Minkoulou Engamba
University Teaching Hospital, Lusaka, Zambia
2:30 PM2:30 PM
953 - Unmasking and Tracking Tuberculosis Risk During HIV Acquisition and Antiretroviral Therapy
Fatoumatta Darboe
University of California San Francisco, San Francisco, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-01) Long-Acting Antiretrovirals for Pregnant and Breastfeeding Women
2:30 PM2:30 PM
1014 - LA-ART for Breastfeeding Women With HIV in Zimbabwe: Clinical Impact and Cost-Effectiveness
Sujata Tewari
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1015 - Long-Acting Cabotegravir/Rilpivirine in Pregnancy
William R. Short
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1016 - Modeling Tail-Phase PK From Early Pregnancy to Postpartum and Fetal Exposure to Long-Acting CAB-RPV
Shakir Atoyebi
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
1017 - A Long-Acting Dolutegravir Formulation Improves Drug Safety Profile During Pregnancy
Emma G. Foster
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
1018 - Population PK and CYP3A Inhibition Capacity of Ritonavir in Pregnancy: A Model-Based Meta-Analysis
Safa Algharbi
University of California San Diego, La Jolla, CA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-02) Complications in Maternal HIV
2:30 PM2:30 PM
984 - Patterns of Adiposity and Gestational Weight Gain in Pregnant South African Women Living With HIV
Mustafa Shuaib
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
985 - Genome-Wide Association With Postpartum Weight Change in Mothers on DTG or EFV in DolPHIN-2
Rebecca Jensen
University of Liverpool, Liverpool, UK
2:30 PM2:30 PM
986 - Depression, Sleep, and Anxiety Among Pregnant and Postpartum Women Using Dolutegravir and Efavirenz
Danni Wu
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
987 - Sleep Patterns in South African Pregnant Women Living With HIV on Dolutegravir: A Prospective Study
Hayli Geffen
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
988 - Prior Pregnancy Affects Aging-Related Non-AIDS Comorbidity Burden in US Women With and Without HIV
Lauren F. Collins
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
989 - Characteristics and Outcomes of Pregnant Women With HIV Undergoing Tuberculosis Screening in Uganda
Christina Yoon
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
990 - Incidence of Tuberculosis in South African Women Living With HIV During Pregnancy and Postpartum
Jasantha Odayar
University of Cape Town, Cape Town, South Africa
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-01) Health and Outcomes of Children Exposed to HIV/ART in Utero
2:30 PM2:30 PM
1019 - Neurodevelopmental Disorders in French HIV-/ARV-Exposed Uninfected Children: A National Cohort Study
Mathis Collier
Cochin Hospital, Paris, France
2:30 PM2:30 PM
1020 - Prenatal PrEP Exposure and Language Development Among Children at 5 Years
Lauren A. Gomez
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1021 - Growth Faltering Is Partially Ameliorated by Infant Gut Bifidobacterium in Children Exposed to HIV
Nicole Tobin
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1022 - Insulin-Like Growth Factors and Stunting in African Infants Exposed to HIV and Uninfected
Brenda C. Kakayi
Makerere University–Johns Hopkins University Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1023 - Cardiometabolic Outcomes in HEU vs HU Children in a SA Birth Cohort: Influence of Maternal Lipids
Calli Dogon
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1024 - Obesity and Metabolic Comorbidities in Young Adults With Perinatal HIV Exposure Without Infection
Nikhita Chahal
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1025 - Transcriptome Perturbations in Peripheral Blood Cells of HIV-Exposed Uninfected Infants
Li Yin
National Institute of Allergy and Infectious Diseases, Baltimore, MD, USA
2:30 PM2:30 PM
1026 - Comparing Telomere Length Between Children Who Were and Were Not Exposed to HIV in Kenya
Jillian Neary
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1027 - HIV Exposure Affects Gut Virome Richness but Not Diversity Among Kenyan Infants
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1028 - HIV Exposure Does Not Affect Cytomegalovirus Acquisition Risk in a Setting of Optimized Maternal ART
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1029 - Rapid Waning in Hepatitis B Virus Vaccine Immunity Among Children HIV-Exposed Uninfected in Botswana
Lynette Bhebhe
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-02) Mpox Epidemiology
2:30 PM2:30 PM
1090 - Understanding Mpox and HIV Coinfection: Insights From a Major Cohort Study in Brazil
Matheus Oliveira Bastos
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1092 - Mpox Reinfections in California, May 2022 to August 2024
Jessica Watson
California Department of Public Health, Richmond, CA, USA
2:30 PM2:30 PM
1093 - Sexual Behaviors Among GBMSM Infected With Mpox in California (May 2022 -July 2024)
Kayla Saadeh
California Department of Public Health, Richmond, CA, USA
2:30 PM2:30 PM
1094 - Long-Term Sequelae of Mpox: A Cohort Study in 2 Tertiary Centers
Rene Bulnes
UT Southwestern, Dallas, TX, USA
2:30 PM2:30 PM
1095 - Mpox Viral Load and Illness Severity in MSM Living With and Without HIV by Vaccine Status
Guido Schäfer
ICH Study Center, Hamburg, Germany
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-03) The Intersection of HIV With COVID-19
2:30 PM2:30 PM
1096 - Impact of COVID-19 Healthcare Disruptions on ART Initiation and Viral Suppression: US, 2018-2021
Sarita Shah
Rollins School of Public Health, Atlanta, GA, USA
2:30 PM2:30 PM
1097 - Disparities in COVID-19 Therapeutics Access Among People With and Without HIV: An N3C Analysis
Emmanuel Nazaire Essam Nkodo
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
1098 - Impact of COVID-19 Pandemic on the Newly Diagnosed PWH: Data From 2 Clinical Centres in Italy
Andrea Carbone
Universita Cattolica del Sacro Cuore, Milan, Italy
2:30 PM2:30 PM
1099 - Impact of COVID-19 Pandemic in Deaths of PLWH From ART Program of a Peruvian Hospital
Jorge Tello Arana
Universidad Científica del Sur, Lima, Peru
2:30 PM2:30 PM
1100 - Differential Impact of Social Determinants of Health by Sex in HIV for COVID-19 Hospitalizations
Rena C. Patel
University of Alabama, Tuscaloosa, AL, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-04) Criminal Justice, Mental Health, and Syndemics Intersect With HIV
2:30 PM2:30 PM
1101 - A Syndemic View of Criminal Justice: Jail’s Impact on HIV, Syphilis, and Overdose in Washington 2023
Steven J. Erly
Washington State Department of Health, Olympia, WA, USA
2:30 PM2:30 PM
1102 - HIV Acquisition After Prison Release in Washington State and Implications for Prevention Efforts
Danika A. Troupe
Washington State Department of Health, Olympia, WA, USA
2:30 PM2:30 PM
1103 - Exploring Depression and Interventions Among PLHIV: Insights From the African Cohort Study
Gabriel Saemisch
United States Agency for International Development, Washington, DC, USA
2:30 PM2:30 PM
1105 - HIV Diagnosis Following Discharge From Psychiatric Hospitalization: A Claims-Based, Real-World Study
Samuel Bunting
University of Chicago Medical Center, Chicago, IL, USA
2:30 PM2:30 PM
1106 - Housing Status and HIV Outcomes Among Reproductive-Age Women Living With HIV in the Southern US
Shreya Ganguly
Emory University, Atlanta, GA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-05) Epidemiology of HIV in Transgender and Nonbinary Persons
2:30 PM2:30 PM
1108 - Recent HIV Acquisition Among Transgender Women From Midwest Brazil
Sylvia L. M. Teixeira
Oswaldo Cruz Institute – Fiocruz, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1109 - High HIV Burden Among Transgender Women in the State Capital and Rural Towns in Central Brazil
Bruno Vinícius D. Diniz e Silva
Federal University of Goias, Goiânia, Brazil
2:30 PM2:30 PM
1110 - Time to Antiretroviral Initiation Among Transgender Women Living With HIV in France (1997-2022)
Juliette Hemery
French National Institute of Health and Medical Research (Inserm), Paris, France
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-01) Self, Couple, and Mobile Testing
2:30 PM2:30 PM
1177 - Expanding HIV Self-Test Reach: Comparative Outcomes Across Facility, Community, and Online Channels
Thi Thi Win
Community Partners International, Yangon, Myanmar
2:30 PM2:30 PM
1178 - National HIV Self-Test Distribution Program: HIV Testing, Diagnosis, and Treatment, 3/2023 - 5/2024
Allison Lale
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1179 - Estimating Need for Annual HIV Testing Met by a Nationwide Mailed HIV Self-Testing Program
Patrick S. Sullivan
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1180 - Engaging Male Partners of HIV-Negative Pregnant Women in HIV Testing Using Oral HIV Self-Test
Maganizo B. Chagomerana
University of North Carolina Project–Malawi, Lilongwe, Malawi
2:30 PM2:30 PM
1181 - Moderators of a Home-Based Couple Intervention on Couple HIV Testing and Counselling Uptake in Kenya
Zachary A. Kwena
Kenya Medical Research Institute-UCSF Infectious Disease Research Training Program, Kisumu, Kenya
2:30 PM2:30 PM
1182 - Evaluating the Effectiveness and Population Impact of Status-Neutral HIV Screening in AZ
Lazaro Ruiz
University of Arizona, Tucson, AZ, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-01) Choice and Options as Prevention Tools
2:30 PM2:30 PM
1200 - Persistence of Oral PrEP Use in the United States, 2017-2023
Ya-Lin A. Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1201 - HIV Nonoccupational Post-Exposure Prophylaxis Use Among Transgender Women: 7 Cities, 2019-2020
Thomas G. Buchanan
Oak Ridge Institute for Science and Education, Atlanta, GA, USA
2:30 PM2:30 PM
1202 - Evaluating Pharmacy-Based PrEP Delivery for Sex Workers in Zimbabwe: Pilot Quasi-Experimental Study
Oppah Kuguyo
Centre for Sexual Health and HIV/AIDS Research Zimbabwe, Harare, Zimbabwe
2:30 PM2:30 PM
1203 - Patterns of Choice, Switching, and Discontinuation of Oral and Injectable PrEP Among Adolescents
Laio Magno Santos de Sousa
Federal University of Bahia, Salvador, Brazil
2:30 PM2:30 PM
1204 - Support for Over-the-Counter PrEP Among Transgender Women and Transfeminine Nonbinary People
Lauren R. Violette
Harvard Medical School, Boston, MA, USA
2:30 PM2:30 PM
1205 - Male Circumcision, HIV, and Hepatitis B: Results From the Tanzania HIV Impact Survey
Alexander Kailembo
2:30 PM2:30 PM
1206 - Online and Less Frequent Monitoring of Oral HIV PrEP Use Are Noninferior to Standard of Care
Marije L. Groot Bruinderink
Public Health Service Amsterdam, Amsterdam, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-02) Epidemic Prevention Strategies
2:30 PM2:30 PM
1207 - Spillover Infections Drive Transmission in HIV Prevention Trials: BCPP/Ya Tsie Study
Sikhulile Moyo
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
1208 - Cost-Effectiveness of Vaccination Strategies to Control Future Mpox Outbreaks in England
Peter Vickerman
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1209 - Estimating Population Immunity and Impact of COVID-19 Vaccination in Washington and Oregon
Mia Moore
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1210 - Epidemiology and Predictors of COVID-19 Vaccine Uptake Among People With HIV in the US, 2020-23
Adrienne E. Shapiro
University of Washington, Seattle, WA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-01) Still Here: Syphilis
2:30 PM2:30 PM
1239 - Syphilis Screening in Hospitalized People With HIV: A Key Strategy to Tackle HIV and STI Epidemics
Mayara Secco Torres da Silva
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1240 - Differences in Presentation and Outcome of Subsequent Episodes of Syphilis in People Living With HIV
Jose L. Casado
Hospital Ramón y Cajal, Madrid, Spain
2:30 PM2:30 PM
1241 - Unravelling the Pathogenesis and Outcome of Serofast Status in People Living With HIV
Jose L. Casado
Hospital Ramón y Cajal, Madrid, Spain
2:30 PM2:30 PM
1242 - No CSF Study in Neuro Asymptomatic Syphilis in People With HIV: Clinical and Serologic Outcomes
María L. Otth
University of Chile, Santiago, Chile
2:30 PM2:30 PM
1243 - Describing the Cascade of Care for Neurosyphilis in People Living With HIV: Finding the Gaps
Shaul A. Navarro-Lara
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
1244 - Syphilis Among Women of Reproductive Age With or Without HIV in the Southern US
Maria L. Alcaide
University of Miami Miller, Miami, FL, USA
2:30 PM2:30 PM
1245 - Epidemic of Treponema pallidum Strains in Japan and Biomarkers for Molecular Epidemiology
Eisuke Adachi
University of Tokyo Institute of Medical Science, Tokyo, Japan
2:30 PM2:30 PM
1246 - Temporal Changes in Syphilis Prevalence and Population Characteristics Among MSM in India
Mihili Gunaratne
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1247 - Has Rapid Scale-Up of Dual HIV/Syphilis Testing in Antenatal Care Improved Syphilis Testing Coverage?
Cheryl C. Johnson
World Health Organization, Geneva, Switzerland
2:30 PM2:30 PM
1248 - Monitoring the Success of Public Health Efforts to Reduce Congenital Syphilis, King County, WA
Tim W. Menza
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1249 - Risk Factors for Incomplete Treatment for Syphilis in Pregnant Oral PrEP Users in South Africa
Kalisha Bheemraj
University of Cape Town, Cape Town, South Africa
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-02) Advances in Sexual and Reproductive Health in HIV
2:30 PM2:30 PM
1250 - HIV Status and Other Factors Associated With Infection Complicating Abortion in Botswana
Bogadi Loabile
Hospital of the University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1251 - Irregular Menstruation Among Women Is Associated With COVID-19 Infection, but Not Vaccination
Emily M. Cherenack
University of Miami, Miami, FL, USA
2:30 PM2:30 PM
1252 - Incidence of Intended & Unintended Pregnancies Among Women With HIV on ART: 5-Year Cohort in Abidjan
Prescilia Visi Vumba
University of Bordeaux, Bordeaux, France
2:30 PM2:30 PM
1253 - Unmet Need for Family Planning Underestimated Among Women Living With HIV in Kenya
Alison Drake
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1254 - Effect of Antiretroviral Regimen on Contraceptive Failure Among Women Using Injectable Contraception
Karen Diepstra
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1255 - PrEP Eligible but Missed: Preliminary Evidence Unlocking the Potential of Family Planning Services
Brenice Duroseau
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
1256 - Multipurpose Vaginal Rings: Preferences From a National Discrete Choice Survey With US Women
Ann Gottert
Population Council, New York, NY, USA
2:30 PM2:30 PM
1257 - Oral PrEP and Sexual Health Screening Services Uptake Among Diverse Gender Identities in India
Rifa T. Khan
YR Gaitonde Center for AIDS Research and Education, Chennai, India
2:30 PM2:30 PM
1258 - STAR: A Prospective Cohort of Women of Reproductive Age With and Without HIV in the Southern US
Elizabeth F. Topper
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
1259 - Substance Use and Treatment Among Reproductive-Age Women With/Without HIV in the Southern US
Ayako W. Fujita
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1260 - Physical, Psychosocial, and Sexual Health in Adults Aged 50+ With and Without HIV in Denmark
Ditte Scofield
Hvidovre Hospital, Hvidovre, Denmark
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-01) Modeling
2:30 PM2:30 PM
1289 - Testing Healthcare System Resilience Using Microsimulation Modeling Under Various Shocking Scenarios
Viviane D. Lima
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1290 - Estimated Benefits of Providing On-Demand PrEP Options for Women in Cape Town: A Modeling Study
Dobromir Dimitrov
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1291 - Model-Projected Costs Associated With Increasing Numbers of Medicare Beneficiaries With HIV Aged 65+
Emily Hyle
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1292 - Modeling the Impact of Increased PrEP Use on Sexually Acquired HIV Incidence in the United States
Tamar Tchelidze
Roche Diagnostics, Somerville, NJ, USA
2:30 PM2:30 PM
1293 - Dynamic Choice HIV Prevention With Cabotegravir (CAB-LA): A Model-Based Cost-Effectiveness Analysis
Matt Hickey
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1294 - Cost-Effectiveness of PrEP and Medications for Opioid Use Disorder in People Who Inject Drugs
John Chiosi
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1295 - Ending the HIV Epidemic Among Men Who Have Sex With Men in the United States: A Modeling Analysis
Kenneth A. Freedberg
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1296 - Optimizing Investment in HIV Testing Services, ART, and PrEP to Reduce HIV Incidence in South Africa
Caitlin Dugdale
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1297 - Impact of Rapid Long-Acting PrEP Scale-Up Among MSM: Closing the Unmet Needs and Towards Ending HIV
Haoyi Wang
Maastricht University, Maastricht, Netherlands
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-02) Cardiovascular Risk, Weight
2:30 PM2:30 PM
1298 - Trajectories of Weight Changes After GLP-1 Receptor Agonists Initiation Among Patients With HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1299 - Cardiometabolic Risks and the Transition to InSTIs in Aging PLWH in South Africa
Julia K. Rohr
Harvard TH Chan School of Public Health, Boston, MA, USA
MAR10
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-03) Mental Health
2:30 PM2:30 PM
1300 - Addressing Alcohol Use and Depression as a Strategy to Reduce HIV in KwaZulu-Natal, South Africa
Mellesia Jeetoo
New York University Langone Medical Center, New York, NY, USA
2:30 PM2:30 PM
1301 - Impact of SEARCH Person-Centered Care/Prevention on Clinical Outcomes by Alcohol Use in East Africa
James Ayieko
Kenya Medical Research Institute, Kilifi, Kenya
2:30 PM2:30 PM
1302 - Depression and Suicide Risk Among Sexual and Gender Minorities: Insights From the ImPrEP CAB Brasil
David Richer Araujo Coelho
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1303 - Effects of a Cash Transfer Intervention on Internalized HIV Stigma Among ART Initiates in Tanzania
Emmanuel Katabaro
Health for a Prosperous Nation, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
1304 - Low-Barrier HIV Care Outcomes in the Context of Homelessness, Substance Use, and Mental Illness
Julie Dombrowski
University of Washington, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-03) Persistence and Evolution of SARS-CoV-2
2:30 PM2:30 PM
309 - ScRNA-seq of HRSV/SARS-CoV-2 Co-Infection Reveals Unique Cellular Responses and lncRNA Signatures
Claudia Vanetti
University of Milan, Milan, Italy
2:30 PM2:30 PM
310 - Emergence of Divergent Spike Haplotypes in Individuals With Persistent SARS-CoV-2 Infections
Luke Blagdon Snell
King's College London, London, UK
2:30 PM2:30 PM
311 - Evolving of Immune Evasion During a SARS-CoV-2 Chronic Infection: A Pathway to Variants of Concern
Rui Galao
King's College London, London, UK
2:30 PM2:30 PM
312 - Genetic Mutation Differences Patterns of SARS-CoV-2 in Immunocompromised Patients Versus Controls
Karen Zafilaza
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
313 - SARS-CoV-2 Intrahost Evolution During Acute Infection in People With COVID-19
Agostino Riva
Luigi Sacco University Hospital, Milan, Italy
2:30 PM2:30 PM
314 - Prevalence, Spread, and Mutation of SARS-CoV-2 Variants in COVID-19 Testing in Salvador, Brazil
Anna Carolina Dantas
Federal University of Bahia, Salvador, Brazil
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-04) Nuclear Events in HIV-1 Replication and the Control of Gene Expression and Viral Production
2:30 PM2:30 PM
315 - CPSF6 Regulates Cellular Permissivity to HIV-1 Infection Through Alternative Polyadenylation
Daphne Cornish
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
316 - A Targeted CRISPR Screen Identifies ETS1 as a Regulator of HIV Latency
David M. Margolis
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
317 - HIV-1 Membraneless Organelles Orchestrate Viral Genome Maturation and Immune Evasion
Francesca Di Nunzio
Institut Pasteur, Paris, France
2:30 PM2:30 PM
318 - Design of SHIVs Encoding HIV-1 Recombinase Brec1 Recognition Site for Nonhuman Primate Cure Studies
Ryan Krause
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
319 - Convergence of NF-κB Pathways Increases HIV-1C Transcriptional Fitness
Hrimkar B. Buch
Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India
2:30 PM2:30 PM
320 - Fatty Acid Synthesis Controls Both Cellular Susceptibility to HIV and New Particle Production
Joshua A. Acklin
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
321 - Direct Sequencing of Full-Length HIV-1 RNA Reveals the Functional Significance of Site-Specific m6As
Sanggu Kim
Ohio State University, Columbus, OH, USA
2:30 PM2:30 PM
322 - Functional Study of N6-Methyladenosine (m6A) Machinery in HIV Infection of Primary CD4+ T Cells
Lacy M. Simons
Northwestern University, Chicago, IL, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-03) Effect of HIV on the Immune System
2:30 PM2:30 PM
359 - Single-Cell Multi-Omics Uncovers the Immune Heterogeneity in HIV-Infected INRs
Xiaosheng Liu
Tsinghua University, Beijing, China
2:30 PM2:30 PM
360 - Variability in Immunometabolic Signatures Among People w/ HIV Defines Immune Outcomes and Progression
Simon Gressens
French National Institute of Health and Medical Research (Inserm), Paris, France
2:30 PM2:30 PM
361 - Effect of Delayed ART Initiation on Anti-CD4 Autoantibodies in ART-Naive People With HIV
Shweta Mistry
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
362 - CD4-Binding Site Abs Modify the Negative Association Between Cluster A Abs and CD4 Count in PWH
Mehdi Benlarbi
Université de Montréal, Montreal, Canada
2:30 PM2:30 PM
363 - Prevalence and Activity of Anti-Interferon Autoantibodies in People Living With HIV
Olivia Payne
University College London, London, UK
2:30 PM2:30 PM
364 - Secreted ORF8 Reprograms Macrophages to Enhance Lung Epithelial Cell Infection by SARS-CoV-2
Yusuke Matsui
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
365 - Occult CMV Replication Is a Persistent Driver of Effector T-Cell Expansion in PWH on Effective ART
Nived Collercandy
Toulouse University Hospital, Toulouse, France
2:30 PM2:30 PM
366 - IL-10/PD-1 Blockade Leads to Enhanced BA Synthesis and Type I IFN Production
Khader Ghneim
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
367 - Activated Platelets Render Functionally Deficient Natural Killer Cells in People Living With HIV
Brita Ostermeier
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
368 - Elevated Lymph Node Metabolic Activity During Long-Term Antiretroviral Therapy
Chuen-Yen Lau
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
369 - Immunometabolism of Innate Lymphocytes in People Living With HIV-1 Versus HIV-2
Maryam Khan
Queen Mary University of London, London, UK
2:30 PM2:30 PM
370 - Non-HIV Chronic/Latent Viruses and Immune Aging: Sex Effects Comparable to Those of HIV and CMV
Renying (Loulou) Cai
University of British Columbia, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-04) Nonimmune Effects of HIV Infection
2:30 PM2:30 PM
371 - Sex Differences in Cytokine Responses and Genetic Regulation Thereof in People Living With HIV
Suzanne D. E. Ruijten
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
372 - Dynamic Changes in the Peripheral Blood Monocytes Following Long-Acting Injectable CAB/RPV in PLWH
Maria Antonella Zingaropoli
Sapienza University of Rome, Rome, Italy
2:30 PM2:30 PM
373 - Changes in Serum Level of Cell-Free Mitochondrial DNA Fragments in Acute and Chronic HIV Infection
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
374 - The Molecular Cargo of Exosomes Is Able to Discriminate Between PLWH With or Without NADCs
Norma Rallón
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
375 - HIV-Encoded Proteins Induce Pulmonary Arterial Hypertension via Increases in Podocan-Like Protein 1
Laszlo Kovacs
Augusta University, Augusta, GA, USA
2:30 PM2:30 PM
376 - Compromised Intestinal Barrier Resilience to Cytokine Disruption Causing Leakage in People With HIV
Mohamed Abdel-Mohsen
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
377 - Acute HIV-1 Infection Triggers Myelopoiesis Suppression and Pancytopenia Through IFN-γ Signaling
Shuai Gao
Washington University, St Louis, MO, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-03) Using Vaccines for Therapy
2:30 PM2:30 PM
425 - Age Inversely Correlates With T-Cell Response to MVA.HIVconsvX Vaccination in PWH on ART
Nilu Goonetilleke
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
426 - Unadjuvanted CD40.HIVRI.ENV Vaccine Late Boost Induces Durable Immune Responses: ANRS/VRI06 Trial
Yves Levy
Vaccine Research Institute, Créteil, France
2:30 PM2:30 PM
427 - Augmenting HIV-Specific CAR-T Cell Functionality by Treatment With Novel Cytokine-Based Scaffold
Sara Lamcaj
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
428 - ChAdOx1.HIVconsvX and MVA.HIVconsvX Vaccination Is Safe and Immunogenic in PWH on ART: The CM Study
Cynthia L. Gay
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
429 - A Novel Immunotherapeutic Platform for Amplifying HIV, CMV, or SARS-CoV-2-Specific T-Cell Responses
Marta Santos Bravo
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
430 - Therapeutic HIV Vaccine ± TLR4 Adjuvant Impact on Monocyte Subsets in Early-Treated Youths With HIV
Alessia Neri
University of Rome Tor Vergata, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-04) Preventive Vaccine Strategies
2:30 PM2:30 PM
431 - Enhanced HIV Antibody Precursor Development With Early-Life Germline Targeting Immunization
Yasmine Issah
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
432 - A VLP-Forming mRNA Vaccine Protects Macaques From Heterologous SHIV Infection
Mamta Singh
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
433 - Cytoplasmic Tail Engineering of Stabilized mRNA Env Immunogens Enhances Neutralizing Response
Edward Kreider
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
434 - Improved Immunogenicity of a VLP-Forming mRNA Vaccine for HIV-1
Mamta Singh
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
435 - An AI-Redesigned Contemporary HIV-1 Env Consensus Antigen Is More Immunogenic Than a Native Sequence
Eric Lewitus
United States Military HIV Research Program
2:30 PM2:30 PM
436 - Incidence and Predictors of STIs and Effect on Immune Activation in the HVTN 705/HPX2008 Trial
Mitch M. Matoga
University of North Carolina Project–Malawi, Lilongwe, Malawi
2:30 PM2:30 PM
437 - 3-Step Heterologous Immunization Schema Results in Development of Cross-Neutralizing VRC01-Class Abs
Parul Agrawal
Fred Hutchinson Cancer Center, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-05) Immunity to Mpox
2:30 PM2:30 PM
438 - Evolution and Durability of Mpox-Specific Antibodies Among Vaccinated or Infected Individuals
Wang-Da Liu
National Taiwan University Hospital, Taipei, Taiwan
2:30 PM2:30 PM
439 - Antibody Responses Decline Post-MVA Vaccination but Persist Following Mpox Infection
Joanne Byrne
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
440 - Immune Response to Mpox in PWH and PrEP Users After Infection, but Not in Response to Vaccination
Olivia de la Calle-Jiménez
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
441 - MVA Vaccine Produces Potent Serologic and Immunologic Response to Mpox in People With HIV
Maryam Khan
Queen Mary University of London, London, UK
2:30 PM2:30 PM
442 - Mpox-Specific T-Cell Responses in Recovered and Vaccinated Individuals
Aideen S. Teeling
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
443 - Immune Response After 2 Years From MVA-BN Vaccination by HIV Infection and CD4 Cell Count
Valentina Mazzotta
National Institute for Infectious Diseases L Spallanzani, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-06) Natural-Born Killers: NK Cells
2:30 PM2:30 PM
444 - RV550: IL-15 Superagonist N-803 With ART in Acute HIV Infection Enhances T and NK Cell Proliferation
Hiroshi Takata
Oregon Health and Science University, Portland, OR, USA
2:30 PM2:30 PM
445 - NF-kappa-B Signaling in Natural Killer Cells Predicts Post-Treatment HIV Control
Ashley F. George
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
446 - HLA-E Prevents Natural Killer Cell Inhibition of HIV-1 Replication in Peripheral Blood CD4+ T Cells
Amanda M. Dudek
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
447 - Differential CD8T/NK Cell-Mediated HIV-1 Control After TIGIT or KLRG1 Blockade and ART in hBLT Mice
Ildefonso Sánchez-Cerrillo
Hospital Universitario de La Princesa, Madrid, Spain
2:30 PM2:30 PM
448 - Elucidating the Role of Natural Killer Cells in Antibody Breadth During HIV Infection
Izumi de los Rios Kobara
Stanford University, Stanford, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-07) New Concepts in Immunotherapy
2:30 PM2:30 PM
449 - Combination of eCD4-IgG1 Delivered by AAV9 and AZD5582 in SIV-Infected, ART-Suppressed Infant RM
Jairo A. Fonseca
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
450 - Using Nanobodies as an Intracellular Biological to Block HIV-1 Through Innate Antiviral Mechanisms
Florence M. Stel
Amsterdam University Medical Centers, Amsterdam, Netherlands
2:30 PM2:30 PM
451 - Viral Genetic Traits of Durable Control in Dual Immunotherapy-Treated SHIV-Infected Rhesus Macaques
Manukumar Honnayakanahalli Marichannegowda
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
453 - HIV-Induced Sialoglycans on Infected Cells Promote Immune Evasion From Myeloid Cell-Mediated Killing
Shalini Singh
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
454 - Sialidase Conjugation Enhances the Anti-HIV Activity of the 10-1074 Antibody in Humanized Mice
S. M. Shamsul Islam
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
455 - Cannabidiol Has Sex-Dependent Anti-Inflammatory Effects in Long-Term Suppressed HIV-1 Adults
Clémence Couton
Centre de Biophysique Moléculaire, Orléans, France
2:30 PM2:30 PM
456 - IFI16 Controls PVR and Gal-9 Expression and Its Targeting Improves Immunotherapy Against HIV-1
Enrique Martin Gayo
Universidad Autónoma de Madrid, Madrid, Spain
2:30 PM2:30 PM
457 - Investigating the Effects of ADCC and CAR NK/T Cells on HIV-1 Cell-to-Cell Transmission
Tanvi Mathur
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
458 - Natural Killer Cells Preferentially Kill HIV-Infected CD4 T Cells Using Death Receptors
Lesley R. de Armas
University of Miami, Miami, FL, USA
2:30 PM2:30 PM
459 - Tri-Specific Killer Engagers in Macaques Potently Induce NK Cell Responses in Blood and Tissues
Julien A. Clain
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
460 - Extracellular Acyl-CoA-Binding Protein Prevents Autophagy and T-Cell Function in People With HIV
Stephane Isnard
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
461 - Gut Microbiome Dynamics and Immune Responses in People With HIV Receiving N-803
Ashma Chakrawarti
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
462 - Heterogeneity of PD-1 Expression in PLHIV and Its Relationship With Host and Viral-Related Factors
Adriana Navas
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
463 - IL-10 Treatment Enhances CD8 T-Cell Activation and Cytotoxicity in SIV Infection: The Yin and Yang
Nongthombam Boby
Texas Biomedical Research Institute, San Antonio, TX, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-03) HIV Reservoirs in Cells and Tissues
2:30 PM2:30 PM
514 - CD4+ T Cells Harboring Inducible HIV Genomes Display a Senescent-Like Phenotype
Remi Fromentin
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
515 - Macrophage-Tropic TF SHIV D-Infected NHP Model of Reservoir Persistence and Decay on ART
Ryan Krause
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
516 - Anatomical Sites in FIND 2.0 Decedents Harbor Compartmentalized, Transcriptionally Intact HIV-1 Env
Melanie Moodie
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
517 - Biomarkers of HIV Latency in Tissues From People With HIV
Nadejda Beliakova-Bethell
Veterans Affairs San Diego Healthcare System, San Diego, CA, USA
2:30 PM2:30 PM
518 - HIV Can Persist in Multiple Subsets of SARS-CoV-2-Specific CD4+ T Cells in Tissues During ART
Xiaoyu Luo
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
519 - Women With HIV Have a Lower Frequency of Monocyte Reservoir Reactivation Than Men With HIV
Rebecca Veenhuis
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
520 - Well-Seeded Reservoirs in Gut Are Associated With Tertiary Lymphoid Structures With Activated ISR
Ramon Lorenzo-Redondo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
521 - HIV-1 Clade C Reservoir Traits in Blood and Lymph Node Tissue in Acute and Chronic Treated Infection
Kavidha Reddy
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
522 - HIV Burden Is Associated With Specific Bacteriome Profiles Relative to Specific Gut Segments
Mattia Trunfio
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
523 - Viral and Microbial Environment in the Male Genital Tract of People Living With HIV
Elizabeth Hastie
University of California San Diego, La Jolla, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-06) Immune Pressure on HIV Reservoirs
2:30 PM2:30 PM
539 - Resistance of Inducible, Infectious HIV-1 to Autologous Neutralizing IgG After Long-Term ART
Natalie F. McMyn
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
540 - High Networked CD8+ T-Cell Epitopes Exhibit Markedly Reduced Mutability in the Latent HIV Reservoir
Fernando Senjobe
Harvard University, Cambridge, MA, USA
2:30 PM2:30 PM
541 - Autologous IgGs Mediate Log Reductions in HIV Infection in a PTC, Contributing to ART-Free Remission
Junlin Zhuo
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
542 - Afucosylation of Broadly Neutralising Antibodies to Eliminate HIV+ CD4+ T Cells and Macrophages
Morgane Brunton-O'Sullivan
Burnet Institute, Melbourne, Australia
2:30 PM2:30 PM
543 - Immune Dynamics During Reproductive Aging and Substance Use in Women With HIV
Konstantin Leskov
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
544 - Latency Reversal Induced by CD4+ T-Cell Recognition of HIV-1 Alternate Reading Frame Proteins
Joel Sop
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
545 - Reduced Metabolic Flux Protects HIV-Expressing CD4+ T-Cells From CTL-Mediated Elimination
Alberto Herrera
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
546 - Engineering Natural Killer Cells With NKp30-Based Chimeric Antigen Receptors (CARs) to Target HIV
Ruoxi Pi
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
547 - Preclinical Evaluation of Effector Function-Enhanced Variants of N6 bNAb
David Wensel
ViiV Healthcare, Branford, CT, USA
2:30 PM2:30 PM
548 - Long-Term ART Enhances Cytotoxic Response and Reduces the Reactivation Capacity of HIV-1 Reservoir
Alicia Simón Rueda
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
549 - Plasma Cytokines and NF-κB Signaling Drive Transcriptomic Diversity in CD4+ T Cells From PWH on ART
Alton Barbehenn
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
550 - TLRS Ligands and IL-15 Induce Trained Immunity in CD4 Cells and Limit HIV Infection and Persistence
Muhammad Bilal Latif
Emory University, Atlanta, GA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-07) HIV Clones in the Reservoir
2:30 PM2:30 PM
551 - Phenotypic and Functional Heterogeneity Contribute to the Persistence of the Clonal CD4 Reservoir
Isabella A. T. M. Ferreira
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
552 - Latent HIV Clonal Dynamics: Integration Sites and Their Role in Maintenance of Latency In Vivo
Virender K. Pal
The Rockefeller University, New York, NY, USA
2:30 PM2:30 PM
553 - Targeting of HIV-Infected Clones by Cognate Peptide Stimulation and Antiproliferative Drugs
Filippo Dragoni
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
554 - Sequencing of HIV-1 Proviruses in Large Infected T-Cell Clones Reveals a Predominance of Solo-LTRs
Dimiter Demirov
Leidos Biomedical Research, Inc, Frederick, MD, USA
2:30 PM2:30 PM
555 - Chromosomal Integration Site Profile of HTLV-1-Infected Cells Is Distinct From HIV-1-Infected Cells
Alex Hochroth
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
556 - Reservoir-Harboring T-Cell Clones Have a Cytotoxic Immunophenotype That May Affect HIV Inducibility
Alberto Herrera
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
557 - The Paucity of Clonal SIV Proviral Sequences During Early ART Treatment
Margaret Hallmets
Tulane National Primate Research Center, Covington, LA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-04) Addressing NeuroHIV in Lower- and Middle-Income Settings
2:30 PM2:30 PM
615 - Neuronal Injury in a Subset of PWH During Acute HIV Infection and Up to 5 Years After Immediate ART
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
616 - Plasma Microbiome Composition Among Neurobehavioral Phenotypes (NBPs) in People With HIV (PWH)
Mohammadsobhan Sheikh Andalibi
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
617 - High Anticholinergic Burden and Poor Sleep Quality in People With HIV
Maria Mazzitelli
Azienda Ospedaliera di Padova, Padua, Italy
2:30 PM2:30 PM
618 - Prevalence of Mental Disorders Among PWH in Rwanda: A Low-Cost Nurse-Led Screening Approach
Michel Gasana
Rwanda Biomedical Centre, Kigali, Rwanda
2:30 PM2:30 PM
619 - Cognitive and Sensorimotor Difficulties in Well-Controlled People With HIV Living in Uganda
Leah H. Rubin
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
620 - No Impact on the CNS After Switching to Dolutegravir/Lamivudine From a 3-Drug Regimen
Linn Renborg
Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
2:30 PM2:30 PM
621 - Dual Group-Based Trajectories of Brain-Derived Neurotrophic Factor and Cognition in People With HIV
Henry U. Michael
Research Institute of McGill University Health Centre, Montreal, Canada
2:30 PM2:30 PM
622 - Greater Cognitive Decline in Cognitively Unimpaired Older Thai PWH at Baseline
Akarin Hiransuthikul
Chulalongkorn University, Bangkok, Thailand
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-05) It's All About the Vessels: NeuroHIV and Vascular Dysfunction
2:30 PM2:30 PM
623 - Hypertension: A Major Factor in Low Verbal Fluency Among People Aged 50+ Living With HIV in Senegal
Caroline Couturier
Université de Bordeaux, Bordeaux, France
2:30 PM2:30 PM
624 - No Evidence of a Detrimental Effect of Pitavastatin on Neurocognitive Function Among People With HIV
Kristine M. Erlandson
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
625 - Number and Effectiveness of Antihypertensives Are Associated With Cognitive Performance in PWH
Azin Tavasoli
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
626 - Reduced Cerebral Arterial Transit Time in Obese Females With HIV and Metabolic Syndrome
Eric Decloedt
Stellenbosch University, Cape Town, South Africa
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-02) Drug-Drug Interactions and Pharmacology Challenges With Important Coconditions
2:30 PM2:30 PM
645 - Drug Interactions Between Dolutegravir (DTG) and Escalating Doses of Rifampicin (RIF): DORIS Study
Yashna Singh
Desmond Tutu HIV Foundation, Cape Town, South Africa
2:30 PM2:30 PM
646 - TAF Achieves Adequate Intracellular Tenofovir-DP Concentrations With Rifampicin-Based TB Therapy
Rephaim Mpofu
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
647 - Pharmacokinetics of Twice-Daily TAF in Adults With HIV-Associated TB on BIC/FTC/TAF and Rifampicin
Emmanuella C. Osuala
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
648 - Estradiol Concentrations in Trans Women on BIC/FTC/TAF Compared to Those Without HIV
Alice Tseng
University Health Network, Toronto, Canada
2:30 PM2:30 PM
649 - Reduced Metformin Concentrations in Obese Women With HIV Treated With Dolutegravir
Roland van Rensburg
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
650 - Pharmacokinetics of Switching to B/F/TAF in PWH Post-Renal Transplant: BIK Switch Study
Corwin Coppinger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-02) Long-Acting Therapy: What Observational Data Tell Us About the "Real World"
2:30 PM2:30 PM
674 - Long-Term CAB+RPV LA Effectiveness in Virologically Suppressed Individuals in the OPERA Cohort
Michael Sension
CAN Community Health, Fort Lauderdale, FL, USA
2:30 PM2:30 PM
675 - Outcomes on Cabotegravir + Rilpivirine in Suppressed People With HIV (PWH) in TRIO Health US Cohort
Paul Sax
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
676 - Clinical Outcomes Among Virologically Suppressed Women Receiving CAB+RPV LA in the OPERA Cohort
Jessica A. Altamirano
CAN Community Health, Fort Lauderdale, FL, USA
2:30 PM2:30 PM
677 - Long-Acting Cabotegravir and Rilpivirine in Older People With HIV in the GEPPO Cohort
Andrea Calcagno
University of Turin, Turin, Italy
2:30 PM2:30 PM
678 - Long-Acting Cabotegravir/Rilpivirine in Real Life: Sex-Based Characteristics, PROs, and Effectiveness
Ana González-Cordón
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
679 - Interim Week 48 Results in Young South Africans on Long-Acting Injectable ART: The AFINAty Study
Lauren Jennings
Desmond Tutu HIV Foundation, Cape Town, South Africa
2:30 PM2:30 PM
680 - Impact of Oral Lead-In on PK and Virologic Outcomes in People With HIV Transitioning to CAB+RPV LA
Marta Fernández-González
Hospital General Universitario de Elche, Elche, Spain
2:30 PM2:30 PM
681 - Low-Level Viremia and Risk Factors for Failure on Long-Acting Cabotegravir/Rilpivirine (LA CAB/RPV)
Natalie Nielsen
Ohio State University, Columbus, OH, USA
2:30 PM2:30 PM
682 - Outcomes of LAI ART for People With Detectable HIV Viremia in the NYC Public Healthcare System
Anthony Gerber
Bellevue Hospital, New York, NY, USA
2:30 PM2:30 PM
683 - Why Do People With HIV Stop Long-Acting Injectable Cabotegravir/Rilpivirine and What Happens?
Katerina Christopoulos
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
684 - What Do Early Adopters of Long-Acting Injectable Cabotegravir/Rilpivirine Think About It?
Katerina Christopoulos
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
685 - Outcomes in Those Who Discontinued Injectable Cabotegravir/Rilpivirine and Resumed Oral ART
Tali Faggiano
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
686 - Implementation of LA-CAB/RPV in US Clinic Settings: A Survey of Front-Line Clinicians
William R. Short
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
687 - Distance to Care Measures Predict Injection Visit No-Shows Among Cabotegravir/Rilpivirine Recipients
Nimish Patel
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
688 - First Year of Lenacapavir Long-Acting Injectable Use in the OPERA Cohort
Karam Mounzer
Philadelphia FIGHT, Philadelphia, PA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-04) New Agents and Novel Administration
2:30 PM2:30 PM
701 - A 24-Week Phase II Maintenance Study of TMB-365/TMB-380 Q8W in People With Suppressed HIV-1 Infection
Jacob P. Lalezari
Quest Clinical Research, San Francisco, CA, USA
2:30 PM2:30 PM
702 - A Multicenter Study of Albuvirtide Combined With 3BNC117 in Multidrug-Resistant HIV-1 Infection
Yuanyuan Qin
Chongqing Public Health Medical Center, Chongqing, China
2:30 PM2:30 PM
703 - Efficacy of Switching to Ainuovirine-Based Antiretroviral Regimen in Virologically Suppressed PWH
Hong Qin
Jiangsu Aidea Pharmaceutical Co, Ltd, Yangzhou, China
2:30 PM2:30 PM
704 - Evaluating Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube
Joshua T. Mercure
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
705 - Creating an Ultralong-Acting Dolutegravir Prodrug Homodimer
Bhoomika Gowda
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
706 - Development of a 2-Drug Long-Acting Removable Formulation for HIV Suppression
Manse Kim
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
707 - Identification and Characterization of Novel Chemical Scaffolds With Anti-HIV Activities
Ryan Jeep
Colorado State University, Fort Collins, CO, USA
2:30 PM2:30 PM
708 - A Strategy for Durable AAV-Vectored bNAb Expression in Adult Rhesus Macaques
Michael Kuipa
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
709 - Trosunilimab Safety, Pharmacokinetics, and Pharmacodynamics in People With and Without HIV-1
Franco Antonio Felizarta
Private Practice, Bakersfield, CA, USA
2:30 PM2:30 PM
710 - Preclinical Evaluation of an Ultra-Long-Acting Tenofovir Prodrug Nanosuspension
Samiksha S. Raut
University of Nebraska Medical Center, Omaha, NE, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-02) Epidemiology of HIV Drug Resistance
2:30 PM2:30 PM
729 - High Prevalence of Baseline NRTI Resistance in PWH Switched From Second-Line PI/r to B/F/TAF
Jean Bernard Marc
GHESKIO Center, Port-au-Prince, Haiti
2:30 PM2:30 PM
730 - HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024
Ron M. Kagan
Quest Diagnostics, San Clemente, CA, USA
2:30 PM2:30 PM
731 - Rilpivirine Drug-Resistant Mutations in Experienced Patients in Mexico: Impact on Long-Acting ART
Luis E. Soto-Ramirez
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
732 - Despite Increasing Use of INIs to Treat HIV Infection, Resistance to This Class Remains Stable
Vincent Calvez
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
733 - Molecular Epidemiology of HIV-1 Transmitted Drug Resistance Among Subtypes Circulating in Italy
Daniele Armenia
Saint Camillus International University of Health Sciences, Rome, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-03) HBV Diagnostics and Treatment
2:30 PM2:30 PM
767 - Changes in Antiviral Treatment Eligibility With the New WHO 2024 Guidelines in Senegal
Bruce Shinga S. Wembulua
Centre Hospitalier Universitaire de Fann, Dakar, Senegal
2:30 PM2:30 PM
768 - Continuum of Hepatitis B Surface Antigen Expression Among PWID and MSM Living With HIV in India
Talia A. Loeb
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
769 - HBsAg Seroclearance in HBV-Coinfected People With HIV in the Era of Tenofovir-Containing Therapy
Chien-Ching Hung
National Taiwan General Hospital Yunlin, Yunlin, Taiwan
2:30 PM2:30 PM
770 - Hepatitis B Reactivation in PWH With Isolated Anti-Core Pattern on Therapies Excluding Tenofovir
María del Mar Arcos-Rueda
La Paz University Hospital, Madrid, Spain
2:30 PM2:30 PM
771 - HBV Reactivation Post-Switch to HBV-Inactive ART: A Scoping Review
Kyle Ring
Queen Mary University of London, London, UK
2:30 PM2:30 PM
772 - Outcomes in HIV-Hepatitis B Coinfection Without Tenofovir-Containing Antiretroviral Therapy
Amir Mohareb
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
773 - Hepatic Flare Is Associated With HBsAg Seroclearance in HBV/HIV-1 Co-Infection
Weiyin Lin
Guangzhou Eighth People's Hospital, Guangzhou, China
2:30 PM2:30 PM
774 - Increased Detection of HBV DNA and Mutational Analysis in HBsAg-Negative Specimens at NHLS/DGM
Nondumiso A. Nkosi
Sefako Makgatho Health Sciences University, Ga-Rankuwa, South Africa
2:30 PM2:30 PM
775 - HBV Seroconversion in People With HIV: Relevance of Clinical History and Viral Markers Monitoring
Marianna Menozzi
AOU Policlinico di Modena, Modena, Italy
2:30 PM2:30 PM
776 - Performance Evaluation of the Xpert Hepatitis B Molecular Test Among Pregnant Women in Uganda
Viola Kasone
Ministry of Health Uganda, Kampala, Uganda
2:30 PM2:30 PM
777 - The Impact of HIV Infection on All-Cause Mortality Among Individuals Treated for HBV in Rwanda
Jean Damascene Makuza
University of British Columbia, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-03) HIV-Related Cancer: Epidemiology, Incidence, Demographics
2:30 PM2:30 PM
798 - Trends in Common Cancer Diagnoses Among People With HIV in North America, 2006-2020
Sally B. Coburn
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
799 - Cancer Risk of People With HIV Younger Than 50 Years: Italy, 1997-2023
Camilla Muccini
IRCCS San Raffaele Scientific Institute, Milan, Italy
2:30 PM2:30 PM
800 - Predictors of Mortality Among Patients With Virus-Associated Cancers in a High HIV-Prevalence Region
Dorothy Mangale
Washington University, St Louis, MO, USA
2:30 PM2:30 PM
802 - Cancer Risk Among People Who Inject Drugs With HIV in the United States, 2010-2019
Carol-Ann Swain
New York State Department of Health, Albany, NY, USA
2:30 PM2:30 PM
803 - Cancer Incidence in Women With HIV in Europe and Australia: A Combined D:A:D and Respond Analysis
Win Min Han
Kirby Institute, Sydney, Australia
2:30 PM2:30 PM
804 - Low-Level HIV Viremia Increases Immunosuppressive Markers Elevating Cancer and CVD Risk in InSTI Era
Violeta Lara-Aguilar
Instituto de Salud Carlos III, Madrid, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-03) Antiretroviral Therapy and CVD Risk
2:30 PM2:30 PM
824 - Change in Cardiometabolic Risk Markers Following Switch to Integrase Inhibitors Differs by Sex
Cecile D. Lahiri
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
825 - Dolutegravir-Based Antiretroviral Therapy and Cardiometabolic Health Risk in Persons With HIV
Katuku Aizire
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
826 - Changes in Cardiometabolic Parameters After ART Initiated Within 1 Year of HIV Acquisition
Nikos Pantazis
National and Kapodistrian University of Athens, Athens, Greece
2:30 PM2:30 PM
827 - Potential of the Short Chain Fatty Acid Caproic Acid in Protection Against CVD in HIV Infection
Mohamed El-Far
Centre de Recherche du CHUM, Montreal, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-04) Frailty and Aging
2:30 PM2:30 PM
877 - Statins Reduce Frailty in People With HIV
Giovanni Guaraldi
University of Modena and Reggio Emilia, Modena, Italy
2:30 PM2:30 PM
878 - Frailty and All-Cause Mortality Among People With HIV Engaged in Clinical Care in the United States
Stephanie A. Ruderman
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
879 - Clinical and Economic Benefits of Preventing Physical Frailty and Falls Among PWH in the US
Karen C. Smith
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
880 - Housing Instability and Frailty Among People With HIV Engaged in Clinical Care in the United States
Carolyn A. Fahey
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
881 - Prognostic Factors of Physical Function Decline in the PREPARE Study
Grace Ditzenberger
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
882 - Understanding the Life Expectancy Sex Gap: Disparate Patterns in Noncommunicable Disease Mortality
Katherine Kooij
BC Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
883 - 10-Minute Targeted Geriatric Assessment Identifies Vulnerable and Frail Older Persons With HIV
Marilia Bordignon Antonio
University of São Paulo, São Paulo, Brazil
2:30 PM2:30 PM
884 - The 10-Year Prevalence of Hearing Loss and Dementia Among People With HIV in the United States
Emily Hyle
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
885 - Clinical Outcomes of Immune Nonresponse Among Virally Suppressed Adults Living With HIV in Thailand
Worapong Nasomsong
Phramongkutklao Hospital and College of Medicine, Bangkok, Thailand
2:30 PM2:30 PM
886 - Falls Associated With High Medication Regimen Complexity in People With HIV
Yunhan Chen
Boston Medical Center, Boston, MA, USA
2:30 PM2:30 PM
887 - Integrated Digital Strategy for Stigma Evaluation in Routine Care for PWH
Alfonso Cabello
Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
888 - Latent Class Analysis Identifies Distinct Comorbidity Profiles in Older (>65 years) People With HIV
Fabrizio Drago
Rutgers University, Piscataway, NJ, USA
2:30 PM2:30 PM
889 - Multimorbidity and Quality of Life Among Older People Living With HIV in Urban Tanzania
Theresia A. Ottaru
Muhimbili University of Health and Allied Sciences, Dar es Salaam, United Republic of Tanzania
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-05) Weight Gain
2:30 PM2:30 PM
890 - Weight and Body Composition After Switch to DTG/3TC From DTG/3TC/ABC: A Randomized Open-Label Trial
Thomas Benfield
University of Copenhagen, Copenhagen, Denmark
2:30 PM2:30 PM
891 - Re-Examining InSTI Effects on Weight Gain Among Treatment-Naive People With HIV in North America
Kassem Bourgi
Nashville CARES, Nashville, TN, USA
2:30 PM2:30 PM
892 - Weight Change on F/TAF vs Placebo: Using Common F/TDF Groups to Bridge Data Across Clinical Trials
David Glidden
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
893 - Body Composition Changes in People With HIV Switching From or Maintaining TDF-Based Regimens
Giovanni Guaraldi
University of Modena and Reggio Emilia, Modena, Italy
2:30 PM2:30 PM
894 - Risk Factors Associated With Extreme Weight Gain in People With HIV
Stefan Esser
University Hospital Essen, Essen, Germany
2:30 PM2:30 PM
895 - Serum Metabolomic Signatures Associated With InSTI-Related Weight Gain in Women With HIV
Chin-An Yang
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
896 - Weight Change in Trial of Switching From Second-Line bPI to B/F/TAF in a Context of Food Insecurity
Vanessa Rouzier
GHESKIO, Port-au-Prince, Haiti
2:30 PM2:30 PM
897 - Body Composition Changes in People With HIV Switching to DTG/3TC or BIC/TAF/FTC
Esteban Martinez
Hospital Clinic of Barcelona, Barcelona, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-02) PASC: Immunobiologic, Metabolic, and Cardiovascular Complications
2:30 PM2:30 PM
927 - Hormonal Dysregulation in Long COVID: Exploring the Salivary Cortisol Profile
Marta Camici
IRCCS Lazzaro Spallanzani, Rome, Italy
2:30 PM2:30 PM
928 - In Vitro Modeling of the Effects of Impaired HDL on Atherogenesis in Long COVID Syndrome
Theodoros Kelesidis
University of Texas Southwestern Medical Center, Dallas, TX, USA
2:30 PM2:30 PM
929 - Age-Dichotomous Associations of Long COVID With Frequency of Public SARS-CoV-2 Memory TCRs
Selin Akbas
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
930 - Persistent Immune Dysregulation and Metabolic Alterations Following SARS-CoV-2 Infection
Michael Peluso
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
931 - Immune and Virologic Trajectories 1.5 Years Before and After COVID-19 in an Early-Treated HIV Cohort
Ferron Ocampo
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
932 - Longitudinal Changes in Arterial Stiffness and Inflammation From Pre- to Post-COVID-19 Infection
Jhony Baissary
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
933 - [18F]F-AraG PET Imaging Reveals Increased Gut T-Cell Activation in People With Long COVID
Emilio De Narvaez
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
934 - Evidence of B-Cell Dysfunction in Individuals With Long COVID-Associated Dysautonomia
Montserrat Torres
Instituto de Salud Carlos III, Madrid, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-02) Pathogenesis of TB Disease/TB Drug Exposure Relationships
2:30 PM2:30 PM
954 - Impact of Cytomegalovirus Infection on the Progression of TB Disease in People With HIV on ART
Sivaporn Gatechompol
Mahidol University, Bangkok, Thailand
2:30 PM2:30 PM
955 - Immune Profiles Can Differentiate Mycobacterial and KSHV Inflammatory Syndromes in Advanced HIV
Shweta Mistry
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
956 - NAT-2 Polymorphism and Risk of Antituberculosis-Induced Hepatotoxicity in Thai People With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
957 - Isoniazid Exposure Among Patients With Tuberculosis and Diabetes in Brazil
Felipe Ridolfi
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
958 - Genetics of Plasma Rifapentine Clearance During Pulmonary Tuberculosis Treatment in Study 31/A5349
Ava Y. Xu
University of California San Francisco, San Francisco, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-03) Novel TB Case-Finding Strategies and Diagnostic Testing
2:30 PM2:30 PM
959 - High Diagnostic Yield of a Novel HIV-TB Case-Finding Strategy at Social Drinking Venues in Zambia
Andrew Kerkhoff
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
960 - Effectiveness of Portable Digital X-Ray Machine in Tuberculosis Case-Finding in Nigeria
Patrick Dakum
Institute of Human Virology Nigeria, Abuja, Nigeria
2:30 PM2:30 PM
961 - Machine Learning-Based Prediction of Active Tuberculosis in People With HIV Using Clinical Data
Johannes Nemeth
University Hospital Zurich, Zurich, Switzerland
2:30 PM2:30 PM
962 - Genome-Wide Meta-Analysis Identifies Genetic Associations With Resistance to Mtb Infection
Matheus Fernandes Gyorfy
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
963 - Healthcare Worker- Versus Self-Collected Tongue Swabs for Mycobacterium tuberculosis Detection
Anura David
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
964 - Evaluating the Accuracy of Standard F TB-Feron FIA for TB Infection Diagnosis in Vietnam
Han Thi Nguyen
Karolinska Institute, Stockholm, Sweden
2:30 PM2:30 PM
965 - Diagnostic Accuracy of the FujiLAM Assay to Detect Tuberculosis in Advanced HIV
Tessa Adzemovic
Infectious Disease Institute, Kampala, Uganda
2:30 PM2:30 PM
966 - Diagnosis and Prognosis of Blood XpertUltra and Myco/F Blood Culture for TB in Advanced HIV Disease
Phuong Le Trinh
Oxford University Clinical Research Unit in Vietnam, Hanoi, Vietnam
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-04) TB Preventive Therapy: Testing, Treatment Strategies, and Outcomes
2:30 PM2:30 PM
967 - Gaps in Latent Tuberculosis Infection Testing Practices: A 15-Year Serial Cross-Sectional Study
Jorge R. Ledesma
Kaiser Permanente Division of Research, Oakland, CA, USA
2:30 PM2:30 PM
968 - Effect of Alcohol Use on Active TB Incidence Among PWH With Prior Receipt of TB Preventive Therapy
Judith A. Hahn
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
969 - The Impact of Rifampin Drug Interactions on TPT Completion and Safety Using High-Dose vs Standard
Jinell White
Alberta Health Services, Calgary, Canada
2:30 PM2:30 PM
970 - Weekly Rifapentine and Isoniazid (3HP) vs Isoniazid Preventive Therapy (6H) Among People With HIV
Dickens Onyango
Kisumu County Department of Medical Services, Public Health, and Sanitation, Kisumu, Kenya
2:30 PM2:30 PM
971 - Patient and Provider Preferences for Long-Acting Tuberculosis Preventive Therapy
Marcia C. Vermeulen
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
972 - Effect of Tuberculosis Preventive Therapy on Mtb-Specific T-Cell Profile in the A5279/BRIEF TB Trial
Pablo C. Alarcon
University of Cincinnati Medical Center, Cincinnati, OH, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-03) Managing Maternal HIV
2:30 PM2:30 PM
991 - High Viral Suppression in Pregnant/Postpartum Women With HIV in a Couples-Based Behavioral Trial
Karen Hampanda
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
992 - Childhood Exposure to Violence and Pregnancy-to-Postpartum Viral Load of US Women With HIV
Deborah Kacanek
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
993 - Rapid Return of Viral Load (VL) Results to Pregnant/Postpartum Women via Mentor Mothers in Kenya
Pam Murnane
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
994 - Evaluating and Revising an Adapted Scale for Antiretroviral Therapy (ART) Adherence Self-Efficacy
Lauren Sheu
University of Chicago, Chicago, IL, USA
2:30 PM2:30 PM
995 - The Impact of Care Transitions on Pregnant Youth Living With HIV in Kisumu, Kenya
Rabbia Imran
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
996 - HIV Drug Resistance Patterns Among Pregnant Women After Dolutegravir Scale-Up in Sub-Saharan Africa
Linda Stoeger
Barcelona Institute for Global Health, Barcelona, Spain
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-04) Antiretrovirals and Birth Outcomes
2:30 PM2:30 PM
1000 - Impact of TLD on Birth Outcomes in South African Women: The ORCHID Cohort
Jamie E. Meyer
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1001 - Impact of Gestational Diabetes on Pregnancy Outcomes in South African Women Living With HIV
Elton Mukonda
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1002 - Immune Markers During Pregnancy and Birth Outcomes in South African WLH
Thokozile R. Malaba
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1003 - Antiretroviral Drugs Disrupt Macrophage Function and Vascular Development
Doty B. A. Ojwach
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1004 - Antiretroviral Drugs Affect the Placental Vasculature
Micah Summerlin
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
997 - Perinatal and Infant Outcomes After Bictegravir Exposure in Pregnancy: A Canadian Surveillance Study
Jeffrey Man Hay Wong
University of British Columbia, Vancouver, Canada
2:30 PM2:30 PM
998 - Prematurity and Low Birth Weight in Children Born to Mothers Living With HIV in Spain
Talía Sainz
La Paz University Hospital, Madrid, Spain
2:30 PM2:30 PM
999 - Birth Outcomes and HIV-1 Transmission in a Contemporary HIV Pregnancy Cohort, Washington State
Jane Hitti
University of Washington, Seattle, WA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-02) Exploring the Pediatric Reservoir
2:30 PM2:30 PM
1030 - Long-Term HIV Reservoir Dynamics in Early Treated Thai Children
Marta Massanella
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
1031 - NK Cell KIR Education Is Associated With Low HIV DNA Load in Early ART-Treated Children
Nicholas G. Herbert
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1032 - Evolving Expression of Co-Inhibitory Receptors and Plasma Cytokines in Children Living With HIV
Hugo Soudeyns
Centre Hospitalier Universitaire Sainte-Justine, Montreal, Canada
2:30 PM2:30 PM
1033 - Proviral HIV-1 DNA Below Detection in Early-Treated Adolescents After Prior Treatment Interruption
Louise Kuhn
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1034 - Pediatric ART Interruptions Transiently Raise HIV DNA Without Large Changes to Long-Term Reservoirs
Daniel B. Reeves
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1035 - Children With Very Early ART and Favorable Profiles for ART-Free Viral Control Research: Thai Cohort
Rapisa Nantanee
Chulalongkorn University, Bangkok, Thailand
2:30 PM2:30 PM
1036 - Association Between HIV-Specific Antibodies and HIV Reservoir Markers in Early-Treated Children
Rapisa Nantanee
Chulalongkorn University, Bangkok, Thailand
2:30 PM2:30 PM
1037 - Baseline Viral Load Impacts Premature Aging in Infants With Perinatally Acquired HIV in EARTH Cohort
Maria Raffaella Petrara
University of Padova, Padova, Italy
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-03) Informing Cure Strategies in Children and Youth
2:30 PM2:30 PM
1038 - Negative HIV Serology in Children Treated Early Reflects a Unique Immunologic Profile
Florence Buseyne
Institut Pasteur, Paris, France
2:30 PM2:30 PM
1039 - Distinct Innate Immune-Driven TNFa Pathway Is Linked With Durable ART-Free Aviremia in Pediatric HIV
Nicholas Lim
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1040 - Germline-Targeting SOSIP Trimer Immunizations Reduced Post-Rebound SHIV Loads in Infant Macaques
Ria Goswami
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1041 - Immune Correlates of Viral Rebound During Broadly Neutralizing Antibody Treatment in Children
Melanie Lancien
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
1042 - HIV-Specific T-Cell Dynamics in Acute-Treated, Chronic-Treated, and Elite Controller People With HIV
Alicer K. Andrew
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
1043 - Transcriptomics of Proviral Latency Reversal in Reservoirs of Youth With Perinatal HIV-1
Kristen Kelly
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-04) Pharmacokinetics, Safety, and Efficacy of Antiretrovirals
2:30 PM2:30 PM
1044 - Maternal Antiretroviral Formulation Preferences for Neonates
Lario Viljoen
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1045 - Acceptability of a Dolutegravir Dispersible Tablet and a Novel Oral Film Formulation in Neonates
Lario Viljoen
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1046 - Safety and Pharmacokinetics of Long-Acting Cabotegravir and Rilpivirine in Children 20 to 40 kg
Moherndran Archary
Africa Health Research Institute, Mtubatuba, South Africa
2:30 PM2:30 PM
1047 - PK and Safety of Chronic Dolutegravir Administration in Neonates Exposed to HIV-1 (IMPAACT 2023)
Jeremiah Momper
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
1048 - Alternative Dosing of ABC/3TC Dispersible Tablets to Align With Dolutegravir Dosing in Neonates
Tim Cressey
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1049 - Week 24 Outcomes of F/TAF Plus Cobicistat-Boosted Protease Inhibitors in Children ≥2 y and ≥14 kg
Hilda A. Mujuru
University of Zimbabwe, Harare, Zimbabwe
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-01) The HIV Care and Prevention Cascades: Novel Insights
2:30 PM2:30 PM
1076 - Low Rates of HIV Pre-Exposure Prophylaxis Prescriptions Among US Youth in a Claims Database
Nicholas Venturelli
Boston Children's Hospital, Boston, MA, USA
2:30 PM2:30 PM
1077 - Oral and Injectable PrEP Use Among US Adolescents and Young Adults, 2019-2023
Laura M. Mann
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1078 - Durable Viral Suppression Using Different Definitions in a Ryan White HIV Program Clinic, 2018-2021
Kathleen A. McManus
University of Virginia, Charlottesville, VA, USA
2:30 PM2:30 PM
1079 - Characteristics of Men Who Have Sex With Men Recruited via Virtual- v In-Person Venue-Based Sampling
Danielle Lonbong Njiometio
Oak Ridge Institute for Science and Education, Atlanta, GA, USA
2:30 PM2:30 PM
1080 - Identifying Effective Recruitment Strategies to Engage Black Sexual Minority Men Living With HIV
Derek Dangerfield II
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1081 - Refining Clinical Retention Metrics to Reflect the Realities of HIV Care in North America
Peter F. Rebeiro
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
1082 - Neighborhood Resources and ARV Adherence Among Partnered US GBMSM: Mediation by Social Determinants
Loren Dobkin
University of Michigan, Ann Arbor, MI, USA
2:30 PM2:30 PM
1083 - Geographically Diverse National Survey of People With HIV on Grindr Shows High Virologic Suppression
Hannah R. Schmidt
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1084 - Viral Nonsuppression Among PWH Diagnosed at an Older Age: Implications for Secondary HIV Prevention
Lauren O'Connor
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1085 - Changes in the HIV Care Cascade and Prevalence From 2013 to 2023 in Rural Kenya and Uganda in SEARCH
Gabriel Chamie
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1086 - High Burden of Untreated HIV in Malawian Fishermen: Prospective Data From a Cluster Randomized Trial
Augustine T. Choko
Malawi Liverpool Wellcome Trust, Blantyre, Malawi
2:30 PM2:30 PM
1087 - PMTCT and KP Appropriate Services Improve HIV Viral Suppression Among Female Sex Workers: IBBSS 2023
Ikuzo Basile
Rwanda Biomedical Centre, Kigali, Rwanda
2:30 PM2:30 PM
1088 - Unique Predictors of Retention and Viral Suppression Among People With HIV in Dominican Republic
Wilfredo R. Matias
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
1089 - Higher Baseline CD4 and Treatment Initiation Among Contacts of PLHIV: Thailand, 2020-2023
Junya Danyuttapolchai
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-06) Race/Ethnicity and HIV
2:30 PM2:30 PM
1111 - Temporal Variations of Racial Disparities in HIV Incidence in the United States From 2008 to 2021
Fanghui Shi
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
1115 - Changes of Racial Disparities in Viral Suppression in People With HIV, 2013-2020
Xueying Yang
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
1116 - Effect of the Ending the HIV Epidemic (EHE) Initiative on Racial/Ethnic Disparities in HIV Incidence
Lauren Zalla
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1117 - Studying Medication Adherence for Black People Living With HIV: An Intersectional Lens
Anais Mahone
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
1118 - HIV Testing Barriers in Structurally Vulnerable Communities in St Louis: Best-Worst Scaling Survey
Noelle Le Tourneau
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
1120 - Racial/Ethnic and Regional Disparities in HIV Testing Before, During, and After COVID-19 in the US
Rena C. Patel
University of Alabama, Tuscaloosa, AL, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-07) Incident HIV Infection
2:30 PM2:30 PM
1121 - Estimated HIV Incidence in 15-24-Year-Olds Across 2 Population HIV Impact Assessments (PHIA)
Elaine Abrams
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1122 - HIV Incidence and Viral Suppression Among Ugandan Males With Female Bar and Sex Worker Partners
Xinyi (Cindy) Feng
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1123 - HIV Incidence Among Adults With Multiple Sex Partners in Kisumu County, Western Kenya
John Owuoth
Walter Reed Project–Kisumu, Kisumu, Kenya
2:30 PM2:30 PM
1124 - Contact Investigation of Incident HIV in a Population Cohort: Implications for Case Finding and PrEP
Robert Ssekubugu
Rakai Health Sciences Program, Kalisizo, Uganda
2:30 PM2:30 PM
1125 - Uncovering Risk for Recent HIV Infections in 9 Provinces: Thailand, 2023-2024
Theerawit Tasaneeyapan
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1126 - Recent HIV Infection Among Youth in Thailand: Who Is at Risk?
Suvimon Tanpradech
US Centers for Disease Control and Prevention Nonthaburi, Nonthaburi, Thailand
2:30 PM2:30 PM
1127 - New HIV-1 Diagnoses Among Different Generations of MSM in the Netherlands: Focus on Gen-Z
Annemarie M. J. Wensing
University Medical Center Utrecht, Utrecht, Netherlands
2:30 PM2:30 PM
1128 - Development of an HIV Risk Prediction Model Using Electronic Health Record Data in Spain
Arkaitz Imaz
Bellvitge University Hospital, Barcelona, Spain
2:30 PM2:30 PM
1129 - Trend in the Proportion of Recent HIV Infections by Risk, Age, and Region in Armenia (2018-2022)
Tamara Hovsepyan
National Center for Infection Diseases, Yerevan, Armenia
2:30 PM2:30 PM
1130 - Examining PopART Intervention Impact on HIV in the General Populations of Zambia and South Africa
Bonnie Shook-Sa
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-08) Advanced HIV
2:30 PM2:30 PM
1131 - Addressing Advanced HIV Disease: Insights on CD4 Testing and AHD Prevalence at PEPFAR Sites
Gabriel Saemisch
United States Agency for International Development, Washington, DC, USA
2:30 PM2:30 PM
1132 - Trends in Advanced HIV Disease Prevalence in 5 African Countries: An Analysis of Household Surveys
Mateo Prochazka
World Health Organization, Geneva, Switzerland
2:30 PM2:30 PM
1133 - Advanced HIV Disease in Individuals Already in Care: Incidence and Comparison With Late Presentation
Andrea Antinori
National Institute for Infectious Diseases L Spallanzani, Rome, Italy
2:30 PM2:30 PM
1134 - The Effect of Treat-All on People With Advanced HIV Disease in Lesotho
Shanyah L. Mitchell
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1135 - Burden of AIDS-Defining Conditions Among Adults With Perinatal HIV in North America, 2000-2022
Nel Jason Haw
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1136 - C-Reactive Protein as a Predictor of Hospitalization and Mortality in Advanced HIV Disease in Uganda
Elizabeth L. Schwartz
University of Minnesota, Minneapolis, MN, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-09) Sexual Partner, Sexual Risk
2:30 PM2:30 PM
1137 - Vaginal and Anal Intercourse With Women Reported by Men Who Have Sex With Men, 2015-2019
Karen W. Hoover
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1139 - Geospatial Heterogeneity in Potential HIV Transmission Locations Among MSM in Bhopal, India
Griffin J. Bell
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1140 - Age-Stratified Sexual Partner Profiles to Characterize HIV Risk Across Lifespan: Botswana and Zambia
Kristen A. Stafford
University of Maryland, Baltimore, MD, USA
2:30 PM2:30 PM
1141 - Couples-Based Homophily in HIV Testing and Treatment Engagement: A Multicountry Analysis
Kathryn Risher
Pennsylvania State University, Hershey, PA, USA
2:30 PM2:30 PM
1142 - HIV Prevalence in Intersecting Subgroups of Southern African Women: Insights From PHIA
Craig J. Heck
Columbia University Irving Medical Center, New York, NY, USA
2:30 PM2:30 PM
1143 - Utilization of Assisted Partner Notification Services and Outcomes: A Population-Based Study
Nakawooya Hadijja
Rakai Health Sciences Program, Kalisizo, Uganda
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-02) Improving HIV Testing in Clinical Settings
2:30 PM2:30 PM
1183 - Effectiveness of Clinical Decision Support in Improving HIV Screening in Pediatric Primary Care
Sarah Wood
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
1184 - Impact of a New Opt-In Targeted Strategy for HIV Testing in Emergency Departments
Jose Guardiola
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
2:30 PM2:30 PM
1185 - Validation of a National HIV Testing Eligibility Screening Tool in Tanzania
Galal N. King'ori
2:30 PM2:30 PM
1186 - Transfusion Risk of HIV, HBV, and HCV in Low- and Middle-Income Countries Without Nucleic Acid Testing
Jodie L. White
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1187 - Clinical Features Are Poor Identifiers of Advanced HIV Disease in the Absence of CD4 Quantification
Phoebe Allebone-Salt
St George's University of London, London, UK
2:30 PM2:30 PM
1188 - HIV Recent Infection Surveillance Adds 17 Minutes to HIV Testing Services per Patient With HIV
Suzue Saito
ICAP at Columbia University, New York, NY, USA
2:30 PM2:30 PM
1189 - Missed Opportunities: HIV Screening Deficits in Japanese Syphilis Patients
Toshibumi Taniguchi
Chiba University, Chiba, Japan
2:30 PM2:30 PM
1190 - Machine Learning Risk Stratification Compared With a Counselor-Guided Screening Tool
Daniel G. Wandina
Gold Star Kenya, Karuri, Kenya
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-03) Biomarkers and Technology to Support PrEP Use
2:30 PM2:30 PM
1211 - Self-Reported PrEP Use Is Associated With Short- and Long-Term Pharmacologic Metrics in Kenyan Women
Jennifer Velloza
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1212 - Point-of-Care Urine Tenofovir Feedback Counseling Improves PrEP Adherence for US MSM in Pilot RCT
Matthew A. Spinelli
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1213 - Oral Fluid Concentrations of Tenofovir and Emtricitabine for Antiretroviral Adherence Monitoring
Xin Niu
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1214 - Are Sex-Specific Cutoffs Needed With a Next-Gen Urine Tenofovir Assay for Adherence Monitoring?
Xin Niu
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1215 - Technology-Based Oral Daily Pre-Exposure Prophylaxis Intervention for Online Population in India
Jalpa Thakker
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-04) Barriers to Uptake and Persistence With Biomedical Prevention
2:30 PM2:30 PM
1216 - Suboptimal Laboratory Testing of PrEP Users: United States, 2022-2023
Karen W. Hoover
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1217 - Factors Associated With PrEP Uptake, Persistence, and Adherence Among Incarcerated People in Zambia
Brianna R. Lindsay-Renninger
University of Maryland, Baltimore, MD, USA
2:30 PM2:30 PM
1218 - Trends in 2016 CDC-Recommended PEP Regimens and Bictegravir for HIV PEP: United States, 2015-2023
Ya-Lin A. Huang
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1219 - Impact of Initiation Delay, Duration, and Prior PrEP Usage on FTC/TDF-Containing PEP Efficacy
Lanxin Zhang
Robert Koch Institute, Berlin, Germany
2:30 PM2:30 PM
1220 - Impact of the Anti-Homosexuality Act 2024 on HIV Prevention Efforts and PrEP Uptake Among Young MSM
Cecilia Birungi
Makerere University, Kampala, Uganda
2:30 PM2:30 PM
1221 - Cost-Effectiveness of Different Risk-Group Targeting Across 3 Types of PrEP in Zimbabwe
Yao-Rui Yeo
New York University Langone Medical Center, New York, NY, USA
2:30 PM2:30 PM
1222 - Leveraging Community to Provide PrEP to Key Population in China: Results From a PrEP Clinical Trial
Weiming Tang
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1223 - Longer Distances Traveled by Rural vs Urban PrEP Users for PrEP Care: United States, 2023
Weiming Zhu
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1224 - Pre-Exposure Prophylaxis Uptake in High Female-to-Male HIV Prevalence Regions in the US
Ashvini Vaidya
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1225 - Self-Reported Frequent vs Infrequent HIV Risk and Actual Diagnoses in MSM: Implications for PrEP
Nicolas Salvadori
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1226 - The Influence of Racialized Economic Segregation on Unmet HIV Prevention Needs in the Real World
Li Tao
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1227 - The County-Level Analysis of PrEP-to-Need Ratio With HIV Diagnosis in the US, 2012-2021
Xueying Yang
University of South Carolina, Columbia, SC, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-05) PrEP Implementation: Hopes, Dreams, and Aspirations
2:30 PM2:30 PM
1228 - Diagnosis, Resistance, and ART Outcomes After HIV Acquisition on CAB-LA PrEP in Routine Care in US
Catherine A. Koss
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1229 - The Cost-Effectiveness and Optimal Price Level of Injectable PrEP With Lenacapavir in South Africa
Gesine Meyer-Rath
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1230 - PURPOSE 1: Preference for Twice-Yearly Injection vs Daily Oral Pills for HIV PrEP in Cisgender Women
Leila E. Mansoor
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
1231 - Characteristics of Persons Diagnosed With HIV in a Population-Based PrEP Program in British Columbia
Raquel M. Espinoza
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-03) Understanding HPV
2:30 PM2:30 PM
1261 - Probability of Anal Human Papillomavirus Infection Following Acute HIV Acquisition in Thailand
Supanat Thitipatarakorn
Institute of HIV Research and Innovation, Bangkok, Thailand
2:30 PM2:30 PM
1262 - Incidence and Clearance of Anal Human Papillomavirus Infection in an Acute HIV Cohort in Thailand
Supanat Thitipatarakorn
Institute of HIV Research and Innovation, Bangkok, Thailand
2:30 PM2:30 PM
1263 - HPV Clearance After Immunization: Investigating Risk Factors Associated With Clearance at Anal Site
Elena Bruzzesi
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
1264 - Sustained HIV Viral Suppression as a Predictor of High-Risk Human Papillomavirus Infection
Douglas Gaitho
Academic Model Providing Access to Healthcare, Eldoret, Kenya
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-04) Global STI Epidemiology
2:30 PM2:30 PM
1265 - Diagnostic Screening and Treatment of Curable STIs in Pregnancy and Impact on Pregnancy Outcomes
Dorothy C. Nyemba
University of Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1266 - High Incidence of Curable Sexually Transmitted Infections in HPTN 084: A Tertiary Analysis
Harriet Nuwagaba-Biribonwoha
ICAP at Columbia University, New York, NY, USA
2:30 PM2:30 PM
1267 - Geospatial Trends of Sexually Transmitted Infections in South Carolina (SC), 2008-2020
Syeda Shehirbano Akhtar
University of South Carolina at Columbia, Columbia, SC, USA
2:30 PM2:30 PM
1268 - Depressive Symptoms on the Incidence of Sexually Transmitted Infections Among Reproductive-Age Women
Paul N. Zivich III
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1269 - High STI Prevalence and Low Past PrEP Use Among Women Who Engage in Sex Work in Southwestern Uganda
Catherine A. Koss
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1270 - Sexually Transmitted Infection Prevalence Among Adolescents and Adults in Western Kenya
Julius L. Tonzel
US Military HIV Research Program, Bethesda, MD, USA
2:30 PM2:30 PM
1271 - Asymptomatic Sexually Transmitted Infections in a Population of High-Risk Men Who Have Sex With Men
Pierluigi Francesco Salvo
Universita Cattolica del Sacro Cuore, Milan, Italy
2:30 PM2:30 PM
1272 - Epidemiology of Bacterial STIs in MSM With or At Risk of HIV in the Region of Madrid (2021-2023)
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
2:30 PM2:30 PM
1273 - Identification of Clinical Phenotypes in MSM With HIV From a Prospective Study on Acute HCV and STIs
Juan Berenguer
Hospital General Universitario Gregorio Marañón, Madrid, Spain
2:30 PM2:30 PM
1274 - Prevalence and Incidence of HIV/STIs Among MSM and Men Who Have Sex With Women in the SAMURAI Study
Elizabeth (Liz) Montgomery
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-04) Machine Learning and mHealth
2:30 PM2:30 PM
1305 - Comparing 2 mHealth Technologies to Support PrEP Use Among MSM and Transgender People in the US
Albert Y. Liu
San Francisco Department of Public Health, San Francisco, CA, USA
2:30 PM2:30 PM
1306 - Characteristics of Dapivirine Ring Users in the SEARCH Dynamic Choice HIV Prevention Studies
Elijah Kakande
Infectious Diseases Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1307 - Machine Learning to Predict Persons With HIV at Risk of Falling Out of Care
Thomas Martin
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
1308 - An AI-Powered Preventive Intervention for Stigma and Suicidal Ideation in HIV Self-Management
Diego S. Villanueva Guzman
Research Institute of McGill University Health Centre, Montreal, Canada
2:30 PM2:30 PM
1309 - Developing Machine Learning Algorithms to Predict Treatment Interruptions in HIV Care in Uganda
Alex Mirugwe
Makerere University–University of California San Francisco Research Collaboration, Kampala, Uganda
2:30 PM2:30 PM
1310 - Exposure and Engagement Drive Impact: Results From a Digital Health Trial With Rwandan Adolescents
Rebecca Hemono
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
1311 - Digital Strategy to Improve PrEP Adherence Among MSM: A Stepped-Wedge Randomized Trial in China
Chunyan Li
University of Tokyo, Tokyo, Japan
2:30 PM2:30 PM
1312 - Impact Analysis and Machine Learning Forecasts of HIV Viral Load Suppression in 21 African Countries
Amobi A. Onovo
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
1313 - Enhanced Language Models for Predicting and Understanding HIV Care Disengagement
Junzhe Shao
University of California Berkeley, Berkeley, CA, USA
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-05) Novel Interventions
2:30 PM2:30 PM
1314 - Hair Salons as a Promising Space to Offer HIV Prevention Services for Young Women in Lesotho
Mamaswatsi Kopeka
George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1315 - Capacity for PrEP Implementation at Pharmacies in Baltimore and San Diego: A Mixed-Methods Study
Lipin Lukose
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1316 - Evaluating Spatially Targeted HIV and Harm Reduction Strategies Among People Who Inject Drugs
Jasmine Wang
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1317 - Traditional Healers: A Nontraditional Gateway to Engagement in HIV Care in Rural Uganda
Radhika Sundararajan
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1318 - Home CAB/RPV Provides Novel Approach to Achieve Viral Suppression in PWH With Adherence Challenges
Megan E. Dieterich
Whitman-Walker Health, Washington, DC, USA
2:30 PM2:30 PM
1319 - Uptake of Online HIV PrEP and PEP in Kenya After Removal of Subsidies: A Pilot Extension Study
Daniel K. Were
Jhpiego - Nairobi, Nairobi, Kenya
2:30 PM2:30 PM
1320 - Community-Based Versus Facility-Based Services to Improve HIV Care in the Gold Mining Zones of Mali
Luis Sagaon Teyssier
Aix-Marseille Université, Marseille, France
2:30 PM2:30 PM
1321 - Community FSW Peer Model or HIV Prevention to Reach Epidemic Control and Sustainability: Tanzania
Neema Makyao
Amref Health Africa in Tanzania, Dar es Salaam, United Republic of Tanzania
2:30 PM2:30 PM
1322 - Trial of Enhanced Peer Referral With HIV Self-Testing on PrEP Initiation Among Young Kenyan Women
Katrina Ortblad
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
1323 - nPEP When You Need It: A 24/7 Post-Exposure Prophylaxis Hotline in the District of Columbia
Rachel Harold
District of Columbia Department of Health, Washington, DC, USA
2:30 PM2:30 PM
1324 - HIV Health Care Transition: Five-Year Rates of Retention and Viral Suppression
Camille Knable
University of Maryland Medical Center, Baltimore, MD, USA
2:30 PM2:30 PM
1325 - Impact of Differentiated HIV Service Delivery Models on Quality of Life in Uganda
Benson Nasasira
Infectious Diseases Institute, Kampala, Uganda
MAR11
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-06) Treatment Continuity
2:30 PM2:30 PM
1326 - Trends in HIV Viral Nonsuppression and Drug Resistance Among PWID on Dolutegravir ART in Kenya
Loice W. Mbogo
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
1327 - Heterogeneity of Disengagement From Antiretroviral Care Matters for Treatment Success
Claire M. Keene
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1328 - Patterns of Engagement After Restarting Antiretroviral Treatment in South Africa
Claire M. Keene
University of Oxford, Oxford, UK
2:30 PM2:30 PM
1329 - Reasons for Discontinuation of Cabotegravir Long-Acting (CAB-LA) Among Clients in Zambia
Damian J. Phiri
John Snow, Inc, Lusaka, Zambia
2:30 PM2:30 PM
1330 - Detection and Linkage of PLWH Who Are Out of Care in 94 Emergency Departments Across the US
Jamie L. Mignano
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1331 - HIV Treatment Interruptions: A Lorenz Curve Analysis of Countries Achieving the 95-95-95 Targets
Rituparna Pati
PEPFAR, Washington, DC, USA
2:30 PM2:30 PM
1332 - Point-of-Care Urine Self-Testing Feasibility to Measure TFV Adherence and Predict Viral Suppression
Renata Buccheri
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
1333 - Effect of COVID-19 Pandemic on ART Access and Timely Initiation in Adults With HIV in 31 Countries
Ben Farhat Jihane
Epicentre, Paris, France
2:30 PM2:30 PM
1334 - HIV Treatment Continuity in Haiti: Lorenz Curve Analysis of IIT, 2022-2024
Michael J. A. Reid
PEPFAR, Washington, DC, USA
2:30 PM2:30 PM
1335 - Clinical and HIV Surveillance Data to Determine Care Status for People With HIV in Washington, DC
Shannon Hammerlund
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1336 - Does Retention in Care Still Correlate With HIV Viral Suppression: Do We Need Different Strategies?
Joshua Craft
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1337 - Uptake of Injectable Cabotegravir/Rilpivirine for Treatment of HIV Infection in US, 2021-2023
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1338 - Comparative Yield of Data Sources for Health Department Data to Care Services
Julie Dombrowski
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1339 - Developing Analytic Strategies to Investigate Long-Acting Injectable Antiretroviral Effectiveness
Sarah E. Rutstein
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1340 - Prevalence of Unsuppressed Viral Load: Comparison of 2016-17 and 2022-23 Tanzania HIV Impact Surveys
Abbas Ismail
US Centers for Disease Control and Prevention Dar es Salaam, Dar es Salaam, Tanzania
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(A-05) Antiviral Inhibition of Viral Replication and Evasion by HIV-1
2:30 PM2:30 PM
323 - Host Gene SLC35A2 Restricts CXCR4-Tropic HIV-1 Replication at the Stage of Viral Fusion
Jamie Guenthoer
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
324 - Novel Strategy to Inhibit HIV by Targeting Integrase/INI1 Interaction Based on the TAR RNA Mimicry
Swati Haldar
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
325 - Novel Functions of TRIM21: Post-Translational Regulation of Cytoplasmic Antiretroviral APOBEC3s
Aubrey M. Sawyer
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
326 - The Effects of Accessory Genes on T/F HIV Infection of Primary CD4+ T Cells From Tissues
Harnoor Virk
Gladstone Institutes, San Francisco, CA, USA
2:30 PM2:30 PM
327 - RhoA Restricts HIV-1 by Modulating IFN Signaling and Is Counteracted by Vpr
Caterina Prelli Bozzo
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
328 - The Role of Capsid-Host Interaction on Lentiviral Evolution
Clare Gill
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
329 - Capsid Mutant HIV-CRISPR Screens Reveal Mechanisms of TRIM5 Restriction
Isaiah Grant
University of California Berkeley, Berkeley, CA, USA
2:30 PM2:30 PM
330 - A Virus-Packageable CRISPR Screen to Uncover Genes Underlying SIVcpz Replication in Human Cells
Michael Young
University of California Berkeley, Berkeley, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-05) HIV and Inflammation
2:30 PM2:30 PM
378 - HIV Drives CARD8 Inflammasome Activation and Proinflammatory Cytokine Release by Myeloid Cells
Marilia R. Pinzone
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
379 - Genome-Wide Association of NLRP3 Inflammasome Plasma Cytokines in Virally Suppressed People With HIV
Sonia Savur
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
380 - Extracellular Vesicles From the Cells Harboring HIV Defective Provirus Initiate Inflammatory Cascade
Hongyan Sui
Frederick National Laboratory for Cancer Research, Frederick, MD, USA
2:30 PM2:30 PM
381 - Extracellular Vesicles’ miRNAs Correlate With Inflammatory Markers in Tanzanians With HIV
Mussa H. Bago
Kumamoto University, Kumamoto, Japan
2:30 PM2:30 PM
382 - Proinflammatory Markers in Persons Living With HIV, HCV, and/or Drug Use
Jason T. Blackard
University of Cincinnati Medical Center, Cincinnati, OH, USA
2:30 PM2:30 PM
383 - The Systemic Inflammatory Profile Differs According to the Mechanism of HIV Control
Jose M. Benito
Instituto de Investigación Sanitaria Fundación Jiménez Díaz, Madrid, Spain
2:30 PM2:30 PM
384 - Host Transcriptional Signatures Associated With Distinct Inflammatory Bioprofiles in People With HIV
Dana Alalwan
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
385 - Intestinal CD4:CD8 Ratio and Systemic Inflammatory Parameters in Suppressed HIV-1 Infection
Francesca Cossarini
Icahn School of Medicine at Mount Sinai, New York, NY, USA
2:30 PM2:30 PM
386 - Living With HIV Mimics the Proinflammatory FUT2 Non-Secretor Phenotype in the Intestines
Leila B. Giron
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
387 - Ultra-Low Level Soluble p24 Is Associated With Inflammation in People With HIV on Suppressive ART
Matteo Augello
University of Milan, Milan, Italy
2:30 PM2:30 PM
388 - Inflammatory and Microbial Signatures Linked to Cardiovascular Outcomes in People With/Without HIV
Rachel MacCann
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
389 - Methamphetamine Use Disorder in ART PWH Is Associated With Elevated NLRP3 Inflammasome Activation
Felipe Ten-Caten
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
390 - Understanding NLRP3 Inflammasome Activation at the Intersection of HIV and Aging
Heidi Zapata
Yale University, New Haven, CT, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(B-06) Animal Models of Infection
2:30 PM2:30 PM
391 - Ex Vivo Isolation and Characterization of Live, Envelope Expressing, SHIV-Infected CD4 T Cells
Joseph P. Casazza
Vaccine Research Center, Bethesda, MD, USA
2:30 PM2:30 PM
392 - Lobule Zone-Dependent Accumulation of Vd1 and Vd2 gd-T Cells in the Livers of SIV+ Infant Macaques
Nina Derby
Seattle Children's Research Institute, Seattle, WA, USA
2:30 PM2:30 PM
393 - IL-15, Type I Interferon, Fatty and Amino Acid Pathways Link to SIV Reservoir and Rebound in Infants
Tehillah Chinunga
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
394 - Immunometabolic Reprogramming by Caloric Restriction Leads to Protection From SIV in Rhesus Macaques
Naveen Suresh Babu
Tulane University, Metairie, LA, USA
2:30 PM2:30 PM
395 - A New Mouse Model of HIV in Pregnancy: The EcoHIV Pregnancy Model
Michelle M. Ranjbar
University of Toronto, Toronto, Canada
2:30 PM2:30 PM
396 - Clinical and Immune Characteristics of ART+SIV/P. fragile Infected Macaques With Persistent Viremia
Sydney Nemphos
Tulane National Primate Research Center, Covington, LA, USA
2:30 PM2:30 PM
397 - Analysis of SIV Envelope Diversity During Untreated Infection
Haoyue Li
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
398 - STLV-1 in Chlorocebus aethiops as a Model for New Approaches to Human Retrovirus Research
Víctor Â. Folgosi
Universidade de São Paulo, São Paulo, Brazil
2:30 PM2:30 PM
399 - Western Diet Boosts Immune Activation and Inflammation in SIV-Infected Macaques on Antiretrovirals
Briana Thompson
University of Pittsburgh, Pittsburgh, PA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-08) Coordinated Immune Responses and Viral Control
2:30 PM2:30 PM
464 - Distinct Signatures of Trained Immunity Reveal Heterogeneity Among Elite HIV Controllers
Joao Lucas Lima Calandrini de Azevedo
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
465 - Lymph Node Dendritic Cells Harbor an Altered Transcriptomic Profile Despite Years of Suppressive ART
Riddhima Banga
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
2:30 PM2:30 PM
466 - Mapping the Spatial Landscape of Lymph Nodes With Undetectable Versus Active HIV Replication
Candace Liu
Stanford University, Stanford, CA, USA
2:30 PM2:30 PM
467 - Longitudinal Phenotypic and Transcriptional Profiling of Immune Cells in Early-Treated Acute HIV
Jozefien De Clercq
HIV Cure Research Center, Ghent University, Ghent, Belgium
2:30 PM2:30 PM
468 - Markers of Immunologic Control for Future Identification of HIV Post-Treatment Controllers
Elena Bruzzesi
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
469 - Impaired Antigen Presentation and TGFβ Signaling Fosters Th17 Differentiation in PLWH Under ART
Valentino D'Onofrio
Ghent University, Ghent, Belgium
2:30 PM2:30 PM
470 - Females With HIV Favor Interferon Responses Over Inflammation Upon TLR7 Activation
Alisa Huber
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
471 - CITE-Seq and Single Cell αβ TCRseq Unravels HIV-1 Specific GZMB Subset in Post-Treatment Controllers
Giacomo Schmidt Frattari
Aarhus University, Aarhus, Denmark
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(C-09) Immunity to SARS-CoV-2 and Other Viruses
2:30 PM2:30 PM
472 - Diminished Immune Imprinting at the Upper Respiratory Tract Following SARS-CoV-2 Breakthrough Infection
Xuan He
West China Hospital of Sichuan University, Chengdu, China
2:30 PM2:30 PM
473 - Spike Ferritin Nanoparticle (SpFN) Recalls Memory B Cells in SARS-CoV-2-Experienced Donors
Lauren Smith
Henry M Jackson Foundation, Bethesda, MD, USA
2:30 PM2:30 PM
474 - Optimized ACE2-Fc With Picomolar Pan-Neutralization of SARS-CoV-2 Variants, Including JN.1 and KP.2
Ferran Abancó i Espuga
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
475 - Long COVID Is Associated With Lower Percentages of Mature, Cytotoxic NK-Cell Phenotypes
Tasha Tsao
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
476 - The XBB.1.5 mRNA Booster Vaccine Does Not Significantly Increase XBB.1.5 Mono-Reactive T Cells
Joel Sop
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
477 - Evaluation of Salivary Antibody in Protection From SARS-CoV-2 Infection
Sharon Walmsley
University Health Network, Toronto, Canada
2:30 PM2:30 PM
478 - Evaluation of the PHH-1V COVID-19 Vaccine-Induced T-Cell Responses in Adolescents: HIPRA-HH-3 Study
Ignasi Esteban
Hospital Clinic of Barcelona, Barcelona, Spain
2:30 PM2:30 PM
479 - T-Cell Immunity of PHH-1V COVID-19 Vaccine in PWH and Adults With Immunosuppressive Conditions
Raúl Pérez-Caballero
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
480 - Torque Teno Virus: A Predictive Biomarker for SARS-CoV-2 Vaccine Response in Immunosuppressed People
Gonzalo Cabrerizo
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
2:30 PM2:30 PM
481 - Limited Effectiveness of High-Dose Flu Vaccine in Augmenting Immunity in Older People With HIV
Jonah Kupritz
University of Miami Miller, Miami, FL, USA
2:30 PM2:30 PM
482 - Herpes Zoster Reactivation in a Cohort of People Living With HIV Vaccinated With Recombinant Vaccine
Stefania Arsuffi
University of Brescia, Brescia, Italy
2:30 PM2:30 PM
483 - Persistence of Seroprotection After Modified Hepatitis B Vaccine Schedule in People Living With HIV
Caroline Troccoli
Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-08) HIV Reservoir Landscape and Dynamics
2:30 PM2:30 PM
558 - Longitudinal Analysis of HIV Reservoir Dynamics Using Q4ddPCR in Individuals Who Are ART-Treated
Rachel K. Scheck
Charité – Universitätsmedizin Berlin, Berlin, Germany
2:30 PM2:30 PM
559 - Paucity of HIV Envelope Expressing Cells Upon Latency Reversal in ART-Suppressed PWH
Jonathan Richard
Centre de Recherche du CHUM, Montreal, Canada
2:30 PM2:30 PM
560 - Early ART Initiation Is Associated With Faster Decay of the Transcriptionally Active HIV Reservoir
Cordelia M. Isbell
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
561 - In-Depth Evaluation of the Intact Proviral DNA Assay for the Quantification of HIV-1 Reservoir
Frank Maldarelli
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
562 - Deciphering the HIV-2 Proviral Reservoir in Antiretroviral-Naive Individuals
Charlotte Charpentier
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
563 - CCR5 Expression Is Critical for the Maintenance of HIV Control and Reservoir Size
Jéssica dos Santos
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
564 - Ex Vivo Antigen Stimulation Induces HIV-1 Viral Outgrowth From a Pericentromeric Provirus
Angelica Camilo-Contreras
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
565 - Multiomics Clustering Reveals Distinct HIV Reservoir Profiles in the 2000HIV Cohort
Victoria Rios Vazquez
Radboud University Medical Center, Nijmegen, Netherlands
2:30 PM2:30 PM
566 - Sex-Specific Immune Responses Shape Proviral Landscapes in Individuals on Long-Term Suppressive ART
Toong Seng Tan
Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
2:30 PM2:30 PM
567 - Female Sex Is Associated With Continuous Decline in Intact HIV-1 Proviruses
Yijia Li
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
568 - A Virology Quality Assurance Program to Assess Inter-Lab Reproducibility of HIV-1 Reservoir Assays
Maria Blasi
Duke University School of Medicine, Durham, NC, USA
2:30 PM2:30 PM
569 - The Cross Subtype Intact Proviral DNA Assay Detects 97% of Proviruses From Diverse HIV Clades
Dara A. Lehman
Fred Hutchinson Cancer Center, Seattle, WA, USA
2:30 PM2:30 PM
570 - Impact of Early ART Initiation With BIC/FTC/TAF on HIV-1 Reservoir Decay During Primary Infection
Sònia Vicens-Artés
August Pi i Sunyer Biomedical Research Institute, Barcelona, Spain
2:30 PM2:30 PM
571 - Rapid Clearance of the Inducible HIV-1 Reservoir After Initiation of Antiretroviral Therapy
Maria C. Puertas
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
572 - HIV Proviral Populations Differ by Sex and Immune Activation Levels During Antiretroviral Therapy
Chuen-Yen Lau
National Institutes of Health, Bethesda, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-09) Molecular Mechanisms of HIV Persistence and Latency
2:30 PM2:30 PM
573 - BACH2 Controls Seeding and Establishment of Long-Lived HIV-1 Reservoir in Memory CD4+ T Cells
Hongbo Gao
Washington University in St Louis, St Louis, MO, USA
2:30 PM2:30 PM
574 - Blockade of HIV Latency Reversal in CD4+ T Cells From ART-Suppressed PLWH by the Antisense RNA AST
Rui Li
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
575 - HIV Reactivation Potential Evaluated by RNA-Seq and DNA Methylation Following LRA Stimulation
Giuseppe Rubens Pascucci
Bambino Gesu Children's Hospital, Rome, Italy
2:30 PM2:30 PM
576 - Activation of Latent HIV-1 by Retinol Binding Protein 4
Chiara Pastorio
Ulm University Medical Center, Ulm, Germany
2:30 PM2:30 PM
577 - Zaprinast Reprogrammes Resting CD4+ T-Cell Metabolism and Induces HIV Latency Reversal Ex Vivo
Valentin de Masson d'Autume
University College Dublin, Dublin, Ireland
2:30 PM2:30 PM
578 - Anti-HIV Gene Editing Is Inhibited in Active HIV Provirus Through Long-Terminal Repeat Demethylation
Mohamed Bouzidi
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
579 - Macrophage Training Reactivates Latent HIV-1 From HAART-Suppressed PBMCs of PLWH
Sinu P. John
National Institutes of Health, Bethesda, MD, USA
2:30 PM2:30 PM
580 - Interference of HIV Integration via Changes in CPSF6 and SC35 Expression Due to TKIs in Macrophages
Clara Sánchez Menéndez
Instituto de Salud Carlos III, Madrid, Spain
2:30 PM2:30 PM
581 - Thymosin α1 Enhances IL-15 Pathway Between MoDCs and CD8+ T Cells and Restrains HIV Latency In Vitro
Chaoyu Chen
Fudan University, Shanghai, China
2:30 PM2:30 PM
581.5 - Cyclic Adenosine 3',5'-Monophosphate Agonist Prevents Establishment and Reversal of HIV Latency
Prerna Dabral
Vitalant Research Institute, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(D-10) HIV Reservoirs in Tissues
2:30 PM2:30 PM
582 - Predominance of Non-T Follicular Helper Cell Subsets in the Lymph Node Viral Reservoir During ART
Vincent H. Wu
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
583 - Lymph Node Immune Landscape Reveals the Role of Innate Immunity on HIV Reservoir in ART-PLWH
Susan P. Ribeiro
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
584 - Depletion of CX3CR1+ Effector CD8 TRM Cells Is Associated With HIV-1 Reservoir in the Colon on ART
Nived Collercandy
Toulouse University Hospital, Toulouse, France
2:30 PM2:30 PM
585 - HIV Reservoir in Jejunum Exhibits Distinct Phenotypic Features and Evokes Innate Cell Redistribution
Marta Calvet-Mirabent
Gladstone Institute, San Francisco, CA, USA
2:30 PM2:30 PM
586 - Single Cell Characterization of the Gastrointestinal HIV Reservoir
Nancie Archin
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
587 - HIV Transcriptional Regulation in the CNS of ART-Suppressed People With HIV
Janna Jamal Eddine
RMIT University, Melbourne, Australia
2:30 PM2:30 PM
588 - Association of CSF Viral Compartmentalization and Macrophage Tropism With Neurosymptomatic HIV
Laura P. Kincer
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-06) CNS HIV Reservoirs
2:30 PM2:30 PM
627 - HIV Transcripts in Blood May Identify Patients at Lower Risk of Brain Injury in Cure Research
Kazuo Suzuki
St Vincent's Centre for Applied Medical Research, Darlinghurst, Australia
2:30 PM2:30 PM
628 - Unmasking the Independent Role of CSF HIV RNA Dynamics by Single Copy Assay in Neurobiotypes
Lucette A. Cysique
University of New South Wales Sydney, Sydney, Australia
2:30 PM2:30 PM
629 - Adenosine, Guardian of the Brain: Possible Role in Protecting From HIV Neuropathogenesis
Yoelvis Garcia-Mesa
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
630 - Neuroinflammation Associated With Levels of HIV DNA in the Frontal Cortex of Virally Suppressed PWH
Thomas Angelovich
RMIT University, Melbourne, Australia
2:30 PM2:30 PM
631 - HIV-Infected Microglia Drive Transcriptional and Metabolic Changes in Complex Human Brain Organoids
Leanne C. Helgers
Academic Medical Center, Amsterdam, Netherlands
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(E-07) Aging and NeuroHIV: Understanding Pathogenesis and Trajectories
2:30 PM2:30 PM
633 - Plasma Neopterin as a Potential Biomarker for Neurocognitive Impairment in Aging People With HIV
Marta Ruiz-Riol
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
634 - A Blip or a Trend? Interpreting Fluctuations in Cognition Over Time in Older Adults With HIV
Marie-Josée Brouillette
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
635 - Obstructive Sleep Apnea Contributes to Cognitive Difficulties Among Older Adults With HIV
Marie-Josée Brouillette
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
636 - Association of Delayed HIV Diagnosis or ART Initiation With Risk of Age-Associated Dementia
Jennifer O. Lam
Kaiser Permanente Northern California, Oakland, CA, USA
2:30 PM2:30 PM
637 - Incidence and Risk Factors for Neurocognitive Disorders Among Persons With HIV in Washington, DC
Shannon K. Barth
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
638 - Systemic Immune-Inflammation Index Links to Slower Psychomotor Speed in Older People With HIV
Crystal Wang
University of California San Diego, La Jolla, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(F-03) Pharmacokinetics in the Real World: Long-Acting Drugs, Alternative Matrices, and Adherence
2:30 PM2:30 PM
651 - Tenofovir Diphosphate in Dried Blood Spots and HIV-1 RNA Suppression Among PWH on TAF (ACT Study)
Ryan P. Coyle
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
653 - TFV-DP Is Associated With Baseline Virologic Suppression in PWH on TAF: Results From ACTG A5359
Stefanie Schwab
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
654 - Association of Trough Concentrations of Cabotegravir and Rilpivirine and HIV-1 RNA
Sebastian Noe
MVZ München am Goetheplatz, Munich, Germany
2:30 PM2:30 PM
655 - Inter- and Intraindividual Variability of LA CAB/RPV Pharmacokinetics After 1 Year of Continuous Use
Shawnalyn W. Sunagawa
University of Nebraska Medical Center, Omaha, NE, USA
2:30 PM2:30 PM
656 - Plasma Concentrations of Lenacapavir in People Living With Multidrug-Resistant HIV: Real-Life Study
Minh Le
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
657 - Intracellular Pharmacokinetics of Favipiravir-5’-Ribofuranosyl Triphosphate in People With COVID-19
Elizabeth Challenger
University of Liverpool, Liverpool, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-03) ART in Vulnerable and Treatment-Experienced Populations
2:30 PM2:30 PM
689 - Long-Term Virologic Suppression Rates in the Ward 86 HIV Clinic’s Long-Acting ART Program (SPLASH)
Monica Gandhi
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
690 - Long-Acting Injectable ART in Persons With HIV-1 Viremia in the South: A Tool to End the Epidemic
Jonathan Colasanti
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
691 - Long-Acting Injectable Versus Oral HIV Antiretroviral Therapy for People Experiencing Homelessness
Kathleen O'Connor
San Francisco Department of Public Health, San Francisco, CA, USA
2:30 PM2:30 PM
692 - A5359: Decreasing Oral Induction Duration in Support of LAI ART Use With Hardly Reached Populations
Aadia Rana
University of Alabama at Birmingham, Birmingham, AL, USA
2:30 PM2:30 PM
693 - Simplified Access and Retention Model for Vulnerable People With HIV: SIMPLIFIED Study Results
Pablo Ryan
Hospital Universitario Infanta Leonor, Madrid, Spain
2:30 PM2:30 PM
694 - Forgiveness of Dolutegravir-Based Regimens Using Medication Possession Ratio: Andhra Pradesh, India
Ramesh Allam
US Centers for Disease Control and Prevention, Delhi, India
2:30 PM2:30 PM
695 - Less Frequent Clinical and Viral Load Assessments During COVID-19 Did Not Increase Virologic Failure
Andrew Carr
St Vincent's Hospital, Sydney, Australia
2:30 PM2:30 PM
696 - Predictive Factors of Virologic Failure After Switching to B/F/TAF (ANRS-CO3-AquiVIH-NA)
Camille Tumiotto
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
697 - Achievement of Undetectable HIV RNA in the PROMISE-US Study in Subjects Viremic at Baseline
Smitha Gudipati
Henry Ford Hospital, Detroit, MI, USA
2:30 PM2:30 PM
698 - Outcomes for Persons With Triple-Class Resistant HIV and a History of Virologic Failure
Suzanne M. Ingle
University of Bristol, Bristol, UK
2:30 PM2:30 PM
699 - Characteristics and Treatment Outcomes of People With HIV Prescribed Fostemsavir in the Trio Cohort
Moti Ramgopal
Midway Immunology and Research Center, Fort Pierce, FL, USA
2:30 PM2:30 PM
700 - Effectiveness of Antiretroviral Therapy in People With and Without TB in the IeDEA Cohort
Lea Faure
University of Bordeaux, Bordeaux, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(G-05) Antiviral Therapy for SARS-CoV-2
2:30 PM2:30 PM
711 - Potent, Pan-Coronavirus Antiviral Activity of the Novel 3CLpro Inhibitor ALG-097558
Andreas Jekle
Aligos Therapeutics, San Francisco, CA, USA
2:30 PM2:30 PM
712 - Novel Class of Small Molecules Inhibits SARS-CoV-2 PLpro Through Molecular Glue-Induced Dimerization
David Hardee
AbbVie, Inc, North Chicago, IL, USA
2:30 PM2:30 PM
713 - SARS-CoV-2 Ensitrelvir Resistance-Associated Mutations in Phase III Randomized Clinical Trial
Manish C. Choudhary
Brigham and Women's Hospital, Boston, MA, USA
2:30 PM2:30 PM
714 - Patterns of Remdesivir Initiation in Immunocompromised Patients Hospitalized With COVID-19
Mark Berry
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
715 - Machine Learning Identifies Predictors of Delayed Remdesivir Use in Hospitalized COVID-19 Patients
Anne-Maud Ferreira
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
716 - Tracking Key Remdesivir Resistance Mutations in SARS-CoV-2 Using GISAID Data (2020-2024)
Toshibumi Taniguchi
Chiba University, Chiba, Japan
2:30 PM2:30 PM
717 - Nirmatrelvir/Ritonavir for Chronic COVID-19: Outcome in 16 Severely Immunocompromised Patients
Hanne Lamberink
Erasmus University Medical Center, Rotterdam, Netherlands
2:30 PM2:30 PM
718 - Synergistic Effect of NMV/r and Acquired Immunity in Reducing Severe COVID-19
Warren Bao
Pfizer Biostatistics, New York, NY, USA
2:30 PM2:30 PM
719 - Metformin on Time to Sustained Recovery in Adults With COVID-19: ACTIV-6 Randomized Clinical Trial
Carolyn Bramante
University of Minnesota, Minneapolis, MN, USA
2:30 PM2:30 PM
720 - Optimal Timing and Immunogenicity of COVID-19 Booster Vaccination: The EU-COVAT-2 BOOSTAVAC Trial
Elena Alvarez
University College Dublin, Dublin, Ireland
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-03) Clinical Impact of Drug Resistance in Trials and Cohorts
2:30 PM2:30 PM
734 - No Virologic Failure in Patients Switched to Doravirine Treatment With Past Resistance Mutations
Basma Abdi
Assistance Publique – Hôpitaux de Paris, Paris, France
2:30 PM2:30 PM
735 - HIV-1 Resistance Analysis of Treatment-Naive People With HIV and HBV Receiving B/F/TAF or DTG+F/TDF
Michelle D'Antoni
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
736 - Resistance Analysis of Weekly Islatravir Plus Lenacapavir in People With HIV at 48 Weeks
Laurie Vanderveen
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
737 - Virologic Success on InSTI-Based ART Despite Archived InSTI DRMs
Yanis Merad
Hospices Civils de Lyon, Lyon, France
2:30 PM2:30 PM
738 - Bictegravir + Lenacapavir: Baseline and Week 48 Resistance in ARTISTRY-1 Phase II
Nicolas Margot
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
739 - Real-World Robustness of B/F/TAF at Virologic Failure in the ANRS-CO3-AquiVIH-NA Cohort
Camille Tumiotto
Bordeaux University Hospital, Bordeaux, France
2:30 PM2:30 PM
740 - Shifting Paradigms: Doravirine's Potential in Treating Non-Group M HIV-1, the DORAVI-O Study
Elodie Alessandri-Gradt
University of Rouen Normandy, Normandy, France
2:30 PM2:30 PM
741 - Impact of Resistance to Antiretroviral Therapy Among Veterans With Human Immunodeficiency Virus
Mary J. Christoph
Gilead Sciences, Inc, Foster City, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(H-04) Dolutegravir Resistance
2:30 PM2:30 PM
742 - Population-Based Longitudinal Dynamics of HIV Drug Resistance During Dolutegravir Rollout in Uganda
Michael A. Martin
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
743 - Plasma DTG Exposure Test as Objective Tool to Identify People With HIV at Highest Risk of Resistance
Kim Steegen
National Health Laboratory Service, Johannesburg, South Africa
2:30 PM2:30 PM
744 - Plasma Dolutegravir Exposure as a Triaging Tool for HIV Drug Resistance Testing by ONT Sequencing
Hendrik J. Coetser
University of the Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
745 - HIV Drug Resistance by Next-Generation Sequencing After Transition to TLD in Uganda and South Africa
Suzanne McCluskey
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
746 - HIV Drug Resistance Among Individuals on Dolutegravir With Low-Level Viremia in Malawi
Newton L. Kalata
US Centers for Disease Control and Prevention Lilongwe, Lilongwe, Malawi
2:30 PM2:30 PM
747 - Predictors of HIV Drug Resistance to Dolutegravir in 4 PEPFAR-Supported Countries
Juliana D. Da Silva
Centers for Disease Control and Prevention, Atlanta, GA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(I-04) Hepatitis Epidemiology and Immunology
2:30 PM2:30 PM
778 - HeCaPred: An AI-Based Algorithm for HCC Prediction in Patients With HCV Chronic Infection After SVR
Anaïs Corma-Gómez
Hospital Universitario Virgen de Valme, Sevilla, Spain
2:30 PM2:30 PM
779 - A New Point-of-Care Ultrasound Protocol for Chronic Hepatitis B and HBV/HIV Coinfection in Zambia
Costanza Bertoni
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
780 - High Prevalence of Triple Infection (HIV/HBV/HDV) Among Key Populations With HIV in India
Sunil S. Solomon
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
782 - Simulation Modeling of Hepatitis B Virus Disease Progression, Hepatitis Flares, and Functional Cure
Amir Mohareb
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
783 - HIV/HCV Coinfection: Extracellular Vesicles Modulate NK Functionality in Relation to Liver Fibrosis
Ariel A. Osegueda
Instituto de Investigaciones Biomédicas en Retrovirus y SIDA, Buenos Aires, Argentina
2:30 PM2:30 PM
784 - In Vitro and In Vivo Immunogenicity of a Dendritic Cell-Based Vaccine Targeting HBV Epitopes
Sylvain Cardinaud
Vaccine Research Institute, Créteil, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(J-04) Cervical and Anal Cancer: Prevention and Screening
2:30 PM2:30 PM
805 - HPV Detection by Vaginal Self-Sampling and Urine Collection in Women Living With HIV: AUTOCol Study
Jade Ghosn
Hôpital Bichat-Claude-Bernard, Paris, France
2:30 PM2:30 PM
806 - The Ivorian Cervical Cancer Screening Cascade: A 10-Year Program Evaluation According to HIV Status
Simon Boni
PAC-CI Program, Abidjan, Côte d'Ivoire
2:30 PM2:30 PM
807 - 2 vs 3 Doses of HPV9-Valent Vaccine in Women With HIV: Safety & Immunogenicity From Randomized Trial
Debora R. Konopnicki
Saint-Pierre University Hospital, Brussels, Belgium
2:30 PM2:30 PM
808 - Optimizing Anal Cancer Screening in PWH: The Role of ADAR1 mRNA in Predicting High-Grade Lesions
Melissa Bello-Perez
Hospital General Universitario de Elche, Elche, Spain
2:30 PM2:30 PM
809 - Anal Cancer Incidence Among Privately Insured People With and Without HIV in South Africa
Eliane Rohner
University of Bern, Bern, Switzerland
2:30 PM2:30 PM
810 - Evaluation of Anal Cancer Screening in 18–34-Year-Old Men Who Have Sex With Men Living With HIV
Serina S. Applebaum
Yale University, New Haven, CT, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-04) CVD Risk Prediction
2:30 PM2:30 PM
828 - Genomic Analyses of Cardiovascular Risk in People With HIV From the MVP Cohort
Vincent C. Marconi
Emory University, Atlanta, GA, USA
2:30 PM2:30 PM
829 - The Additive Value of Coronary Calcium in Identifying Cardiovascular Risk in Ageing People With HIV
Maithili Varadarajan
Chelsea and Westminster Hospital, London, UK
2:30 PM2:30 PM
830 - BMI Is a Poor Surrogate for Excess Visceral Adiposity and Cardiovascular Risk in Persons With HIV
Karam Mounzer
Philadelphia FIGHT, Philadelphia, PA, USA
2:30 PM2:30 PM
831 - Investigating the Predictive Role of NLR and PLR in Cardiovascular and Neurologic Outcomes in PWH
Teresa H. Evering
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
832 - Cardiovascular Risk Assessment in Women Living With and Without HIV Using the PREVENT Model
Tetiana Povshedna
University of British Columbia, Vancouver, Canada
2:30 PM2:30 PM
833 - Prediction of Cardiovascular Risk Among PWH: Comparing the PREVENT and Pooled Cohort Equations
Matthew S. Durstenfeld
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
834 - Lipidomic, Metabolomic, and Immune Profiles Precede Cardiovascular Events in People With HIV
Joana Vitalle
Institute of Biomedicine of Sevilla, Sevilla, Spain
2:30 PM2:30 PM
835 - Patterns of Social and Biological Risk Factors in People With HIV and Risk of Cardiovascular Disease
Cynthia N. Ramirez
Kaiser Permanente Division of Research, Oakland, CA, USA
2:30 PM2:30 PM
836 - Agrarian Diet Intervention Improves Metabolic Health in Men With HIV Who Have Sex With Men
John O'Connor
University of Colorado Anschutz Medical Campus, Aurora, CO, USA
2:30 PM2:30 PM
837 - Decreased Anti-Inflammatory Tryptophan Metabolites Correlate With Higher CVD Risk in PWH
Manuela Ceccarelli
Università Kore di Enna, Enna, Italy
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-05) Atherosclerosis and Vascular Disease
2:30 PM2:30 PM
838 - Risk of Obesity, Cardiometabolic Disease, and MACE After Switch to Integrase Inhibitor in REPRIEVE
Emma M. Kileel
Boston University, Boston, MA, USA
2:30 PM2:30 PM
839 - Determinants of De-Novo High-Risk Carotid Ultrasound Features in Middle-Aged People Living With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
840 - Seven-Year Progression of Coronary Artery Calcium Score in Middle-Aged Thai People Living With HIV
Napon Hiranburana
HIV Netherlands Australia Thailand Research Collaboration, Bangkok, Thailand
2:30 PM2:30 PM
841 - Markers of Arterial Stiffness in People Living With HIV and Echocardiographic Outcomes
Karl Reis
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
842 - Multiomics Profiles of SHBG Are Associated With Subclinical Atherosclerosis in Men With HIV
Yi Wang
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
843 - Multiomics Analysis of Gut Microbiome and Carotid Artery Atherosclerosis in Men With and Without HIV
Zheng Wang
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
844 - PLHIV Exhibit a COVID-19 Independent Increase of Cardiovascular Mortality in Brazil, 2019-2023
Rodrigo Moreira
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
845 - Effect of Treatment for Opioid Use Disorder on Endothelial Function in People With and Without HIV
Corrilynn O. Hileman
MetroHealth Medical Center, Cleveland, OH, USA
2:30 PM2:30 PM
846 - Cholesterol Synthesis Pathways in Monocyte-Derived Macrophages Link CMV and HIV to Atherosclerosis
Katelyn O'Hare
Case Western Reserve University, Cleveland, OH, USA
2:30 PM2:30 PM
847 - Endothelial Colony-Forming Cells From People With HIV Display an Interferon Gene Signature
Akif A. Khawaja
Imperial College London, London, UK
2:30 PM2:30 PM
848 - CHIP Is Associated With Plasma Inflammatory Biomarkers and Vascular Events in People With HIV on ART
Caroline H. Sheikhzadeh
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
849 - ALDH Activity as a New Marker of Subclinical Atherosclerosis During ART-Treated HIV-1 Infection
Jonathan Dias
University of Montreal, Montreal, Canada
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(K-06) Statins: Impact and Usage
2:30 PM2:30 PM
850 - Statin Effect Heterogeneity on Plaque Volume and Composition in the REPRIEVE Mechanistic Substudy
Borek Foldyna
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
851 - People With HIV at High Cardiovascular Risk Were Undertreated With Statins
Stefan Esser
University Hospital Essen, Essen, Germany
2:30 PM2:30 PM
852 - Low-Density Lipoprotein Changes in People With HIV Initiating Statins for Primary Prevention
Thibaut Davy-Mendez
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
853 - Time-Updated Win Ratio Aligns With Primary REPRIEVE Findings and Suggests Early Pitavastatin Benefit
Emma Davies Smith
Harvard TH Chan School of Public Health, Boston, MA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-06) Diabetes and Metabolic Dysfunction
2:30 PM2:30 PM
898 - Incident Diabetes Among People With HIV After Switching to Integrase Strand Transfer Inhibitors
Y. Joseph Hwang
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
899 - Decreased Adipose Tissue Gene Expression After a 48-Week Switch From an InSTI Regimen to TDF/3TC/DOR
Claudine Duvivier
Necker Hospital, Paris, France
2:30 PM2:30 PM
900 - In Vitro Modulation of Adipocyte Differentiation by TAF/TDF After Challenge With New ARV Regimens
Alessandra Guida
AORN dei Colli Ospedale Cotugno, Naples, Italy
2:30 PM2:30 PM
901 - HIV-Induced Immunomodulation and Cardiometabolic Disease Development in Mice on High-Fat Diets
Victoria R. Stephens
Vanderbilt University Medical Center, Nashville, TN, USA
2:30 PM2:30 PM
902 - HIV and Antiretrovirals Have Unique In Vivo Effects on Insulin Resistance in HIV
Theodoros Kelesidis
University of Texas Southwestern Medical Center, Dallas, TX, USA
2:30 PM2:30 PM
903 - Menopause Is Associated With Faster Increases in Insulin Resistance in Women With HIV
Rebecca Abelman
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
904 - Obstructive Sleep Apnea and Prevalent Diabetes Mellitus in the Multicenter AIDS Cohort Study
Wassim A. Bouhsane
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
905 - Impact of HIV Infection on Adipose Tissue Fibrosis and Its Association With Insulin Resistance
Diana L. Alba
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
906 - Early Pregnancy Insulin Dynamics in South African Women With HIV on Dolutegravir: The ORCHID Study
Jennifer Jao
Northwestern University, Chicago, IL, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(L-07) Other Comorbidities
2:30 PM2:30 PM
907 - Noncommunicable Diseases: A Significant Cause of Death Among People Living With HIV in Nigeria
Chiamaka H. Onuoha
APIN Public Health Initiatives, Abuja, Nigeria
2:30 PM2:30 PM
908 - Risk Factors for Osteonecrosis Among People With HIV in Care Across the US in the Current ART Era
Heidi M. Crane
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
909 - Validation of SCORE and OST for Osteoporosis Risk Estimation in People Aging With HIV in Peru
Joselito Malca Hernandez
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
910 - Prevalence, Incidence, and Correlates of Autoimmune Diseases in People With HIV From 1997 to 2023
Emanuela Zappulo
University of Naples Federico II, Naples, Italy
2:30 PM2:30 PM
911 - Disparities in Hospitalization Among People in the HIV Outpatient Study, United States, 2008-2022
Kate Buchacz
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
912 - Uncovering Differential Disparities at the Intersection of Race, Sex, & HIV in Patients With Sepsis
Joshua A. Barocas
University of Colorado School of Medicine, Aurora, CO, USA
2:30 PM2:30 PM
913 - HIV Status and Psychiatric Diagnoses Among Transgender and Gender-Diverse Individuals
Fanghui Shi
University of South Carolina, Columbia, SC, USA
2:30 PM2:30 PM
914 - Kynurenine-Tryptophan (KT) Ratio and Inflammatory Biomarkers Associated With COPD in People With HIV
Kristina Crothers
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
915 - Characteristics of Secondary Hemophagocytic Lymphohistiocytosis in People Living With HIV/AIDS
Xavier A. Flores-Andrade
National Institute of Respiratory Diseases, Mexico City, Mexico
2:30 PM2:30 PM
916 - Safety of Full-Spectrum Cannabidiol for PWH: A Double-Blind, Randomized, Placebo-Controlled Study
Clémence Couton
Centre de Biophysique Moléculaire, Orléans, France
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(M-03) PASC: Biological Clues to Pathogenesis
2:30 PM2:30 PM
935 - Long COVID Associates With Slow Viral Clearance and Viral Rebound During Acute SARS-CoV-2 Infection
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
936 - Preserved Adrenal Function in People With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
937 - Lack of Association of SARS-CoV-2 N- and S-Antigenemia With Long COVID
Annukka Antar
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
938 - Exploring the Molecular Pathways of Long COVID With Post-Exertional Fatigue: A Multiomic Approach
Marta Massanella
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
939 - Distinct Proinflammatory/Proangiogenetic Signatures Distinguish Children With Long COVID
Danilo Buonsenso
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy
2:30 PM2:30 PM
940 - Plasma Biomarkers in Children and Young People With Long COVID
Jon Izquierdo-Pujol
IrsiCaixa, Badalona, Spain
2:30 PM2:30 PM
941 - Key Inflammatory Biomarkers Differentiate MIS-C From Convalescent COVID-19 and Kawasaki Disease
Tetyana Pidkova
IrsiCaixa Institute for AIDS Research, Badalona, Spain
2:30 PM2:30 PM
942 - Immune Profile of Children With Post-COVID-19 Cardiac Contractility Alterations: A Prospective Study
Costanza Di Chiara
University of Padova, Padova, Italy
2:30 PM2:30 PM
943 - Autoantibody Prevalence After SARS-CoV-2 Infection: Comparing Baltimore, USA, and Rakai, Uganda
Xianming Zhu
The Johns Hopkins University, Baltimore, MD, USA
2:30 PM2:30 PM
944 - Novel Plasma Biomarkers for the Detection of Long COVID Defined by Multiapproach Analysis
Mohamed R. Joma
French National Institute of Health and Medical Research (Inserm), Paris, France
2:30 PM2:30 PM
945 - ACE2 Autoantibodies in Post-Acute Sequelae of SARS-CoV-2 Infection
Melissa Agsalda-Garcia
University of Hawaii at Manoa, Honolulu, HI, USA
2:30 PM2:30 PM
946 - Shared Autoantibody Signature Is Not Identified in CSF During Long COVID
Debanjana Chakravarty
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
947 - Post-Acute SARS-CoV-2 Antigenemia Is Associated With Some but Not All Long COVID Symptoms
Michael Peluso
University of California San Francisco, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-05) Cryptococcal Meningitis: Where Do We Go From Here?
2:30 PM2:30 PM
973 - Uptake of New Guidelines for Cryptococcal Meningitis in Botswana, Malawi, Uganda, and Zimbabwe
David S. Lawrence
London School of Hygiene & Tropical Medicine, London, UK
2:30 PM2:30 PM
974 - Clinical Outcomes of People With HIV-Cryptococcal Meningitis on the New Treatment Regimen in Uganda
Esther M. Nasuuna
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
975 - Trends in Cryptococcal Meningitis Mortality Using Routine Longitudinal National Data From Botswana
James Milburn
Botswana Harvard AIDS Institute Partnership, Gabarone, Botswana
2:30 PM2:30 PM
976 - Pathway to Care Among Inpatients With Symptomatic Cryptococcal Meningitis in Johannesburg, SA
Lia F. Edkins
WITS Health Consortium, Johannesburg, South Africa
2:30 PM2:30 PM
977 - CMV and EBV Co-Infections and Mortality Risk in Patients With HIV-Associated Cryptococcal Meningitis
Jayne P. Ellis
London School of Hygiene & Tropical Medicine, London, UK
2:30 PM2:30 PM
978 - Catastrophic Healthcare Expenditure From Cryptococcal Meningitis in Eastern and Southern Africa
David S. Lawrence
London School of Hygiene & Tropical Medicine, London, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(N-06) OI Pathogenesis and Recent Trends in ART and OI Treatment Outcomes
2:30 PM2:30 PM
979 - Epigenetic Changes With T. gondii in Brains of People With HIV and Their Possible Link to Gliomas
Megha Srivatsa
University of California San Diego, La Jolla, CA, USA
2:30 PM2:30 PM
980 - Factors Associated With Virologic Suppression in People Living With HIV and Tuberculosis in Brazil
Nathalie De Castro
Hôpital Saint-Louis, Paris, France
2:30 PM2:30 PM
981 - Recent Trends in Opportunistic Infections at ART Initiation in the NA-ACCORD of IeDEA, 2017-2021
Keri N. Althoff
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
982 - Ceftriaxone or Aqueous Penicillin for Neurosyphilis: A Mexican Multicentric Retrospective Study
Rodrigo Ville Benavides
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
2:30 PM2:30 PM
983 - Burden of Opportunistic Infections and Causes of Death in Hospitalized Patients With AHD in Vietnam
Nam Xuan Ha
Oxford University Clinical Research Unit in Vietnam, Ho Chi Minh, Vietnam
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-05) HIV Acquisition and Prevention During Pregnancy and Breastfeeding
2:30 PM2:30 PM
1005 - Incident HIV Infection Among Pregnant Women in Botswana Has Decreased Since 2022
Aamirah Mussa
Botswana–Harvard AIDS Institute Partnership, Gaborone, Botswana
2:30 PM2:30 PM
1006 - Social Determinants Associated With Recent HIV Infection in Treatment-Naive Pregnant Women in Malawi
Shuntai Zhou
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
2:30 PM2:30 PM
1007 - STI Testing Is Associated With Lower PrEP Discontinuation Among Women Initiating PrEP in Pregnancy
Jerusha Mogaka
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1008 - Impact of Offering PrEP Choice on HIV Incidence in High-Risk Pregnant Women in Kenya
Tessa Concepcion
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1009 - PrEP Adherence and Acceptability of Urine Tenofovir Testing in Pregnant and Postpartum Women
Dvora L. Joseph Davey
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1010 - TFV-DP Concentrations in PBMCs and Safety of Daily Directly Observed F/TDF PrEP During Pregnancy
Linxuan Wu
University of Washington, Seattle, WA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(O-06) Emerging Perspectives on Perinatal HIV Transmission
2:30 PM2:30 PM
1011 - Vertical HIV Transmission: Substantial Reductions but Not Elimination With Universal ART
Nisha Jacob
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1012 - The Role of Maternal Broadly Neutralizing Antibody Activity in Perinatal Transmission of HIV-1
Krithika Karthigeyan
Weill Cornell Medicine, New York, NY, USA
2:30 PM2:30 PM
1013 - ART Reverses Negative Natural Selection of HIV Disease-Linked HLA-I in KwaZulu-Natal, South Africa
Nicholas G. Herbert
University of Oxford, Oxford, UK
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-05) Risks and Responses to ART
2:30 PM2:30 PM
1050 - Infants With HIV Starting ART Within 4 Months of Age Can Achieve Sustained Undetectable HIV-1 DNA
Alfredo Tagarro
Fundación para la Investigación Biomédica Hospital 12 de Octubre, Madrid, Spain
2:30 PM2:30 PM
1051 - Hospitalization Incidence Among Young Children Living With HIV in the Western Cape, South Africa
Kim Anderson
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1052 - Inflammatory Cytokines in ART-Naive Kenyan Children Diagnosed With HIV at Hospital Admission
Emily R. Begnel
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1053 - HIV Viral Load Patterns Since Dolutegravir Initiation in Children and Adolescents Living With HIV
Sophie Desmonde
Université Toulouse III - Paul Sabatier, Toulouse, France
2:30 PM2:30 PM
1054 - Viral Suppression 12 Months After Switch to Dolutegravir by nRTI Backbone in Children/Adolescents
Renee de Waal
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1055 - Transitioning Adolescents With HIV to TDF/3TC+DTG Improves Virologic Outcome: CIPHER-ADOLA Study
Aude Christelle Ka'e
2:30 PM2:30 PM
1056 - Prevalence and Consequences of Low-Level Viremia Among Adolescents Living With HIV in South Africa
Zea Leon
University of Cape Town, Cape Town, South Africa
2:30 PM2:30 PM
1057 - HIV-1 Drug Resistance at Low- and High-Level Viremia in Kenyan Youth on Dolutegravir-Based Therapy
Rami Kantor
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1058 - Enhanced Adherence Counselling Among Adolescents With Detectable Viremia in Cameroon
Alex Durand Nka
2:30 PM2:30 PM
1059 - Differentiated Service Delivery Programme Impact on Clinical Outcomes Among Adolescents With HIV
Lara Lewis
Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
2:30 PM2:30 PM
1060 - HIV Status Disclosure Among ART-Experienced Adolescents and Young Adults in 4 African Countries
Trevor Crowell
US Military HIV Research Program, Bethesda, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-06) Health and Outcomes of Young People With HIV
2:30 PM2:30 PM
1061 - Long-Term Outcomes of Young Adults With Perinatal HIV Infection in the US and Puerto Rico
Leah Kern
University of California San Diego Medical Center, La Jolla, CA, USA
2:30 PM2:30 PM
1063 - Psychotic Disorders in Young Adults With Perinatally Acquired HIV: A Multicentre UK Study
Indira Mallik
Imperial College Healthcare NHS Trust, London, UK
2:30 PM2:30 PM
1064 - Changes in Suicidality, Depression, and Anxiety After Integrative Mental Health Care in Thai Youth
Tavitiya Sudjaritruk
Chiang Mai University, Chiang Mai, Thailand
2:30 PM2:30 PM
1066 - Kidney Dysfunction in Young People Living With HIV on Dolutegravir-Based Regimens in Kampala, Uganda
Esther M. Nasuuna
Infectious Diseases Institute, Kampala, Uganda
2:30 PM2:30 PM
1067 - Long-Term Immune Response to Vaccines in Vertically Infected People Living With HIV
Daniele Donà
University of Padova, Padova, Italy
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(P-07) Inflammation and Cardiovascular Complications
2:30 PM2:30 PM
1068 - Characterisation of Cardiac Disease in Adolescents With HIV in the Antiretroviral Therapy Era
Edith D. Majonga
Biomedical Research and Training Institute, Harare, Zimbabwe
2:30 PM2:30 PM
1069 - Left Ventricular Mass Adjustment for Body Size in Youth With Perinatal HIV or Perinatal HIV Exposure
George W. Sawyer
Harvard TH Chan School of Public Health, Boston, MA, USA
2:30 PM2:30 PM
1070 - Distinct Metabolic and Inflammation Signatures in Urban vs Rural Ugandan Youth With HIV
Sahera Dirajlal-Fargo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1071 - US and Ugandan HIV Youth: Exploring Differences in Inflammatory, Chemokine, and Vascular Signatures
Sahera Dirajlal-Fargo
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1072 - HIV Modifies Association of Biomarkers on Cardiac Fibrosis and Inflammation in South African Youth
Jennifer Jao
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1073 - Changes in Inflammatory Biomarkers Among Youth Living With Perinatal HIV Infection and Exposure
Russell B. Van Dyke
Tulane University, Metairie, LA, USA
2:30 PM2:30 PM
1074 - Inflammation Phenotypes in Children With Perinatally Acquired HIV in South Africa
Claire Davies
Stellenbosch University, Cape Town, South Africa
2:30 PM2:30 PM
1075 - Early-Treated Children With Perinatal HIV Show Elevated Monocyte Activation Into Late Childhood
Claire Davies
Stellenbosch University, Cape Town, South Africa
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-10) HIV and Substance Use
2:30 PM2:30 PM
1144 - Increasing Methamphetamine Use and Group Sex Observed in MSM With Acute HIV Infection in Bangkok
Phillip Chan
Yale University, New Haven, CT, USA
2:30 PM2:30 PM
1145 - Unstable Housing, Methamphetamine Use, and HIV Incidence Among Racial and Ethnic Minority Men
Marjan Javanbakht
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1146 - Substance Use Is Associated With Higher HIV Viral Load and Reduced Viral Suppression in 6 US Cohorts
Ryan P. Kyle
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1147 - Missed Opportunities for Drug Use Screening and Discussions Among People With HIV
Sydney Bornstein
The George Washington University, Washington, DC, USA
2:30 PM2:30 PM
1148 - Impact of Residing or Injecting in Testing Center Catchments on HIV Testing in Churachandpur, India
Talia A. Loeb
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1149 - HIV Outcomes Among People With HIV Who Inject Drugs in West Virginia
Rebecca Reece
West Virginia University, Morgantown, WV, USA
2:30 PM2:30 PM
1150 - Scope of the Overdose Crisis: Fatal Overdoses Among People With HIV Experiencing a Nonfatal Overdose
Megan E. Marziali
Columbia University, New York, NY, USA
2:30 PM2:30 PM
1151 - Progress Towards UNAIDS 95-95-95 Targets Among PWID Living With HIV Over 10 Years in Punjab, India
Griffin J. Bell
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1152 - The Impact of Semaglutide on Alcohol Use Among People With HIV in Routine Clinical Care in the US
Heidi M. Crane
University of Washington, Seattle, WA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-11) HIV Transmission Insights Through Phylogenetics
2:30 PM2:30 PM
1153 - Introduction and Acquisition of HIV-1 Related to Recent Migration to Quebec (2016-2023)
Jean-Pierre Routy
McGill University Health Centre Research Institute, Montreal, Canada
2:30 PM2:30 PM
1154 - HIV Molecular Clusters Attributed to Sexual Transmission in the United States, 2015-2023
Kathryn G. Curran
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1155 - Changing Clustering Rates in the Rhode Island HIV-1 Epidemic
Rami Kantor
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1156 - Evolution of HIV-1 A6 Clusters in Poland Following Full-Scale Armed Conflict in Ukraine
Karol Serwin
Pomeranian Medical University, Szczecin, Poland
2:30 PM2:30 PM
1157 - People Living With HIV Diagnosed Late Provide Source of HIV Infection to Others With Recent Diagnosis
Evangelia G. Kostaki
National and Kapodistrian University of Athens, Athens, Greece
2:30 PM2:30 PM
1158 - Distribution of HIV-1 Variants in Population-Based National Surveys in Sub-Saharan Africa, 2015-2022
Peter D. Ghys
Independent Consultant, Tannay, Switzerland
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-12) Life Expectancy and Mortality Among People With HIV
2:30 PM2:30 PM
1159 - Life Expectancy Among Virally Suppressed Women and Men With HIV in the Bronx, New York, 1997-2021
Brandilyn A. Peters
Albert Einstein College of Medicine, Bronx, NY, USA
2:30 PM2:30 PM
1160 - Mortality Trends Among Persons With Perinatal HIV in United States and Territories, 1978-2022
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1161 - Mortality in the HIV Outpatient Study (HOPS), Trends and Risks: 2007-2022
Frank Palella
Northwestern University, Chicago, IL, USA
2:30 PM2:30 PM
1162 - Reducing HIV Diagnoses and Mortality Rate Further Increases Aging Resource Needs for PWH Into 2040
Siobhan M. O'Connor
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1163 - Factors Associated With Mortality Among People With Advanced HIV Disease in Rural Uganda, 2018-2021
Kabali Bwogi
C-CARE International Hospital, Kampala, Uganda
2:30 PM2:30 PM
1164 - Projecting Demographics and Causes of Death Among People With HIV in Western Europe to 2050
Julie Ambia
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1165 - Causes of Mortality Among Persons Living With HIV in Thailand, 2007-2022
Wiphawee Kiatchanon
Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand
2:30 PM2:30 PM
1166 - Text Clustering Model for Defining Cause of Death Among PLHIV in Thailand (2020-2022)
Apiratee Kanphukiew
Thailand Ministry of Public Health–US CDC Collaboration, Nonthaburi, Thailand
2:30 PM2:30 PM
1167 - Changes Over Calendar Time in Discrimination of Prognostic Models for People With HIV Starting ART
Suzanne M. Ingle
University of Bristol, Bristol, UK
2:30 PM2:30 PM
1168 - Clinical Outcomes in Lung Transplantation in People Living With HIV: A Competing Risk Analysis
German Contreras
University of Texas Medical Branch, Galveston, TX, USA
2:30 PM2:30 PM
1169 - Epigenetic Age Acceleration and Mortality Among Persons Who Inject Drugs With Poorly Controlled HIV
Jing Sun
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(Q-13) HIV Epidemiology
2:30 PM2:30 PM
1170 - The HIV Epidemic Is Growing Faster in Countries Excluded From Gilead Voluntary Licenses
Samuel Cross
NHS Greater Glasgow and Clyde, Glasgow, UK
2:30 PM2:30 PM
1171 - Characteristics and Needs of Adult Lifetime Survivors With HIV in the United States, 2015-2022
Athena Kourtis
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1172 - Clinical and Programmatic Factors Associated With Low-Level Viremia in West Africa
Ebiere C. Herbertson
Nigerian Institute of Medical Research, Lagos, Nigeria
2:30 PM2:30 PM
1175 - Prevalence and Risk Factors of HIV Viral Blips in the NA-ACCORD, 2010-2020
Raynell Lang
University of Calgary, Calgary, Canada
2:30 PM2:30 PM
1176 - Time From HIV Infection to Diagnosis Using CD4 Depletion Model: Thailand, 2014-2021
Suchunya Aungkulanon
National Health Security Office, Chiang Mai, Thailand
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(R-03) Challenging and Innovative HIV Testing
2:30 PM2:30 PM
1191 - HIV Serologic Reactivity in Persons With HIV Who Started ART During Acute/Early Stages of Infection
Vivian I. Avelino-Silva
Vitalant Research Institute, San Francisco, CA, USA
2:30 PM2:30 PM
1192 - Laboratory-Based HIV-1/2 Ag/Ab Immunoassay Performance in the United States, 2019-2023
Patricia Bessler
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1193 - Use of DNA Profiling to Resolve Discrepant HIV Tests in the Setting of Injectable Cabotegravir PrEP
Jessica M. Fogel
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1194 - Can HIV Testing Data and Recent HIV Infection Surveillance Identify Similar Signals of Transmission?
Misheck Luhanga
US Centers for Disease Control and Prevention Lilongwe, Lilongwe, Malawi
2:30 PM2:30 PM
1195 - Preferences for HIV Testing Technologies in Seattle, Washington: A Mixed-Methods Study
Lauren R. Violette
Harvard Medical School, Boston, MA, USA
2:30 PM2:30 PM
1196 - Clinical Validation of iMune qPCR as a Novel Solution to CD4 Counting Off Dried Blood Spots
Tracy M. Sungu
University of Witwatersrand, Johannesburg, South Africa
2:30 PM2:30 PM
1197 - Screening of MPXV, VZV, HSV-1, and HSV-2 Causing Mucocutaneous Vesicular Rashes by Multiplex HRM-PCR
Joany Guy
AFYIA Diagnostics, Grabels, France
2:30 PM2:30 PM
1198 - Impact of Point-of-Care HIV-1 RNA Testing on Time to HIV Confirmation and ART Start in Buenos Aires
Carina Cesar
Fundación Huésped, Buenos Aires, Argentina
2:30 PM2:30 PM
1199 - Characteristics of First-Time HIV Self-Testers Using the Online HIV Service ‘Stand By You’
Kantarida Sripanidkulchai
Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(S-06) Innovations in PrEP Products
2:30 PM2:30 PM
1232 - MK-8527 PK/PD Threshold and Phase II Dose Selection for Monthly Oral HIV-1 Preexposure Prophylaxis
Yash Kapoor
Merck Research Laboratories, Rahway, NJ, USA
2:30 PM2:30 PM
1233 - A Biodegradable Implant Releasing Low-Dose Islatravir Protects Macaques From Rectal SHIV Infection
Leah Johnson
RTI Health Solutions, Research Triangle Park, NC, USA
2:30 PM2:30 PM
1234 - Qualitative Assessment of Acceptability and Preferences for Injectable and Oral PrEP in PURPOSE 1
Elizabeth (Liz) Montgomery
2:30 PM2:30 PM
1235 - Cost-Effectiveness of Community Pharmacy-Based HIV PrEP for Men Who Have Sex With Men in Atlanta
Jacinda Tran
University of Washington, Seattle, WA, USA
2:30 PM2:30 PM
1236 - Long-Acting Injectable CAB/MPA MPT Implant for Prevention of HIV and Unintended Pregnancy
Jasmine King
CIDRZ / University of North Carolina, Chapel Hill, NC, USA
2:30 PM2:30 PM
1237 - Acceptability and Usability of a TAF/EVG Insert Among Women in a Multinational Phase I Trial
Ellen Luecke
RTI International, Berkeley, CA, USA
2:30 PM2:30 PM
1238 - Dose-Ranging Pharmacokinetics and Efficacy of a 90-Day Multipurpose IVR Delivering Islatravir
S. Rahima Benhabbour
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(T-05) DoxyPEP Reflections
2:30 PM2:30 PM
1275 - Postexposure Prophylaxis With Doxycycline (Doxy PEP) in a Cohort of High-Risk MSM: The PRIDOX Study
Cristina Gómez-Ayerbe
Hospital Universitario Virgen de la Victoria, Málaga, Spain
2:30 PM2:30 PM
1276 - Doxycycline Post-Exposure Prophylaxis Continuum of Care Among MSM in Philadelphia, 2023
Tanner Nassau
Philadelphia Department of Public Health, Philadelphia, PA, USA
2:30 PM2:30 PM
1277 - Characteristics of Breakthrough Chlamydia Cases Among Cisgender Women Assigned to Doxycycline PEP
Jenell Stewart
Hennepin Healthcare Research Institute, Minneapolis, MN, USA
2:30 PM2:30 PM
1278 - Acceptability of Doxycycline as Post-Exposure Prophylaxis in Southeastern Louisiana
Shafay Shams
Louisiana State University, New Orleans, LA, USA
2:30 PM2:30 PM
1279 - Factors Influencing Doxy-PEP Awareness Among Sexual/Gender Minorities: A Web-Based Survey in Brazil
Mayara Secco Torres da Silva
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1280 - Young Black Sexually Minoritized Men Living With HIV, Substance Use, and Syphilis Want Doxy-PEP
Jade Pagkas-Bather
University of Chicago, Chicago, IL, USA
2:30 PM2:30 PM
1281 - Increased Knowledge and Use of Doxycycline Postexposure Prophylaxis in King County, Washington
Jennifer E. Balkus
Public Health–Seattle & King County, Seattle, WA, USA
2:30 PM2:30 PM
1282 - The Actual Need for DoxyPEP Might Not Be as Large as Expected
Roberto Rossotti
ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
2:30 PM2:30 PM
1283 - Topical Doxycycline Inserts Show High Efficacy Against Vaginal Chlamydia Acquisition in Macaques
David A. Garber
Centers for Disease Control and Prevention, Atlanta, GA, USA
2:30 PM2:30 PM
1284 - Antimicrobial Consumption Among Users of Doxycycline Postexposure Prophylaxis in Milan, Italy
Angelo Roberto Raccagni
San Raffaele Vita-Salute University, Milan, Italy
2:30 PM2:30 PM
1285 - Antimicrobial Resistance of N. gonorrhoeae at a Community-Based Clinic, 2023-2024
Philip A. Chan
Brown University, Providence, RI, USA
2:30 PM2:30 PM
1286 - Effectiveness of Ceftriaxone Monotherapy for Gonorrhea Treatment
Chiara Fusetti
Luigi Sacco University Hospital, Milan, Italy
2:30 PM2:30 PM
1287 - Prevalence of Tetracycline-Resistant Gonorrhea in British Columbia’s HIV Treatment and PrEP Program
K. Junine Toy
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1288 - DoxyPrEP Impact on the Microbiome of Men Who Have Sex With Men and Transgender Women on HIV PrEP
Troy Grennan
BC Centre for Disease Control, Vancouver, Canada
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-07) PrEP and PEP Use
2:30 PM2:30 PM
1341 - A Comparative Analysis of Access and Retention of Oral PrEP and CAB-LA at 1 Month in Zambia
Damian J. Phiri
John Snow, Inc, Lusaka, Zambia
2:30 PM2:30 PM
1342 - Patterns of PrEP Use Among Rural South Africa Youth Given Choice: Process Data From the LAPIS Trial
Maryam Shahmanesh
University College London, London, UK
2:30 PM2:30 PM
1343 - Peer Mobilisation Into Sexual Health Clinics Creates PrEP Demand Among High-Risk Rural Youth in SA
Maryam Shahmanesh
University College London, London, UK
2:30 PM2:30 PM
1344 - Injectable Cabotegravir PrEP Discontinuations at a Peer Specialist-Led Program in Washington, DC
Juan Carlos Loubriel
Whitman-Walker Health, Washington, DC, USA
2:30 PM2:30 PM
1345 - Outcomes From a Multilevel Trial With Clinics and Young Women for PrEP in South Africa
Alexandra Minnis
RTI International, Berkeley, CA, USA
2:30 PM2:30 PM
1346 - Impact of CAB-LA Versus Oral PrEP in Reducing HIV Incidence Among MSM in Thailand: A Modelling Study
David Van de Vijver
Erasmus University Medical Center, Rotterdam, Netherlands
2:30 PM2:30 PM
1347 - PrEP Use Trajectories and HIV Incidence Among PrEP Users in Brazil: Findings From the ImPrEP Study
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1348 - US Socioeconomic Disparities and Geographic Variations in HIV Preexposure Prophylaxis Providers
Li Tao
Gilead Sciences, Inc, Foster City, CA, USA
2:30 PM2:30 PM
1349 - Social Networks Influence PrEP Use and Preference for Long-Acting PrEP Among MSM In Baltimore
Steven J. Clipman
The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2:30 PM2:30 PM
1350 - Disparities in PrEP Use Among Latinx and Black Transgender Women in Los Angeles County, 2019 vs 2023
Yingbo Ma
Los Angeles County Department of Public Health, Los Angeles, CA, USA
2:30 PM2:30 PM
1351 - Early PEPFAR Implementation of Cabotegravir-LA and Implications for Long-Acting HIV Prevention
Carly E. LoVullo
PEPFAR, Washington, DC, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-08) PrEP Choice and Preferences
2:30 PM2:30 PM
1352 - “I Like It but I Can’t Be the First”: Sex Workers’ Preferences for LAI PrEP Delivery in South Africa
Katherine Rucinski
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1353 - HIV PrEP Method Preferences Among Transgender and Gender-Diverse Adults in the United States
Dovie L. Watson
University of Pennsylvania, Philadelphia, PA, USA
2:30 PM2:30 PM
1354 - Expanding the PrEP Market: Early Insights Offering Oral, Ring, and CAB PrEP in Sub-Saharan Africa
Urvi Parikh
University of Pittsburgh, Pittsburgh, PA, USA
2:30 PM2:30 PM
1355 - Long-Acting PrEP Preference Among Brazilian Sexual and Gender Minorities: Key Influencing Factors
Thiago Torres
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1356 - PrEP Choices Among Sexual and Gender Minorities in Brazil: The ImPrEP CAB-LA Study
Beatriz Grinsztejn
Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
2:30 PM2:30 PM
1357 - Acceptability of Long-Acting Cabotegravir Among Pregnant and Lactating People in South Africa
Nafisa Wara
University of California Los Angeles, Los Angeles, CA, USA
2:30 PM2:30 PM
1358 - Regional Disparities in DoxyPEP Uptake Despite High Awareness Among MSM With HIV in the US
Tyler Martinson
University of California San Francisco, San Francisco, CA, USA
MAR12
2:30 PMto4:00 PMPDT
12:00 PMto5:00 PMPDT
(U-09) Long-Acting Injectable ART Implementation
2:30 PM2:30 PM
1359 - Characteristics of People With HIV Prescribed Long-Acting Cabotegravir/Rilpivirine in a US Cohort
Sita Lujintanon
The Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
2:30 PM2:30 PM
1360 - Clinical Consequences of Delaying Implementation of LA-ART for PWH With Persistent Viremia in the US
Kenneth A. Freedberg
Massachusetts General Hospital, Boston, MA, USA
2:30 PM2:30 PM
1361 - Longitudinal Renal Safety of a Population-Level TDF-Based HIV PrEP Program in British Columbia
K. Junine Toy
British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada
2:30 PM2:30 PM
1362 - Disposition of Referrals for Long-Acting Antiretrovirals at the Ward 86 HIV Clinic in San Francisco
Chesa Cox
University of California San Francisco, San Francisco, CA, USA
2:30 PM2:30 PM
1363 - Impact of 6-Monthly ART Dispensing on Retention in Malawi: A Target Trial Emulation Study
Khumbo Shumba
Health Economics and Epidemiology Research Office, Johannesburg, South Africa
